protocolSection.identificationModule.briefTitle,protocolSection.statusModule.statusVerifiedDate,protocolSection.statusModule.overallStatus,protocolSection.statusModule.completionDateStruct.date,protocolSection.sponsorCollaboratorsModule.responsibleParty.type,protocolSection.sponsorCollaboratorsModule.responsibleParty.investigatorFullName,protocolSection.sponsorCollaboratorsModule.leadSponsor.name,protocolSection.conditionsModule.conditions,protocolSection.designModule.studyType,protocolSection.designModule.enrollmentInfo.count,protocolSection.designModule.enrollmentInfo.type,protocolSection.armsInterventionsModule.interventions,protocolSection.conditionsModule.keywords,protocolSection.eligibilityModule.studyPopulation
Psychological Therapy for Patients With ALS,2021-04,COMPLETED,2020-11-15,PRINCIPAL_INVESTIGATOR,Anja Mehnert,University of Leipzig,"['Amyotrophic Lateral Sclerosis', 'Psychological Stress']",INTERVENTIONAL,5.0,ACTUAL,"[{'name': 'Adaptation of ""CALM""', 'description': 'The therapy is built up by 3-8 sessions (duration about 45-60 min) over a period of 6 months. All dimensions are explored with every patient, but the order and extent of each dimension are adapted to the individual needs of the patient.\n\nThe sessions address the 4 dimensions of the original program designed for palliative cancer patients:\n\n1. Symptom management and communication with healthcare providers\n2. Changes in self and relations with each others\n3. Spirituality, sense of meaning, and purpose\n4. Thinking of the future, hope, and mortality\n\nAs an adaptation, the investigators will especially focus on two other aspects which take into account the specific symptoms and challenges in patients with ALS: (i) communication skills and (ii) emotional expression and control.'}]",,
"Study of Social Behavior and Emotion in Frontotemporal Dementia, Alzheimer's Disease and Controls",2011-10,UNKNOWN,2014-07,PRINCIPAL_INVESTIGATOR,Mario F. Mendez,"University of California, Los Angeles","['Frontotemporal Dementia', 'Frontotemporal Degeneration', ""Alzheimer's Disease"", 'Social Behavior']",OBSERVATIONAL,99.0,ESTIMATED,,"['Frontotemporal dementia', ""Alzheimer's disease"", 'Young-Onset', 'Frontotemporal degeneration', 'control', 'social', 'behavior', 'observation', 'emotion', 'morality', 'dementia', 'brain', 'relationships', 'caregiver', 'MRI', 'neurology']",Patients evaluated by Dr. Mario Mendez at the UCLA Frontotemporal Dementia Clinic
Investigation on the Cortical Communication System,2024-01,RECRUITING,2027-10,PRINCIPAL_INVESTIGATOR,"Erik Aarnoutse, PhD",UMC Utrecht,"['Locked-in Syndrome', 'Neuromuscular Diseases', 'Brainstem Stroke', 'Traumatic Brain Injury']",INTERVENTIONAL,2.0,ESTIMATED,"[{'name': 'ECoG (electrocorticography) sensing', 'description': 'Implant electrodes and pedestal connector and use, through amplifier and decoding, for control of BCI'}]","['Locked-in', 'Amyotrophic lateral sclerosis', 'Neurodegenerative disease']",
Customized Masks in Non-Invasive Mechanical Ventilation,2024-01,RECRUITING,2024-05,SPONSOR,,Hospital Universitario 12 de Octubre,"['COPD, Severe Early-Onset', 'Ventilatory Failure', 'Als', 'Non Invasive Ventilation']",INTERVENTIONAL,10.0,ESTIMATED,"[{'name': '3d printed mask', 'description': ""* Concurrent, prospective, non-randomized inclusion, cross-over design. A minimum of 6 patients will be included for each group, COPD, and ALS.\n* T0: Patient enrollment (informed consent signing), retrospective review of the respirator log (1 month prior), variable extraction (extracting EDF files from the respirator log and data obtained from ResScan).\n* During the first week, a 3D scan of the patient's face will be conducted, and the personalized 3D-printed mask (M3D) will be manufactured.\n* Once ready, the mask will be fitted, and the 1-month evaluation period will begin (T1: after 1 month of M3D use). The respirator card will be downloaded in the same manner as at T0, and a respiratory polygraphy (RP) will be scheduled.\n* T2: At the end of the study month, the patient will resume using a similar MC, which is new and well-fitted. After one month of MC use, the respirator log will be reviewed, and a new RP will be conducted.""}]","['non invasive ventilation', '3d printed mask']",
Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease,2023-03,ACTIVE_NOT_RECRUITING,2024-01-30,SPONSOR,,Gold Coast Hospital and Health Service,"['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease']",INTERVENTIONAL,17.0,ACTUAL,"[{'name': 'MediCabilis CBD Oil', 'description': '50 mg of CBD: \\<2mg of THC in one ml. The cannabis oil consists of CBD extract in MCT oil.'}, {'name': 'Placebo Oil', 'description': 'Placebo will contain only hemp seed oil.'}]",,
Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS),2020-09,COMPLETED,2018-02-23,SPONSOR,,PTC Therapeutics,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,19.0,ACTUAL,"[{'name': 'EPI-589', 'description': 'An immediate release film-coated table at a 250 mg dosage strength will be administered per dose and schedule specified in arm.'}]",,
Determination and Comparison of Short-term Effectiveness of Three Methods Used for Recognition of Arrhythmias in People With Different Degrees of Medical Training (Advanced Life Support Workshop Participants-ALS): Randomized Controlled Educational Experiment.,2021-05,COMPLETED,2017-06,SPONSOR,,Universidad Nacional de Colombia,['Arrhythmias'],INTERVENTIONAL,76.0,ACTUAL,"[{'name': 'Arrhythmia diagnosis with the 10 steps method'}, {'name': 'Arrhythmia diagnosis with the 6 steps method'}, {'name': 'Arrhythmia diagnosis with the 4 steps method'}]",,
"N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)",2023-11,COMPLETED,2022-11-07,SPONSOR,,IntraBio Inc,"['Niemann-Pick Disease, Type C']",INTERVENTIONAL,33.0,ACTUAL,"[{'name': 'IB1001', 'description': 'IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.'}]",,
Effects of Tolcapone on Frontotemporal Dementia,2019-08,COMPLETED,2014-10,PRINCIPAL_INVESTIGATOR,"Edward D Huey, MD",Columbia University,['Frontotemporal Lobar Degeneration'],INTERVENTIONAL,28.0,ACTUAL,"[{'name': 'Tolcapone', 'description': '200 mg by mouth three times a day'}, {'name': 'Placebo', 'description': '200 mg by mouth three times a day'}]","['Dementia Treatment', 'Frontotemporal Dementia', 'Dopamine', 'Frontotemporal Lobar Degeneration']",
Study of ALS Reversals 4: LifeTime Exposures,2020-07,COMPLETED,2020-06-01,SPONSOR,,Duke University,"['Amyotrophic Lateral Sclerosis', 'Progressive Muscular Atrophy', 'Motor Neuron Disease']",OBSERVATIONAL,25.0,ACTUAL,,"['amyotrophic lateral sclerosis', 'progressive muscular atrophy', 'motor neuron disease', 'ALS Reversal', 'PMA Reversal']",Participants will be recruited from the cohort of subjects (38 to-date) who participated in the Documentation of Known ALS Reversals (Duke IRB Pro00076395) protocol and were subsequently thought to have an ALS Reversal.
Amyotrophic Lateral Sclerosis: a New Paradigm,2017-03,COMPLETED,2018-06,SPONSOR,,"Conde, Bebiana, M.D.",['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,30.0,ACTUAL,"[{'name': 'ALS patients genetic characterization', 'description': 'Genetic findings in ALS patients'}, {'name': 'ALS patients epidemiological caracterization', 'description': 'Epidemiological characterization in ALS patients'}]","['Amyotrophic Lateral Sclerosis', 'Bulbar disfunction', 'Rik factors ALS']",Patients with Amyotrophic Lateral Sclerosis sent to a medical consultation
Transmembrane Electromyography (TM-EMG) for the Assessment of Neuromuscular Function in the Oropharynx,2022-06,COMPLETED,2021-03-26,SPONSOR,,Powell Mansfield Inc.,"['Obstructive Sleep Apnea', 'Amyotrophic Lateral Sclerosis', 'Muscular Dystrophies', 'Healthy']",INTERVENTIONAL,50.0,ACTUAL,"[{'name': 'Transmembrane EMG Oropharynx Probe', 'description': 'Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmembrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).'}]",,
Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis,2018-10,WITHDRAWN,2016-09,SPONSOR,,Neurogen Brain and Spine Institute,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Stem Cell', 'description': 'intrathecal autologous bone marrow mononuclear cell transplantation'}]","['Motor Neuron Disease', 'Amyotrophic Lateral Sclerosis', 'Autologous Mononuclear Cell therapy', 'Stem cells']",
"The Reliability and Validity of Turkish Version of ''The Dyspnea-ALS-Scale (DALS-15)""",2021-04,COMPLETED,2021-04-08,PRINCIPAL_INVESTIGATOR,Esma Nur KOLBAÅžI,Istanbul Medeniyet University,"['Amyotrophic Lateral Sclerosis', 'Dyspnea']",OBSERVATIONAL,52.0,ACTUAL,,,Patients who are diagnosed with Amyothrophic Lateral Sclerosis
European Home Mechanical Ventilation Registry,2020-04,TERMINATED,2019-01,SPONSOR,,ResMed,"['Pulmonary Disease, Chronic Obstructive', 'Amyotrophic Lateral Sclerosis', 'Spinal Cord Injury', 'Muscular Dystrophies', 'Obesity Hypoventilation Syndrome', 'Kyphoscoliosis', 'Congenital Central Hypoventilation Syndrome', 'Duchenne Muscular Dystrophy', 'Myopathies', 'Myotonic Dystrophy']",OBSERVATIONAL,37.0,ACTUAL,,,"The registry will target all adult individuals who have an indication for HMV (including those with amyotrophic lateral sclerosis \[ALS\], central hypoventilation syndrome \[CHS\], chronic obstructive pulmonary disease \[COPD\], kyphoscoliosis, obesity hypoventilation syndrome \[OHS\], spinal cord injury \[SCI\], Duchenne muscular dystrophy \[DMD\], muscular dystrophies \[MDs\] other than DMD, myopathies and myotonic dystrophy \[Steinert's muscular dystrophy; SMD\]). All newly-diagnosed patients with chronic respiratory diseases who are eligible for HMV treatment as part of routine care can be included in the registry. Patients who satisfy all the inclusion criteria will be consecutively enrolled into the registry."
Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS,2023-07,ACTIVE_NOT_RECRUITING,2023-09,SPONSOR,,Amylyx Pharmaceuticals Inc.,['ALS'],INTERVENTIONAL,14.0,ESTIMATED,"[{'name': 'AMX0035', 'description': 'Fixed dose combination of Sodium Phenylbutyrate and taurursodiol.'}]","['Neurodegenerative Diseases', 'Motor Neuron Disease', 'Amyotrophic Lateral Sclerosis', 'Nervous System Diseases', 'Neuromuscular Diseases']",
Circulating Biomarker for Amyotrophic Lateral Sclerosis (ALS),2023-03,RECRUITING,2024-12-01,PRINCIPAL_INVESTIGATOR,Alba Di Pardo,Neuromed IRCCS,['Amyotrophic Lateral Sclerosis (ALS)'],OBSERVATIONAL,60.0,ESTIMATED,,,"A total of 60 individuals (30 subjects clinically diagnosed as ALS patients and 30 healthy controls) will be recruited at Centre for Rare Diseases, IRCCS Neuromed"
A Study of Caregiver Connections Via Technology in Dementia,2023-03,RECRUITING,2024-12,PRINCIPAL_INVESTIGATOR,"Julie A. Fields, Ph.D., L.P.",Mayo Clinic,"['Caregiver Stress', 'Dementia', 'Alzheimer Disease', 'Lewy Body Dementia', 'Parkinson Disease Dementia', 'Frontotemporal Dementia']",INTERVENTIONAL,355.0,ESTIMATED,"[{'name': 'Algorithm', 'description': 'For purpose of finding peer-to-peer support, current and/or former caregivers of persons with dementia will be matched using an algorithm. They can then choose make a connection and maintain a connection for the duration of the study.'}, {'name': 'Random Match', 'description': 'For purpose of finding peer-to-peer support, current and/or former caregivers of persons with dementia will be randomly matched. They can then choose make a connection and maintain a connection for the duration of the study.'}]",,
Cistanche Total Glycosides for Amyotrophic Lateral Sclerosis: A Randomized Control Trial (RCT) Study Assessing Clinical Response,2008-09,UNKNOWN,2010-10,,,Peking University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,40.0,ESTIMATED,"[{'name': 'Cistanche Total Glycosides', 'description': 'Drug: Cistanche Total Glycosides Cistanche Total Glycosides ,1.8g/day(6 capsules) po Qd\\*9months Arms: 1 Drug: blank capsules 6 capsules po Qd\\*9months\n\nArms: 2'}]","['Amyotrophic Lateral Sclerosis', 'Cistanche Total Glycosides', 'Randomized Control Trial Study']",
"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis",2023-04,COMPLETED,2021-06-21,SPONSOR,,Biogen,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,49.0,ACTUAL,"[{'name': 'BIIB100', 'description': 'Administered as specified in the treatment arm.'}, {'name': 'Placebo', 'description': 'Administered as specified in the treatment arm.'}]",,
Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing,2024-01-04,RECRUITING,2030-12-31,SPONSOR,,National Institute of Neurological Disorders and Stroke (NINDS),"['Amyotrophic Lateral Sclerosis Type 4', 'Inherited Neurological Disorders of RNA Processing']",OBSERVATIONAL,315.0,ESTIMATED,,"['Natural History Study', 'Biomarker Development', 'Natural History']",Disease cohorts with defined mutations
Clinical Trial on The Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis (Extension CMN/ELA),2015-11,COMPLETED,2015-11-20,SPONSOR,,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,63.0,ACTUAL,"[{'name': 'Laminectomy and bone marrow stem cells transplantation', 'description': 'Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.\n\nT3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation'}, {'name': 'Intrathecal infusion of autologous bone marrow stem cells', 'description': 'Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.\n\nPatients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells.'}, {'name': 'Intrathecal infusion of placebo (saline solution).', 'description': 'Patients were infused 2 ml of saline solution'}]","['Amyotrophic Lateral Sclerosis', 'Bone marrow', 'Stem cells', 'Autologous', 'Safety']",
"Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency",2023-11,COMPLETED,2023-10-19,SPONSOR,,"Genzyme, a Sanofi Company",['Sphingomyelin Lipidosis'],INTERVENTIONAL,36.0,ACTUAL,"[{'name': 'placebo (saline)', 'description': 'Pharmaceutical form: solution administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to placebo.\n\nRoute of administration: intravenous infusion'}, {'name': 'GZ402665', 'description': 'Pharmaceutical form: Powder for concentrate for solution for infusion administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to olipudase alfa, and during the extension treatment period for all participants.\n\nRoute of administration: intravenous infusion'}]",,
Repeated Mesenchymal Stem Cell Injections in ALS,2020-05,COMPLETED,2020-12-31,SPONSOR,,Hadassah Medical Organization,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,20.0,ACTUAL,"[{'name': 'Mesenchymal stem cells (MSC)', 'description': 'Intrathecal injections of autologous bone marrow derived mesenchymal stem cells'}]","['ALS', 'Mesenchymal stem cells', 'ALSFRSr']",
Neurogenic Dysphonia/Dysphagia Registry,2016-09,TERMINATED,2016-09,SPONSOR,,"Merz North America, Inc.","['Neurogenic Dysphonia', 'Neurogenic Dysphagia']",OBSERVATIONAL,146.0,ACTUAL,,"['dysphonia', 'dysphagia', 'neurogenic', 'vocal fold augmentation', 'VFA', 'vocal fold insufficiency', 'Prolaryn', 'Radiesse', 'Coaptite', 'voice', ""Parkinson's Disease"", 'Multiple Sclerosis', 'Amyotrophic Lateral Sclerosis', 'ALS', 'MS', 'calcium hydroxylapatite', 'hyaluronic acid']",Adults with neurogenic dysphonia/dysphagia treated with vocal fold augmentation
Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis: Pilot Study,2018-04,COMPLETED,2015-03-17,SPONSOR,,Institut Pasteur,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,19.0,ACTUAL,"[{'name': 'skin biopsy', 'description': 'biopsy 5mm maximum on healthy skin under local anaesthesia.'}]",,
Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults,2023-07,NOT_YET_RECRUITING,2024-07,SPONSOR,,Neurodegenerative Disease Research Inc,"['Safety Issues', 'Tolerance']",INTERVENTIONAL,24.0,ESTIMATED,"[{'name': 'FC-12738', 'description': 'Retro enversio pentapeptide of thymopentin'}, {'name': 'Saline', 'description': 'placebo'}]",,
New Therapeutic Strategy in ALS Based on Metabolic Status and Associated Metabolic Pathways.,2023-11,ACTIVE_NOT_RECRUITING,2024-01,SPONSOR,,"University Hospital, Tours",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,9.0,ESTIMATED,"[{'name': 'Samples', 'description': 'Blood sample, skin biopsy'}, {'name': 'Indirect calorimetry', 'description': 'Measurement of energy expenditure by indirect calorimetry'}, {'name': 'Electrical bioimpedance', 'description': 'Measurement of electrical bioimpedance'}]","['Amyotrophic Lateral Sclerosis', 'Metabolomics', 'Transcriptomics', 'Biomarkers', 'Fibroblast']",
A Longitudinal Analysis of Biomarkers in Patients With ALS,2023-09,RECRUITING,2024-09,SPONSOR,,"Holy Cross Hospital, Florida",['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,90.0,ESTIMATED,"[{'name': 'Venipuncture', 'description': 'Venipuncture'}, {'name': 'Lumbar Puncture', 'description': 'Lumbar Puncture'}]",,60 ALS subjects and 30 control subjects will be enrolled in the study
A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS),2017-10,COMPLETED,2016-03,PRINCIPAL_INVESTIGATOR,"Sabrina Paganoni, M.D.",Massachusetts General Hospital,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,32.0,ACTUAL,"[{'name': 'Inosine', 'description': 'Twenty-five eligible subjects will receive inosine for 12 weeks (administered in the form of 500 mg capsules, 1 to 6 capsules a day for a total daily dose of up to 3 gm). The dose of inosine will be titrated to target urate levels of 7-8 mg/dL based on urate level measurement that will occur at Week 2, Week 4, Week 6, and Week 9 after Baseline.'}]","['ALS', 'Inosine', 'Uric acid', 'Urate', 'Glutathione', 'Biomarker', 'Oxidative stress', 'Oxidative damage', 'proof-of-concept']",
From Movement Preparation to Gait Execution in ALS,2021-08,COMPLETED,2015-12-21,SPONSOR,,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,59.0,ACTUAL,,"['movement preparation', 'gait', 'gait initiation', 'postural control', 'neuroimaging']",ALS patients with motor deficit with or without postural instability
Test of A Model of Representational Knowledge Stored in the Human Prefrontal Cortex,2010-04-07,COMPLETED,2010-04-07,,,National Institute of Neurological Disorders and Stroke (NINDS),"['Intracranial Central Nervous System Disorder', 'Mental Disorder', 'Healthy']",OBSERVATIONAL,949.0,ACTUAL,,"['Cognition', 'Frontal Lobes', 'Frontotemporal Dementia', 'Focal Lesions', 'Executive Functions', 'Frontotemporal Lobe Dementia', 'Frontal Lobe', 'Frontal Lobe Dementia', 'Healthy Volunteer', 'HV', 'Normal Control']",
A Complex Intervention Study on a Palliative Rehabilitation Blended Learning Program to Support Relatives and Health Care Providers of People With ALS and Cognitive Impairments in Coping With Challenges,2023-02,COMPLETED,2022-10-31,PRINCIPAL_INVESTIGATOR,Lene Klem Olesen,Danish Rehabilitation Centre for Neuromuscular Diseases,"['Relatives', 'Health Care Providers', 'Cognitive Impairment', 'Rehabilitation']",INTERVENTIONAL,28.0,ACTUAL,"[{'name': 'EMBRACE (relatives)', 'description': 'Online support program for both relatives'}, {'name': 'EMBRACE (Health care providers)', 'description': 'Online support program for health care providers'}]","['Relatives, informal carer, family carer', 'ALS/MND', 'Cognitive impairment', 'Palliative rehabilitation', 'Blended learning', 'Online support, telehealth, e-learning', 'Peer-support', 'Health care providers']",
Respiratory Care in Intensive Care Unit for Neuromuscular Patients,2017-08,UNKNOWN,2017-10,SPONSOR,,Hospices Civils de Lyon,['Respiratory Failure'],OBSERVATIONAL,300.0,ESTIMATED,"[{'name': 'Ventilatory support', 'description': 'Initiation of mechanical ventilatory support, invasive or non-invasive, Or modification of mechanical ventilatory support (modification of the parameters of the device, change of material, switch from non-invasive to invasive)'}]","['Neuromuscular Diseases', 'Muscular dystrophy', 'Amyotrophic Lateral Sclerosis', 'Acute respiratory failure', 'respiratory care', 'mechanical ventilation', 'weaning', 'Intensive Care Unit', 'Critical Care', 'Survival']","Adult patients presenting a neuromuscular disease, with involvement of respiratory or bulbar muscles.

Neuromuscular diseases concerned :

Central or Peripheral metabolic, toxic, or inflammatory neuropathies, Central or peripheral neurodegenerative or hereditary disorders Myopathies, amongst them dystrophinopathies, myotonic dystrophies Myasthenia gravis Tetraplegy, consequence of cervical spinal cord injury"
Palmitoylethanolamide Combined With Luteoline in Frontotemporal Dementia Patients. A Randomized Controlled Trial,2022-06,COMPLETED,2023-06-30,SPONSOR,,I.R.C.C.S. Fondazione Santa Lucia,['Frontotemporal Dementia'],INTERVENTIONAL,50.0,ACTUAL,"[{'name': 'PEA-LUT', 'description': 'PEA-LUT administration at the oral dosage of 700 mg x 2/day'}, {'name': 'PLACEBO', 'description': 'PLACEBO administration at the oral dosage of 700 mg x 2/day'}]","['dopamine', 'frontal cortex', 'GABA']",
"Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS",2022-02,COMPLETED,2018-10-08,SPONSOR,,"Biohaven Pharmaceuticals, Inc.","['Amyotrophic Lateral Sclerosis', 'ALS', 'Lou Gehrig Disease', ""Lou Gehrig's Disease"", 'Lou-Gehrigs Disease', 'Motor Neuron Disease, Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,22.0,ACTUAL,"[{'name': 'BHV-0223', 'description': 'BHV-0223, 40 mg BID'}]","['Amyotrophic Lateral Sclerosis', 'ALS', 'Biohaven', 'Motor Neuron Disease, Amyotrophic Lateral Sclerosis', ""Lou Gehrig's Disease"", 'Lou-Gehrigs Disease', 'Lou Gehrig Disease', 'Riluzole', 'RilutekÂ®', 'Neuroprotective Agents', 'Administration, Sublingual', 'Administration, Oral', 'Biological Availability']",
Xavier Electromyographic Wheelchair Control for Limited Mobility Patients,2021-03,COMPLETED,2019-10-30,PRINCIPAL_INVESTIGATOR,Bjorn E. Oskarsson,Mayo Clinic,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,4.0,ACTUAL,"[{'name': 'Xavier wheelchair controller', 'description': 'Controlling a wheelchair using the Xavier surface EMG system'}]",,
Cluster Randomized Trial of Stepped Care Intervention vs. Treatment as Usual for Patients With Depression,2015-07,COMPLETED,2015-05,PRINCIPAL_INVESTIGATOR,PD Dr. phil. Birgit Watzke,UniversitÃ¤tsklinikum Hamburg-Eppendorf,['Depression'],INTERVENTIONAL,737.0,ACTUAL,"[{'name': 'Active monitoring', 'description': 'General physician performs monitoring every 2 weeks using the PHQ-9 depression scale.'}, {'name': 'Bibliotherapy', 'description': 'Patient works with self-help book ""Selbsthilfe bei Depressionen"" (GÃ¶rlitz, 2010) under general physician\'s supervision.'}, {'name': 'Online self-help', 'description': 'Patient works with online self-help program ""Deprexis"" under general physician\'s supervision.'}, {'name': 'Outpatient psychotherapy', 'description': 'Patient receives outpatient psychodynamic or cognitive-behavioural psychotherapy from a psychotherapist participating in the network.'}, {'name': 'Psychiatric treatment', 'description': 'Patient receives treatment from psychiatrist or general physician participating in the network, this includes psychopharmacotherapy. Treatment takes place within routine care, thus psychiatrists or general physicians individually determine the type of medication and are committed to follow the recommendations of the German S3-Guideline/National Disease Management Guideline for Unipolar Depression.'}, {'name': 'Combined psychotherapy and psychopharmacological treatment', 'description': 'Patient receives psychotherapy combined with psychopharmacological treatment, if necessary in inpatient setting.'}, {'name': 'Control group: treatment as usual', 'description': 'treatment as usual'}]","['depression', 'stepped care', 'evidence-based medicine', 'health services research', 'psychotherapy', 'complex intervention', 'guideline']",
"Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS",2023-05,RECRUITING,2025-07,SPONSOR,,University of Alberta,"['Amyotrophic Lateral Sclerosis', 'Primary Lateral Sclerosis', 'Progressive Muscular Atrophy', 'Frontotemporal Degeneration']",OBSERVATIONAL,150.0,ESTIMATED,,"['Biomarker', 'Biorepository', 'ALS', 'Disease Progression', 'MRI', 'Biofluids']","People living with ALS and related motor neuron diseases including ALS-Frontotemporal Dementia (ALS-FTD), Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA) and asymptomatic individuals with a known ALS mutation

AND

Healthy controls that are age and sex matched to patients"
Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen in Norway: A Validation Study,2022-03,RECRUITING,2022-12-31,SPONSOR,,Haukeland University Hospital,"['Amyotrophic Lateral Sclerosis', 'Cognitive Impairment']",OBSERVATIONAL,50.0,ESTIMATED,"[{'name': 'ECAS-N', 'description': 'All participants included will be tested with the ECAS-N'}, {'name': 'MoCA', 'description': 'All included patients With ALS will be tested With the MoCA'}]","['Amyotrophic lateral sclerosis', 'Cognitive', 'Screening', 'Validation']","Patients who fulfill the inclution criteria and attending to the ALS-unit at HUH, St.Olavs Hospital, Hospital of Southern Norway or Namsos Hospital, within 4 months after being diagnosed With ALS.

Healthy People and patients with dementia will constitute Control groups"
A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation,2020-07,COMPLETED,2019-12-31,SPONSOR,,Alector Inc.,"['Healthy', 'Frontotemporal Dementia']",INTERVENTIONAL,64.0,ACTUAL,"[{'name': 'AL001', 'description': 'Active dose of AL001'}, {'name': 'Placebo', 'description': 'Saline solution administered as a single infusion as palcebo.'}]",,
A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia,2022-11,WITHDRAWN,2024-12,PRINCIPAL_INVESTIGATOR,"Julie A. Fields, Ph.D., L.P.",Mayo Clinic,"['Caregiver Stress', 'Dementia', 'Alzheimer Dementia', 'Lewy Body Dementia', 'Parkinson Disease Dementia', 'Frontotemporal Dementia']",INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Algorithm', 'description': 'Current and/or former Care Partners of persons with dementia will be matched using an algorithm to other Care Partners who might provide emotional support.'}, {'name': 'Random Match', 'description': 'Current and/or former Care Partners of persons with dementia will be randomly matched to other Care Partners who might provide emotional support.'}]",,
Relationship Between Neurological Disability and Visual Impairment in Patients With ALS or Friedreich's Ataxia,2018-04,UNKNOWN,2020-02,SPONSOR_INVESTIGATOR,Jose Luis Urcelay Segura,Jose Luis Urcelay Segura,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,90.0,ESTIMATED,,"['optical coherence tomography', 'amyotrophic lateral sclerosis']",Amyotrophic lateral sclerosis patients Friedreich's ataxia patients Healthy volunteers
Language in Primary Progressive Aphasia,2023-01,RECRUITING,2027-04,PRINCIPAL_INVESTIGATOR,Marsel Mesulam,Northwestern University,['Primary Progressive Aphasia'],OBSERVATIONAL,500.0,ESTIMATED,,"['primary progressive aphasia', 'frontotemporal dementia', 'semantic dementia', 'progressive nonfluent aphasia', 'progressive aphasia', 'frontotemporal lobar degeneration']","Participants with PPA will be recruited from the Northwestern University Alzheimer's Disease Center Core registry, the Northwestern University Neurobehavior and Memory Clinic, and from those who contact the center that are interested in PPA research."
Muscular Biomarkers in Amyotrophic Lateral Sclerosis,2021-04,COMPLETED,2019-12-09,SPONSOR,,"University Hospital, Tours",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,37.0,ACTUAL,"[{'name': 'Samples', 'description': 'Blood samples, muscle biopsy'}]","['Amyotrophic Lateral Sclerosis', 'Muscle metabolism', 'Metabolomics', 'Transcriptomics']",
Allogeneic Hematopoietic Stem Cell Transplantation,2011-01,UNKNOWN,2009-04,,,"University Hospital, Clermont-Ferrand","['Solid Tumors', 'Hematologic Neoplasms']",INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'Fludarabine, Busulfan, Thymoglobulin', 'description': 'study :\n\n* acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post transplantation\n* the effectiveness of the protocol on tumor response\n* overall survival'}]","['Allograft', 'Children', 'malignancy', 'Reduced Intensity Conditioning', 'Fludarabin', 'Busulfex', 'Thymoglobulin']",
Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients,2015-07,COMPLETED,2014-01,SPONSOR,,"Genzyme, a Sanofi Company",['Human Acid Sphingomyelinase Deficiency'],INTERVENTIONAL,5.0,ACTUAL,"[{'name': 'Recombinant human acid sphingomyelinase', 'description': 'Administered intravenously every 2 weeks for 26 weeks'}]",['Human acid sphingomyelinase deficiency'],
AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis,2023-08,RECRUITING,2025-03-28,PRINCIPAL_INVESTIGATOR,"Hon K. Yuen, PhD",University of Alabama at Birmingham,"['Spinal Cord Injuries', 'Multiple Sclerosis', 'Transverse Myelitis', 'Amyotrophic Lateral Sclerosis']",OBSERVATIONAL,160.0,ESTIMATED,,,Sex: both Race/Ethnicity: all Age: aged 18 years or above Health status: Healthy
Treatment for Speech and Language in Primary Progressive Aphasia,2023-12,ACTIVE_NOT_RECRUITING,2024-06-30,SPONSOR,,University of Texas at Austin,"['Primary Progressive Aphasia', 'Semantic Dementia', 'Semantic Memory Disorder', 'Logopenic Progressive Aphasia', 'Nonfluent Aphasia, Progressive', 'Aphasia', 'Aphasia, Progressive']",INTERVENTIONAL,60.0,ACTUAL,"[{'name': 'Lexical Retrieval Training (LRT)', 'description': 'In person or via teletherapy: Participants work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) sessions per week with a clinician plus daily home practice exercises.'}, {'name': 'Video-Implemented Script Training for Aphasia (VISTA)', 'description': 'In person or via teletherapy: Participants work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes 30 minutes per day of home practice, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts. Biweekly (one hour each) sessions with a clinician target clear and accurate script production, script memorization, and conversational usage of scripts.'}]",,
A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency,2023-09,COMPLETED,2023-09-06,SPONSOR,,"Genzyme, a Sanofi Company",['Sphingomyelin Lipidosis'],INTERVENTIONAL,25.0,ACTUAL,"[{'name': 'GZ402665', 'description': 'Pharmaceutical form: Powder for concentrate for solution for infusion\n\nRoute of administration: intravenous infusion'}]",,
RHAPSODY-plus: Online Counseling for Family Caregivers of Patients With Young Onset Dementia,2019-09,COMPLETED,2019-05-30,PRINCIPAL_INVESTIGATOR,Janine Diehl-Schmid,Technical University of Munich,"['Early Onset Alzheimer Disease', 'Frontotemporal Dementia']",INTERVENTIONAL,20.0,ACTUAL,"[{'name': 'RHAPSODY online program and MEET online sessions', 'description': 'internet-based information and skill-building program (RHAPSODY) specifically developed for family carers of care recipients with young onset dementia (Kurz, et al., 2016).\n\nMEET is a software for online meetings.'}]","['Young onset dementia', 'caregiver', 'online intervention', 'online communication technology']",
Modafinil for Treatment of Fatigue in ALS Patients,2012-02,COMPLETED,2008-07,SPONSOR,,New York State Psychiatric Institute,['Fatigue'],INTERVENTIONAL,32.0,ACTUAL,"[{'name': 'Modafinil', 'description': 'Dose schedule: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day as clinically indicated, in the absence of dose-limiting side effects. Dose is daily, in A.M., for 4 weeks.'}, {'name': 'Placebo', 'description': 'Placebo capsules are administered on the same schedule as active drug: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day in the absence of clinical improvement and dose limiting side effects. Dose is daily, in A.M.'}]","['Fatigue', 'low energy', 'ALS', 'treatment']",
Exploratory Evaluation of [11C]MPC6827,2023-10,RECRUITING,2025-09,PRINCIPAL_INVESTIGATOR,Akiva Mintz,Columbia University,"['Neurodegenerative Diseases', 'Alzheimer Disease', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,40.0,ESTIMATED,"[{'name': '[11C]MPC6827', 'description': 'Subjects will receive a microdose ( 10 Âµg) of \\[11C\\]MPC6827 (dose of 20 mCi)'}]",['[11C]MPC6827'],
Stem Cell Transplant for Inborn Errors of Metabolism,2017-12,COMPLETED,2010-06,SPONSOR,,"Masonic Cancer Center, University of Minnesota","['Adrenoleukodystrophy', 'Metachromatic Leukodystrophy', 'Globoid Cell Leukodystrophy', ""Gaucher's Disease"", 'Fucosidosis', 'Wolman Disease', 'Niemann-Pick Disease', 'Batten Disease', 'GM1 Gangliosidosis', 'Tay Sachs Disease', 'Sandhoff Disease']",INTERVENTIONAL,135.0,ACTUAL,"[{'name': 'Stem Cell Transplant', 'description': ""The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains an enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut).""}, {'name': 'Busulfan, Cyclophosphamide, Antithymocyte Globulin', 'description': 'Subjects will receive BUSULFAN intravenously (IV)- patients \\< or= 12 kg 1.1 mg/kd/dose IV every 6 hours for 16 doses; patients \\> 12kg 0.8 mg/kg/dose IV every 6 hours for 16 doses - via the Hickman line four times daily for 4 days, CYCLOPHOSPHAMIDE intravenously (50 mg/kg/day IV over 2 hours) via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV (15 mg/kg/day over 2 hours) via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow ""take"" and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG.'}]","['Inborn errors', 'Storage disease', 'errors of metabolism', 'stem cell transplant']",
Muscle Ultrasound: A New Tool for Measuring Progression in Amyotrophic Lateral Sclerosis (ALS),2009-12,COMPLETED,2009-08,,,Vanderbilt University,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,10.0,ACTUAL,,"['Amyotrophic Lateral Sclerosis', 'Ultrasonography', 'Atrophy']",Patients diagnosed with ALS (Amyotrophic Lateral Sclerosis)
"A Multicenter, Open-label Extension Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis",2023-05,RECRUITING,2026-06-30,SPONSOR,,Ferrer Internacional S.A.,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,225.0,ESTIMATED,"[{'name': 'FAB122', 'description': 'FAB122 Daily dose 100 mg'}]",,
Lung Volume Recruitment Combined With Expiratory Muscle Strength Training in ALS,2023-02,COMPLETED,2022-12-30,SPONSOR,,University of Minnesota,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,23.0,ACTUAL,"[{'name': 'Expiratory Muscle Strength Training (EMST)', 'description': ""EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.""}, {'name': 'EMST + Lung Volume Recruitment (LVR)', 'description': ""EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.\n\nLVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough. Half of the participants will perform the LVR technique in addition to the ESMT technique.""}]",,
Human CNS Tau Kinetics in Tauopathies,2022-04,COMPLETED,2022-03-04,SPONSOR,,Washington University School of Medicine,"['Progressive Supranuclear Palsy (PSP)', 'Corticobasal Degeneration (CBD)', 'Frontotemporal Dementia (FTD MAPT Mutation)']",OBSERVATIONAL,27.0,ACTUAL,"[{'name': '13C6 Leucine', 'description': 'Recruited participants will be given 13C6-labeled leucine through intravenous infusion (4mg/kg/hr for 16hrs)'}]",['Tauopathies'],"Progressive Supranuclear Palsy (PSP): N=12

Corticobasal Degeneration (CBD): N=8

Frontotemporal Dementia (FTD): MAPT: Family members with or at-risk of tau mutations (e.g. P301L) N=12"
Biomarker for Niemann Pick Type C Disease (BioNPC),2023-02,WITHDRAWN,2021-02-28,SPONSOR,,CENTOGENE GmbH Rostock,"['Niemann-Pick Disease', 'Niemann-Pick Disease, Type C']",OBSERVATIONAL,0.0,ACTUAL,,"['Genetic Diseases', 'Lipidoses', 'Lipid Metabolism', 'Lysosomal Storage Diseases', 'Metabolic Diseases', 'Lipid Metabolism Disorders']",Patients with Niemann Pick Disease Type C (NPC1/NPC2) or profound suspicion for Niemann Pick Disease Type C disease (NPC1/NPC2)
NeuRx Diaphram Pacing System (DPS) Use in Amyotrophic Lateral Sclerosis (ALS),2020-03,WITHDRAWN,2018-02-12,SPONSOR,,Synapse Biomedical,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'NeuRx DPS', 'description': 'Patients who are diagnosed with ALS, have initiated NIV and choose to have the NeuRx DPS implanted.'}]",['Diaphragm Pacing'],
Safety and Preliminary Efficacy of Aleeto in Amyotrophic Lateral Sclerosis,2023-12,NOT_YET_RECRUITING,2024-10-30,PRINCIPAL_INVESTIGATOR,yilong Wang,Beijing Tiantan Hospital,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,24.0,ESTIMATED,"[{'name': 'Aleeto', 'description': 'According to the groups, patients would be treated with Aleeto via intrathecal injection or intravenous injection, and the specific dosage and administration method of Aleeto will depend on the grouping.'}, {'name': 'intravenous injection', 'description': 'According to the groups, patients would be treated with Aleeto or placebo +100ml sodium chloride injection via intravenous injection, depend on the grouping'}, {'name': 'intrathecal injection', 'description': 'According to the groups, patients would be treated with Aleeto or placebo + 8ml sodium chloride injection via intrathecal injection, depend on the grouping.'}]","['Placebo parallel-controlled', 'Single-center Study', 'Double Blind Study', 'Randomized Controlled Trial', 'Dose escalation clinical study', 'Aleeto']",
An Evaluation of Low Level Laser Light Therapy on Improving the Symptoms of Alzheimer's Disease,2021-05,COMPLETED,2020-10-15,SPONSOR,,Erchonia Corporation,"[""Alzheimer's Disease""]",INTERVENTIONAL,43.0,ACTUAL,"[{'name': 'Erchonia ALS Laser', 'description': ""The Erchonia ALS Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. The total energy delivered to the subject per procedure administration is 22.5 joules.""}, {'name': 'Placebo Laser', 'description': ""The Placebo Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. There is no energy delivered to the subject.""}]",,
Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients,2021-03,COMPLETED,2020-09-03,SPONSOR,,Leti Pharma GmbH,"['Allergic Rhinoconjunctivitis', 'Allergic Asthma']",OBSERVATIONAL,168.0,ACTUAL,"[{'name': 'Immunotherapy', 'description': 'subcutaneous injection'}]","['Allergy', 'Rhinoconjuctivitis', 'Combined Symptom and Medication Score', 'Allergic Asthma', 'Pollen', 'Mites']","adults and adolescents suffering from allergic diseases (rhinitis, rhinoconjunctivitis, with or without concomitant asthma)"
IC14 for ALS Patients Expanded Access,2020-06,NO_LONGER_AVAILABLE,,SPONSOR,,Implicit Bioscience,['Amyotrophic Lateral Sclerosis'],EXPANDED_ACCESS,,,"[{'name': 'IC14', 'description': 'monoclonal antibody directed against CD14'}]","['Motor Neurone Disease', 'Compassionate use']",
Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS),2021-10,COMPLETED,2017-12,SPONSOR,,MediciNova,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,70.0,ACTUAL,"[{'name': 'Placebo (for MN-166)'}, {'name': 'MN-166'}, {'name': 'riluzole', 'description': 'Patient is given 50 mg riluzole twice daily.'}]","['amyotrophic lateral sclerosis', 'pharmacotherapy', 'intervention', 'prospective', 'safety endpoint', 'preliminary efficacy', 'ibudilast']",
Study of the Role of G72 in Amyotrophic Lateral Sclerosis: Biomarker Discovery and Mechanism Investigation,2011-06,UNKNOWN,,,,China Medical University Hospital,"['Amyotrophic Lateral Sclerosis', 'Alzheimer Disease', ""Parkinson's Disease""]",OBSERVATIONAL,120.0,ESTIMATED,,"['Amyotrophic Lateral Sclerosis', 'G72', 'SNP']",patients were from Taipei city hospital-ZhongXiao branch.
A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS),2021-05,COMPLETED,2017-10-18,SPONSOR_INVESTIGATOR,"Sabrina Paganoni, M.D.","Sabrina Paganoni, M.D.",['ALS'],INTERVENTIONAL,24.0,ACTUAL,"[{'name': 'RNS60', 'description': 'RNS60 will be administered in two ways: by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) for 23 weeks.\n\nIn addition, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug. Study drug will be given by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) during the extension phase.'}]",,
Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS,2023-10,TERMINATED,2023-09-29,SPONSOR,,Mitsubishi Tanabe Pharma America Inc.,['ALS'],INTERVENTIONAL,202.0,ACTUAL,"[{'name': 'MT-1186', 'description': 'Oral edaravone'}, {'name': 'Placebo', 'description': 'Oral'}]",,
Factors Associated With Success of NIPPV in ALS Patients,2022-10,ACTIVE_NOT_RECRUITING,2023-09-22,PRINCIPAL_INVESTIGATOR,Jaewon Beom,Seoul National University Bundang Hospital,['ALS'],OBSERVATIONAL,51.0,ACTUAL,,"['Noninvasive positive pressure ventilation', 'Amyotrophic lateral sclerosis', 'Adherence']",ALS patients who were admitted for applying non-invasive positive pressure ventilation initially.
The Effects of a Multimodal Approach for the Treatment of Primary Progressive Aphasia,2023-02,RECRUITING,2024-04-04,SPONSOR,,IRCCS Centro San Giovanni di Dio Fatebenefratelli,['Primary Progressive Aphasia'],INTERVENTIONAL,45.0,ESTIMATED,"[{'name': 'Active tDCS', 'description': 'Active tDCS anode is applied over the left DLPFC with the cathode over the right supraorbital region.'}, {'name': 'Placebo tDCS', 'description': 'Placebo tDCS is applied but the current is turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period.'}, {'name': 'Language training', 'description': 'patients receive language training'}, {'name': 'Unstructured cognitive training', 'description': 'patients receive unstructured cognitive training.'}]",,
"Psychological Management by Meditation of Full COnscience in Virtual REality of People With Amyotrophic Lateral Sclerosis: Effects on Cognition, Behavior, Quality of Life and Psychological Well-being",2022-05,NOT_YET_RECRUITING,2023-06,SPONSOR,,"University Hospital, Angers","['Lateral Sclerosis Amyotrophy', 'Mindfulness Meditation']",INTERVENTIONAL,46.0,ESTIMATED,"[{'name': 'mindfulness meditation care', 'description': 'mindfulness meditation care'}, {'name': 'no mindfulness meditation care', 'description': 'no mindfulness meditation care'}]",,
Assessment of Voluntary and Reflex Cough in Patients With ALS,2015-10,UNKNOWN,2016-06,PRINCIPAL_INVESTIGATOR,Irene Battel,"IRCCS San Camillo, Venezia, Italy","['ALS', 'Cough']",INTERVENTIONAL,60.0,ESTIMATED,"[{'name': 'Cough Assessment in ALS Patients', 'description': '1. Volitional Cough assessment by spirometer:\n\n   a) Peak Cough Espiratory Flow (PCEF)\n2. Cough Reflex Test a) Peak Cough Espiratory Flow (PCEF)'}]","['ALS and Dysphagia', 'ALS and cough', 'cough reflex test']",
Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks,2020-04,UNKNOWN,2022-03-31,PRINCIPAL_INVESTIGATOR,Mario F. Mendez,"University of California, Los Angeles","['Alzheimer Disease, Early Onset', 'Alzheimer Disease', 'Alzheimer Disease, Late Onset', 'Dementia, Alzheimer Type', 'Logopenic Progressive Aphasia', 'Primary Progressive Aphasia', 'Visuospatial/Perceptual Abilities', 'Posterior Cortical Atrophy', 'Executive Dysfunction', 'Corticobasal Degeneration', 'Ideomotor Apraxia']",OBSERVATIONAL,180.0,ESTIMATED,,"[""Alzheimer's disease"", 'Young-onset', 'variant', 'visuospatial', 'language', 'apraxia', 'control', 'dementia', 'memory', 'MRI', 'neurology', 'neuropsychology', 'brain']","Patients with a diagnosis of early-onset Alzheimer's disease (EOAD; with a diagnosis before age 65), including early-onset neurodegenerative conditions such as primary progressive aphasia (PPA), other aphasias (logopenic, semantic, and non-fluent), posterior cortical atrophy (PCA), ideomotor limb apraxias, and executive dysfunction."
ALS Study Determining Various Biomarkers and Strength Comparison After Exercise,2019-12,COMPLETED,2018-04-18,SPONSOR,,University of Kansas Medical Center,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,9.0,ACTUAL,"[{'name': 'Resistance Exercise Program', 'description': 'The resistance exercise program will involve three sets of 10 repetitions of each exercise in levels 1 and 2 every day. Participants will be given instructions to follow.'}]",['ALS'],
Fatigue in Patients With Amyotrophic Lateral Sclerosis,2021-02,WITHDRAWN,2021-02-10,SPONSOR_INVESTIGATOR,Cara Donohue,Cara Donohue,"['Amyotrophic Lateral Sclerosis', 'Dysphagia', 'Dyspnea', 'Respiration Disorders']",INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Experimental expiratory muscle strength training (EMST)', 'description': ""The experimental EMST will involve blowing into a device with a spring-loaded valve set to 50% of the patient with ALS' maximum expiratory pressure.""}, {'name': 'Sham expiratory muscle strength training (EMST)', 'description': 'The sham EMST will involve blowing into a device without a spring-loaded valve (0% resistance).'}]",,
Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis,2022-12,RECRUITING,2027-09-30,PRINCIPAL_INVESTIGATOR,Orla Hardiman,"University of Dublin, Trinity College","['ALS (Amyotrophic Lateral Sclerosis)', 'Postpoliomyelitis Syndrome', 'Spinal Muscular Atrophy']",OBSERVATIONAL,400.0,ESTIMATED,"[{'name': '128 electrode electroencephalography (EEG), Bipolar surface electromyography (sEMG), High-density electromyography (HD-EMG)', 'description': '128 electrode EEG and 8 bipolar EMG or HD-EMG will be noninvasively recorded from electrodes placed in a montage over the scalp and arm muscles while the participant is resting or performing tasks designed to engage specific cortical networks of interest (cognitive, behavioural, motor and sensory)'}]","['EEG', 'Corticomuscular coherence', 'Biomarkers', 'Electrophysiology', 'Neuromuscular disease', 'EMG']","MND (ALS, PLS, PMA, SMA, Polio or MS) patients will be recruited from the national MND/ALS register, an ongoing registry run in conjunction with Beaumont Hospital ALS clinic, run by Professor Orla Hardiman. Healthy controls will be recruited from the student population and age-matched controls from the general public, as well as a dataset of pre-consented healthy volunteers which is maintained at the Academic Unit of Neurology, Trinity College Dublin."
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS),2023-10,COMPLETED,2023-08-08,SPONSOR,,Mitsubishi Tanabe Pharma America Inc.,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,124.0,ACTUAL,"[{'name': 'MT-1186', 'description': 'Treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period up to 96 weeks of treatment or until the drug is commercially available in that country.'}]",,
Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),2012-06,COMPLETED,2008-12,SPONSOR,,Ono Pharmaceutical Co. Ltd,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,420.0,ACTUAL,"[{'name': 'ONO-2506PO', 'description': '1200 mg QD / 18 months'}, {'name': 'ONO-2506PO', 'description': '0 mg QD / 18 months'}]","['ONO-2506PO', 'Amyotrophic Lateral Sclerosis', 'ALS']",
Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis,2014-11,COMPLETED,2012-04,PRINCIPAL_INVESTIGATOR,Alberto Albanese,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,34.0,ACTUAL,"[{'name': 'tauroursodeoxycholic acid (TUDCA)', 'description': 'Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year'}, {'name': 'Placebo', 'description': 'identical placebo by oral route at the same dosing schedule'}]","['ALS', 'Therapy', 'Tauroursodeoxycholic acid', 'TUDCA', 'antioxidant', 'antiapoptotic drug', 'neuroprotective drug']",
Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial,2023-10,NOT_YET_RECRUITING,2025-01-01,PRINCIPAL_INVESTIGATOR,Shanna Trenaman,Nova Scotia Health Authority,"['Insomnia', 'Dementia', 'Frontotemporal Dementia']",INTERVENTIONAL,1.0,ESTIMATED,"[{'name': 'Lemborexant 5 MG', 'description': 'The participant will receive 8 weeks of treatment Week 1 = placebo Week 2 = lemborexant 5mg Week 3 = lemborexant 10 mg Week 4 = placebo Week 5 = lemborexant 10 mg Week 6 = placebo Week 7 = placebo Week 8 = lemborexant 10 mg'}]",,
Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis,2020-09,COMPLETED,2020-09-01,PRINCIPAL_INVESTIGATOR,Bjorn E. Oskarsson,Mayo Clinic,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,22.0,ACTUAL,"[{'name': 'Perampanel', 'description': 'Oral tablet'}, {'name': 'Placebo', 'description': 'Placebo (not drug)'}]",,
Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS,2021-07,COMPLETED,2018-10-02,PRINCIPAL_INVESTIGATOR,"Timothy M. Miller, MD, PhD",Washington University School of Medicine,['C9ORF72 Amyotrophic Lateral Sclerosis (ALS)'],OBSERVATIONAL,128.0,ACTUAL,,"['Amyotrophic Lateral Sclerosis', 'ALS', 'C9ORF72 gene mutation', 'Chromosome 9 open reading frame 72 protein', 'Natural history', 'Biomarkers', 'Amyotrophic Lateral Sclerosis, Familial', 'Amyotrophic Lateral Sclerosis, Sporadic', 'Frontotemporal Dementia-Amyotrophic Lateral Sclerosis']",Known positive C9ORF72 ALS status upon enrollment
Speech Analysis in ALS Patients,2023-03,COMPLETED,2021-04-30,PRINCIPAL_INVESTIGATOR,Jeremy Shefner,Barrow Neurological Institute,"['ALS', 'Amyotrophic Lateral Sclerosis', 'Lou Gehrig Disease']",OBSERVATIONAL,26.0,ACTUAL,,"['ALS', 'Cognitive dysfunction', 'Speech']","Patients with ALS, diagnosed as definite, probable, or possible ALS according to the modified El Escorial Criteria."
Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS),2022-11,COMPLETED,2023-05-24,SPONSOR,,The University of Queensland,"['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease']",INTERVENTIONAL,21.0,ACTUAL,"[{'name': 'Trimetazidine Dihydrochloride', 'description': 'Oral tablet, twice-daily'}]",,
Open-Label and Single-Arm Study of MYOBLOCÂ® in the Treatment of Troublesome Sialorrhea in Adults,2019-11,COMPLETED,2017-06,SPONSOR,,"Supernus Pharmaceuticals, Inc.",['Sialorrhea'],INTERVENTIONAL,187.0,ACTUAL,"[{'name': 'MYOBLOC', 'description': 'After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections of 3,500 Units of MYOBLOC every 13 weeks (Â±2 weeks) for a total of 4 treatments via injections into the submandibular and parotid glands. Subjects will undergo safety and effectiveness assessments at Weeks 4, 8, 13, 17, 26, 30, 39, 43, and 52, and telephone follow up will occur at Weeks 21, 34, and 47'}]","['Cerebral Palsy', 'ALS', 'Stroke', 'Neuroleptics']",
4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2,2024-01,ACTIVE_NOT_RECRUITING,2024-12,SPONSOR,,"University of California, San Francisco","['Corticobasal Degeneration (CBD)', 'Corticobasal Syndrome (CBS)', 'Cortical-basal Ganglionic Degeneration (CBGD)', 'Progressive Supranuclear Palsy (PSP)', 'Nonfluent Variant Primary Progressive Aphasia (nfvPPA)', 'Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)']",OBSERVATIONAL,232.0,ESTIMATED,[{'name': 'Observational Study'}],"['CBD', 'CBS', 'CBGD', 'PSP', 'nfvPPA', 'oPSP', 'vPSP', 'o/vPSP', 'Corticobasal Degeneration', 'Corticobasal Syndrome', 'Cortocal-basal Ganglionic Degeneration', 'Progressive Supranuclear Palsy', 'Nonfluent Variant Primary Progressive Aphasia', 'Oligosymptomatic Progressive Supranuclear Palsy', 'Variant Progressive Supranuclear Palsy', 'Biomarker', 'Neuroimaging', 'MRI', 'PET', 'Tau', 'Oculomotor', 'Retinal Imaging']","Participants diagnosed with Corticobasal Syndrome (CBS), Corticobasal Degeneration (CBD), Progressive Supranuclear Palsy, or Oligo- or Variant- Progressive Supranuclear Palsy (o/vPSP); Healthy Volunteers."
Optic Coherence Tomography in Patients With Amyotrophic Lateral Sclerosis,2017-12,UNKNOWN,2018-09-28,PRINCIPAL_INVESTIGATOR,Achraf Makki,American University of Beirut Medical Center,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'Optic coherence tomography', 'description': 'Optic coherence tomography measures retinal layer thickness, macular volume , and cell inner plexiform layer.'}, {'name': 'Pulmonary function test', 'description': 'Pulmonary function test measures forced vital capacity and forced expiratory volume in one second.'}]",,
The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study,2023-03,RECRUITING,2027-12,PRINCIPAL_INVESTIGATOR,Michael Benatar,University of Miami,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,500.0,ESTIMATED,,"['FALS', 'SOD1', 'familial', 'genetic testing', 'genetic counseling', 'ALS', 'C9ORF72', 'TARDBP', 'VCP', 'FUS', 'PFN1']",Healthy individuals who harbor a mutation in a gene associated with ALS.
Patient's TeleMonitoring With Amyotrophic Lateral Sclerosis Treated by Non Invasive Ventilation at Home.,2023-08,RECRUITING,2024-02-29,SPONSOR,,"University Hospital, Toulouse","['Amyotrophic Lateral Sclerosis', 'Noninvasive Ventilation']",INTERVENTIONAL,33.0,ESTIMATED,"[{'name': 'teleconsultation', 'description': 'Patients will benefit from a quarterly teleconsultation to assess the study criteria through different questionnaires during 12 months.'}]","['Telemonitoring', 'amyotrophic lateral sclerosis', 'noninvasive ventilation', 'feasibility']",
"Phenotype, Genotype & Biomarkers in ALS and Related Disorders",2023-08,ENROLLING_BY_INVITATION,2025-07,PRINCIPAL_INVESTIGATOR,Michael Benatar,University of Miami,"['Amyotrophic Lateral Sclerosis', 'Frontotemporal Dementia', 'Primary Lateral Sclerosis', 'Hereditary Spastic Paraplegia', 'Progressive Muscular Atrophy', 'Multisystem Proteinopathy']",OBSERVATIONAL,700.0,ESTIMATED,,"['natural history, biomarkers, phenotype, genotype']","Patients with ALS or a related neurodegenerative disorder, including FTD, HSP, PLS, PMA and MSP. Select family members of affected participants."
HEALEY ALS Platform Trial - Regimen C CNM-Au8,2023-06,COMPLETED,2023-03-07,SPONSOR_INVESTIGATOR,"Merit E. Cudkowicz, MD","Merit E. Cudkowicz, MD",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,161.0,ACTUAL,"[{'name': 'CNM-Au8', 'description': 'Drug: CNM-Au8\n\nAdministration: Oral\n\nDosage: 30 mg or 60 mg daily'}, {'name': 'Matching Placebo', 'description': 'Drug: Matching Placebo\n\nAdministration: Oral\n\nDosage: 2 bottles daily'}]","['ALS', 'Placebo-Controlled', 'Double-Blind', 'Regimen-Specific Appendix', ""Lou Gehrig's Disease"", 'CNM-Au8', 'Clene Nanomedicine']",
Study of Inherited Neurological Disorders,2024-02-07,RECRUITING,,SPONSOR,,National Institute of Neurological Disorders and Stroke (NINDS),"['Motor Neuron Disease', 'Muscular Disease', 'Muscular Dystrophy', 'Peripheral Nervous System Disease']",OBSERVATIONAL,3500.0,ESTIMATED,,"['Myopathy', 'Muscular Dystrophy', 'Motor Neuron Disease']",general population
Serial Fasciculation Measurements in Motor Neurone Disease,2019-08,COMPLETED,2019-03-01,SPONSOR,,King's College Hospital NHS Trust,"['Motor Neuron Disease', 'Benign Fasciculation-Cramp Syndrome']",INTERVENTIONAL,25.0,ACTUAL,"[{'name': 'High-density surface electromyography', 'description': 'High-density surface electromyography'}]",,
Determining the Safety of L-serine in ALS,2015-07,UNKNOWN,,SPONSOR,,"Phoenix Neurological Associates, LTD",['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,20.0,ESTIMATED,[{'name': 'L-Serine'}],"['ALS', 'L-Serine', 'BMAA']",
Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome,2016-10,TERMINATED,2015-01,SPONSOR,,Hanmi Pharmaceutical Company Limited,['Abdominal Obesity Metabolic Syndrome'],INTERVENTIONAL,200.0,ACTUAL,"[{'name': 'ALS-L1023', 'description': 'daily twice for 12 weeks'}, {'name': 'placebo', 'description': 'daily twice for 12 weeks'}]",,
Intranasal Oxytocin for Frontotemporal Dementia,2023-11,ACTIVE_NOT_RECRUITING,2024-12-31,SPONSOR,,Lawson Health Research Institute,['Frontotemporal Dementia'],INTERVENTIONAL,112.0,ESTIMATED,"[{'name': 'Syntocinon', 'description': 'Intranasal Oxytocin'}]","['oxytocin', 'frontotemporal dementia', 'apathy', 'empathy']",
Quantitative Measurement of Nutritional Substrate Utilization in Patients With Amyotrophic Lateral Sclerosis (ALS),2015-10,TERMINATED,2014-09,SPONSOR,,Drexel University College of Medicine,"['Amyotrophic Lateral Sclerosis', 'Neurodegenerative Diseases']",OBSERVATIONAL,107.0,ACTUAL,,"['Amyotrophic Lateral Sclerosis', 'Gastric Motility', 'Autonomic Nervous System', 'Neurodegenerative Diseases', 'Movement Disorders', 'Substrate Utilization']",ALS clinic patients at MDA/ALS Center of Hope.
Ultrasound and Videofluoroscopy for Diagnosing Swallowing Disorders,2005-11,COMPLETED,2005-11,,,National Institutes of Health Clinical Center (CC),"['Deglutition Disorder', 'Motor Neuron Disease']",OBSERVATIONAL,750.0,,,"['Swallowing Disorders', 'Neuromotor Dysfunction', 'Aspiration', 'Imaging']",
Compassionate Use of Ceftriaxone in Patients With Amyotrophic Lateral Sclerosis (ALS),2017-03,COMPLETED,2015-10,SPONSOR,,Drexel University College of Medicine,"['Amyotrophic Lateral Sclerosis', 'Cerebrospinal Fluid', 'Neurodegenerative Disease', 'Motor Neuron Disease']",OBSERVATIONAL,1.0,ACTUAL,,"['Amyotrophic Lateral Sclerosis', 'Cerebrospinal Fluid', 'Neurodegenerative Disease', 'Motor Neuron Disease', 'Autonomic Nervous System', 'Neurodegenerative Diseases', 'Movement Disorders']",ALS clinic patients at MDA/ALS Center of Hope.
Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease,2022-09,RECRUITING,2025-05-31,SPONSOR_INVESTIGATOR,"James M Noble, MD, MS, CPH, FAAN","James M Noble, MD, MS, CPH, FAAN",['Alzheimer Disease'],INTERVENTIONAL,100.0,ESTIMATED,"[{'name': '11C-ER176', 'description': ""11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. 11C-ER176 will be administered at activity up to 20 millicurie (mCi) per injection.""}, {'name': '18F-MK6240', 'description': 'MK-6240 measures a protein called in the brain. MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.'}, {'name': '18F-Florbetaben', 'description': ""Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. florbetaben measures amyloid in the brain.""}, {'name': 'Lumbar Puncture', 'description': 'Inflammation can also be measured by looking at certain proteins in the spinal fluid. In order to measure these proteins in the spinal fluid, the investigators will perform a lumbar puncture (spinal tap).'}]","['Inflammation', 'PET scans', 'Cognitive Impairment', 'Posterior Cortical Atrophy', 'Logopenic Variant Primary Progressive Aphasia', ""Amnestic Alzheimer's Disease"", 'MK-6240']",
Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C Patients,2021-08,COMPLETED,2021-03-03,SPONSOR,,"Cyclo Therapeutics, Inc.","['Niemann-Pick Disease, Type C1']",INTERVENTIONAL,12.0,ACTUAL,"[{'name': 'Hydroxypropyl-beta-cyclodextrin', 'description': 'Used in the treatment of Niemann-Pick C1'}]",,
Trial of Early Noninvasive Ventilation for Amyotrophic Lateral Sclerosis (ALS),2013-07,COMPLETED,2012-03,PRINCIPAL_INVESTIGATOR,Kirsten Gruis,University of Michigan,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,60.0,ACTUAL,"[{'name': 'BiPAPÂ® S/T System', 'description': 'The BiPAPÂ® S/T System is a NIPPV device that provides intermittent ventilatory assistance to people with difficulty breathing secondary to respiratory muscle weakness.'}, {'name': 'sham-NIPPV', 'description': 'a sham-device'}]","['amyotrophic lateral sclerosis', 'ALS', 'nocturnal noninvasive positive pressure ventilation', 'NIPPV', 'forced vital capacity', 'FVC']",
A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis,2023-01,COMPLETED,2022-12-29,SPONSOR,,"Helixmith Co., Ltd.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,8.0,ACTUAL,"[{'name': 'Engensis', 'description': 'Lyophilized biologic to be reconstituted containing Engensis'}, {'name': 'Placebo', 'description': 'Injectable Liquid'}]",,
CBT Training for Cognitive Reappraisal as an Intervention for Patients With Functional Tremor - an EEG Study,2023-09,RECRUITING,2024-04,SPONSOR,,Medical University of Graz,['Functional Movement Disorder'],INTERVENTIONAL,40.0,ESTIMATED,"[{'name': 'Cognitive Reappraisal', 'description': 'Patients complete 14 tasks on an app in a time span of 4 weeks in which they are asked to cognitively reappraise fear or anger inducing situations and are encouraged to implement this strategy into their daily lifes.'}, {'name': 'Reflection', 'description': 'Patients complete 14 tasks on an app in a time span of 4 weeks in which they are asked to reflect on certain topics of their day.'}]","['EEG', 'Psychology', 'neuropsychology', 'cognitive reappraisal', 'cognitive behavioral therapy', 'Emotional Regulation']",
Biological Treatment of Amyotrophic Lateral Sclerosis,2014-07,UNKNOWN,2017-12,PRINCIPAL_INVESTIGATOR,Milosz Kawa,Pomeranian Medical University Szczecin,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,50.0,ESTIMATED,"[{'name': 'Biological: Cell-based therapeutics', 'description': 'Human autologous bone marrow-derived stem/progenitor cell transplantation in ALS patients.'}, {'name': 'Symptomatic treatment of ALS', 'description': 'Symptomatic neurological treatment of ALS'}]","['cell-based therapy', 'autologous bone marrow-derived stem/progenitor cells', 'stem cell infusion, stem cell transplantation', 'biological therapy with neurotrophic factors', 'bioactive neurotrophic factors']",
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL),2023-03,ACTIVE_NOT_RECRUITING,2024-07,SPONSOR,,Woolsey Pharmaceuticals,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ACTUAL,"[{'name': 'Fasudil (WP-0512)', 'description': 'Oral fasudil up to 240 mg/day'}]",['Fasudil'],
Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),2016-06,COMPLETED,2015-11,PRINCIPAL_INVESTIGATOR,James D. Berry MD,Massachusetts General Hospital,"['Amyotrophic Lateral Sclerosis', ""Lou Gehrig's Disease"", 'Primary Lateral Sclerosis', 'Nervous System Diseases', 'Hereditary Spastic Paraparesis']",OBSERVATIONAL,475.0,ACTUAL,"[{'name': 'No intervention', 'description': 'Sample collection'}]","['Biomarkers', 'Plasma', 'Cerebrospinal Fluid', 'DNA', 'Serum']",Volunteers will be invited to participate in this study by their neurologists either in clinic or at a regular scheduled appointment visit.
Modifiable Variables in Parkinsonism (MVP),2022-03,RECRUITING,2030-12,PRINCIPAL_INVESTIGATOR,Laurie Mischley,Bastyr University,"[""Parkinson's Disease"", 'Parkinsonism', 'MSA - Multiple System Atrophy', 'Progressive Supranuclear Palsy', 'Shy-Drager Syndrome', 'Corticobasal Degeneration', 'Dementia With Lewy Bodies', 'Pick Disease', 'Olivopontocerebellar Atrophies']",OBSERVATIONAL,2000.0,ESTIMATED,,"[""Parkinson's Disease"", 'PD', 'Complementary and Alternative', 'CAM']",Any individual with PD is invited to participate.
Mindfulness-Based Stress Reduction in Dementia Caregivers,2022-04,COMPLETED,2022-04-04,SPONSOR,,"University of California, San Francisco","['Mindfulness Based Stress Reduction', 'Caregiver Burnout', 'Caregiver Stress Syndrome', 'Dementia', 'Dementia Frontal', 'Frontotemporal Dementia', 'Frontotemporal Lobar Degeneration']",INTERVENTIONAL,40.0,ACTUAL,"[{'name': 'Mindfulness-Based Stress Reduction', 'description': 'Eight MBSR sessions of 1.5 hours per week'}, {'name': 'Self-Guided Mindfulness eCourse', 'description': 'Six weeks of a mindfulness ecourse, and two weeks of coping skills training led by a licensed neuropsychologist'}]",,
Voices Of Individuals: Challenges and Experiences Of bvFTD,2024-01,ENROLLING_BY_INVITATION,2024-12,SPONSOR,,University of Pennsylvania,"['Frontotemporal Dementia', 'Frontotemporal Degeneration', 'Frontotemporal Dementia, Behavioral Variant', 'FTD']",OBSERVATIONAL,30.0,ESTIMATED,"[{'name': 'Telephone Interview', 'description': 'Participants will be asked to answer questions about their experiences with FTD.'}]","['FTD', 'Interview', 'Genetics', 'Persons diagnosed', 'Frontotemporal degeneration', 'bvFTD', 'Chromosome 9 open reading frame 72 (C9ORF72)', 'Microtubule-associated protein tau (MAPT)', 'Progranulin (GRN)', 'TAR DNA-binding protein (TARDBP)', 'Valosin-Containing Protein (VCP)', 'Charged multivesicular body protein 2B (CHMP2B)']","Participants for the study will be recruited through the University of Pennsylvania and ClinicalTrials.gov. Previously, participants were also recruited through Johns Hopkins University, through a dementia research study at the National Institutes of Health, through the Penn FTD Center Caregiver Conference, and through through a private Facebook group for individuals with C9orf72 mutations."
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS),2020-10,COMPLETED,2010-03,PRINCIPAL_INVESTIGATOR,Dr. Robert Miller,Forbes Norris MDA/ALS Research Center,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,109.0,ACTUAL,"[{'name': 'lithium carbonate', 'description': 'The dosage of lithium carbonate will be adjusted for each individual. The maximum dose is 450mg/day.'}]","['ALS', 'Amyotrophic Lateral Sclerosis', ""Lou Gehrig's Disease"", 'Lithium', 'Lithium Carbonate']",
Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,2023-08,TERMINATED,2021-07-02,SPONSOR,,ZevraDenmark,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,120.0,ACTUAL,"[{'name': 'Arimoclomol', 'description': '2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily'}]","['Arimoclomol', 'ALS']",
Pennsylvania Consortium: Clinical Database,2016-06,TERMINATED,2015-12,SPONSOR,,Drexel University College of Medicine,"['Amyotrophic Lateral Sclerosis', 'Neurodegenerative Disease', 'Motor Neuron Disease']",OBSERVATIONAL,25.0,ACTUAL,,"['Amyotrophic Lateral Sclerosis', 'Cerebrospinal Fluid', 'Neurodegenerative Disease', 'Motor Neuron Disease', 'Autonomic Nervous System', 'Neurodegenerative Diseases', 'Movement Disorders']",Patients seen in the MDA/ALS Center of Hope at Drexel University College of Medicine Patients seen in the Department of Neurology at Drexel University College of Medicine
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis,2023-01,ACTIVE_NOT_RECRUITING,2025-12,SPONSOR,,Calico Life Sciences LLC,"['ALS', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,31.0,ACTUAL,"[{'name': 'ABBV-CLS-7262', 'description': 'Oral'}, {'name': 'Placebo', 'description': 'Oral'}]",,
Telemedicine for Patients With Chronic Respiratory Insufficiency,2015-03,COMPLETED,2007-04,SPONSOR_INVESTIGATOR,Michele Vitacca,Michele Vitacca,['Chronic Respiratory Failure'],INTERVENTIONAL,240.0,ACTUAL,"[{'name': 'telemedicine program', 'description': 'One year TM with continuous (h 24) on call accessibility to a nurse and/or a pulmonologist, a web-based call centre and a pulse oxymetry tracing will be provided.'}]","['COPD', 'ALS', 'Telemedicine', 'mechanical ventilation', 'Integrated care', 'strict follow up', 'impact and costs on health care resources', 'telemedicine programme', 'home mechanical ventilation (HMV)', 'frail patients', 'chronic respiratory failure (CRF)']",
Assessment of the Effects of Sheffield Support Snood in MND Patients,2015-06,COMPLETED,2015-12,SPONSOR,,Sheffield Teaching Hospitals NHS Foundation Trust,['Motor Neurone Disease'],INTERVENTIONAL,15.0,ACTUAL,"[{'name': 'Head movements', 'description': 'Participants will be asked to perform a series of movements of exploration of their maximum neck range of motion, including: flexion, extension, right and left lateral flexion, right and left axial rotation.'}, {'name': 'Activities of daily living (drinking, washing hand and eating)', 'description': 'Patients will be asked to perform a series of activities of daily living (drinking, eating and washing hands).'}, {'name': 'Sheffield Support Snood'}, {'name': 'sEMG'}]",,
Development and Test of a Headset for BCI Until Obtaining an Efficient and Comfortable System That Can be Used in Daily Practice by ALS People,2024-02,RECRUITING,2025-02,SPONSOR,,Centre Hospitalier Universitaire de Nice,"['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease', 'Spinal Cord Diseases', 'Alternative Communication Devices', 'Neurodegenerative Diseases', 'Nervous System Diseases', 'Neuromuscular Diseases']",INTERVENTIONAL,5.0,ESTIMATED,"[{'name': 'New headset prototype', 'description': 'creation of a new headset prototype for using the P300 Speller, comfortable to use in everyday life by people with disabilities.'}]",,
Eye Gaze Strategies During Facial Emotion Recognition in Neurodegenerative Diseases: Links With Neuropsychiatric Disorders (EYE-ToM Study),2021-02,COMPLETED,2020-11-01,SPONSOR,,Centre Hospitalier Princesse Grace,"[""Alzheimer's Dementia"", 'Parkinson Disease(PD)', 'Fronto-Temporal Dementia']",OBSERVATIONAL,70.0,ACTUAL,"[{'name': 'No intervention. Only survey and normal use of eye-tracking', 'description': 'The study is conducted in accordance with usual practices of eye-tracking and neuropsychological evaluations carried out at the Center Rainier III.\n\nEye-TrackerÂ® is used at the Centre Rainier III since August 2014. It is a non-invasive device for eye movements recording, allowing doctors and researchers to measure standard parameters related to eye movements. Developed by the Eye Brain Company (France), this is a Class IIa medical device, CE marking, according to Annexe IX of the directive 93/42/CE.'}]","['Eye-Tracking', 'Neuropsychological evaluations']","Patient 45 years old and above healthy or with FTD, AD or PD pathology"
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells,2023-09,RECRUITING,2024-10,SPONSOR_INVESTIGATOR,"Joanne Kurtzberg, MD","Joanne Kurtzberg, MD","['Adrenoleukodystrophy', 'Batten Disease', 'Mucopolysaccharidosis II', 'Leukodystrophy, Globoid Cell', 'Leukodystrophy, Metachromatic', 'Neimann Pick Disease', 'Pelizaeus-Merzbacher Disease', 'Sandhoff Disease', 'Tay-Sachs Disease', 'Brain Diseases, Metabolic, Inborn', 'Alpha-Mannosidosis', 'Sanfilippo Mucopolysaccharidoses']",INTERVENTIONAL,40.0,ESTIMATED,"[{'name': 'DUOC-01', 'description': 'Intrathecal administration of DUOC-01'}]","['Adrenoleukodystrophy', 'Batten Disease', 'Hunter Syndrome', 'Krabbe', 'Metachromatic Leukodystrophy', 'ALD', 'MLD', 'PMD']",
Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis,2017-08,COMPLETED,2017-06-01,SPONSOR,,GlaxoSmithKline,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,25.0,ACTUAL,"[{'name': 'Faros Sensor (FS) and LifeInsight Hub', 'description': ""Each subject will be issued one FS and a MAT LifeInsight Hub for use during the study. At each clinic visit in the Pilot and Core Study Phases, the Faros sensor will be placed on the subject just prior to the defined reference tasks and will be worn on the subject's sternum during completion of the tasks. The morning after the clinic visit, the subject will re-attach the sensor and wear it for approximately 3 days. In between visits during the Core Study Phase the subject will wear the FS every month for approximately 3 days to enable data collection on a monthly basis over the 48 week study period. Movement/physical activity data will be collected by the FS throughout the study.""}, {'name': 'Fast Fix electrode patch', 'description': ""The Fast Fix electrode patch will be worn with the FS on the subject's sternum according to the same schedule as the FS. The Fast Fix electrode patch will be replaced by the subject on a daily basis during the 3 day monitoring period. Subjects will be provided instructions on how to operate and wear the Fast Fix electrode patch.""}, {'name': 'Quantitative Measure of Speech (Core Phase Only)', 'description': 'Subjects will follow simple prompts on a computer screen instructing them to say a series of vowels, words, and paragraphs which will be recorded using a high definition digital microphone and stored securely on a laptop. The speech waveform data will be sent via secure method to GSK/MAT for processing.'}]","['Amyotrophic Lateral Sclerosis', 'Biotelemetry']",
"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",2020-03,COMPLETED,2014-03,SPONSOR,,Cytokinetics,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,711.0,ACTUAL,"[{'name': 'CK-2017357', 'description': 'CK-2017357 125 mg tablets twice daily'}, {'name': 'Placebo tablets', 'description': 'Tablets'}, {'name': 'Riluzole', 'description': 'Tablets'}]",,
Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders,2023-04,RECRUITING,2026-12-31,PRINCIPAL_INVESTIGATOR,Seward Rutkove,Beth Israel Deaconess Medical Center,"['Amyotrophic Lateral Sclerosis (ALS)', 'Myasthenia Gravis', 'Myopathies', 'Stroke', ""Parkinson's Disease""]",OBSERVATIONAL,200.0,ESTIMATED,,"['ALS', 'Myasthenia Gravis', 'Myopathy', 'Stroke', ""Parkinson's Disease"", 'Bulbar', 'Orofacial', 'Ultrasound', 'Electrical Impedance Myography']",Patients will be recruited principally from the BIDMC outpatient clinics and inpatient ward service. Healthy volunteers will be recruited through online advertising.
Cervical Electrical Stimulation for ALS,2022-09,COMPLETED,2021-06-01,SPONSOR,,VA Office of Research and Development,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,19.0,ACTUAL,"[{'name': 'CES at rest', 'description': 'CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.\n\nThis is an experiment designed to measure CES interactions with other central and peripheral nerve circuits.'}, {'name': 'CES plus active hand or wrist movements', 'description': 'CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.\n\nThis is an experiment designed to detect momentary changes in muscle function.'}]","['Transcutaneous Electric Nerve Stimulation', 'transcranial magnetic stimulation']",
ECoG BMI for Motor and Speech Control,2022-07,RECRUITING,2030-08-15,PRINCIPAL_INVESTIGATOR,Karunesh Ganguly,"University of California, San Francisco","['ALS', 'SCI - Spinal Cord Injury', 'Stroke', 'Multiple Sclerosis', 'Muscular Dystrophies']",INTERVENTIONAL,3.0,ESTIMATED,"[{'name': 'PMT/Blackrock Combination Device', 'description': 'PMT Subdural Cortical Electrodes/Blackrock NeuroPort Array and NeuroPort System'}]",,
Sport Therapy and Osteopathy Manipulative Treatment in ALS,2015-09,COMPLETED,2015-05,SPONSOR,,University of Milano Bicocca,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ACTUAL,"[{'name': 'Sport therapy', 'description': 'Frequency: 60 min three times/week\n\n1. 20 min: aerobic training on bicycle ergometer.\n2. 20 min: strength training at 60% of maximal load.\n3. 20 min: proprioception and stretching exercises.'}, {'name': 'Osteopathic treatment', 'description': 'Frequency: 60 min weekly'}]","['amyotrophic lateral sclerosis', 'sport therapy', 'osteopathic manual treatment', 'muscle oxidative metabolism']",
Dexpramipexole Japanese PK Study,2014-11,COMPLETED,2012-02,SPONSOR,,Knopp Biosciences,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,57.0,ACTUAL,"[{'name': 'Single dose reduced', 'description': 'Treatment 1 (Part A)'}, {'name': 'Single dose standard', 'description': 'Treatment 2 (Part A)'}, {'name': 'Multiple Dose', 'description': 'Treatment 3 (Part A)'}, {'name': 'Multiple Dose', 'description': 'Part B'}]",,
IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS),2020-06,WITHDRAWN,2021-07-12,SPONSOR,,Implicit Bioscience,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Biologic: IC14 (monoclonal antibody against human CD14)', 'description': 'IC14 intravenous infusion daily for four days on two successive weeks then MR-PET Scan evaluation for impact on glial activation.'}]","['Motor Neurone Disease (MND)', 'Amyotrophic Lateral Sclerosis (ALS)']",
Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS),2023-09,COMPLETED,2022-08-30,SPONSOR_INVESTIGATOR,"Richard Bedlack, M.D., Ph.D.","Richard Bedlack, M.D., Ph.D.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,100.0,ACTUAL,"[{'name': 'Theracurmin HP', 'description': 'The intervention is based on the twice daily dosage of Theracurmin 90 mg capsules used in a trial of patients with mild cognitive impairment'}]",,
"Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease",2018-03,COMPLETED,2018-12-30,SPONSOR,,Implicit Bioscience,"['Motor Neuron Disease', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,10.0,ACTUAL,"[{'name': 'IC14', 'description': 'chimeric monoclonal antibody against human IC14'}]","['motor neurone disease', 'amyotrophic lateral sclerosis', 'IC14 [anti-CD14 (cluster of differentiation 14) monoclonal antibody]', 'monoclonal antibody', 'anti-CD14']",
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis,2019-06,UNKNOWN,2019-11-01,PRINCIPAL_INVESTIGATOR,Jeffrey Statland,University of Kansas Medical Center,['ALS'],INTERVENTIONAL,20.0,ESTIMATED,"[{'name': 'Ranolazine 500 MG', 'description': 'Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).'}, {'name': 'Ranolazine 1000 MG', 'description': 'Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).'}]",,
Treating Primary Progressive Aphasia and Apraxia of Speech Using Non-invasive Brain Stimulation,2023-10,RECRUITING,2024-06-30,PRINCIPAL_INVESTIGATOR,"John Hart, Jr.",The University of Texas at Dallas,"['Primary Progressive Aphasia', 'Apraxia of Speech']",INTERVENTIONAL,12.0,ESTIMATED,"[{'name': 'Transcranial direct current stimulation', 'description': 'Other Names:\n\ntDCS\n\n1 milliamp tDCS High definition tDCS High definition transcranial direct current stimulator, Neuroelectrics Starstim tES, SN E20200930-10 Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.'}]",,
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford,2024-01,RECRUITING,2100-12,SPONSOR,,Sanford Health,"['Rare Disorders', 'Undiagnosed Disorders', 'Disorders of Unknown Prevalence', 'Cornelia De Lange Syndrome', 'Prenatal Benign Hypophosphatasia', 'Perinatal Lethal Hypophosphatasia', 'Odontohypophosphatasia', 'Adult Hypophosphatasia', 'Childhood-onset Hypophosphatasia', 'Infantile Hypophosphatasia', 'Hypophosphatasia', 'Kabuki Syndrome', 'Bohring-Opitz Syndrome', 'Narcolepsy Without Cataplexy', 'Narcolepsy-cataplexy', 'Hypersomnolence Disorder', 'Idiopathic Hypersomnia Without Long Sleep Time', 'Idiopathic Hypersomnia With Long Sleep Time', 'Idiopathic Hypersomnia', 'Kleine-Levin Syndrome', 'Kawasaki Disease', 'Leiomyosarcoma', 'Leiomyosarcoma of the Corpus Uteri', 'Leiomyosarcoma of the Cervix Uteri', 'Leiomyosarcoma of Small Intestine', 'Acquired Myasthenia Gravis', 'Addison Disease', 'Hyperacusis (Hyperacousis)', 'Juvenile Myasthenia Gravis', 'Transient Neonatal Myasthenia Gravis', 'Williams Syndrome', 'Lyme Disease', 'Myasthenia Gravis', 'Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome)', 'Isolated Klippel-Feil Syndrome', 'Frasier Syndrome', 'Denys-Drash Syndrome', 'Beckwith-Wiedemann Syndrome', 'Emanuel Syndrome', 'Isolated Aniridia', 'Axenfeld-Rieger Syndrome', 'Aniridia-intellectual Disability Syndrome', 'Aniridia - Renal Agenesis - Psychomotor Retardation', 'Aniridia - Ptosis - Intellectual Disability - Familial Obesity', 'Aniridia - Cerebellar Ataxia - Intellectual Disability', 'Aniridia - Absent Patella', 'Aniridia', 'Peters Anomaly - Cataract', 'Peters Anomaly', 'Potocki-Shaffer Syndrome', 'Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11', 'Silver-Russell Syndrome Due to Imprinting Defect of 11p15', 'Silver-Russell Syndrome Due to 11p15 Microduplication', 'Syndromic Aniridia', 'WAGR Syndrome', 'Wolf-Hirschhorn Syndrome', '4p16.3 Microduplication Syndrome', '4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome', 'Autosomal Recessive Stickler Syndrome', 'Stickler Syndrome Type 2', 'Stickler Syndrome Type 1', 'Stickler Syndrome', 'Mucolipidosis Type 4', 'X-linked Spinocerebellar Ataxia Type 4', 'X-linked Spinocerebellar Ataxia Type 3', 'X-linked Intellectual Disability - Ataxia - Apraxia', 'X-linked Progressive Cerebellar Ataxia', 'X-linked Non Progressive Cerebellar Ataxia', 'X-linked Cerebellar Ataxia', 'Vitamin B12 Deficiency Ataxia', 'Toxic Exposure Ataxia', 'Unclassified Autosomal Dominant Spinocerebellar Ataxia', 'Thyroid Antibody Ataxia', 'Sporadic Adult-onset Ataxia of Unknown Etiology', 'Spinocerebellar Ataxia With Oculomotor Anomaly', 'Spinocerebellar Ataxia With Epilepsy', 'Spinocerebellar Ataxia With Axonal Neuropathy Type 2', 'Spinocerebellar Ataxia Type 8', 'Spinocerebellar Ataxia Type 7', 'Spinocerebellar Ataxia Type 6', 'Spinocerebellar Ataxia Type 5', 'Spinocerebellar Ataxia Type 4', 'Spinocerebellar Ataxia Type 37', 'Spinocerebellar Ataxia Type 36', 'Spinocerebellar Ataxia Type 35', 'Spinocerebellar Ataxia Type 34', 'Spinocerebellar Ataxia Type 32', 'Spinocerebellar Ataxia Type 31', 'Spinocerebellar Ataxia Type 30', 'Spinocerebellar Ataxia Type 3', 'Spinocerebellar Ataxia Type 29', 'Spinocerebellar Ataxia Type 28', 'Spinocerebellar Ataxia Type 27', 'Spinocerebellar Ataxia Type 26', 'Spinocerebellar Ataxia Type 25', 'Spinocerebellar Ataxia Type 23', 'Spinocerebellar Ataxia Type 22', 'Spinocerebellar Ataxia Type 21', 'Spinocerebellar Ataxia Type 20', 'Spinocerebellar Ataxia Type 2', 'Spinocerebellar Ataxia Type 19/22', 'Spinocerebellar Ataxia Type 18', 'Spinocerebellar Ataxia Type 17', 'Spinocerebellar Ataxia Type 16', 'Spinocerebellar Ataxia Type 15/16', 'Spinocerebellar Ataxia Type 14', 'Spinocerebellar Ataxia Type 13', 'Spinocerebellar Ataxia Type 12', 'Spinocerebellar Ataxia Type 11', 'Spinocerebellar Ataxia Type 10', 'Spinocerebellar Ataxia Type 1 With Axonal Neuropathy', 'Spinocerebellar Ataxia Type 1', 'Spinocerebellar Ataxia - Unknown', 'Spinocerebellar Ataxia - Dysmorphism', 'Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature', 'Spasticity-ataxia-gait Anomalies Syndrome', 'Spastic Ataxia With Congenital Miosis', 'Spastic Ataxia - Corneal Dystrophy', 'Spastic Ataxia', 'Rare Hereditary Ataxia', 'Rare Ataxia', 'Recessive Mitochondrial Ataxia Syndrome', 'Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature', 'Posterior Column Ataxia - Retinitis Pigmentosa', 'Post-Stroke Ataxia', 'Post-Head Injury Ataxia', 'Post Vaccination Ataxia', 'Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract', 'Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus', 'Non-hereditary Degenerative Ataxia', 'Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity', 'Olivopontocerebellar Atrophy - Deafness', 'NARP Syndrome', 'Myoclonus - Cerebellar Ataxia - Deafness', 'Multiple System Atrophy, Parkinsonian Type', 'Multiple System Atrophy, Cerebellar Type', 'Multiple System Atrophy', 'Maternally-inherited Leigh Syndrome', 'Machado-Joseph Disease Type 3', 'Machado-Joseph Disease Type 2', 'Machado-Joseph Disease Type 1', 'Leigh Syndrome', 'Late-onset Ataxia With Dementia', 'Infection or Post Infection Ataxia', 'GAD Ataxia', 'Hereditary Episodic Ataxia', 'Gliadin/Gluten Ataxia', 'Friedreich Ataxia', 'Fragile X-associated Tremor/Ataxia Syndrome', 'Familial Paroxysmal Ataxia', 'Exposure to Medications Ataxia', 'Episodic Ataxia With Slurred Speech', 'Episodic Ataxia Unknown Type', 'Episodic Ataxia Type 7', 'Episodic Ataxia Type 6', 'Episodic Ataxia Type 5', 'Episodic Ataxia Type 4', 'Episodic Ataxia Type 3', 'Episodic Ataxia Type 1', 'Epilepsy and/or Ataxia With Myoclonus as Major Feature', 'Early-onset Spastic Ataxia-neuropathy Syndrome', 'Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity', 'Early-onset Cerebellar Ataxia With Retained Tendon Reflexes', 'Early-onset Ataxia With Dementia', 'Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia', 'Dilated Cardiomyopathy With Ataxia', 'Cataract - Ataxia - Deafness', 'Cerebellar Ataxia, Cayman Type', 'Cerebellar Ataxia With Peripheral Neuropathy', 'Cerebellar Ataxia - Hypogonadism', 'Cerebellar Ataxia - Ectodermal Dysplasia', 'Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss', 'Brain Tumor Ataxia', 'Brachydactyly - Nystagmus - Cerebellar Ataxia', 'Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia', 'Autosomal Recessive Syndromic Cerebellar Ataxia', 'Autosomal Recessive Spastic Ataxia With Leukoencephalopathy', 'Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay', 'Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria', 'Autosomal Recessive Spastic Ataxia', 'Autosomal Recessive Metabolic Cerebellar Ataxia', 'Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine', 'Autosomal Recessive Ataxia, Beauce Type', 'Autosomal Recessive Ataxia Due to Ubiquinone Deficiency', 'Autosomal Recessive Ataxia Due to PEX10 Deficiency', 'Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia', 'Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency', 'Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency', 'Autosomal Recessive Congenital Cerebellar Ataxia', 'Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome', 'Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency', 'Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency', 'Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency', 'Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome', 'Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity', 'Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency', 'Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect', 'Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion', 'Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation', 'Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness', 'Autosomal Recessive Cerebellar Ataxia', 'Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly', 'Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation', 'Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy', 'Autosomal Dominant Spastic Ataxia Type 1', 'Autosomal Dominant Spastic Ataxia', 'Autosomal Dominant Optic Atrophy', 'Ataxia-telangiectasia Variant', 'Ataxia-telangiectasia', 'Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy', 'Autosomal Dominant Cerebellar Ataxia Type 4', 'Autosomal Dominant Cerebellar Ataxia Type 3', 'Autosomal Dominant Cerebellar Ataxia Type 2', 'Autosomal Dominant Cerebellar Ataxia Type 1', 'Autosomal Dominant Cerebellar Ataxia', 'Ataxia-telangiectasia-like Disorder', 'Ataxia With Vitamin E Deficiency', 'Ataxia With Dementia', 'Ataxia - Oculomotor Apraxia Type 1', 'Ataxia - Other', 'Ataxia - Genetic Diagnosis - Unknown', 'Acquired Ataxia', 'Adult-onset Autosomal Recessive Cerebellar Ataxia', 'Alcohol Related Ataxia', 'Multiple Endocrine Neoplasia', 'Multiple Endocrine Neoplasia Type II', 'Multiple Endocrine Neoplasia Type 1', 'Multiple Endocrine Neoplasia Type 2', 'Multiple Endocrine Neoplasia, Type IV', 'Multiple Endocrine Neoplasia, Type 3', 'Multiple Endocrine Neoplasia (MEN) Syndrome', 'Multiple Endocrine Neoplasia Type 2B', 'Multiple Endocrine Neoplasia Type 2A', 'Atypical Hemolytic Uremic Syndrome', 'Atypical HUS', 'Wiedemann-Steiner Syndrome', 'Breast Implant-Associated Anaplastic Large Cell Lymphoma', 'Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA)', 'Hemophagocytic Lymphohistiocytosis', ""Behcet's Disease"", 'Alagille Syndrome', 'Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD)', 'Lowe Syndrome', 'Pitt Hopkins Syndrome', '1p36 Deletion Syndrome', 'Jansen Type Metaphyseal Chondrodysplasia', 'Cockayne Syndrome', 'Chronic Recurrent Multifocal Osteomyelitis', 'CRMO', 'Malan Syndrome', 'Hereditary Sensory and Autonomic Neuropathy Type Ie', 'VCP Disease', 'Hypnic Jerking', 'Sleep Myoclonus', 'Mollaret Meningitis', 'Recurrent Viral Meningitis', 'CRB1', 'Leber Congenital Amaurosis', 'Retinitis Pigmentosa', 'Rare Retinal Disorder', 'KCNMA1-Channelopathy', 'Primary Biliary Cirrhosis', 'ZMYND11', 'Transient Global Amnesia', 'Glycogen Storage Disease', 'Alstrom Syndrome', 'White Sutton Syndrome', 'DNM1', 'EIEE31', 'Myhre Syndrome', 'Recurrent Respiratory Papillomatosis', 'Laryngeal Papillomatosis', 'Tracheal Papillomatosis', 'Refsum Disease', 'Nicolaides Baraitser Syndrome', 'Leukodystrophy', 'Tango2', 'Cauda Equina Syndrome', 'Rare Gastrointestinal Disorders', 'Achalasia-Addisonian Syndrome', 'Achalasia Cardia', 'Achalasia Icrocephaly Syndrome', 'Anal Fistula', 'Congenital Sucrase-Isomaltase Deficiency', 'Eosinophilic Gastroenteritis', 'Idiopathic Gastroparesis', 'Hirschsprung Disease', 'Rare Inflammatory Bowel Disease', 'Intestinal Pseudo-Obstruction', 'Scleroderma', 'Short Bowel Syndrome', 'Sacral Agenesis', 'Sacral Agenesis Syndrome', 'Caudal Regression', 'Scheuermann Disease', 'SMC1A Truncated Mutations (Causing Loss of Gene Function)', 'Cystinosis', 'Juvenile Nephropathic Cystinosis', 'Nephropathic Cystinosis', 'Kennedy Disease', 'Spinal Bulbar Muscular Atrophy', 'Warburg Micro Syndrome', 'Mucolipidoses', 'Mitochondrial Diseases', 'Mitochondrial Aminoacyl-tRNA Synthetases', 'Mt-aaRS Disorders', 'Hypertrophic Olivary Degeneration', 'Non-Ketotic Hyperglycinemia', 'Fish Odor Syndrome', 'Halitosis', 'Isolated Congenital Asplenia', 'Lambert Eaton (LEMS)', 'Biliary Atresia', 'STAG1 Gene Mutation', 'Coffin Lowry Syndrome', 'Borjeson-Forssman-Lehman Syndrome', 'Blau Syndrome', 'Arginase 1 Deficiency', 'HSPB8 Myopathy', 'Beta-Mannosidosis', 'TBX4 Syndrome', 'DHDDS Gene Mutations', 'MAND-MBD5-Associated Neurodevelopmental Disorder', 'Constitutional Mismatch Repair Deficiency (CMMRD)', 'SPATA5 Disorder', 'SPATA5L1 Related Disorder']",OBSERVATIONAL,20000.0,ESTIMATED,,"['Rare Diseases', 'Neglected Diseases', 'Orphan Diseases', 'Rare Disease Research', 'Registries', 'WAGR Syndrome', 'Ataxia', 'Cornelia de Lange Syndrome', 'Stickler Syndrome', 'Ataxia Telangiectasia', 'Kawasaki Disease', 'Batten Disease', 'Mucolipidosis IV', 'Klippel-Feil Syndrome', 'Multiple Endocrine Neoplasia', 'Atypical Hemolytic Uremic Syndrome', 'Undiagnosed', 'Uncommon Disease', 'Kabuki Syndrome', 'Hypersomnia', 'Hyperacusis', 'Kleine-Levin Syndrome', 'Marinesco-Sjogren Syndrome', 'Leiomyosarcoma', '4p-/Wolf-Hirschhorn Syndrome', 'Hypophosphatasia', 'Narcolepsy', 'Wiedermann-Steiner Syndrome', 'Breast Implant-Associated Anaplastic Large Cell Lymphoma', 'Autoimmune/inflammatory Syndrome Induced by Adjuvants (ASIA)', 'Hemophagocytic Lymphohistiocytosis (HLH)', ""Behcet's Disease"", 'Alagille Syndrome', 'Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia (IBMPFD)', 'Lowe Syndrome', 'Pitt Hopkins Syndrome', '1p36 deletion syndrome', 'Jansen metaphyseal chondrodysplasia', 'Cockayne Syndrome', 'Chronic recurrent multifocal osteomyelitis (CRMO)', 'Malan syndrome', 'Hereditary Sensory and Autonomic Neuropathy', 'Cystinosis', 'Juvenile nephropathic cystinosis', 'Nephropathic infantile cystinosis', 'Ocular cystinosis', 'Kennedy disease', 'Spinal Bulbar Muscular Atrophy (SBMA)', 'SMC1A Truncated Mutations (causing loss of gene function)', 'Leigh syndrome', 'Warburg Micro Syndrome', 'Mucolipidosis', 'Mitochondrial aminoacyl-tRNA synthetases (Mt-aaRS Disorders)', 'Shine Syndrome', 'Hypertrophic Olivary Degeneration', 'Non-Ketotic Hyperglycinemia', 'Intestinal Bromhidrosis Syndrome', 'Fish odor syndrome', 'Autosomal recessive extra oral halitosis', 'CACNA1H mutation', 'Dimethylglycine dehydrogenase deficiency']","Unaffected carriers, undiagnosed and those with a rare disease or rare condition."
Epidemiology and Genetics of the Amyotrophic Lateral Sclerosis in the French West Indies,2017-11,UNKNOWN,2023-05-13,SPONSOR,,Centre Hospitalier Universitaire de Pointe-a-Pitre,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,70.0,ESTIMATED,"[{'name': 'Blood sample and environmental survey', 'description': 'The intervention corresponds to a 10 ml of Blood sample and an environmental survey.'}]","['amyotrophic lateral sclerosis', 'epidemiology', 'genetic', 'environmental factor']",
Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS,2019-11,COMPLETED,2021-01-19,SPONSOR,,NeuroSense Therapeutics Ltd.,"['Amyotrophic Lateral Sclerosis', 'ALS']",INTERVENTIONAL,16.0,ACTUAL,"[{'name': 'Fixed dose combination Ciprofloxacin/Celecoxib', 'description': 'Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day'}]",,
Safety Study of High Doses of Zinc in ALS Patients,2012-03,COMPLETED,2012-03,SPONSOR,,"Phoenix Neurological Associates, LTD",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,10.0,ESTIMATED,"[{'name': 'Zinc and Copper', 'description': 'Optizinc 90 mg/d Copper 1 mg'}]","['ALS treatment', 'Zinc', 'Copper', 'BMAA', 'ALS']",
Creatine for the Treatment of Amyotrophic Lateral Sclerosis,2006-08,COMPLETED,2006-05,,,National Center for Complementary and Integrative Health (NCCIH),['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,110.0,,[{'name': 'creatine monohydrate'}],"['ALS', 'Creatine']",
Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS),2017-01,COMPLETED,2017-01,PRINCIPAL_INVESTIGATOR,DELRIEU Jacqueline,"Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,66.0,ACTUAL,"[{'name': 'PtcCO2', 'description': 'Nocturnal assessment will be performed during the initial polysomnography (and at 6 months) with a combined PtcCO2/pulse oxymetry TOSCA500 Radiometer monitoring evaluating different physiological parameters.'}]",,
Repetitive Transcranial Magnetic Stimulation as Therapy for Depression in Amyotrophic Lateral Sclerosis,2020-02,WITHDRAWN,2021-12-31,PRINCIPAL_INVESTIGATOR,Jakub Antczak,Jagiellonian University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'active repetitive transcranial magnetic stimulation', 'description': 'High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex'}, {'name': 'sham repetitive transcranial magnetic stimulation', 'description': 'High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex'}]","['Amyotrophic Lateral Sclerosis', 'depression', 'rTMS']",
Investigation of Cannabinoid 2-receptor Expression in the Brain and Spine of ALS-patients Compared to Healthy Controls With PET (18F-RoSMALS),2023-05,NOT_YET_RECRUITING,2026-09,SPONSOR_INVESTIGATOR,Markus Weber,Markus Weber,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ESTIMATED,"[{'name': '[18F]-RoSMA-18-d6', 'description': '\\[18F\\]-RoSMA-18-d6 will be administered intravenously by a bolus injection followed by a subsequent PET/CT-scan of the brain and the spine'}]",['Amyotrophic Lateral Sclerosis (ALS)'],
Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS),2018-07,COMPLETED,2009-05,SPONSOR,,Mitsubishi Tanabe Pharma Corporation,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,181.0,ACTUAL,"[{'name': 'MCI-186', 'description': ""Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days ) - observation (14 days) cycle is repeated eight times.""}, {'name': 'Placebo of MCI-186', 'description': ""Two ampoules of placebo injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated eight times.""}]",['Amyotrophic lateral sclerosis (ALS)'],
Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls,2015-05,COMPLETED,2014-10,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,16.0,ACTUAL,"[{'name': 'SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM', 'description': '123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter.\n\n123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter.'}]","['ALS', 'serotonin', 'dopamine']",
Tongue Strength in Amyotrophic Lateral Sclerosis (ALS),2016-01,UNKNOWN,2018-07,SPONSOR,,Assistance Publique Hopitaux De Marseille,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,60.0,ESTIMATED,[{'name': 'medical device'}],,
"T Cell Phenotypes in Amyotropic Lateral Sclerosis (ALS), Influence of Vitamin D",2020-05,COMPLETED,2020-05-25,SPONSOR,,"University Hospital, Montpellier",['ALS'],INTERVENTIONAL,97.0,ACTUAL,"[{'name': 'phenotyping Tcells', 'description': 'Collecting blood for analyses of the T cells phenotypes'}, {'name': 'Supplementation in vitamin D', 'description': 'Supplementation in vitamin D for the patients who are deficient on vitamin D'}]",,
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.,2023-10,RECRUITING,2025-01,SPONSOR_INVESTIGATOR,Dr. StÃ©phanie Delstanche,Dr. StÃ©phanie Delstanche,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,45.0,ESTIMATED,"[{'name': 'ActimyoÂ°', 'description': 'ActimyoÂ° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.'}]","['Actimyo', 'Accelerometry', 'Daily living']",
Biological Sample Collection for Research and Biobanking,2023-03,ACTIVE_NOT_RECRUITING,2030-01,PRINCIPAL_INVESTIGATOR,Scott Noggle,New York Stem Cell Foundation Research Institute,"['Parkinson Disease', 'Diabetes Mellitus, Type 1', 'Macular Degeneration', 'ALS', 'Cancer', 'Alzheimer Disease', 'Huntington Disease']",OBSERVATIONAL,1279.0,ACTUAL,"[{'name': 'Biological sample collection', 'description': 'Biological sample collection for biobanking and research'}]","['stem cell', 'observational', 'biobank', 'disease modeling', 'genetics']","Individuals with a diagnosis of one or more of the listed conditions.

Individuals with a known genetic mutation, with or without a diagnosed condition.

Individuals without a genetic mutation or condition to serve as healthy controls (a comparison group for those with conditions)."
Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis,2013-05,UNKNOWN,2016-11,SPONSOR,,Neuralstem Inc.,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,18.0,ESTIMATED,"[{'name': 'Human spinal cord stem cell implantation', 'description': 'Human spinal cord stem cell implantation in ALS patients.'}]","['Human spinal cord derived neural stem cell transplantation', 'ALS']",
Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALS,2017-04,COMPLETED,2017-04,SPONSOR,,Royan Institute,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,19.0,ACTUAL,"[{'name': 'mesenchymal stem cells', 'description': 'mesenchymal stem cells injection via peripheral vein.'}]",['adipose tissue mesenchymal stem cell intravenous injection ALS'],
Neurofilament Light Chains and Cognitive Impairment in Chronic Psychiatric Disease,2022-10,RECRUITING,2025-10-22,SPONSOR,,HÃ´pital le Vinatier,"['Schizophrenia', 'Bipolar Disorder', 'Alzheimer Disease', 'FTD']",INTERVENTIONAL,120.0,ESTIMATED,"[{'name': 'blood sample taken', 'description': 'Comparaison of Neurofilament light chain serum concentration between the arms'}]","['dementia', 'biomarker']",
Study of Electrical Impedance Myography (EIM) in ALS,2016-05,COMPLETED,2016-03,SPONSOR,,"Skulpt, Inc.","['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease', 'Charcot-Marie-Tooth Disease', 'Multiple Sclerosis']",OBSERVATIONAL,106.0,ACTUAL,"[{'name': 'Electrical impedance myography (EIM)', 'description': 'In EIM, high-frequency alternating electrical current is applied to localized areas of muscle via surface electrodes and the consequent surface voltage patterns analyzed.\n\nEIM is very sensitive to the compositional and structural elements of muscle. Data from both human subjects and animal disease models, including ALS, spinal muscular atrophy (SMA), and Duchenne muscular dystrophy (DMD), show that EIM may be sensitive to a variety of pathological states. It is anticipated that EIM will thus likely be able to assist in quantifying the severity of the disease affecting various muscle groups as well as in measuring changes in the disease over time.'}]",,"People with ALS People diagnosed with early ALS (possible, probable, probable- laboratory supported or definite ALS according to El Escorial criteria)

Other Neurological Diseases People with a diagnosis of a disease that mimics ALS

Healthy Controls Healthy Volunteers that do not have ALS or another neurological disease that mimics ALS."
Home-based tDCS in Frontotemporal Dementia or Alzheimer's Disease,2023-08,RECRUITING,2025-08-10,SPONSOR,,Johns Hopkins University,"['Mild Cognitive Impairment', 'Primary Progressive Aphasia', 'Dementia']",INTERVENTIONAL,50.0,ESTIMATED,"[{'name': 'Computerized Cognitive Training via BrainHQ', 'description': 'Computerized Cognitive training (BrainHQ)'}, {'name': 'Active tDCS (tDCS) on DLPFC', 'description': 'Device: Active tDCS on DLPFC Stimulation will be delivered by a constant current stimulator (Mind STIM). The electrical current will be administered to a pre-specified region of the brain (DLPFC). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.'}]",,
Biomarkers Of Lung InVolvement In ASMD,2023-06,RECRUITING,2024-09-01,SPONSOR_INVESTIGATOR,Eline C. B. Eskes,Eline C. B. Eskes,"['Asmd, Visceral Type']",INTERVENTIONAL,68.0,ESTIMATED,"[{'name': 'eNose', 'description': 'Collection of breath profile with eNose'}, {'name': 'Volatile exhaled breath sample', 'description': 'Collection of exhaled breath in Tedlar bag'}, {'name': 'Condensate sample', 'description': 'Collection of exhaled breath condensate with EcoScreen'}]",,
Therapy in Amyotrophic Lateral Sclerosis (TAME),2022-11,COMPLETED,2021-07-22,PRINCIPAL_INVESTIGATOR,"Richard J. Barohn, MD",University of Kansas Medical Center,"['Amyotrophic Lateral Sclerosis', 'Frontal Temporal Dementia']",INTERVENTIONAL,89.0,ACTUAL,"[{'name': 'Memantine', 'description': 'All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.'}, {'name': 'Placebo (for Memantine)', 'description': 'All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.'}]","['ALS', 'FTD', 'Tau', 'pNF-H/C3']",
Open Label Extension of TUDCA-ALS Study,2023-02,RECRUITING,2025-03-31,SPONSOR,,Humanitas Mirasole SpA,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,184.0,ESTIMATED,"[{'name': 'Tauroursodeoxycholic Acid', 'description': 'Tauroursodeoxycholic acid (TUDCA) 250 mg capsules Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal Mode of administration: orally Duration: 18 months'}]","['Bile acids', 'Deoxycholic Acid']",
Clinical Trial of Ezogabine (Retigabine) in ALS Subjects,2019-08,COMPLETED,2018-02,SPONSOR_INVESTIGATOR,Brian Wainger,Brian Wainger,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,65.0,ACTUAL,"[{'name': 'Ezogabine', 'description': 'Potiga is FDA-approved for adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments.'}, {'name': 'Placebo', 'description': 'Matched placebo'}]","['Amyotrophic Lateral Sclerosis', 'ALS', 'Lou Gehrig']",
A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery,2023-11,COMPLETED,2015-03,SPONSOR,,Sanguine Biosciences,"[""Alzheimer's Disease"", 'Multiple Sclerosis', ""Parkinson's Disease"", ""Huntington's Disease"", 'Amyotrophic Lateral Sclerosis (ALS)']",OBSERVATIONAL,20.0,ACTUAL,,"[""Alzheimer's Disease"", 'Multiple Sclerosis', ""Parkinson's Disease"", ""Huntington's Disease"", 'Amyotrophic Lateral Sclerosis (ALS)']","A diagnosis of Multiple Sclerosis, Alzheimer's, Huntington's, or Parkinson's Disease."
Non-invasive BCI-controlled Assistive Devices,2022-12,RECRUITING,2023-12-30,SPONSOR,,University of Texas at Austin,"['Motor Disorders', 'Healthy', 'Spinal Cord Injuries', 'Muscular Diseases', 'Motor Neuron Disease', 'Stroke', 'Traumatic Brain Injury', 'Movement Disorders']",INTERVENTIONAL,40.0,ESTIMATED,"[{'name': 'NMES-BCI', 'description': 'Electroenceauphalography (EEG) signals will be recorded from subjects as they perform cued tasks for flexing/extending their non-dominant hand. The signals will be processed and classified in real-time using machine learning algorithms to trigger electrical stimulation on the flexors/extensors of the targeted arm contingent to the detection of a subject-specific flexion/extension EEG patterns.'}, {'name': 'Visual-BCI', 'description': 'Electroenceauphalography (EEG) signals will be recorded from subjects as they perform cued tasks for flexing/extending their non-dominant hand. The signals will be processed and classified in real-time using machine learning algorithms to control the right/left movement of a bar on a computer screen. The bar feedback is contingent to the detection of a subject-specific flexion/extension EEG patterns.'}]","['motor deficits', 'able-bodied, healthy', 'unilateral and bilateral stroke', 'spinal cord injury', 'motor neuron diseases', 'muscular diseases (i.e. myopathy)', 'traumatic or neurological pain', 'movement disorders']",
Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis,2022-09,NO_LONGER_AVAILABLE,,SPONSOR,,Hope Biosciences Stem Cell Research Foundation,['Amyotrophic Lateral Sclerosis'],EXPANDED_ACCESS,,,"[{'name': 'HB-adMSCs', 'description': 'Hope Biosciences autologous adipose-derived mesenchymal stem cells'}]","['Neurodegenerative', 'MSCs', 'Stem cells', 'Sclerosis', 'ALS', 'Amyotrophic']",
Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS),2023-08,TERMINATED,2022-12-20,SPONSOR_INVESTIGATOR,Elijah W. Stommel,Elijah W. Stommel,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,43.0,ACTUAL,"[{'name': 'L-Serine', 'description': 'L-Serine is a naturally occurring dietary amino acid. It is abundant in soy products, some edible seaweeds, sweet potatoes, eggs and meat.'}]",,
Assessment of the Cyberlink Control System for Use by the Amyotrophic Lateral Sclerosis (ALS) Patient,2013-03,TERMINATED,2009-04,SPONSOR,,Drexel University College of Medicine,"['Amyotrophic Lateral Sclerosis', 'Neurodegenerative Disease', 'Motor Neuron Disease']",OBSERVATIONAL,1.0,ACTUAL,,"['Amyotrophic Lateral Sclerosis', 'Cerebrospinal Fluid', 'Neurodegenerative Disease', 'Motor Neuron Disease', 'Autonomic Nervous System', 'Neurodegenerative Diseases', 'Movement Disorders']",ALS clinic patients at MDA/ALS Center of Hope.
ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach,2023-06,NOT_YET_RECRUITING,2025-07,SPONSOR,,ZIWIG,"['Amyotrophic Lateral Sclerosis, Sporadic', 'Amyotrophic Lateral Sclerosis']",OBSERVATIONAL,600.0,ESTIMATED,"[{'name': 'Saliva sample', 'description': 'During the inclusion visit :\n\n* a neurological examination is taken\n* a saliva sample is taken'}, {'name': 'Saliva sample', 'description': 'During the inclusion visit :\n\n* a saliva sample is taken'}]","['ALS', 'RNA', 'Saliva sample']","The study population will be made up with amyotrophic lateral sclerosis (ALS) patients defined or probable according to El Escorial criteria (""ALS patients"" group) and patients with no medical history or neurological symptoms (Control Group).

The control group will be made up of people accompanying the patients (with or without ALS).

The ALS patients in the study already benefit from routine medical care in ALS expert centers in France. .

The patients concerned by the study are managed without modification of the care pathway, no modification of the therapeutic indications, no modification of the diagnostic examinations or follow-up necessary according to the context, which are carried out according to the recommendations of the HAS."
Rehabilitative Trial for the Rescue of Neurophysiological Parameters in Progranulin Deficient Subjects,2020-03,COMPLETED,2019-06-30,PRINCIPAL_INVESTIGATOR,Barbara Borroni,Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,"['Frontotemporal Dementia', 'GRN Related Frontotemporal Dementia']",INTERVENTIONAL,70.0,ACTUAL,"[{'name': 'Anodal transcranial direct current stimulation', 'description': '10 sessions of anodal transcranial direct current stimulation (5 days/week for 2 weeks)'}, {'name': 'Sham transcranial direct current stimulation', 'description': '10 sessions of sham transcranial direct current stimulation (5 days/week for 2 weeks)'}]","['TMS', 'tDCS', 'Rehabilitation']",
"A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418",2023-08,NOT_YET_RECRUITING,2024-12,SPONSOR,,"1ST Biotherapeutics, Inc.","['Parkinson Disease Psychosis', 'Amyotrophic Lateral Sclerosis (ALS)']",INTERVENTIONAL,64.0,ESTIMATED,"[{'name': 'FB418', 'description': 'Oral dose'}]",,
Combined Respiratory Training in Persons With ALS,2023-08,RECRUITING,2026-09-30,PRINCIPAL_INVESTIGATOR,"Lauren Tabor Gray, PhD",Nova Southeastern University,"['ALS', 'Respiratory Insufficiency', 'Dysphagia']",INTERVENTIONAL,34.0,ESTIMATED,"[{'name': 'Respiratory Muscle Strength Training (LVR+EMST)', 'description': 'Combined respiratory muscle strength training regimen that will be completed daily for 5 weeks.'}]","['Breathing', 'Swallowing', 'Exercise', 'Bulbar']",
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation,2023-07,RECRUITING,2027-08-07,SPONSOR,,Biogen,['Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation'],INTERVENTIONAL,150.0,ESTIMATED,"[{'name': 'Tofersen', 'description': 'Administered as specified in the treatment arm'}, {'name': 'Placebo', 'description': 'Administered as specified in the treatment arm'}]",,
ALS Treatment Extension Study,2022-02,UNKNOWN,2022-12-31,SPONSOR,,Collaborative Medicinal Development Pty Limited,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,28.0,ACTUAL,"[{'name': 'Cu(II)ATSM', 'description': 'copper-containing synthetic small molecule'}]",,
Muscle Training of Patients With Amyotrophic Lateral Sclerosis (ALS),2016-06,COMPLETED,2016-06,PRINCIPAL_INVESTIGATOR,Line Jensen,University of Southern Denmark,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,6.0,ACTUAL,"[{'name': 'Muscle training', 'description': '12 weeks of strength training 2-3 times/week'}]","['Nervous System Disease', 'Neurodegenerative Disease', 'Motor Neuron Disease', 'ALS', 'Muscle training', 'Muscle atrophy']",
Diagnosis of Alzheimer's Disease Using Event Related Potentials,2022-09,RECRUITING,2023-07,PRINCIPAL_INVESTIGATOR,Katherine Turk,VA Boston Healthcare System,['Mild Cognitive Impairment'],OBSERVATIONAL,170.0,ESTIMATED,[{'name': 'No intervention is part of this study but patients use an EEG device during observational data collection.'}],"[""Alzheimer's disease"", 'Frontotemporal Dementia', 'Lewy Body Dementia', 'Diagnosis']",Patients with a memory disorder based on caregiver or referring clinician report who are being seen in the memory disorders clinic for the first time as well as age-matched older healthy controls without a neurologic condition.
PRISM Registry: Pseudobulbar Affect Registry Series,2014-04,COMPLETED,2012-09,SPONSOR,,Avanir Pharmaceuticals,"[""Alzheimer's Disease"", 'Amyotrophic Lateral Sclerosis (ALS)', 'Multiple Sclerosis (MS)', ""Parkinson's Disease"", 'Stroke', 'Traumatic Brain Injury']",OBSERVATIONAL,5290.0,ACTUAL,,['pseudobulbar affect'],The population for this study will be 18 years and over
Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients,2021-08,TERMINATED,2021-07-01,PRINCIPAL_INVESTIGATOR,Johnny Salameh,American University of Beirut Medical Center,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,6.0,ACTUAL,"[{'name': 'Fycompa', 'description': 'Dose will be increased by 2mg/day increments every one week to reach a maximum dose of 8 mg/day. Treatment phase will be stable dose for 12 weeks then followed by washout period over 2 weeks.'}]","['Safety', 'Tolerability', 'Perampanel']",
COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry,2023-03,COMPLETED,2023-01-31,SPONSOR,,Wake Forest University Health Sciences,"['Covid19', 'Amyotrophic Lateral Sclerosis']",OBSERVATIONAL,47.0,ACTUAL,,,Our study population consists of qualifying cases of patients with ALS who have had a laboratory confirmed COVID-19 infection.
Metacognition in Semantic Dementia: Comparison With Alzheimer's Disease,2023-08,COMPLETED,2022-04-27,SPONSOR,,"University Hospital, Grenoble","['Semantic Dementia', 'Alzheimer Disease', 'Healthy']",OBSERVATIONAL,40.0,ACTUAL,"[{'name': 'Metacognition tests', 'description': 'Test on episodic or semantic memory'}]",,"Patients with Alzheimer's disease will be patients at the CHU of Grenoble.

Patients with Alzheimer's disease will be recruited in the CHU Grenoble, CHU Angers, CHU Bordeaux, CHU Colmar, CHU Lyon, CHU Rennes and CHUV Lausanne.

Controls will be recruited via the database ""Seniors pour la Science "", https://seniorspourlascience.fr/"
Efficacy and Safety Study of MYOBLOCÂ® Followed by Open-Label Multiple-Treatment With MYOBLOCÂ® in the Treatment of Troublesome Sialorrhea in Adult Subjects,2019-08,COMPLETED,2017-01,SPONSOR,,"Supernus Pharmaceuticals, Inc.",['Sialorrhea'],INTERVENTIONAL,187.0,ACTUAL,"[{'name': 'MYOBLOC', 'description': 'MYOBLOC (rimabotulinumtoxinB) Injection, or botulinum toxin type B, is the ""B"" serotype of botulinum toxin. It is the only commercially available ""B"" serotype, and also the only available botulinum toxin that does not require reconstitution for use.'}, {'name': 'PLACEBO'}]","['Sialorrhea', ""Parkinson's disease"", 'Amyotrophic lateral sclerosis (ALS)', 'stroke', 'neuroleptics']",
Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS),2022-03,COMPLETED,2021-07-13,SPONSOR,,Clene Nanomedicine,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,45.0,ACTUAL,"[{'name': 'CNM-Au8', 'description': 'CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a nominal concentration of 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose 60 mL HDPE containers.'}, {'name': 'Placebo', 'description': 'Placebo is liquid with identical color and taste'}]","['Gold', 'Nanocrystal', 'electromyography', 'ALS', 'Nanoparticle']",
Communication Bridge: A Person-centered Internet-based Intervention for Individuals With Primary Progressive Aphasia,2023-06,COMPLETED,2023-03-23,PRINCIPAL_INVESTIGATOR,Emily Rogalski,Northwestern University,['Primary Progressive Aphasia'],INTERVENTIONAL,95.0,ACTUAL,"[{'name': 'Communication Bridgeâ„¢', 'description': 'Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.'}, {'name': 'Evidence-Based Impairment Focused', 'description': 'Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.'}]","['aphasia', 'primary progressive aphasia', 'dementia', 'communication', 'frontotemporal dementia', ""Alzheimer's disease""]",
Technical Evaluation of Earswitch Phase A,2023-05,NOT_YET_RECRUITING,2024-09,PRINCIPAL_INVESTIGATOR,Dario Cazzola,University of Bath,['Motor Neuron Disease'],INTERVENTIONAL,110.0,ESTIMATED,"[{'name': 'Earswitch device', 'description': 'The Earswitchâ„¢ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.'}]","['Assistive Technology', 'Ear rumble', 'Tensor Tympani']",
Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS),2018-08,COMPLETED,2018-04,PRINCIPAL_INVESTIGATOR,Jessica Mandrioli,Azienda Unita' Sanitaria Locale Di Modena,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,65.0,ACTUAL,"[{'name': 'Standard motor rehabilitation treatment', 'description': 'Standard treatment: 2 sessions/week of motor rehabilitation treatment (45 minutes each one) for 10 weeks for a total of 20 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 20 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up'}, {'name': 'Intensive motor rehabilitation treatment', 'description': 'Intensive treatment is characterized by an increased exercises volume: 5 sessions/week)(45 minutes each one) for 10 weeks for a total of 50 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 50 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up'}]","['Motor Rehabilitation Treatment', 'Intensive versus standard', 'Motor Disability']",
Investigation of the Epidemiological Factors Associated With the Development of Amyotrophic Lateral Sclerosis (ALS),2021-02,RECRUITING,2050-01,SPONSOR,,Hadassah Medical Organization,['ALS'],OBSERVATIONAL,2000.0,ESTIMATED,[{'name': 'Observation'}],,"Population referred to ALS clinic with suspected, possible, probable ,definite ALS"
Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis,2016-08,UNKNOWN,2018-09,SPONSOR,,Assistance Publique Hopitaux De Marseille,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,60.0,ESTIMATED,[{'name': 'sodium MRI'}],,
TAS-102 in Treating Advanced Biliary Tract Cancers,2023-06,COMPLETED,2021-09-16,SPONSOR,,Mayo Clinic,"['Cholangiocarcinoma', 'Stage III Gallbladder Cancer AJCC v7', 'Stage IIIA Gallbladder Cancer AJCC v7', 'Stage IIIB Gallbladder Cancer AJCC v7', 'Stage IV Gallbladder Cancer AJCC v7', 'Stage IVA Gallbladder Cancer AJCC v7', 'Stage IVB Gallbladder Cancer AJCC v7']",INTERVENTIONAL,28.0,ACTUAL,"[{'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies'}, {'name': 'Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102', 'description': 'Given PO'}]",,
Transplantation of Autologous Peripheral Blood Mononuclear Cells for Amyotrophic Lateral Sclerosis,2018-02,COMPLETED,2013-06,PRINCIPAL_INVESTIGATOR,Liu Jing,The First Affiliated Hospital of Dalian Medical University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,14.0,ACTUAL,"[{'name': 'PBMC autotransplantation', 'description': 'Fourteen amyotrophic lateral sclerosis (ALS) patients are received peripheral blood mononuclear cell (PBMC) autotransplantation.'}]",,
Control Cohort CTRL COH,2024-01,RECRUITING,2028-08-08,SPONSOR,,Hospices Civils de Lyon,"[""Parkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Disease; Rheumatoid Polyarthritis""]",INTERVENTIONAL,350.0,ESTIMATED,"[{'name': 'Collection of biological sample (blood and/or CSF)', 'description': 'Blood sample will be collected one time for each patient:\n\n2 \\*4ml of blood on dry tube 2 \\*4ml of blood on EDTA tube\n\nIf cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml).'}]","['Biological collection, control cohort,, new biomarkers']",
Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS,2016-03,COMPLETED,2010-08,PRINCIPAL_INVESTIGATOR,Michael Strong,Lawson Health Research Institute,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,32.0,ACTUAL,"[{'name': 'Vitamin E', 'description': 'Vitamin E 800IU bid'}]","['amyotrophic lateral sclerosis', 'vitamin E', 'muscle cramp']",
Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis,2022-08,COMPLETED,2021-03-10,SPONSOR_INVESTIGATOR,"Dwight Koeberl, M.D., Ph.D.","Dwight Koeberl, M.D., Ph.D.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,25.0,ACTUAL,"[{'name': 'Clenbuterol', 'description': 'The intervention is treatment with oral clenbuterol at 40-80 micrograms twice daily for 24 weeks. Dosage will initially be 40 mcg daily for one week, then 40 mcg BID per oral daily for the next 5 weeks. If the 40 mcg BID per oral is well tolerated in the opinion of Dr. Bedlack, the dose will be increased to 80 mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID per oral for the remainder of the study. The selected target dose (80 mcg BID) is based upon the experience with the long-term administration of clenbuterol, specifically the beneficial muscle effects in a Phase I/II clinical trial that enrolled patients with late-onset Pompe disease who were previously treated with enzyme replacement therapy (Koeberl et al. 2018).'}]",,
National Multicenter Interventional Study Aimed at Evaluating the Effect on the Intestinal Microbiota in Chronically Frail Patients Who Share Alterations in Intestinal Function.,2023-08,COMPLETED,2023-03-31,SPONSOR,,"Institute of Biomedical Technologies-National Research Council, Italy","['Adhd', 'ALS', 'Bronchial Asthma']",INTERVENTIONAL,64.0,ACTUAL,"[{'name': 'Prebiotic fiber', 'description': 'Moradyn active prebiotic fiber product'}, {'name': 'Dietary fiber', 'description': 'Fibregum non-active fiber product'}, {'name': 'Probiotic', 'description': 'Defense Plus probiotic complex'}]",,
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial,2023-05,RECRUITING,2024-10-01,PRINCIPAL_INVESTIGATOR,Mark W Albers,Massachusetts General Hospital,"['Amyotrophic Lateral Sclerosis', 'Alzheimer Disease', 'Mild Cognitive Impairment']",INTERVENTIONAL,20.0,ESTIMATED,"[{'name': 'Baricitinib', 'description': 'Each participant will be treated with open-label baricitinib for 24 weeks. Participants will receive 2 mg baricitinib by mouth daily for the first 8 weeks and 4 mg baricitinib by mouth daily for the remaining 16 weeks.'}]","['Amyotrophic Lateral Sclerosis', 'Alzheimer Disease', 'Mild Cognitive Impairment', 'Baricitinib', 'Dementia', 'C9ORF72']",
Social-cognitive Functioning: Validation of a New Neuropsychological Test,2023-10,NOT_YET_RECRUITING,2028-06-01,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,"[""Alzheimer's Disease (AD)"", 'Lewy Body Dementia (LBD)', 'Frontotemporal Degeneration (FTD)']",INTERVENTIONAL,120.0,ESTIMATED,"[{'name': 'REALSOCOG', 'description': 'Patients will be asked to perform the REALSoCog serious game-type social cognition assessment task developed by the LMC2 laboratory (UR 7536). Their performance will be compared to those of control individuals recruited in parallel (independant clinical study: CER-U, IRB NÂ°: 00012020-115). Participants will be asked to think about 16 social situations (6 control situations and 10 experimental situations) encountered in a virtual environment representing a city. REALSoCog can be used on a laptop computer, without any additional technical device.'}, {'name': 'BCS', 'description': 'Social-cognitive tasks from the BCS (EhrlÃ© et al., 2011) will also be offered to patients to test the concurrent validity of REALSoCog. This battery assesses social cognition. It includes paper-and-pencil tasks.'}, {'name': 'Hetero-questionnaires', 'description': ""Hetero-questionnaires assessing patients' social behavior will be transmitted to their relative or primary caregiver (Godefroy \\& le GREFEX, 2008; Gury and EhrlÃ©, in progress of validation) in order to verify the concurrent validity of REALSoCog. These hetero-questionnaires aim to identify and quantify the presence of social skills and behaviour disorders.""}]","['Neurodegenerative diseases', 'Social behavior', 'Social cognition', 'Neuropsychological assessment']",
Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis,2020-03,COMPLETED,2017-02,SPONSOR,,Synapse Biomedical,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,97.0,ACTUAL,"[{'name': 'NeuRx Diaphragm Pacing System (DPS)', 'description': 'The NeuRx DPS is a percutaneous, intramuscular, diaphragm stimulation system which is implanted using standard laparoscopic surgical techniques in an outpatient procedure. The implanted intramuscular diaphragm electrodes are connected to a four channel external stimulator at a percutaneous exit site. DPS is designed to help ALS patients breathe by providing conditioning stimulation of the diaphragm muscles. Recommended frequency of diaphragm conditioning is at least 3 times per day with each session lasting at least 30 minutes. Patients may find it helpful to use the DPS for longer periods to help with breathing. DPS may be used at the same time as non-invasive ventilation. Patents may also sleep with the DPS to assist with breathing difficulties at night.'}]","['amyotrophic lateral sclerosis', 'ALS', 'motor neuron disease', 'diaphragm', 'diaphragm pacing', 'diaphragmatic pacing', 'phrenic pacing', 'phrenic nerve', 'phrenic nerve stimulation', 'NeuRx DPS', 'DPS', 'chronic hypoventilation', 'respiration', 'ventilation', 'breathing', 'Humanitarian Device Exemption', 'HDE', 'post-approval study']",
NYSCF Scientific Discovery Biobank,2024-01,RECRUITING,2045-11-10,SPONSOR,,New York Stem Cell Foundation Research Institute,"['ALS', 'Amyotrophic Lateral Sclerosis', 'Alzheimer Disease', 'Alzheimer Disease, Early Onset', 'Alzheimer Disease, Late Onset', 'Batten Disease', 'Corticobasal Degeneration', 'Dementia', 'Frontotemporal Dementia', 'Huntington Disease', 'Lewy Body Disease', 'Multiple Sclerosis', 'Multiple System Atrophy', 'Parkinson Disease', ""Parkinson's Disease and Parkinsonism"", 'Progressive Supranuclear Palsy', 'INAD', 'Diabetes', 'Diabetes Mellitus', 'Diabetes Mellitus, Type 2', 'Diabetes Mellitus, Type 1', 'Macular Degeneration', 'Ovarian Cancer', 'Cervical Cancer', 'Uterine Cancer', 'Vaginal Cancer', 'Vulvar Cancer', 'PTSD', 'Post Traumatic Stress Disorder']",OBSERVATIONAL,10000.0,ESTIMATED,"[{'name': 'Biological Sample Collection', 'description': 'Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/ leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).'}]","['ALS', 'Amyotrophic Lateral Sclerosis', 'Alzheimer Disease', 'Batten Disease', 'Corticobasal Degeneration', 'Dementia', 'Frontotemporal Dementia', 'Huntington Disease', 'Lewy Body Disease', 'Multiple Sclerosis', 'Multiple System Atrophy', 'Parkinson Disease', 'Parkinsonism', 'Progressive Supranuclear Palsy', 'INAD', 'Diabetes', 'Diabetes Type 1', 'Diabetes Type 2', 'Macular Degeneration', ""Women's Reproductive Cancer"", 'Ovarian Cancer', 'Cervical Cancer', 'Uterine Cancer', 'Vaginal Cancer', 'Vulvar Cancer', 'PTSD', 'Post Traumatic Stress Disorder']",Individuals with a diagnosis of one or more of the listed conditions. Individuals without a condition to serve as healthy controls (a comparison group for those with conditions).
Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease,2019-09,UNKNOWN,2021-06-30,PRINCIPAL_INVESTIGATOR,"Huiwen Zhang, MD","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","['Niemann-Pick Disease, Type C1']",INTERVENTIONAL,18.0,ESTIMATED,"[{'name': 'Lithium Carbonate', 'description': 'To observe whether lithium carbonate has protective role on the brain of Niemann-Pick disease C1'}]",,
Assessing Motor Neuron Disease Mechanisms by Threshold Tracking Transcranial Magnetic Stimulation and Magnetic Resonance Spectroscopy,2024-02,WITHDRAWN,2024-02-01,SPONSOR_INVESTIGATOR,SÃ¡ndor Beniczky,SÃ¡ndor Beniczky,"['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease', 'Cortical Excitability']",OBSERVATIONAL,0.0,ACTUAL,"[{'name': 'MRS, conventional TMS and treshold tracking TMS', 'description': 'Using\n\n* two MagStim 200 magnetic stimulator and a figure-of-eightc double 70 mm coil\n* SPECIAL MR Spectroscopy sequence\n\nIn addition, each group will undergo neurological examination'}]","['Treshold Tracking Transcranial Magnetic Stimulation', 'Magnetic Resonance Spectroscopy', 'Inter-rater agreement', 'Reproducibililty of Results', 'Case-control Studies', 'Biomarkers', 'Intra-rater agreement']","Patients will be recruited among patients examined at the Department of Neurophysiology who are referred for diagnostic neurophysiological examinations without any relation to the proposed project and at the Department of Neurology who are being examining for routine controls.

The healthy participants will be recruited by announcement at the homepage www.forsoegsperson.dk/ and by announcement at Aarhus University and Aarhus University Hospital"
A Study to Explore the Role of Gut Flora in ALS,2021-09,UNKNOWN,2023-07,SPONSOR,,ProgenaBiome,"['ALS', 'Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease']",OBSERVATIONAL,100.0,ESTIMATED,"[{'name': 'No intervention', 'description': 'There is no intervention for this study'}]",,Patients with ALS
Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS),2011-11,COMPLETED,2004-12,SPONSOR,,Novartis Pharmaceuticals,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,551.0,ACTUAL,[{'name': 'TCH346'}],"['ALS', ""Lou Gehrig's disease""]",
Accurate Test of Limb Isometric Strength (ATLIS) in ALS,2018-03,UNKNOWN,2020-02,PRINCIPAL_INVESTIGATOR,"Peggy Allred, PT DPT",Cedars-Sinai Medical Center,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,100.0,ESTIMATED,,"['outcomes measures', 'strength measurement', 'disease progression']",Adults with ALS
Clinical Evaluation of Florbetapir in Primary Progressive Aphasia,2021-02,COMPLETED,2017-02-28,PRINCIPAL_INVESTIGATOR,Emily Rogalski,Northwestern University,"['Primary Progressive Aphasia', 'Alzheimer Disease', 'Dementia']",OBSERVATIONAL,48.0,ACTUAL,"[{'name': 'Florbetapir F 18', 'description': 'A single injection of 10 mCi (370 MBq) florbetapir F 18 will be administered by intravenous bolus injection.'}, {'name': 'Positron Emission Tomography', 'description': 'PET Scan for brain imaging'}]","[""Alzheimer's Disease"", 'Dementia', 'Primary Progressive Aphasia', 'Neurocognitive Disorders', 'Speech Disorders']",Participants will be recruited from other research projects at Northwestern's Mesulam Center. Some of these projects recruit participants from the local Chicagoland area and others recruit participants from across the United States.
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments,2023-09,RECRUITING,2027-10-30,SPONSOR,,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,180.0,ESTIMATED,,,"Group 1: Be affected by Amyotrophic Lateral Sclerosis (ALS) definite, probable or possible (El Escorial criteria) sporadic SALS (no known history in the family) or familial FALS (at least one other member of the family affected)

Group 2: Be a carrier of a known mutation causing ALS and be asymptomatic

Group 3: Have a motor impairment related to ALS including the following pathologies: Motor neuropathy, myopathy, Myositis, Spastic paraplegia, Cram / fasciculation syndrome, Chronic inflammatory polyradiculitis, somatization disorder, Anterior spinal artery syndrome, encephalitis, myelitis, Peroneal neuropathy, cervical myelopathy with radiculopathy, spinocerebellar ataxia, Kennedy disease, Spinal atrophy, Hereditary distal motor neuropathy.

Group 4: Healthy control"
The Effect of Intensive Controlled Exercise in the Early Stages of Amyotrophic Lateral Sclerosis,2009-06,TERMINATED,2008-12,,,Radboud University Medical Center,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,20.0,ESTIMATED,[{'name': 'Intensive Controlled Exercise'}],"['Amyotrophic Lateral Sclerosis', 'Exercise', 'Fatigue', 'Quality-of-life']",
"A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral Sclerosis",2023-06,TERMINATED,2019-08-20,SPONSOR,,TikoMed AB,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,13.0,ACTUAL,"[{'name': 'ILB', 'description': 'The investigational medicinal product ILB will be given as single short-term s.c. injections in the abdomen, the thigh or the buttock, in that order of priority. Subjects will be observed for at least 3 hours after injection.The IMP is a sterile, colourless to pale yellow solution for subcutaneous injection.'}]",,
Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis,2023-11,RECRUITING,2024-07-31,SPONSOR,,UniversitÃ© de Sherbrooke,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,12.0,ESTIMATED,"[{'name': '89Zr-DFO-AP-101', 'description': 'At Day 0, patients will receive one dose of the radiotracer. A PET/CT scan will be done 2h post-dose.\n\nAt 1, 3, 7 and 10 days post-dose, a PET/CT scan will be repeated.'}]","['PET imaging', 'CT imaging', 'AP-101', '89-Zirconium', 'DFO']",
Treating Primary Progressive Aphasia (PPA) Using High-definition tDCS,2023-10,RECRUITING,2024-07,SPONSOR,,University of Pennsylvania,['Primary Progressive Aphasia'],INTERVENTIONAL,66.0,ESTIMATED,"[{'name': 'high-definition transcranial direct current stimulation', 'description': 'High definition transcranial direct current stimulation (HD-tDCS) involves the application of low-intensity current through electrodes placed on the scalp. It is believed to elicit brain effects by producing incremental shifts in the resting membrane potential of large numbers of neurons, which alters neuronal firing rates and thus modulates patterns of brain activity in potentially behaviorally-relevant ways. HD-tDCS differs from conventional transcranial direct current stimulation (tDCS) because it employed smaller electrodes configured in such a way as to deliver more focal stimulation of the brain.'}, {'name': 'modified constraint-induced language therapy', 'description': 'Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.'}]","['non-invasive brain stimulation', 'transcranial direct current stimulation (tDCS)', 'aphasia']",
Study of Predictive Factors of Progression of Motor Neurone Disease,2022-11,RECRUITING,2026-01,SPONSOR,,"University Hospital, Lille","['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease']",OBSERVATIONAL,1000.0,ESTIMATED,"[{'name': 'biomarkers (composite analysis)', 'description': 'biological, imaging, electrophysiological and anatomopathological examinations'}]","['multimodal biomarkers', 'prognosis', 'endophenotypes']","Multicentric French cohort of 1000 ALS patients, 100 neurological controls and 200 healthy controls"
Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol Cyclo (HPÎ²CD) in Niemann-Pick Disease Type C,2021-02,UNKNOWN,2022-03,SPONSOR,,"Cyclo Therapeutics, Inc.","['Niemann-Pick Disease, Type C1']",INTERVENTIONAL,12.0,ESTIMATED,"[{'name': 'Hydroxypropyl-Î²-cyclodextrin', 'description': 'HP-Î²-CD will be administered as TrappsolÂ® Cyclo 25% (250mg/mL) by slow intravenous infusion over a period of 8 up to 9 hours.'}]",,
Remotely Supervised tDCS for Slowing ALS Disease Progression,2023-10,ACTIVE_NOT_RECRUITING,2024-12,PRINCIPAL_INVESTIGATOR,Sangeetha Madhavan,University of Illinois at Chicago,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,100.0,ESTIMATED,"[{'name': 'Transcranial Direct Current Stimulation (tDCS)', 'description': 'Noninvasive brain stimulation'}, {'name': 'Sham tDCS + anodal tDCS', 'description': 'Fake noninvasive brain stimulation or anodal noninvasive brain stimulation'}]",,
Evaluating the Potential of the Diet as Disease Modifier in Amyotrophic Lateral Sclerosis (JERN_ALS),2015-09,COMPLETED,2018-10,PRINCIPAL_INVESTIGATOR,"Christine Dawczynski,PhD",University of Jena,"['Amyotrophic Lateral Sclerosis', 'Dietary Habits', 'Disorder of Fatty Acid Metabolism']",OBSERVATIONAL,50.0,ACTUAL,,"['fatty acids, amyotrophic lateral sclerosis, nutrient status']",ALS patients diagnosed according to El Escorial / Awaji criteria for ALS
Analysis of Human ALS Tissues and Registry of ALS Patients,2022-11,RECRUITING,2025-08-30,PRINCIPAL_INVESTIGATOR,Jeffrey A Loeb,University of Illinois at Chicago,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,40.0,ESTIMATED,,"['Amyotrophic Lateral Sclerosis (ALS)', ""Lou Gehrig's Disease"", 'Neurodegenerative Diseases', 'Neuromuscular Diseases', 'Nervous System Diseases']","Patients aged \> 18 years with a diagnosis of ALS being seen at the Neuromuscular Center Clinics, University of Illinois at Chicago"
More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease,2021-05,COMPLETED,2020-12-31,SPONSOR,,"University of Colorado, Denver","['Parkinson Disease', 'Parkinsonism', 'Lewy Body Disease', 'Supranuclear Palsy, Progressive', 'Parkinsonism Vascular', 'Multiple System Atrophy', 'Corticobasal Degeneration', 'Alzheimer Disease', 'Frontotemporal Dementia', 'Primary Progressive Aphasia', 'Vascular Dementia']",INTERVENTIONAL,783.0,ACTUAL,"[{'name': 'Palliative Care', 'description': 'Palliative care training for community neurologists and use of telemedicine for team-based support of patients'}]","['Palliative Care', 'Supportive Care', 'Movement Disorders', 'Brain Disease', 'Neurodegeneration', ""Parkinson's Disease"", ""Alzheimer's Disease""]",
Immunosuppression in Amyotrophic Lateral Sclerosis (ALS),2017-11,COMPLETED,2016-01,PRINCIPAL_INVESTIGATOR,"Jonathan D. Glass, M.D.",Emory University,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,31.0,ACTUAL,"[{'name': 'Basiliximab', 'description': '20 mg, IV (in the vein) on day 1 and 4.'}, {'name': 'Methylprednisolone', 'description': '125 mg, IV (in the vein) on day 1.'}, {'name': 'Prednisone', 'description': '60 mg PO (by mouth) on days 2-7, 40 mg PO days 8-14, 20 mg PO days 15-21, and 10mg PO days 22-28.'}, {'name': 'Tacrolimus', 'description': '1-5 mg PO, twice a day (BID) days 2-180.'}, {'name': 'Mycophenolate mofetil', 'description': '500 mg PO, BID days 2-7, 500 mg PO each morning and 1000 mg each night, days 8-14, 1000 mg PO BID days 15-180.'}]","['Immunosuppression', 'ALS', 'Neuromuscular Disorders']",
Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease,2001-12,COMPLETED,,,,National Center for Research Resources (NCRR),"['Spinal Muscular Atrophy', 'Amyotrophic Lateral Sclerosis', 'Spinobulbar Muscular Atrophy']",INTERVENTIONAL,40.0,,"[{'name': 'leuprolide'}, {'name': 'testosterone'}]","['amyotrophic lateral sclerosis', 'motor neuron disease', 'neurologic and psychiatric disorders', 'rare disease', 'spinal and bulbar muscular atrophy', 'spinal muscular atrophy', ""Kennedy's Syndrome""]",
A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension Study,2022-10,RECRUITING,2023-10-31,SPONSOR,,Haukeland University Hospital,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,300.0,ESTIMATED,"[{'name': 'EH301 (Nicotinamide Riboside/Pterostilbene)', 'description': 'For this study EH301 is defined as Investigational Product(s) (IP). The ALS extension study is an open label study with active treatment of all patients thet have passed through the NO-ALS trial.'}]",,
Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis,2020-12,TERMINATED,2020-10-28,SPONSOR,,Centre Hospitalier Universitaire de Saint Etienne,['ALS (Amyotrophic Lateral Sclerosis)'],OBSERVATIONAL,136.0,ACTUAL,"[{'name': 'Diaphragmatic endurance test', 'description': 'This consists of hyperventilation in a flask while maintaining the constant level of Carbon Dioxide (CO2). The patient will realize hyperventilation to increasing levels of Maximum Minute Ventilation (MMV), corresponding to increasing levels of respiratory rate, until exhaustion'}]","['Amyotrophic Lateral Sclerosis', 'ALS', 'Diaphragmatic Endurance Test']",Patients with ALS Healthly volonteers
Treatment of Primary CNS Lymphoma ( FTD ),2022-03,COMPLETED,2019-03-02,SPONSOR_INVESTIGATOR,Mingzhi Zhang,Mingzhi Zhang,['Primary CNS Lymphoma (PCNSL)'],INTERVENTIONAL,20.0,ACTUAL,"[{'name': 'HD-MTX-Ara-C regimen', 'description': 'HD-MTX-Ara-C regimen high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine\n\n1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles'}, {'name': 'FTD regimen', 'description': 'FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,temozolomide 150mg/m2 d1-5 po,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 28 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles'}]","['primary CNS lymphoma', 'chemotherapy', 'RR', 'PFS', 'OS']",
Microglial Activation Role In ALS (MARIA),2017-05,WITHDRAWN,2017-03,SPONSOR,,"University Hospital, Tours",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,0.0,ACTUAL,"[{'name': '[18F]DPA-714 PET', 'description': '\\[18F\\]DPA-714 Positron Emission Tomography'}]","['amyotrophic lateral sclerosis disease', 'PET', 'microglial activation']",
Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS),2020-01,COMPLETED,2016-07-27,SPONSOR_INVESTIGATOR,"Richard Barohn, MD","Richard Barohn, MD",['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,80.0,ACTUAL,"[{'name': 'Rasagiline', 'description': 'Rasagiline 2mg once a day for 12 months.'}, {'name': 'Placebo', 'description': 'Placebo (looks like study drug but has no active ingredients) once a day for 12 months.'}]",,
Study of ALS Reversals 2: Genetic Analyses,2024-01,COMPLETED,2023-12-01,SPONSOR,,Duke University,"['Amyotrophic Lateral Sclerosis', 'Progressive Muscular Atrophy']",OBSERVATIONAL,26.0,ACTUAL,,"['amyotrophic lateral sclerosis', 'progressive muscular atrophy', 'motor neuron disease', 'ALS reversals', 'whole genome sequencing']",Participants will be enrolled by invitation only. Potential participants will have had a previously verified diagnosis of ALS or PMA and a verified sustained and robust reversal of disease.
Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS),2012-03,COMPLETED,2007-08,,,The University of Texas Health Science Center at San Antonio,"['Amyotrophic Lateral Sclerosis', 'Sialorrhea']",INTERVENTIONAL,20.0,,"[{'name': 'Botulinum toxin type B (Myobloc)'}, {'name': 'Injection of salivary glands'}]","['ALS', ""Lou Gehrig's Disease"", 'Motor Neuron Disease', 'Amyotrophic Lateral Sclerosis', 'Sialorrhea', 'Hypersalivation', 'Excessive Drooling', 'Myobloc', 'botulinum toxin type B', 'Clostridium botulinum B toxin', 'botulinum B toxin', 'botulinum neurotoxin B', 'NeuroBloc']",
"PREDIGA 2: Spanish Acronym of ""Educational and Diagnostic Project for Gaucher and ASMD""",2022-12,RECRUITING,2025-12-31,SPONSOR,,FundaciÃ³n EspaÃ±ola de HematologÃ­a y HemoterapÃ­a,"['Gaucher Disease', 'Acid SphingoMyelinase Deficiency', 'ASMD', 'Niemann-Pick Diseases', 'Splenomegaly']",OBSERVATIONAL,200.0,ESTIMATED,"[{'name': 'Patient with splenomegaly or splenectomy', 'description': 'No interventional study'}]",,Patients with splenomegaly and unknown splenectomized
A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS),2020-05,UNKNOWN,2020-12-31,PRINCIPAL_INVESTIGATOR,DR. LAWRENCE KORNGUT,University of Calgary,"['ALS', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,100.0,ESTIMATED,"[{'name': 'Pimozide 2mg/day (current) or 4 mg/day (study initiation)', 'description': 'Pimozide 2mg tablets will be taken once daily.'}, {'name': 'Placebo Oral Tablet', 'description': 'Identical matching placebo lactose tablets'}]",['Pimozide'],
Developing a Discrimination Model to Diagnose ALS,2018-05,COMPLETED,2015-10,SPONSOR,,University of Michigan,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,50.0,ACTUAL,"[{'name': 'MRI(magnetic resonance imaging)', 'description': 'Subjects with amyotrophic lateral sclerosis and lower neuron motor skills and healthy subjects will undergo an MRI(magnetic resonance imaging)scans of the brain to assess neurologic condition. The brain scans will take approximately 60 minutes to complete.'}]",,
Telehealth Implementation of Brain-Computer Interface,2023-07,RECRUITING,2024-07-05,PRINCIPAL_INVESTIGATOR,Colin Franz,Shirley Ryan AbilityLab,"['Amyotrophic Lateral Sclerosis', 'Stroke']",INTERVENTIONAL,7.0,ESTIMATED,"[{'name': 'Use of BCI', 'description': 'Clients will utilize BCI with training to communicate wants and needs'}]",['locked in syndrome'],
Determining Feasibility and Acceptability of Sharing Video Recordings With Patients With ALS and Caregivers,2023-02,COMPLETED,2022-06-09,PRINCIPAL_INVESTIGATOR,Paul J. Barr,Dartmouth-Hitchcock Medical Center,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,79.0,ACTUAL,"[{'name': 'HealthPAL', 'description': 'Participants who are randomly assigned to the HealthPAL arm will have immediate post- visit access to audio/video-recordings of their clinical visit through a HIPAA-compliant web-based program called HealthPAL.'}]","['neurology', 'health communications']",
Cognitive Impairement In Frontotemporal Dementia,2020-11,COMPLETED,2020-07-15,SPONSOR,,University of Pennsylvania,"['Frontotemporal Degeneration', 'Progressive Supranuclear Palsy', 'Multiple System Atrophy']",OBSERVATIONAL,997.0,ACTUAL,"[{'name': 'None-Observation Only', 'description': 'No intervention-this is an observational study'}]",,"All individuals with a diagnosis of FTD, PSP, or MSA, previously identified by the PI and sub-investigators through other FTD studies (protocol number 702681) and through the PI's extensive FTD clinical practice at the University of Pennsylvania and at Pennsylvania Hospital's Department of Neurology, will be recruited through letters, brochures, and study flyers."
A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS,2016-01,TERMINATED,2015-10,SPONSOR,,Newron Sweden AB,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,15.0,ACTUAL,"[{'name': 'sNN0029'}, {'name': 'Placebo'}]",,
"Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)",2023-04,TERMINATED,2022-05-03,SPONSOR,,Biogen,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,75.0,ACTUAL,"[{'name': 'BIIB078', 'description': 'Administered as specified in the treatment arm.'}]",,
Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection,2022-11,RECRUITING,2023-12,PRINCIPAL_INVESTIGATOR,Takayuki Yoshino,National Cancer Center Hospital East,"['Colorectal Neoplasms', 'Trifluridine and Tipiracil', 'Circulating Tumor DNA']",INTERVENTIONAL,240.0,ESTIMATED,"[{'name': 'trifluridine and tipiracil', 'description': 'Trifluridine and tipiracil will be orally administered twice daily on Days 1 to 5 and Days 8 to 12. The administration will be repeated until completion of 6 courses(one course consists of 28 days) or until any discontinuation criterion is met.'}, {'name': 'Placebo', 'description': 'Placebo will be orally administered twice daily on Days 1 to 5 and Days 8 to 12. The administration will be repeated until completion of 6 courses(one course consists of 28 days) or until any discontinuation criterion is met.'}]","['Colorectal Neoplasms', 'Gastrointestinal Neoplasms', 'Digestive System Diseases', 'Gastrointestinal Diseases', 'Antineoplastic Agents', 'trifluridine and tipiracil']",
"A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation",2023-10,ACTIVE_NOT_RECRUITING,2026-07-15,SPONSOR,,Biogen,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,99.0,ACTUAL,"[{'name': 'BIIB105', 'description': 'Administered as specified in the treatment arm.'}, {'name': 'Placebo', 'description': 'Administered as specified in the treatment arm.'}]",,
A Safety and Tolerability Study of ILB in Patients With Amyothrophic Lateral Sclerosis (ALS),2021-10,COMPLETED,2021-07-28,SPONSOR,,University of Birmingham,"['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease']",INTERVENTIONAL,11.0,ACTUAL,"[{'name': 'ILB', 'description': 'Administration will be weekly subcutaneous injections at a dose of 2mg/kg once per week for up to a maximum of 48 weeks'}]","['ILB', 'Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease', 'ALS']",
"Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis",2019-02,COMPLETED,2018-09,PRINCIPAL_INVESTIGATOR,"Albert Christian Ludolph, Prof.",University of Ulm,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,207.0,ACTUAL,"[{'name': 'Calogen'}, {'name': 'Placebo'}]","['amyotrophic lateral sclerosis', 'survival time', 'ALS Functional Rating Scale', 'quality of life', 'survival']",
Localized Analysis of Normalized Distance From Scalp to Cortex and Personalized Evaluation (LANDSCAPE),2023-12,RECRUITING,2025-06-14,PRINCIPAL_INVESTIGATOR,LU Hanna,Chinese University of Hong Kong,"['Aging', 'Dementia Alzheimers', 'Parkinson Disease', 'Dementia Frontotemporal', 'Depression in Old Age']",OBSERVATIONAL,488.0,ESTIMATED,"[{'name': 'Transcranial Magnetic Stimulation', 'description': 'One time for each day, lasting for three weeks.'}]","['Aging', 'Scalp-to-cortex distance', 'Transcranial brain stimulation', 'Parkinson disease', 'Simulation', 'Predictor']",Healthy normal ageing adults and adults with neurocognitive disorders
Brown Adipose Tissue in ALS,2021-08,COMPLETED,2019-04-01,SPONSOR,,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,10.0,ACTUAL,"[{'name': 'Indirect Calorimetry.', 'description': 'REE measurement'}, {'name': '18-FDG-PET', 'description': '18-FDG-PET'}]",,
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS,2016-07,COMPLETED,2002-04,,,Avanir Pharmaceuticals,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,100.0,,[{'name': 'AVP-923'}],"['AVP-923', 'Dextromethorphan', 'Quinidine', 'Pseudobulbar Affect']",
Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS,2023-11,COMPLETED,2023-11-01,PRINCIPAL_INVESTIGATOR,Paul Lingor,University Medical Center Goettingen,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,120.0,ACTUAL,"[{'name': 'Fasudil', 'description': 'Fasudil hydrochloride hydrate IV solution'}, {'name': 'Placebo', 'description': 'Placebo to Fasudil hydrochloride hydrate, NaCl 0,9%'}]","['Motor neuron disease', 'Neurodegenerative disease']",
Network Modulation in Alzheimer's Disease,2022-03,COMPLETED,2022-03-01,PRINCIPAL_INVESTIGATOR,"Mark Eldaief, MD",Brigham and Women's Hospital,"['Alzheimer Disease', 'Primary Progressive Aphasia', 'Mild Cognitive Impairment']",INTERVENTIONAL,11.0,ACTUAL,"[{'name': 'repetitive transcranial magnetic stimulation (rTMS)', 'description': 'rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.'}]",,
"Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)",2020-06,COMPLETED,2019-09-23,SPONSOR,,Biogen,"['Frontotemporal Dementia', 'Behavioral Variant Frontotemporal Dementia']",OBSERVATIONAL,47.0,ACTUAL,"[{'name': 'Assessments', 'description': 'Cognitive, Behavioral and Functional as described in the Outcome Measures'}]","['Longitudinal', 'Caregiver', 'Cognitive assessments', 'Behavioral assessments', 'Functional assessments']","Academic centers, Hospitals, Clinics"
Presepsin as a Predictor for Postoperative Complications Following Pancreatic Resection,2020-02,COMPLETED,2019-12-31,SPONSOR,,Medical University Innsbruck,['Postoperative Complications'],INTERVENTIONAL,86.0,ACTUAL,"[{'name': 'Blood draw', 'description': 'One additional blood sample for study purpose from the day before surgery, postoperative 1, 3 and 8.'}]","['Pancreatic resection', 'POPF', 'Inflammatory response']",
Study of Structural and Functional Brain Connectivity Changes in ALS (CoALS-II),2023-07,COMPLETED,2024-01-08,SPONSOR,,Dartmouth-Hitchcock Medical Center,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,31.0,ACTUAL,"[{'name': 'fMRI', 'description': 'fMRI scan for 1 hour'}]","['Amyotrophic Lateral Sclerosis', 'Functional Magnetic Resonance Imaging', 'Connectivity', 'Diffusion Tensor Imaging', 'Dynamometer']",
High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis,2015-02,COMPLETED,2013-05,PRINCIPAL_INVESTIGATOR,"Anne-Marie Alexandra Wills, MD",Massachusetts General Hospital,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,28.0,ACTUAL,"[{'name': 'Oxepa', 'description': 'Oxepa: Tube feed containing 1.5 calories/ml of which 55% calories are from fat, including eicosapentaenoic acid and gamma-linolenic acid. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.'}, {'name': 'Jevity 1.5', 'description': 'Jevity 1.5: Tube feed containing 1.5 calories/ml of which 29.4% are from fat. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.'}, {'name': 'Jevity 1.0', 'description': 'Jevity 1.0: Control tube feed. Subjects will receive 1.0 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.'}]","['Amyotrophic Lateral Sclerosis', 'ALS', 'Motor Neuron Disease', 'MND', 'Fat', 'Lipid', 'Cholesterol', 'Omega-3 fatty acid', 'Diet', 'Tube feed', 'Gastrostomy', 'PEG', 'Adults with Amyotrophic Lateral Sclerosis (ALS)']",
A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis,2019-08,COMPLETED,2019-01-31,PRINCIPAL_INVESTIGATOR,Anthony J. Windebank,Mayo Clinic,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,27.0,ACTUAL,"[{'name': 'autologous mesenchymal stem cells', 'description': 'There will be five treatment groups of up to five patients each. Groups 1, 2 and 4 will receive a single dose of cells. Groups 3 and 5 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:\n\n* Group 1: single intrathecal dose of 1 x 107 cells\n* Group 2: single intrathecal dose of 5 x 107 cells\n* Group 3: one intrathecal dose of 5 x 107 cells followed one month later by a second intrathecal dose of 5 x 107 cells\n* Group 4: single intrathecal dose of 1 x 108 cells\n* Group 5: one intrathecal dose of 1 x 108 cells followed one month later by a second intrathecal dose of 1 x 108 cells'}]",,
"Multifactorial Approach to Dementia, Multicentric Study",2023-07,RECRUITING,2024-09-20,SPONSOR_INVESTIGATOR,Daniel Serrani Azcurra,Daniel Serrani Azcurra,"['Dementia of Alzheimer Type', 'Dementia Frontotemporal', 'Narcissistic Personality Disorder', 'Depression', 'Personality Change']",OBSERVATIONAL,450.0,ESTIMATED,,,"individuals eligible to participate were diagnosed with dementia, or had inconclusive results living at the community or residential institutions invited to attend a follow-up, cognitively healthy or minimally impaired, or had mild cognitive impairment (MCI), or dementia"
HEALEY ALS Platform Trial - Master Protocol,2024-01,RECRUITING,2026-04,SPONSOR_INVESTIGATOR,"Merit E. Cudkowicz, MD","Merit E. Cudkowicz, MD",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,1500.0,ESTIMATED,"[{'name': 'Zilucoplan', 'description': 'Drug: Zilucoplan\n\nAdministration: Subcutaneous injection\n\nDose: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight'}, {'name': 'Verdiperstat', 'description': 'Drug: Verdiperstat\n\nAdministration: Oral\n\nDose: 600mg twice daily'}, {'name': 'CNM-Au8', 'description': 'Drug: CNM-Au8\n\nAdministration: Oral\n\nDose: 30 mg or 60 mg daily'}, {'name': 'Pridopidine', 'description': 'Drug: Pridopidine\n\nAdministration: Oral\n\nDose: 45mg twice daily'}, {'name': 'SLS-005 Trehalose', 'description': 'Drug: SLS-005 Trehalose\n\nAdministration: Infusion\n\nDose: 0.75 g/kg weekly'}, {'name': 'ABBV-CLS-7262', 'description': 'Drug: ABBV-CLS-7162\n\nAdministration: Oral\n\nDose: Dose 1 or Dose 2'}, {'name': 'DNL343', 'description': 'Drug: DNL343\n\nAdministration: Oral\n\nDose: Once per day'}]","['ALS', 'Placebo-Controlled', 'Double-Blind', 'Master Protocol', ""Lou Gehrig's Disease""]",
Food Supplement for the Treatment of Patients With Amyotrophic Lateral Sclerosis,2022-08,WITHDRAWN,2022-05,SPONSOR,,Herb Spirit,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Spirit1', 'description': 'Spirit 1 is a combination of phospholipids and anti-oxidant medicinal plants'}]",,
Amyotrophic Lateral Sclerosis Non-invasive Ventilation Exchange,2023-04,RECRUITING,2025-05,SPONSOR,,"University Hospital, Montpellier",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,58.0,ESTIMATED,"[{'name': 'Telerehabilitation solution (m-Rehab)', 'description': ""Patients in the experimental group will have access to a multimodal digital platform (m-RehabÂ®). The solution includes a website and an application available on smart phones for the patient and caregivers. Patients and caregivers will have access to educational content about the condition and its treatments, NIV compliance data, digital group educational workshops, secure messaging and video conferencing.\n\nAll the professionals forming the patient's circle of care will be able to have access to the solution, after the patient's authorization. The circle of care, in a non-exhaustive way, includes specialist doctors, the general practitioner, the staff of the reference center of the Montpellier University Hospital, the physiotherapist, the speech therapist, the dietician and the psychologist.""}, {'name': 'Usual management including NIV.', 'description': 'Usual management including NIV.'}]","['Amyotrophic lateral sclerosis (ALS)', 'Non invasive ventilation', 'Telemonitoring', 'Telemedicine', 'Multidisciplinary approach']",
Safety Extension Study of TRO19622 in ALS,2016-11,COMPLETED,2012-03,SPONSOR,,Hoffmann-La Roche,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,271.0,ACTUAL,"[{'name': 'TRO19622', 'description': '2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid'}]","['Amyotrophoc Lateral Sclerosis', 'TRO19622', 'Olesoxime', 'Trophos']",
Safety Study of Intranasal Oxytocin in Frontotemporal Dementia,2013-11,COMPLETED,,PRINCIPAL_INVESTIGATOR,Elizabeth Finger,Lawson Health Research Institute,['Frontotemporal Dementia'],INTERVENTIONAL,23.0,ACTUAL,"[{'name': 'oxytocin', 'description': 'Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week'}, {'name': 'Saline Nasal Mist', 'description': 'Placebo arm wil receive saline nasal mist sprays matched in number to oxytocin dose cohorts'}]","['Frontotemporal Dementia', 'oxytocin', ""Pick's disease""]",
Effect of Electrical Stimulation (DC Polarization) to the Brain on Memory,2013-03,COMPLETED,2010-04,SPONSOR,,National Institute of Neurological Disorders and Stroke (NINDS),['Healthy'],INTERVENTIONAL,45.0,ACTUAL,"[{'name': 'DC brain polarization', 'description': '0.08 mA/cm2'}]","['Frontal Lobe', 'Language', 'Dementia', 'Healthy Volunteer', 'HV']",
In-Home Technology for Dementia Caregivers,2022-04,COMPLETED,2020-11-27,PRINCIPAL_INVESTIGATOR,Robert Levenson,"University of California, Berkeley","['Dementia', ""Alzheimer's Disease"", 'Frontotemporal Dementia']",INTERVENTIONAL,78.0,ACTUAL,"[{'name': 'In-home technology', 'description': 'Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using a trusted circle of friends and family who are encouraged to stay in contact and share photos and videos with the caregiver and person with dementia via the digital display.'}, {'name': 'Limited in-home technology', 'description': 'Intelligent bot monitors the in-home water leak sensor and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome conditions occur.'}]","['Caregivers', 'Dementia', 'In-Home Assistive Technology']",
Enhancing Language Function in Aphasia,2023-09,RECRUITING,2028-12-15,SPONSOR,,University of Arizona,"['Aphasia, Acquired', 'Language Disorders', 'Primary Progressive Aphasia', 'Stroke, Cerebrovascular']",INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'individualized speech-language training', 'description': 'Language treatment might include lexical, semantic, and interactive treatment. During treatment, patients may be trained to name words by attempting to self-cue lexical retrieval. The therapy moves incrementally through semantic cuing. The semantic treatment will be implemented using the methods described in (Edmonds et al., 2009, 2014).'}, {'name': 'standard language intervention', 'description': 'Participants will undergo standard speech-language naming therapy'}]",,
Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders,2015-05,TERMINATED,2011-12,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,"['Duchenne Muscular Dystrophy', 'Amyotrophic Lateral Sclerosis', 'Neuromuscular Diseases']",INTERVENTIONAL,14.0,ACTUAL,"[{'name': 'mechanical insufflation - exsufflation', 'description': 'Patients will receive MI-E treatment with the following settings: insufflation pressure of at least +30 cm H2O and an exsufflation pressure â‰¥ -30 cm H2O. There will be at least 6 hyperinflation/exsufflation sequences per session of chest physiotherapy. There will be at least two daily sessions done routinely by the respiratory therapist at 8 hour intervals.'}, {'name': 'Standard respiratory physiotherapy', 'description': 'Traditional chest physiotherapy without mechanical insufflation-exsufflation'}]","['Cough assisted device', 'Neuromuscular disease', 'Respiratory exacerbation', 'Invasive ventilation,', 'Chest physiotherapy', 'Congenital myopathies']",
"Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.",2014-09,COMPLETED,2013-04,SPONSOR,,Avid Radiopharmaceuticals,"[""Alzheimer's Disease"", 'Frontotemporal Dementia']",INTERVENTIONAL,34.0,ACTUAL,"[{'name': 'florbetapir 18F', 'description': 'Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.'}, {'name': '18F-FDG', 'description': 'FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.'}]",,
Extension Study Evaluating The Safety And Tolerability of AMX0035,2024-01,ENROLLING_BY_INVITATION,2026-08,SPONSOR,,Amylyx Pharmaceuticals Inc.,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,600.0,ESTIMATED,"[{'name': 'AMX0035', 'description': 'Combination of 3 g phenylbutyrate and 1 g taurursodiol'}]",,
Online Self-Compassion Course for pALS (Compassion pALS),2022-06,COMPLETED,2022-06-01,SPONSOR,,Washington University School of Medicine,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,5.0,ACTUAL,"[{'name': 'Observational for ALS patients', 'description': 'Open to ALS patients interested in mindfulness training.'}]",,ALS participants will be recruited from a Neuromuscular clinic.
Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,2017-03,COMPLETED,2009-09,SPONSOR,,Avanir Pharmaceuticals,['Pseudobulbar Affect (PBA)'],INTERVENTIONAL,326.0,ACTUAL,"[{'name': 'dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg', 'description': 'Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 20 mg/ Q 10 mg, taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period'}, {'name': 'dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg', 'description': 'Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 30 mg/ Q 10 mg taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period'}, {'name': 'Placebo', 'description': 'Placebo capsules (identical in appearance to AVP-923 capsules being studied in this trial), taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period'}]","[""Amyotrophic Lateral Sclerosis (Lou Gehrig's disease, ALS)"", 'Multiple Sclerosis (MS)']",
Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes,2020-03,COMPLETED,2020-03,SPONSOR,,"University Hospital, Lille","[""Parkinson's Disease"", 'Amyotrophic Lateral Sclerosis', 'Oxidative Stress', 'Iron Overload']",INTERVENTIONAL,90.0,ACTUAL,"[{'name': 'deferiprone', 'description': 'to test the action of deferiprone on lymphocytes from patients and controls ex vivo'}, {'name': 'placebo', 'description': 'to control the action of placebo on lymphocytes from patients and controls ex vivo'}]","[""Parkinson's disease"", 'Amyotrophic lateral sclerosis', 'Peripheral blood mononuclear cells', 'ex vivo model for oxidative stress', 'iron metabolism and chelation']",
"Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease",2009-01,COMPLETED,2008-06,SPONSOR,,Duke University,"['Motor Neuron Disease', 'Amyotrophic Lateral Sclerosis', 'Primary Lateral Sclerosis', 'Progressive Muscular Atrophy']",INTERVENTIONAL,20.0,ACTUAL,"[{'name': 'Levetiracetam', 'description': 'Levetiracetam 1500 mg BID'}]","['motor neuron disease', 'amyotrophic lateral sclerosis primary lateral', 'sclerosis; progressive muscular atrophy', 'cramps', 'spasticity']",
"Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency",2022-03,COMPLETED,2019-12-09,SPONSOR,,"Genzyme, a Sanofi Company",['Sphingomyelin Lipidosis'],INTERVENTIONAL,20.0,ACTUAL,"[{'name': 'Olipudase alfa', 'description': 'Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous infusion'}]",,
Mexiletine in Sporadic Amyotrophic Lateral Sclerosis,2019-11,COMPLETED,2018-09-30,PRINCIPAL_INVESTIGATOR,Michael D Weiss,University of Washington,['Sporadic Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,20.0,ACTUAL,"[{'name': 'Mexiletine'}, {'name': 'Placebo'}]","['SALS', 'Mexiletine', 'TMS', 'NCS']",
Longitudinal Assessment of Autonomic and Sensory Nervous System in ALS,2023-01,RECRUITING,2024-05,SPONSOR,,Istituti Clinici Scientifici Maugeri SpA,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,100.0,ESTIMATED,"[{'name': 'Skin biopsy', 'description': 'A punch skin biopsy of 3mm will be used to analyze cutaneous innervation'}, {'name': 'Cardiovascular Reflexes testing', 'description': 'Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.'}, {'name': 'Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms', 'description': ""We'll characterize patients' symptoms through the administration of clinical scales such as: SCOPA-AUT autonomic symptoms scale; Brief Pain Inventory questionnaire""}, {'name': 'Dinamic Sweat Test', 'description': 'Test for the functional assessment of postganglionic sudomotor pathway'}]","['Autonomic nervous system', 'skin biopsy', 'biomarkers', 'cutaneous sensory an autonomic innervation']",
Diagnosing Frontotemporal Lobar Degeneration,2019-04,UNKNOWN,2019-12,PRINCIPAL_INVESTIGATOR,Carmela Tartaglia,"University Health Network, Toronto","['Corticobasal Syndrome', 'Progressive Supranuclear Palsy', 'Behavioral Variant Frontotemporal Dementia', 'Semantic Dementia', 'Progressive Nonfluent Aphasia', 'Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia']",OBSERVATIONAL,100.0,ESTIMATED,[{'name': 'Observational Study'}],,"Patients with a diagnosis of progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), semantic variant primary progressive aphasia (sv-PPA), non-fluent variant PPA (nfv-PPA), behavioral variant frontotemporal dementia (bvFTD) or FTD-motor neuron disease (FTD-MND)."
Restore Motor Function Through Robotic Arm Exoskeleton and Brain Computer Interface,2019-03,UNKNOWN,2022-12-31,SPONSOR,,University of Aarhus,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,15.0,ESTIMATED,"[{'name': 'REMAP EEG based BCI and SEM-Glove BioServo', 'description': 'EEG-based brain computer interface (BCI) will be adapted to individual ALS patients and modified to control external robotic devices'}]",['brain computer interface'],
Transmagnetic Stimulation Pilot in Primary Progressive Aphasia,2023-10,ENROLLING_BY_INVITATION,2024-03,SPONSOR,,HealthPartners Institute,['Primary Progressive Aphasia'],INTERVENTIONAL,3.0,ESTIMATED,"[{'name': 'Intermittent theta burst stimulation', 'description': 'MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz'}]","['transmagnetic stimulation', 'functional MRI guided Theta Burst Stimulation']",
Influence of G-CSF and EPO on Associative Learning and Motor Skills,2007-04,COMPLETED,2009-03,,,University Hospital Muenster,"['Chronic Stroke', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,180.0,ESTIMATED,"[{'name': 'granulocyte - colony stimulating factor (G-CSF)'}, {'name': 'erythropoetin (EPO)'}]",,
Preventing Language Decline in Dementia,2019-07,COMPLETED,2019-01-31,PRINCIPAL_INVESTIGATOR,Regina Jokel,Baycrest,['Primary Progressive Aphasia'],INTERVENTIONAL,20.0,ACTUAL,"[{'name': 'Language therapy', 'description': 'Participants will receive semantic and phonological therapy for words they cannot retrieve spontaneously. They will be given an opportunity to practice the words in a group setting.'}]",,
Trial of Ascertaining Individual Preferences for Loved One's Role in End-of-Life,2018-08,COMPLETED,2014-03-26,SPONSOR,,Johns Hopkins University,"['Amyotrophic Lateral Sclerosis', 'GI Cancer', 'Pancreatic Cancer']",INTERVENTIONAL,431.0,ACTUAL,"[{'name': 'TAILORED Patient Family Decision Making', 'description': 'Patient-family dyads will receive TAILORED intervention on health decision making'}, {'name': 'standard of care', 'description': 'Patient-family dyads will receive standard of care in health decision-making'}]",,
SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS),2017-05,COMPLETED,2016-05,PRINCIPAL_INVESTIGATOR,Dr. Dale J. Lange,Weill Medical College of Cornell University,['Familial Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,32.0,ACTUAL,"[{'name': 'Pyrimethamine', 'description': 'Open Label, dose escalating,'}]","['ALS', 'Familial ALS', 'SOD1 Gene Mutation']",
Safety and Tolerability of RAG-17 in the Treatment of Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation,2023-06,ENROLLING_BY_INVITATION,2024-02-28,PRINCIPAL_INVESTIGATOR,yilong Wang,Beijing Tiantan Hospital,['Gene Mutation'],INTERVENTIONAL,6.0,ESTIMATED,"[{'name': 'RAG-17', 'description': 'RAG-17 60mg is used'}]","['RAG-17', 'SOD1 Gene Mutation', 'Amyotrophic Lateral Sclerosis']",
A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV,2023-12,SUSPENDED,2026-02,SPONSOR,,Immunity Pharma Ltd.,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,15.0,ESTIMATED,"[{'name': 'IPL344', 'description': 'IPL344 will be administered by intravenously (IV) infusion once a day (every 24Â±6 hours), using a Peripherally Inserted Central Catheter (PICC) line or a permanent port. IPL344 will be administered using an electronic pump at a flow rate that will be determined in protocol 101/2. The dose will be fixed as MTD as established in protocol 101/2 (up to 3.2 mg/kg).'}]",,
RAPA-501 Therapy for ALS,2023-08,RECRUITING,2025-07-01,SPONSOR,,Rapa Therapeutics LLC,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,41.0,ESTIMATED,"[{'name': 'RAPA-501 Autologous T cells', 'description': 'TREG/Th2 cells'}]","['Amyotrophic Lateral Sclerosis', 'Autologous TREG/Th2 cell therapy', 'RAPA-501']",
Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency,2019-10,TERMINATED,2018-10-30,SPONSOR,,"Alexion Pharmaceuticals, Inc.",['Lysosomal Acid Lipase Deficiency'],INTERVENTIONAL,10.0,ACTUAL,"[{'name': 'Sebelipase Alfa', 'description': 'Sebelipase alfa is a recombinant human lysosomal acid lipase. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL-D. Dosing occurred once weekly for up to 3 years.'}]","['LIPA', 'Wolman Disease', 'Wolman Phenotype', 'Acid Lipase Deficiency', 'Acid Cholesteryl Hydrolase', 'Acid Lipase Disease Deficiency, type 2', 'Cholesteryl Ester Storage Disease (CESD)', 'Cholesteryl Ester Hydrolase Deficiency', 'Early Onset Lysosomal Acid Lipase Deficiency (Wolman Disease)', 'LAL Deficiency', 'Late Onset Lysosomal Acid Lipase Deficiency (CESD)', 'Wolman Disease (early onset LAL Deficiency)', 'Related Disorders:', 'Non-alcoholic Fatty Liver Disease (NAFLD)', 'Non-alcoholic Steatohepatitis (NASH)', 'Alcoholic Liver Disease', 'Cryptogenic Cirrhosis', 'Niemann-Pick Disease (NPD) Type C', 'Chanarin Dorfman Syndrome']",
Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD),2023-05,TERMINATED,2017-05,SPONSOR,,TauRx Therapeutics Ltd,"[""Alzheimer's Disease"", 'Behavioral Variant Frontotemporal Dementia']",INTERVENTIONAL,913.0,ACTUAL,"[{'name': 'LMTM', 'description': 'The initial LMTM dose was 200 mg/day (one 100-mg tablet twice daily), except in subjects with bvFTD who were taking a reduced dose (i.e., 100 mg/day) upon entering this extension study. The dose could be increased (after at least 13 weeks of treatment) or decreased (at any time at or after 2 weeks of treatment) by the Investigator in 100-mg increments or decrements. The maximum allowable dose was 300 mg/day (or in those countries where limited by a Competent Authority or Ethics Committee, 200 mg/day).'}]","['Dementia', 'Alzheimer Disease', 'bvFTD', 'Frontotemporal Dementia', 'Neurodegenerative Diseases', 'Brain Diseases', 'Cognitive Disorders']",
An Assistive Powered Wheelchair: Stage 2 Trial,2022-07,COMPLETED,2021-08-31,SPONSOR,,East Kent Hospitals University NHS Foundation Trust,"['Multiple Sclerosis', 'Stroke', 'Cystic Fibrosis', 'Motor Neurone Disease', 'Craniocerebral Trauma', 'Guillain-Barre Syndrome']",OBSERVATIONAL,17.0,ACTUAL,"[{'name': 'Powered Wheelchair Obstacle Alerting System', 'description': 'Evaluation of an Obstacle Alerting System'}]",,Adult non-powered wheelchair users
ALS Testing Through Home-based Outcome Measures,2023-02,COMPLETED,2019-09-30,SPONSOR_INVESTIGATOR,Jeremy Shefner,Jeremy Shefner,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,144.0,ACTUAL,"[{'name': 'Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter', 'description': 'Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter'}]","['ALS', 'neurodegenerative']",ALS patient volunteers will be invited to participate in this study as well as healthy subjects for the control group.
Genomic Translation for Amyotrophic Lateral Sclerosis Care,2022-08,COMPLETED,2022-06-29,SPONSOR,,Columbia University,['ALS'],OBSERVATIONAL,254.0,ACTUAL,,"['genetics', 'genomics', 'amyotrophic lateral sclerosis (ALS)', 'primary lateral sclerosis (PLS)', 'progressive muscular atrophy (PMA)', 'motor neuron disease']","Patients with ALS (meeting El Escorial criteria for definite, probable or possible ALS), or primary lateral sclerosis or progressive bulbar/muscular atrophy."
Effectiveness of Expiratory Muscle Strength Training for Improving Communication in ALS,2023-06,COMPLETED,2022-06-01,PRINCIPAL_INVESTIGATOR,HuberLab,Purdue University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,13.0,ACTUAL,"[{'name': 'Expiratory Muscle Strength Training (EMST-150)', 'description': ""All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure).""}]",,
Safety and Efficacy of Repeated Administrations of NurOwnÂ® in ALS Patients,2021-10,COMPLETED,2020-10-30,SPONSOR,,Brainstorm-Cell Therapeutics,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,263.0,ACTUAL,"[{'name': 'NurOwnÂ® (MSC-NTF cells)', 'description': 'Autologous transplantation of bone marrow derived mesenchymal stem cells propagated ex vivo and induced to secrete neurotrophic factors'}, {'name': 'Placebo', 'description': 'Placebo'}, {'name': 'Bone Marrow aspiration', 'description': 'Bone Marrow aspiration'}]","['MSC', 'Autologous', 'Neurotrophic factors']",
"A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)",2024-01,RECRUITING,2030-10-31,SPONSOR,,AviadoBio Ltd,"['Frontotemporal Dementia', 'FTD', 'FTD-GRN', 'Dementia, Frontotemporal']",INTERVENTIONAL,9.0,ESTIMATED,"[{'name': 'Intrathalamic AAV.PGRN administration', 'description': 'One-time MRI-guided stereotaxic infusion of AAV.PGRN into the brain'}, {'name': 'Intrathalamic AVB-101', 'description': ""AVB-101 is made from an adeno-associated virus, serotype 9 (AAV9). AAVs are small viruses that are naturally occurring and do not cause illness or infection on their own. AVB-101 has been modified to contain a copy of the correct (non-mutated) GRN gene, plus some other genetic material to enable the GRN gene to function inside neurons (cells within the brain). AVB-101 has also been modified so that it cannot divide and make new copies of itself (known as 'replication'), which means that it cannot cause disease or a large immune response in your body.""}]","['Gene Therapy', 'AAV', 'Intrathalamic', 'Intraparenchymal', 'Progranulin', 'Behavioral Variant FTD', 'Primary Progressive Aphasia', 'PGRN', 'Granulin', 'Dementia', 'Dementia Gene Therapy', 'AAV9']",
Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population,2013-03,COMPLETED,2012-05,SPONSOR,,Drexel University College of Medicine,"['Amyotrophic Lateral Sclerosis', 'Neurodegenerative Disease', 'Motor Neuron Disease']",OBSERVATIONAL,25.0,ACTUAL,,"['Amyotrophic Lateral Sclerosis', 'Cerebrospinal Fluid', 'Neurodegenerative Disease', 'Motor Neuron Disease', 'Autonomic Nervous System', 'Neurodegenerative Diseases', 'Movement Disorders']",ALS clinic patients at MDA/ALS Center of Hope.
Use of Dalfampridine in Primary Lateral Sclerosis,2023-08,ACTIVE_NOT_RECRUITING,2024-07,SPONSOR,,"Hospital for Special Surgery, New York","['Motor Neuron Disease, Upper']",INTERVENTIONAL,35.0,ESTIMATED,"[{'name': 'dalfampridine', 'description': 'Pill open label'}]",,
Intravenous Transplantation of Mesenchymal Stem Cell in Patients With ALS,2012-05,COMPLETED,2014-03,SPONSOR,,Royan Institute,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,6.0,ACTUAL,"[{'name': 'intra venous injection of stem cell', 'description': 'Intra venous injection of mesenchymal stem cell'}]",['ALS bone marrow mesenchymal stem cell intravenous injection'],
"IGF-1, IGFBP3, ALS Normative Ranges in Healthy Pediatric Spanish Population",2019-01,TERMINATED,2013-10,SPONSOR,,Ipsen,['IGF-1 Deficiency'],OBSERVATIONAL,304.0,ACTUAL,,,Healthy paediatric Spanish population
Can Magnetic Brain Stimulation Improve Language Function in Primary Progressive Aphasia,2021-03,UNKNOWN,2022-12,SPONSOR,,University of Manitoba,['Logopenic Progressive Aphasia'],INTERVENTIONAL,10.0,ESTIMATED,"[{'name': 'MagStim Rapid2 Transcranial Magnetic Simulation', 'description': 'A non-invasive method of brain stimulation'}]","['Primary Progressive Aphasia', 'Brain Stimulation']",
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients,2023-04,RECRUITING,2023-12,SPONSOR,,AB Science,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,495.0,ESTIMATED,"[{'name': 'Masitinib (6.0)', 'description': 'Masitinib (titration to 6.0 mg/kg/day)'}, {'name': 'Riluzole', 'description': 'Riluzole 50 mg tablet, treatment per os'}, {'name': 'Placebo', 'description': 'treatment per os'}, {'name': 'Masitinib (4.5)', 'description': 'Masitinib (titration to 4.5 mg/kg/day)'}]","['Amyotrophic Lateral Sclerosis', 'ALS', 'Tyrosine kinase inhibitor', ""Lou Gehrig's disease"", ""Charcot's disease"", 'Motor Neuron disease', 'MND']",
Transcranial Static Magnetic Field Stimulation (tSMS) in Amyotrophic Lateral Sclerosis (ALS).,2020-10,UNKNOWN,2023-12,PRINCIPAL_INVESTIGATOR,Di Lazzaro Vincenzo,Campus Bio-Medico University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,40.0,ESTIMATED,"[{'name': 'tSMS', 'description': 'tSMS delivered on bilateral motor cortex'}, {'name': 'sham tSMS', 'description': 'sham tSMS delivered on bilateral motor cortex by a non-magnetic steel cylinder, with same size, weight and appearance of the magnet used for real tSMS'}]","['Amyotrophic Lateral Sclerosis', 'ALS', 'transcranial magnetic stimulation', 'static magnetic field', 'tSMS']",
Effect of Lithium Carbonate in Patients With Amyotrophic Lateral Sclerosis,2009-03,COMPLETED,2011-04,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,23.0,ACTUAL,"[{'name': 'lithium', 'description': 'lithium LP 400mg daily po (doses were adjusted during the study to maintain targeted blood levels.)'}]","['Amyotrophic lateral sclerosis', 'Lithium', 'Survival']",
P-glycoprotein Function in Brain Diseases,2014-08-25,COMPLETED,2014-08-25,,,National Institute of Mental Health (NIMH),"['Alzheimer Disease', 'Parkinson Disease', 'Frontotemporal Lobar Degeneration']",OBSERVATIONAL,20.0,ACTUAL,,"['Alzheimer Disease', ""Parkinson's Disease"", 'Frontotemporal Dementia', 'PET Imaging', 'AD', 'Parkinson Disease', 'PD']",
Assessment of Empathetic Process by Scanpath Study of an Artwork,2022-03,COMPLETED,2019-12-31,SPONSOR,,Centre Hospitalier Princesse Grace,"['Alzheimer Dementia', 'Parkinson Disease', 'Fronto-Temporal Dementia']",INTERVENTIONAL,70.0,ACTUAL,"[{'name': 'Eye-Tracking / Neuropsychological evaluations', 'description': 'Use of Eye-Tracking / Neuropsychological Ã©valuations in 4 groups'}]","['Eye-Tracking', 'Empathy', 'Social cognition', 'Theory of Mind', 'Scanpath', 'Gaze']",
tDCS Intervention in Primary Progressive Aphasia,2023-12,RECRUITING,2024-02,SPONSOR,,Johns Hopkins University,"['Primary Progressive Aphasia', 'MCI', 'FTD']",INTERVENTIONAL,70.0,ESTIMATED,"[{'name': 'Active HD-tDCS plus Speech-Language Therapy', 'description': 'Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.'}, {'name': 'Sham plus Speech-Language Therapy', 'description': 'Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.'}]","['transcranial direct current stimulation (tDCS)', 'neurodegeneration', 'language therapy', 'Primary Progressive Aphasia (PPA)']",
The Healthy Patterns Sleep Study,2021-07,COMPLETED,2021-05-31,SPONSOR,,University of Pennsylvania,"['Dementia', 'Alzheimer Disease', 'Circadian Rhythm Disorders', 'Circadian Rhythm Sleep Disorder', 'Insomnia', 'Hypersomnia', 'Cognitive Impairment', 'Cognitive Decline', 'Mild Cognitive Impairment', 'Frontotemporal Dementia', 'Neurocognitive Disorders', 'Vascular Dementia', 'Sleep Disorder', 'Memory Impairment']",INTERVENTIONAL,210.0,ACTUAL,"[{'name': 'Attention-Control Condition', 'description': ""This condition will contain no active elements beyond its nonspecific components, and no theoretical basis to support an effect on CRDs. The attention-control group will also involve 4 in-home visits and 4 brief telephone education sessions. The attention control group will receive printed educational and training materials from the Alzheimer's Association and the NIH on home modification, health promotion, talking to your doctor, and advanced care planning that coincide with session content.""}, {'name': 'Timed Activity Intervention', 'description': 'The timed activity group will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed activity intervention provides activities delivered at specific times in the daily cycle. The in-home sessions are spaced weekly so that the participants can have the opportunity to practice the activity with the interventionist and then on their own. During each session, the interventionist will reinforce activity use, review problem-solving approaches, and provide education.'}]","['Neuropsychiatric Behaviors', 'Agitation', ""Alzheimer's Disease"", 'Dementia']",
Genetic Study of Amyotrophic Lateral Sclerosis in Norway,2022-07,ENROLLING_BY_INVITATION,2030-12-31,SPONSOR,,Sykehuset Telemark,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,500.0,ESTIMATED,"[{'name': 'Observation', 'description': 'Observation of genetic characteristics'}]","['Genetics', 'Amyotrophic Lateral Sclerosis', 'Neurology', 'Clinical genetics']",Individuals diagnosed with ALS that are being followed through the Norwegian health-care system.
Efficacy and Safety of Nitrazine in the Treatment of ALS,2021-06,UNKNOWN,2022-12-31,SPONSOR,,Peking University Third Hospital,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,150.0,ESTIMATED,"[{'name': 'Nitrofurazone Group 1', 'description': 'Test group 1: Nitroketazine tablet 600 mg group (Nitroketazine 300 mg tablet X2 + placebo 300 mg tablet Ã—2 tablets each time; If the subject progresses and cannot take 300mg tablets, Nitroketazine 100mg tablets x6 + placebo 100mg tablets x6) can be replaced.'}, {'name': 'Nitroketazine Group 2', 'description': 'Test group 2: Nitroketazine tablets 1200 mg group (each oral Nitroketazine 300 mg tablets x4 tablets; If the subject progresses and cannot take 300 mg tablets, Nitroketazine 100mg tablets x12 tablets can be taken instead).'}, {'name': 'placebo group', 'description': 'Control group: placebo group (placebo 300mg tablets x4 tablets each orally; If subjects progress and cannot take 300mg tablets, they may take placebo 100 mg tablets x 12 tablets instead).'}]",,
Outcomes Mandate National Integration With Cannabis as Medicine,2022-02,RECRUITING,2025-12-31,SPONSOR,,"OMNI Medical Services, LLC","['Chronic Pain', 'Chronic Pain Syndrome', 'Chronic Pain Due to Injury', 'Chronic Pain Due to Trauma', 'Fibromyalgia', 'Seizures', 'Hepatitis C', 'Cancer', 'Crohn Disease', 'HIV/AIDS', 'Multiple Sclerosis', 'Traumatic Brain Injury', 'Sickle Cell Disease', 'Post Traumatic Stress Disorder', 'Tourette Syndrome', 'Ulcerative Colitis', 'Glaucoma', 'Epilepsy', 'Inflammatory Bowel Diseases', 'Parkinson Disease', 'Amyotrophic Lateral Sclerosis', 'Chronic Traumatic Encephalopathy', 'Anxiety', 'Depression', 'Insomnia', 'Autism', 'Opioid-use Disorder', 'Bipolar Disorder', 'Covid19', 'SARS-CoV Infection', 'COVID-19', 'Corona Virus Infection', 'Coronavirus']",INTERVENTIONAL,200000.0,ESTIMATED,"[{'name': 'Cannabis, Medical', 'description': 'Patients will be given medical cannabis recommendations and certifications commensurate with the state law in which the encounter occurs. The variations in mechanisms between the states for recommending, registering, certifying, and developing mandated treatment plans or doses will be adhered to; however, variations in state law and cannabis programs should not cause variation in the study design because the end-result is still the same with patients being treated with medical cannabis.'}, {'name': 'RYAH-Medtech Inhaler', 'description': ""Our research study will involve incorporation of RYAH-Medtech company's devices into our protocols. They have an inhaler and a transdermal patch for both hemp-derived CBD and cannabis. RYAH has developed an integrated phone app for tracking product use and patient response. They are currently involved in clinical trials in Europe. OMNI Medical will integrate the partner with RYAH device for several reasons. Primary goals will involve using their integrated smart phone app to collect and secure large quantities of data. Secondary goals will include FDA approval as a medical device. The specific cannabis strain will be tracked using scannable QR codes programed into the smart phone app. This will allow us to track patient feedback and capture data on usage. OMNI Medical will have patients use RYAH's products as part of and FDA Investigational Device Exemption, which requires an IRB. Use of the devices would be completely voluntary by study participants.""}]",,
"Study of ""Post-Polio Syndrome""",2003-05,COMPLETED,2003-05,,,National Institute of Neurological Disorders and Stroke (NINDS),"['Poliomyelitis', 'Postpoliomyelitis Syndrome']",OBSERVATIONAL,360.0,,,"['Poliomyelitis', 'Amyotrophic Lateral Sclerosis', 'Motor Neurons', 'Late Viral Infection', 'Motor Neuron Firing', 'Immune Defects', 'Post-polio Syndrome', 'Post-polio Motor Neuron Disease']",
Evaluation of the Early Use of the Pressure Relaxer in the Respiratory Impairment of Patients With Amyotrophic Lateral Sclerosis: Multicenter Randomized Controlled Study.,2023-09,NOT_YET_RECRUITING,2028-07-01,SPONSOR,,Centre Hospitalier Universitaire de la RÃ©union,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,72.0,ESTIMATED,"[{'name': 'early use of intermittent positive pressure breathing', 'description': 'standard care associated with daily and early use of intermittent positive pressure breathing'}]",,
Epidemiological Study in FRONtoTemporal Dementia,2023-11,ACTIVE_NOT_RECRUITING,2024-09-30,SPONSOR,,CENTOGENE GmbH Rostock,['Frontotemporal Dementia'],OBSERVATIONAL,4500.0,ESTIMATED,"[{'name': 'Genetic Screening', 'description': 'Blood samples will be collected from clinically diagnosed or suspected FTD patients and will be analysed for a broad range of pathogenic variants in genes associated with FTD.'}]",,Participants diagnosed with Frontotemporal Dementia (FTD) and participants clinically suspected for FTD
Awareness Detection and Communication in Disorders of Consciousness,2023-06,RECRUITING,2026-08,SPONSOR,,University of Ulster,"['Disorder of Consciousness', 'Paralysis', 'Motor Neuron Disease', 'Stroke', 'Physical Disability']",INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'Motor imagery based EEG-BCI', 'description': 'Information gathered in this study may be useful when considering diagnosis of prolonged disorder of consciousness and successful adoption of device could lead to assistive communication intervention with therapeutic benefits. Participants undergo quick assessment to test ability to engage in task, if successful this implies they are minimally conscious, have some awareness of self and memory intact to remember commands. During training participant undergoes multiple sessions whereby they are conducting two different imagined movements to move a sound across the azimuthal plane in a direction dictated by an auditory cue. Participant will receive auditory feedback on the position of the sound which acts as a reflection of how well the participant is engaged in the task in terms of performance and consistency across trials. The participant will move on to use the imagined movements to answer a series of biographical, situational, basic logic and numbers/letters questions.'}]",,
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq),2023-09,RECRUITING,2027-04-29,PRINCIPAL_INVESTIGATOR,Darius Ebrahimi-Fakhari,Boston Children's Hospital,"['Hereditary Spastic Paraplegia', 'Neurodegenerative Diseases', 'Pediatric Disorder', 'Spasticity, Muscle', 'Motor Neuron Disease', 'Movement Disorders']",OBSERVATIONAL,200.0,ESTIMATED,,"['Hereditary Spastic Paraplegia', 'Neurodegenerative disease', 'Spasticity', 'SPG3a', 'SPG4', 'SPG11', 'SPG15', 'SPG26', 'SPG47', 'SPG50', 'SPG51', 'SPG52', 'Complex hereditary spastic paraplegia', 'Early Onset hereditary spastic paraplegia', 'Movement disorder', 'Adaptor protein complex 4', 'Neurogenetic disorder', 'Genetic Disease', 'Muscle Spasticity', 'Neurodevelopmental disorders', 'Musculoskeletal Disease']","Male or female, under 30 years, with suspected HSP"
In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis (ALS),2015-10,COMPLETED,2015-02,PRINCIPAL_INVESTIGATOR,Carine DE PREZ,Brugmann University Hospital,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,5.0,ACTUAL,[{'name': 'in-situ cytokine expression'}],"['Amyotrophic lateral sclerosis (ALS)', 'Cytokines', 'Neuropathology']",Archived/residual histopathology slides and paraffin blocks from residual autopsy material from patients who died with amyotrophic lateral sclerosis.
Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function,2011-08,COMPLETED,2009-08,SPONSOR,,Allergan,"['Stroke', 'Muscle Spasticity', 'Motor Neuron Disease']",INTERVENTIONAL,155.0,ACTUAL,"[{'name': 'botulinum toxin Type A', 'description': 'botulinum toxin Type A 240 U injection on Day 1, Week 12, Week 18'}, {'name': 'botulinum toxin Type A', 'description': 'botulinum toxin Type A 360 U injection at Day 1, Week 12, Week 18'}, {'name': 'saline', 'description': 'Saline injection at Day 1, Week 12, Week 18'}]",,
Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS),2015-03,TERMINATED,2012-01,PRINCIPAL_INVESTIGATOR,Vinay Chaudhry,Johns Hopkins University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,1.0,ACTUAL,"[{'name': 'KetoCal', 'description': 'Ketogenic Diet food via gastrostomy tube - 80% fat, 17% protein, 3% carbohydrates'}]","['ALS', 'Ketogenic Diet']",
Mechanical Insufflation in the Philadelphia Amyotrophic Lateral Sclerosis Cohort (MI-PALS) Study,2023-10,NOT_YET_RECRUITING,2025-12-31,SPONSOR,,University of Pennsylvania,"['Amyotrophic Lateral Sclerosis', 'Chronic Respiratory Failure', 'Airway Clearance Impairment', 'Neuromuscular Diseases']",INTERVENTIONAL,20.0,ESTIMATED,"[{'name': 'Mechanical insufflation', 'description': 'Mechanical insufflation (MI) is a chest physiotherapy exercise that will be performed using a type of mechanical insufflator-exsufflator (MI-E) known as the BiWaze Cough device. The device connects to a tube that can interface with a patient using either a facemask or mouthpiece.\n\nMechanical insufflation is a chest physiotherapy exercise that passively inflates the chest with positive pressure that is delivered in coordination with the patient\'s own inspiratory timing until maximal inflation capacity (MIC), determined by the patient or maximal chest rise on visual inspection. At MIC, the patient passively exhales, which completes one ""cycle"". Prior literature has used a ""dose"" of 5 sets of 5 cycles once or twice daily. The maneuver is usually performed with assistance of a caregiver to hold the mask or mouthpiece in place.'}]","['amyotrophic lateral sclerosis', 'chronic respiratory failure', 'neuromuscular weakness', 'mechanical insufflation-exsufflation', 'peak cough flow']",
Exercise and Disease Progression in Amyotrophic Lateral Sclerosis Patients,2017-10,COMPLETED,2015-06-30,PRINCIPAL_INVESTIGATOR,Anna Caroline Braga,University of Lisbon,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,48.0,ACTUAL,"[{'name': 'standard care', 'description': 'A standard care program based on American Academy of Neurology guidelines (Range Of Motion (ROM) exercises, gait and balance training )at home or another rehabilitation units without intensity control.'}, {'name': 'moderate exercise', 'description': 'A moderate exercise protocol two times per week in a treadmill in the lower range of the training zone determined by Cardiopulmonary Exercise Testing, monitored by continuous pulse oximetry evaluation.'}]","['Amyotrophic Lateral Sclerosis', 'aerobic exercise', 'functional outcome', 'non-invasive ventilation', 'oxygen uptake']",
Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis,2023-05,APPROVED_FOR_MARKETING,,SPONSOR,,Biogen,['Superoxide Dismutase 1-Amyotropic Lateral Sclerosis'],EXPANDED_ACCESS,,,"[{'name': 'Tofersen', 'description': 'Administered as intrathecal bolus injection'}]",,
"Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations",2012-04,COMPLETED,2012-01,SPONSOR,,"Ionis Pharmaceuticals, Inc.",['Familial Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,33.0,ACTUAL,"[{'name': 'ISIS 333611', 'description': '5 arms of 12 hour infusion: Arm 1 0.15 mg, Arm 2 0.5 mg, Arm 3 1.5 mg, Arm 4 3.0 mg, matching volume of placebo'}]","['Familial ALS', 'ALS', 'SOD1 Protein', 'ISIS 333611', 'SOD1Rx']",
Neuromuscular Transmission in Amyotrophic Lateral Sclerosis,2009-12,COMPLETED,2012-04,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,14.0,ACTUAL,"[{'name': 'Anconeus Muscle biopsy', 'description': 'Anconeus muscle specimens will be surgically removed. The biopsy will be performed under regional anaesthesia and will require an about 5 cm incision of the skin and muscle fascia from the lateral condyle to over the ridge of the proximal ulna, 3 or 4 cm distal to the tip of the olecranon. A triangular muscle flap will be removed, and then the fascia and skin will be closed with running dissolving suture.'}]","['ALS', 'Motor neuron', 'Pathophysiology', 'Neuromuscular junction', 'Neuromuscular transmission', 'Microelectrodes']",
"Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis",2019-01,COMPLETED,2016-11,PRINCIPAL_INVESTIGATOR,Michael Benatar,University of Miami,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,38.0,ACTUAL,"[{'name': 'Arimoclomol', 'description': 'Drug: Arimoclomol capsules given three times per day'}, {'name': 'Placebo', 'description': 'Drug: Placebo capsules given three times per day'}]","['Hereditary ALS', 'Hereditary neurological disease', ""Lou Gehrig's Disease"", 'Motor Neuron Disease', 'Amyotrophic Lateral Sclerosis (ALS)', 'Familial ALS', 'Neuromuscular disease', 'SOD1 mutation', 'Superoxide dismutase', 'SOD1 positive ALS', 'inherited ALS']",
The Living With a Long-Term Condition Study,2023-09,RECRUITING,2024-01-10,SPONSOR,,King's College London,"['Asthma', 'Atrial Fibrillation', 'Cancer', 'Cerebrovascular Disorders', 'Stroke', 'CKD', 'Copd', 'Fibromyalgia', 'Pain', 'Heart Diseases', 'Heart Disease Chronic', 'Dementia', 'Diabetes', 'Epilepsy', 'Heart Failure', 'High Blood Pressure', 'Hypertension', 'Hiv', 'AIDS', 'IBD', 'IBS', 'Liver Diseases', 'Long COVID', 'Lupus Erythematosus', 'Multiple Sclerosis', 'Obesity', 'Osteoarthritis', 'Arthritis', 'Rheumatoid Arthritis', 'Osteoporosis', 'Parkinson Disease', 'Sickle Cell Disease', 'Hepatitis', 'Endometriosis', 'PCOS', 'Neurological Disorder', 'POTS - Postural Orthostatic Tachycardia Syndrome', 'MND (Motor Neurone DIsease)', 'Cystic Fibrosis', 'Migraine', 'Spondylitis', 'Celiac Disease', 'Hidradenitis Suppurativa', 'Eczema', 'ME/CFS']",OBSERVATIONAL,600.0,ESTIMATED,"[{'name': 'Living with LTC Questionnaire', 'description': 'A questionnaire that will ask about demographic information, mental wellbeing and distress related to chronic illness.'}]","['mental health', 'depression', 'anxiety', 'chronic illness']",Adults in the UK with a diagnosis of a Long-Term Condition or chronic illness.
Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis,2010-03,UNKNOWN,2010-08,,,Fondazione Salvatore Maugeri,"['Amyotrophic Lateral Sclerosis', 'Chronic Respiratory Failure']",INTERVENTIONAL,50.0,ESTIMATED,"[{'name': 'Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers', 'description': 'A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.'}, {'name': 'Non invasive ventilation', 'description': 'A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.'}]","['Amyotrophic Lateral Sclerosis', 'Non-invasive ventilation', 'Chronic Respiratory Failure']",
Application of Motor Unit Estimation Index in Amyotrophic Lateral Sclerosis and Related Diseases,2021-06,UNKNOWN,2022-12-01,SPONSOR,,Peking University Third Hospital,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,90.0,ESTIMATED,"[{'name': 'Basic information', 'description': 'Demographic data registration, medical history taking, physical examination. Electrocardiogram. Pulmonary function tests.'}, {'name': 'Functional scores', 'description': 'depending on the diseases enrolled, ALS and KD chose ALS-FRS functional scores and CMT chose CMTNS2 functional scores'}, {'name': 'MINUX', 'description': 'MUNIX examination was performed on all subjects. A total of eight bilaterally symmetrical muscles were selected, bilateral abductor little finger or abductor pollicis brevis, bilateral biceps or deltoid muscles, bilateral tibialis anterior muscles, and bilateral femurs. For quadriceps, choose a muscle with less muscle atrophy.'}]",,"ALS is a degenerative disease of the nervous system, with an incidence of 2-3 in 100,000. It usually begins in middle age and mainly presents with progressive atrophy and weakness of skeletal muscles throughout the body. After 3 to 5 years, it dies of respiratory muscle involvement. At present, there are no biomarkers for early diagnosis and no effective treatment."
Remotely Supervised Transcranial Direct Current Stimulation (tDCS) for Primary Progressive Aphasia (PPA),2023-12,COMPLETED,2023-08-14,SPONSOR,,NYU Langone Health,['Primary Progressive Aphasia'],INTERVENTIONAL,10.0,ACTUAL,"[{'name': 'Transcranial Direct Current Stimulation (tDCS)', 'description': 'tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through scalp sponge electrodes. The device is preprogrammed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout session (29 minutes), and then ramp down (for 30 seconds) at the end.'}, {'name': 'Word-Naming Activity', 'description': 'During each tDCS session, the tDCS clinician will guide the participant in a word-naming exercise. Participants will be presented with photos of target items and prompted to verbally produce the names of the pictures.'}]",['Transcranial Direct Current Stimulation (tDCS)'],
Music Therapy Protocol to Support Bulbar and Respiratory Functions in ALS,2018-07,UNKNOWN,2020-01-01,SPONSOR_INVESTIGATOR,Alisa Apreleva,Alisa Apreleva,"['Motor Neuron Disease, Amyotrophic Lateral Sclerosis', 'ALS (Amyotrophic Lateral Sclerosis)', 'Dysarthria, Flaccid', 'Dysarthria, Spastic', 'Dysarthria, Mixed', 'Dysphagia', 'Dyspnea', 'Aspiration Pneumonia', 'Hypernasality', 'Breathlessness']",INTERVENTIONAL,8.0,ACTUAL,"[{'name': 'Music therapy', 'description': 'ALS-specific, individualized MT protocol was delivered to study participants in their homes twice weekly for the duration of six weeks by the researcher. Facilitating music structures were composed by the researcher to support cueing, timing and intensity of breathing and vocalization exercises. These structures were regularly modified to suit the unique capabilities, current individual demands and progress of each participant. One familiar song, selected by the participant, was used for each participant in therapeutic singing exercise closing each session. Individualized exercises sets for independent practice were provided at session 3 to each participants. ALS-specific voice health guidelines were provided for participants prior to start of the treatment.'}]","['Music Therapy', 'Neurologic Music Therapy', 'Rehabilitation', 'Amyotrophic Lateral Sclerosis', 'ALS']",
Blood-Brain Barrier Opening Using MR-Guided Focused Ultrasound in Patients With Amyotrophic Lateral Sclerosis,2021-01,UNKNOWN,2022-12-30,SPONSOR,,InSightec,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,8.0,ESTIMATED,"[{'name': 'Blood-Brain Barrier opening with MRgFUS', 'description': 'ExAblate Transcranial MR-guided Focused Ultrasound to temporarily open the Blood-Brain Barrier'}]","['Blood-Brain Barrier disruption', 'Blood-Brain Barrier opening', 'magnetic resonance-guided focused ultrasound']",
Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations,2019-11,COMPLETED,2018-11-25,PRINCIPAL_INVESTIGATOR,"Edward D Huey, MD",Columbia University,"['Frontotemporal Lobar Degeneration (FTLD)', 'Frontotemporal Dementia (FTD)', 'Tauopathies']",INTERVENTIONAL,7.0,ACTUAL,"[{'name': '18F-AV-1451', 'description': 'A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan.'}]","['FTLD', 'FTD']",
"Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis",2019-02,RECRUITING,2025-12,PRINCIPAL_INVESTIGATOR,Seung Hyun Kim,Hanyang University Seoul Hospital,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,64.0,ESTIMATED,"[{'name': 'recombinant human erythropoietin(rhEPO)', 'description': 'Injection of erythropoietin every months (total 12 months)'}]",,
DC Longitudinal Study on Aging and Specimen Bank,2019-10,RECRUITING,2027-01,PRINCIPAL_INVESTIGATOR,R. Scott Turner,Georgetown University,"['Alzheimer Disease', 'Dementia', 'Mild Cognitive Impairment', 'Aging', 'Aging Disorder']",OBSERVATIONAL,1000.0,ESTIMATED,,"['Frontotemporal Dementia', 'Lewy Body Dementia', 'Aging', 'Vascular Dementia']","All genders, races, and ethnicities eligible. Normal controls and those diagnosed with a neurodegenerative disorder eligible."
"Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)",2023-05,TERMINATED,2023-04-28,SPONSOR,,Genuv Inc.,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,23.0,ACTUAL,"[{'name': 'Trametinib (0.5 mg)', 'description': '0.5 mg/day'}, {'name': 'Trametinib (1 mg)', 'description': '1 mg/day'}, {'name': 'Riluzole (100 mg)', 'description': '100 mg/day (50 mg twice)'}]","['ALS', ""Lou Gehrig's disease""]",
PPA Tele-Savvy: A Pilot Study of an Online Intervention for Caregivers of Persons Living With PPA,2023-04,RECRUITING,2023-10-30,PRINCIPAL_INVESTIGATOR,Darby Morhardt,Northwestern University,"['Primary Progressive Aphasia', 'Caregiver Burnout']",INTERVENTIONAL,68.0,ESTIMATED,"[{'name': 'PPA Tele-Savvy Pilot Intervention', 'description': 'We will engage PPA caregivers in the process of adapting the existing Tele-Savvy program to fit their needs and then pilot test the adapted PPA Tele-Savvy program.'}]",,
Satisfaction Survey for Amyotrophic Lateral Sclerosis (ALS) Patients Comparing Rooms With and Without Assistive Technology,2013-03,TERMINATED,2012-02,SPONSOR,,Drexel University College of Medicine,"['Amyotrophic Lateral Sclerosis', 'Neurodegenerative Disease', 'Motor Neuron Disease']",OBSERVATIONAL,5.0,ACTUAL,,"['Amyotrophic Lateral Sclerosis', 'Cerebrospinal Fluid', 'Neurodegenerative Disease', 'Motor Neuron Disease', 'Autonomic Nervous System', 'Neurodegenerative Diseases', 'Movement Disorders', 'Quality of Life']",In-patients from the neurology floor of Hahnemann Hospital
PET Imaging in ALS Patients,2017-03,COMPLETED,2017-03,PRINCIPAL_INVESTIGATOR,"Lyle W. Ostrow, MD, PhD",Johns Hopkins University,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,36.0,ACTUAL,[{'name': 'PET Scanning'}],,
A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS),2023-05,TERMINATED,2023-02-08,PRINCIPAL_INVESTIGATOR,Nurcan Gursoy,Stony Brook University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,12.0,ACTUAL,"[{'name': 'Perampanel'}, {'name': 'Placebo Oral Tablet'}]",,
Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis,2023-09,NOT_YET_RECRUITING,2026-06,SPONSOR,,Revalesio Corporation,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,140.0,ESTIMATED,"[{'name': 'RNS60', 'description': 'Nebulized RNS60 will be administered by daily inhalation for 24 weeks.'}, {'name': 'Placebo', 'description': 'Nebulized Placebo will be administered by daily inhalation for 24 weeks.'}]",,
HEALEY ALS Platform Trial - Regimen A Zilucoplan,2023-06,COMPLETED,2022-05-04,SPONSOR_INVESTIGATOR,"Merit E. Cudkowicz, MD","Merit E. Cudkowicz, MD",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,162.0,ACTUAL,"[{'name': 'Zilucoplan', 'description': 'Drug: Zilucoplan Administration: Subcutaneous injection\n\nDosage: 0.3mg/kg administered daily'}, {'name': 'Matching Placebo', 'description': 'Drug: Matching Placebo\n\nAdministration: Subcutaneous injection\n\nDosage: Daily subcutaneous injection'}]","['ALS', 'Placebo-Controlled', 'Double-Blind', 'Regimen-Specific Appendix', ""Lou Gehrig's Disease"", 'Zilucoplan', 'Ra Pharmaceuticals']",
Escitalopram (Lexapro) for Depression MS or ALS,2011-08,COMPLETED,2010-03,PRINCIPAL_INVESTIGATOR,Meera Narasimhan,University of South Carolina,"['Major Depression', 'Multiple Sclerosis', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,13.0,ACTUAL,"[{'name': 'escitalopram', 'description': 'After confirmation of diagnoses and safety screening escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability. No other psychotropic medications will be permitted during the study. Medications for coexisting medical problems (e.g. hypertension) will be permitted. Study visits will include weekly visits for first 2 weeks and biweekly visits for next 6 weeks. Medications will be dispensed weekly or biweekly and the participants will be followed for 8 weeks.'}]","['Amyotrophic Lateral Sclerosis', 'ALS', 'Multiple Sclerosis', 'MS', 'Major Depression', 'Depression', 'Major Depressive Disorder', 'antidepressants', 'Escitalopram', 'Lexapro']",
A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers,2017-05,COMPLETED,2016-12-31,PRINCIPAL_INVESTIGATOR,James D. Berry MD,Massachusetts General Hospital,"['Amyotrophic Lateral Sclerosis', 'Nervous System Diseases', 'Sclerosis', 'Motor Neuron Disease', 'Spinal Cord Diseases', 'Central Nervous System Diseases', 'Neurodegenerative Diseases', 'Neuromuscular Diseases', 'ALS']",OBSERVATIONAL,139.0,ACTUAL,,"['Biomarkers', 'Biological Markers', 'Surrogate Markers', 'Clinical Markers', 'Plasma', 'Cerebrospinal Fluid', 'DNA', 'Serum', 'RNA']",Volunteers will be invited to participate in this study by their neurologists either in clinic or at a regular scheduled appointment visit
Answer ALS: Individualized Initiative for ALS Discovery,2020-01,COMPLETED,2020-01-01,SPONSOR,,Johns Hopkins University,"['Amyotrophic Lateral Sclerosis', 'Primary Lateral Sclerosis', 'Flail Arm ALS', 'Progressive Muscular Atrophy', 'Monomelic Amyotrophy', 'Motor Neuron Disease', 'Asymptomatic ALS Gene Carriers', 'Healthy Controls']",OBSERVATIONAL,1049.0,ACTUAL,,"['ALS', 'stem cell', 'biomarker', 'disease progression']","patients with ALS, Primary Lateral Sclerosis Flail Arm ALS Progressive Muscular Atrophy Monomelic Amyotrophy Motor Neuron Disease Asymptomatic ALS Gene Carriers"
"An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)",2022-07,NO_LONGER_AVAILABLE,,SPONSOR,,OrphAI Therapeutics,['Frontotemporal Dementia'],EXPANDED_ACCESS,,,"[{'name': 'LAM-002A', 'description': '25mg capsules'}]",,
Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease,2022-06,RECRUITING,2028-02-28,SPONSOR,,University of Melbourne,['Motor Neuron Disease / Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,244.0,ESTIMATED,"[{'name': 'Intervention polysomnography', 'description': ""Please refer to 'Arms: Intervention' section.""}, {'name': 'Sham polysomnography', 'description': ""Please refer to 'Arms: Control' section.""}]","['Non-invasive ventilation', 'Polysomnography', 'Sleep study', 'Amyotrophic lateral sclerosis', 'Chronic respiratory failure']",
Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI,2015-12,COMPLETED,2015-11,SPONSOR,,"Taiho Oncology, Inc.",['Advanced Solid Tumors (Excluding Breast Cancer)'],INTERVENTIONAL,46.0,ACTUAL,"[{'name': 'TAS-102 tablets', 'description': 'Crossover bioavailability part: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout.\n\nExtension part: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.'}, {'name': 'TAS-102 oral solution', 'description': '60 mg/dose, orally, up to 2 single doses separated by 1-week washout'}]",['Advanced solid tumors (excluding breast cancer) for which no standard therapy exists'],
Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia,2011-03,COMPLETED,2011-02,,,Exonhit,"[""Alzheimer's Disease"", 'Dementia']",INTERVENTIONAL,550.0,ESTIMATED,"[{'name': 'Blood sampling', 'description': 'Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)'}]","[""Alzheimer's disease"", 'Other dementia', 'Vascular dementia', 'Mixed dementia', ""Parkinson's Disease dementia"", 'Lewy bodies dementia', 'Frontotemporal dementia', 'Blood signature', 'Diagnosis', 'SpliceArray (tm)', ""Alzheimer's Disease and other non-AD dementia""]",
Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS (Part 1),2019-01,UNKNOWN,2020-09-01,SPONSOR,,"Taipei Veterans General Hospital, Taiwan",['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,20.0,ESTIMATED,,"['Amyotrophic lateral sclerosis, ALS, communication, needs']","Participants with ALS were recruited from ALS clinics(Taipei Veterans General Hospital, Taiwan, R.O.C),20 participants. Participants were eligible for this study if they were diagnosed with definite, probable, probable laboratory-supported, or possible ALS according to the criteria (Brooks et al., 2000)."
"Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly",2020-06,TERMINATED,2021-12,SPONSOR,,University of Utah,"[""Alzheimer's Disease""]",INTERVENTIONAL,2.0,ACTUAL,"[{'name': '11C-PIB PET Scan', 'description': 'Participants will receive an 11C-PIB PET scan of the brain.'}, {'name': 'FDG-PET Scan', 'description': 'Participants will receive an FDG-PET scan of the brain.'}]","[""Alzheimer's disease"", 'AD', 'Frontotemporal dementia', 'FTD']",
Clinical Trial Ceftriaxone in Subjects With ALS,2014-04,COMPLETED,2012-11,PRINCIPAL_INVESTIGATOR,"Merit E. Cudkowicz, MD",Massachusetts General Hospital,"['Amyotrophic Lateral Sclerosis', 'ALS']",INTERVENTIONAL,513.0,ACTUAL,"[{'name': 'ceftriaxone', 'description': 'Participants will be randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants will receive ceftriaxone and one third will receive placebo. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\n\nCeftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years.'}, {'name': 'placebo', 'description': 'an inactive substance'}]","['amyotrophic lateral sclerosis', 'ALS', 'ceftriaxone', 'cephalosporin antibiotic', 'motor neurons']",
Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1),2021-02,COMPLETED,2020-02-10,SPONSOR,,"Cyclo Therapeutics, Inc.","['Niemann-Pick Disease, Type C1']",INTERVENTIONAL,13.0,ACTUAL,"[{'name': 'Hydroxypropyl-beta-cyclodextrin', 'description': 'Used in the treatment of Niemann-Pick Disease C1 ( NPC1)'}]","['intravenous', 'cyclodextrin', 'compassionate', 'Trappsol']",
GENetic Fronto Temporal Dementia Initiative in Lille,2022-02,RECRUITING,2026-04-23,SPONSOR,,"University Hospital, Lille",['Frontotemporal Dementia'],INTERVENTIONAL,20.0,ESTIMATED,"[{'name': 'Investigation procedures', 'description': 'All participants will be assessed longitudinally with a set of clinical evaluation, neuropsychiatric and cognitive assessments, imaging (MRI and PET scans) and biosample (CSF, blood samples)'}]","['Frontotemporal Dementia', 'Biomarker', 'Social cognition', 'Genetic mutation']",
Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit,2023-11,RECRUITING,2025-06-30,PRINCIPAL_INVESTIGATOR,Melanie Fried-Oken,Oregon Health and Science University,"['Amyotrophic Lateral Sclerosis', 'Brainstem Stroke', 'Muscular Dystrophies', ""Parkinson's Disease and Parkinsonism"", 'Multiple System Atrophy', 'Brain Tumor Adult', 'Spinal Cord Injuries', 'Locked-in Syndrome']",INTERVENTIONAL,60.0,ESTIMATED,"[{'name': 'BCI-FIT multi-modal access', 'description': 'Adding a personalized multi-modal access protocol to customize a BCI-FIT access method configuration for each individual end user, based on a combination of user characteristics, clinical expertise, user feedback, and system performance data in the software.'}, {'name': 'BCI-FIT adaptive signal modeling', 'description': 'Adding a BCI-FIT adaptive signal modeling that employs transfer learning and on-line model adaptation techniques with noisy labels in the software of this brain-computer interface to eliminate the need for data collection exclusively for model calibration, as well as to address model drift issues associated with drowsiness, fatigue, and other human and environmental factors.'}, {'name': 'BCI-FIT active querying', 'description': 'Adding BCI-FIT active querying techniques which are software-based optimal action control policies in the brain-computer interface developed with active and reinforcement learning techniques in order to perform efficient user intent inference to improve the entire speed-accuracy trade-off curve for alternative communication.'}, {'name': 'BCI-FIT language modeling', 'description': ""Adding vocabulary and location information (called partner and environmental input) to the language models in the brain-computer interface from a user's communication partner.""}]",['brain-computer interface'],
Living With Frontotemporal Dementia,2016-02-24,TERMINATED,2016-02-24,SPONSOR,,National Human Genome Research Institute (NHGRI),['Adaptation'],OBSERVATIONAL,16.0,ACTUAL,,"['Adaptation', 'Coping', 'Presenile Dementia', 'Caregiver Burden']",
A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral,2022-04,COMPLETED,2022-03-02,SPONSOR,,Andalusian Initiative for Advanced Therapies - FundaciÃ³n PÃºblica Andaluza Progreso y Salud,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,52.0,ACTUAL,"[{'name': 'Intravenous administration of placebo'}, {'name': 'Intravenous administration of 1 million of MSC'}, {'name': 'Intravenous administration of 2 million of MSC'}, {'name': 'Intravenous administration of 4 million of MSC'}]","['safety evaluation', 'intravenous administration', '3 doses of autologous MSC', 'ALS']",
A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia,2019-11,UNKNOWN,2020-11,SPONSOR,,Axon Neuroscience SE,['Primary Progressive Nonfluent Aphasia'],INTERVENTIONAL,33.0,ACTUAL,"[{'name': 'AADvac1 40 Âµg', 'description': 'Active immunotherapy against neurofibrillary pathology.'}, {'name': 'AADvac1 160 Âµg', 'description': 'Active immunotherapy against neurofibrillary pathology.'}]","['tau', 'neurofibrillary', 'degeneration', 'primary progressive aphasia', 'agrammatic', 'tauopathy', 'immunotherapy', 'immunization']",
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Myography,2015-07,COMPLETED,2015-03,SPONSOR,,"Skulpt, Inc.",['Amyotrophic Lateral Sclerosis (ALS)'],OBSERVATIONAL,20.0,ACTUAL,"[{'name': 'EIM Measurements', 'description': ""EIM measurements are taken by applying saline to the skin and placing a sensor on patients' muscles that will record electrical activity. Electrical current is generated by this machine, but patients will not be able to feel it. The electrical activity recorded is returned to the machine and analyzed by a computer.""}]","['ALS', 'EIM']",ALS Patients
PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia,2017-07-13,COMPLETED,2017-07-13,SPONSOR,,National Institute of Mental Health (NIMH),"['Frontotemporal Lobar Degeneration', 'Dementia']",OBSERVATIONAL,108.0,ACTUAL,,"['Inflammation', 'Frontotemporal Dementia', 'Dementia', 'PBR28', 'PET Imaging']",
"Care Planning for a Loved One With Dementia: Knowledge, Preparing for Decisions, and Emotions",2023-10,RECRUITING,2024-05-31,PRINCIPAL_INVESTIGATOR,"Bradford Clark Dickerson, M.D.",Massachusetts General Hospital,"['Dementia', 'Dementia Frontotemporal', 'Dementia Alzheimers', 'Dementia, Mild', 'Dementia Moderate', 'Dementia Severe', 'Caregiver Burnout', 'Caregiver Stress Syndrome']",INTERVENTIONAL,150.0,ESTIMATED,"[{'name': 'Video Intervention Arm', 'description': 'For participants randomized to the video intervention arm, participants will be shown two videos about Advanced Care Planning, and then they will be asked questions regarding the usefulness of the video and their comfort with the video.'}]","['Caregiving', 'Dementia', 'Frontotemporal Dementia (FTD)', 'Caregiver Burden']",
"Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis",2023-09,ACTIVE_NOT_RECRUITING,2024-05-10,SPONSOR,,OrphAI Therapeutics,"['Amyotrophic Lateral Sclerosis', 'ALS']",INTERVENTIONAL,14.0,ACTUAL,"[{'name': 'LAM-002A', 'description': 'LAM-002A (apilimod dimesylate) is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, size 0.'}, {'name': 'Placebo', 'description': 'Microcrystalline cellulose in Swedish orange, size 0 capsules.'}]",['C9ORF72'],
Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized,2011-07,UNKNOWN,2014-01,,,Rambam Health Care Campus,"[""Alzheimer's Disease""]",OBSERVATIONAL,70.0,ESTIMATED,,,"We estimate that about 30 patients with Alzheimer's disease, 20 patients with frontotemporal dementia and 20 controls will be included."
MRI Biomarkers in ALS,2020-12,COMPLETED,2019-04-01,PRINCIPAL_INVESTIGATOR,Sanjay Kalra,University of Alberta,"['Amyotrophic Lateral Sclerosis', 'ALS', 'Motor Neuron Diseases']",OBSERVATIONAL,145.0,ACTUAL,[{'name': 'Magnetic Resonance Imaging'}],"['Magnetic Resonance Imaging', 'MRI', 'Biomarker']",Subjects will be recruited predominantly from ALS clinics at: the University of Alberta Hospital in Edmonton; the Foothills Medical Centre in Calgary; the Sunnybrook Health Sciences Centre in Toronto; the London Health Sciences Centre in London; and the Montreal Neurological Hospital in Montreal.
Brain Function in Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis,2015-08-03,COMPLETED,2015-08-03,SPONSOR,,National Institute of Neurological Disorders and Stroke (NINDS),['Cerebral Cortex Dysfunction'],OBSERVATIONAL,77.0,ACTUAL,,"['Motor Neuron Disease', 'Cognitive Testing', 'Movement-Related Potential', 'MRI', 'Neuropsychologic Testing', 'Primary Lateral Sclerosis', 'PLS', 'Amyotrophic Lateral Sclerosis', 'ALS', 'Healthy Volunteer', 'HV']",
"Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.",2012-08,COMPLETED,2013-03,SPONSOR,,Brainstorm-Cell Therapeutics,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,12.0,ACTUAL,"[{'name': 'MSC-NTF cells transplantation (IM)', 'description': ""In early ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia, intramuscularly into patients' clinically unaffected (or only mildly affected) upper arm biceps and triceps muscles according to a pre-designed grid. Intramuscular injections will be by a 26 gauge needle to a 1.5cm depth (ensuring that injection is into muscle and not adipose tissue). The patients will be injected at 24 sites with a total of 24 million cells""}, {'name': 'MSC-NTF cells transplantation (IT)', 'description': 'In progressive ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia intrathecally(via a standard lumbar puncture)with a total of 60 million cells.'}]","['Mesenchymal Stromal Cells (MSC)', 'Amyotrophic Lateral Sclerosis (ALS)', 'Neuroprotection', 'Neurodegeneration', 'Stem cells', 'ALS']",
SAMi Intervention Study to Evaluate Smartwatch Interventions in Persons With MCI and Dementia,2023-06,COMPLETED,2022-11-10,PRINCIPAL_INVESTIGATOR,Doreen Goerss,University of Rostock,"['Dementia', 'Mild Cognitive Impairment', 'Alzheimer Disease', 'Dementia With Lewy Bodies', 'Dementia, Vascular', 'Dementia, Mixed', 'Dementia Frontotemporal']",INTERVENTIONAL,40.0,ACTUAL,"[{'name': 'drinking reminder and cognitive task (smartwatch-based application)', 'description': 'task A: prompt to drink some water task B: prompt to circle bells on a sheet'}]","['Assistive technology', 'User-centered design', 'Usability', 'Smartwatch', 'Dementia']",
"Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.",2018-09,COMPLETED,2018-08,PRINCIPAL_INVESTIGATOR,Theodore R Brown,"Brown, Theodore R., M.D., MPH","[""Alzheimer's Disease"", 'Amyotrophic Lateral Sclerosis', 'Brain Injury', ""Huntington's Disease"", 'Multiple Sclerosis', ""Parkinson's Disease"", 'Stroke', 'Spinal Cord Injury']",INTERVENTIONAL,24.0,ACTUAL,"[{'name': 'Laughter Therapy', 'description': 'Laughter Therapy (LT) involves simple exercises using playfulness, eye contact and chanting in forms of laughter. LT will be taught by a certified LT instructor in a group session. There will be 8 sessions per group with each session attended by 8-12 participants and lasting 60 minutes'}]",,
Repetitive Transcranial Magnetic Stimulation (rTMS) in Amyotrophic Lateral Sclerosis,2009-01,COMPLETED,2008-12,,,Catholic University of the Sacred Heart,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,20.0,ACTUAL,"[{'name': 'Real rTMS of the brain', 'description': 'Repetitive transcranial magnetic stimulation will be performed using a focal coil held over motor cortex on each hemisphere. Stimulation protocol used will be the cTBS in which three pulses of stimulation are given at 50 Hz, repeated every 200 ms for a total of 300 pulses delivered over the right motor cortex. The stimulus intensity will be set at 80% of Action Motor Threshold.'}, {'name': 'Sham rTMS of the brain', 'description': 'Sham repetitive transcranial magnetic stimulation will be performed using the same stimulator connected to the placebo butterfly coil MCF-P-B-65 which has no stimulating effect on the cortex but produces similar auditory and tactile sensations as the active coil. The site of stimulation and the number of stimuli will be identical to those used for the active magnetic rTMS.'}]","['ALS', 'transcranial brain stimulation']",
Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS.,2018-10,UNKNOWN,2019-12-31,SPONSOR,,"Taipei Veterans General Hospital, Taiwan",['ALS (Amyotrophic Lateral Sclerosis)'],INTERVENTIONAL,60.0,ESTIMATED,"[{'name': 'communication system', 'description': 'We will use the questionnaire ""Amyotrophic Lateral Sclerosis Supportive Care Needs ,Amyotrophic Lateral Sclerosis Specific Quality of Life Instrument-Revised, Beck Depression Inventory and Caregiver Burden Scale.'}]",,
The Effect of RNS60 on ALS Biomarkers,2023-03,COMPLETED,2021-05-30,SPONSOR,,Mario Negri Institute for Pharmacological Research,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,147.0,ACTUAL,"[{'name': 'RNS60', 'description': 'normal saline plus oxigen in nanobubble'}]","['AMYOTROPHIC LATERAL SCLEROSIS', 'RNS60', 'Biomarkers', 'clinical trial', 'therapy']",
A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH,2022-08,COMPLETED,2021-05-11,SPONSOR,,"AngioLab, Inc.",['Nonalcoholic Steatohepatitis'],INTERVENTIONAL,60.0,ACTUAL,"[{'name': 'Placebo oral tablet', 'description': 'Placebo'}, {'name': 'ALS-L1023 1,200mg', 'description': 'ALS-L1023'}, {'name': 'ALS-L1023 1,800mg', 'description': 'ALS-L1023'}]",,
Amyotrophic Lateral Sclerosis (ALS) Families Project,2022-09,RECRUITING,2023-09,SPONSOR,,Columbia University,['ALS'],OBSERVATIONAL,60.0,ESTIMATED,,"['Pre-symptomatic', 'Familial', 'FALS', 'Genetic testing', 'C9orf72', 'SOD1', 'TARDBP', 'FUS', 'VCP', 'PFN1']",Unaffected individuals who have either a family member with a known ALS/FTD-associated gene mutation or have a strong family history of ALS and FTD.
Repetitive Transcranial Magnetic Stimulation as Therapy for Apathy in Amyotrophic Lateral Sclerosis,2020-02,WITHDRAWN,2021-12-31,PRINCIPAL_INVESTIGATOR,Jakub Antczak,Jagiellonian University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'rTMS', 'description': 'High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex.'}]","['Amyotrophic Lateral Sclerosis', 'rTMS', 'apathy', 'depression']",
Coping Effectiveness Training for ALS,2014-11,WITHDRAWN,2013-11,PRINCIPAL_INVESTIGATOR,"Judith G. Rabkin, PhD","Research Foundation for Mental Hygiene, Inc.","['ALS', 'Distress']",INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Coping Effectiveness Training - ALS', 'description': 'Eight coping effectiveness training counseling sessions.'}]","['ALS', 'Coping Effectiveness Training', 'Distress', 'Care Giver']",
"Anti-Cholinergic Receptors Antibodies, Autonomic Profile and Dysautonomia Symptoms in PAF, ALS and POTS (DISAUT-AB)",2021-05,COMPLETED,2019-04,SPONSOR,,Istituto Clinico Humanitas,"['Pure Autonomic Failure', 'Amyotrophic Lateral Sclerosis', 'Postural Orthostatic Tachycardia Syndrome', 'Anti-Cholinergic Receptors Antibodies']",INTERVENTIONAL,75.0,ACTUAL,[{'name': 'Immunoabsorption/plasmapheresis procedure'}],"['Neural control of circulation and respiration', 'Anti-Cholinergic receptors antibodies', 'Power Spectrum Analysis']",
Neurologic Stem Cell Treatment Study,2023-06,RECRUITING,2025-07,SPONSOR,,MD Stem Cells,"['Neurologic Disorders', 'Nervous System Diseases', 'Neurodegenerative Diseases', 'Neurological Disorders', 'Stroke', 'Traumatic Brain Injury', 'Cadasil', 'Chronic Traumatic Encephalopathy', 'Cerebral Infarction', 'Cerebral Ischemia', 'Cerebral Stroke', 'Cerebral Hemorrhage', 'Parkinson', 'Multi-System Degeneration', 'MSA - Multiple System Atrophy', 'Progressive Supranuclear Palsy', 'ALS', 'Amyotrophic Lateral Sclerosis', 'Neuropathy', 'Diabetic Neuropathies', 'Alzheimer Disease', 'Dementia', 'Frontotemporal Dementia', 'Lewy Body Disease', 'Cognitive Impairment', 'Lewy Body Variant of Alzheimer Disease']",INTERVENTIONAL,500.0,ESTIMATED,"[{'name': 'Intravenous and Intranasal BMSC', 'description': 'Autologous Bone Marrow Derived Stem Cells provided intravenous and intranasal (lower 1/3 of nose)'}]","['Neurologic Disease', 'Cerebral Vascular Accident', 'Stroke', 'Traumatic Brain Injury', 'Multiple Sclerosis', 'Parkinsons Disease', 'Neuropathy', 'Diabetic Neuropathy', 'Cerebral Ischemia', 'Cognitive Impairment', 'Dementia', 'Neurodegeneration']",
Phase II Study Using Thalidomide for the Treatment of ALS,2007-11,COMPLETED,2007-11,,,Dartmouth-Hitchcock Medical Center,"['Amyotrophic Lateral Sclerosis', 'ALS']",INTERVENTIONAL,24.0,ESTIMATED,"[{'name': 'Thalidomide', 'description': 'Thalidomide will start at a dose of 100mg/day, dose escalated every 2 weeks by 100mg/day to a target dose of 400mg/day.'}]",['ALS'],
Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients,2023-01,RECRUITING,2027-09-30,SPONSOR,,Peking University Third Hospital,['Sporadic and Familial Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,64.0,ESTIMATED,"[{'name': 'FB1006', 'description': '30mg/day'}, {'name': 'Placebo', 'description': '30mg/day'}]",,
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02),2023-12,RECRUITING,2027-08-31,SPONSOR_INVESTIGATOR,"Leigh R. Hochberg, MD, PhD.","Leigh R. Hochberg, MD, PhD.","['Anarthria', 'Dysarthria', 'Tetraplegia', 'Spinal Cord Injuries', 'Amyotrophic Lateral Sclerosis', 'Brain Stem Infarctions', 'Locked-in Syndrome', 'Muscular Dystrophies']",INTERVENTIONAL,2.0,ESTIMATED,"[{'name': 'BrainGate Neural Interface System', 'description': 'Placement of the BrainGate2 sensor(s) into the speech-related cortex'}]",,
Dopaminergic Therapy for Frontotemporal Dementia Patients,2022-07,ACTIVE_NOT_RECRUITING,2024-04-01,PRINCIPAL_INVESTIGATOR,Giacomo Koch,I.R.C.C.S. Fondazione Santa Lucia,"['Frontotemporal Dementia', 'Dementia', 'Aphasia, Primary Progressive', 'Pick Disease of the Brain', 'Brain Diseases', 'Central Nervous System Diseases', 'Nervous System Diseases', 'Neurocognitive Disorders', 'Mental Disorders', 'Neurodegenerative Diseases', 'Frontotemporal Lobar Degeneration', 'TDP-43 Proteinopathies', 'Proteostasis Deficiencies', 'Metabolic Disease', 'Aphasia', 'Speech Disorders', 'Language Disorders', 'Communication Disorders', 'Neurobehavioral Manifestations', 'Neurologic Manifestations']",INTERVENTIONAL,75.0,ACTUAL,"[{'name': 'Rotigotine 4Mg/24Hrs Patch', 'description': 'Rotigotine 4 mg/24Hrs administration for 24 weeks'}, {'name': 'Rotigotine 6Mg/24Hrs Patch', 'description': 'Rotigotine 6 mg/24Hrs administration for 24 weeks'}, {'name': 'Placebo', 'description': 'Placebo administration for 24 weeks'}]","['dopamine', 'frontal cortex', 'FTD', 'Rotigotine']",
Dexpramipexole and Cimetidine Drug Drug Interaction (DDI),2014-11,COMPLETED,2012-04,SPONSOR,,Knopp Biosciences,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,14.0,ACTUAL,"[{'name': 'Dexpramipexole', 'description': 'Single Oral Dose'}, {'name': 'Cimetidine plus Dexpramipexole', 'description': 'Multiple Oral Doses'}]",,
Multiple Doses of AT-1501-A201 in Adults With ALS,2023-06,COMPLETED,2022-03-24,SPONSOR,,"Anelixis Therapeutics, LLC",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,54.0,ACTUAL,"[{'name': 'AT-1501', 'description': 'AT-1501 monoclonal antibody targeting CD40L given as an IV infusion'}]","['ALS', ""Lou Gehrig's Disease"", 'motor neuron disease', 'motor neuron degeneration', 'AT-1501', 'humanized blocking antibody to CD40LG', 'CD40L inhibitor', 'monoclonal antibody']",
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps,2024-01,RECRUITING,2024-03,SPONSOR_INVESTIGATOR,Hiroshi Mitsumoto,Hiroshi Mitsumoto,"['Amyotrophic Lateral Sclerosis', 'Muscle Cramp']",INTERVENTIONAL,26.0,ESTIMATED,"[{'name': 'TJ-68', 'description': 'For two periods (one period = 2 weeks) during the 11-week participation, participants will take 2.5 g of TJ-68 for three times per day before meals. It will be administered by dissolving 2.5 g of TJ-68 powder in 1 oz. of lukewarm water.'}, {'name': 'Placebo', 'description': 'For two periods (one period = 2 weeks) during the 11-week participation, participants will take 2.5 g of placebo for three times per day before meals. It will be administered by dissolving 2.5 g of the placebo powder in 1 oz. of lukewarm water.'}]",,
Oral Nutritional Supplementation in Amyotrophic Lateral Sclerosis (ALS) Patients,2019-07,COMPLETED,2021-06,SPONSOR,,"University Hospital, Limoges",['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,229.0,ACTUAL,[{'name': 'Oral nutritional supplementation'}],,
"A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis",2023-01,ACTIVE_NOT_RECRUITING,2023-12,SPONSOR,,Denali Therapeutics Inc.,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'DNL343', 'description': 'Oral repeating dose'}, {'name': 'Placebo', 'description': 'Oral repeating dose'}]",['ALS'],
Study of Gene Polymorphisms Involved in the Metabolism and Action of Vitamin D in Amyotrophic Lateral Sclerosis,2016-08,COMPLETED,2017-05,SPONSOR,,Centre Hospitalier Universitaire de NÄ«mes,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,800.0,ACTUAL,,,A national biological (France) collection has been in existence since 1996 and serves as a source for patient and control samples. Patients have a sporadic form of Amyotrophic Lateral Sclerosis and controls are their spouses/partners.
Home-based Remote Digital Monitoring to Assess ALS Progression (Track ALS),2023-07,ACTIVE_NOT_RECRUITING,2024-08-01,SPONSOR,,"St. Joseph's Hospital and Medical Center, Phoenix",['ALS (Amyotrophic Lateral Sclerosis)'],OBSERVATIONAL,80.0,ACTUAL,,,"Patients will be recruited from the ALS patient populations cared for at the BNI and Emory University ALS Clinics. For the virtual recruitment of ALS patients outside of those clinics, the study details with contact information will be posted on IRB-approved websites, social media, and patient advocacy groups, including the Northeast ALS Consortium (NEALS), ALS Association (ALSA) websites and other ALS forums. The National ALS Registry will also be used to promote recruitment."
A Study of IPL344 in the Treatment of ALS Patients,2023-12,SUSPENDED,2025-02,SPONSOR,,Immunity Pharma Ltd.,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,15.0,ESTIMATED,"[{'name': 'IPL344', 'description': ""The study is designed to determine the tolerability, safety and PK of IPL344 administered I.V. once a day for 28 days and to identify the maximum tolerated dose.\n\nAll patients enrolled will have a documented history of ALS disease prior to study enrollment.\n\nTreatment will start with 1.7mg/kg with dose escalation by 0.5 mg/kg every 3-4 days and will increase to the maximum dose of 3.2mg/kg. Day 1 to Day 28 patients will be on active treatment.\n\nAfter completion of 28 treatment days, participants who will choose to continue treatment (at the investigator's discretion), will be enrolled in a follow-up study. Participants that discontinue treatment after Day 28 will be followed up by a nurse phone call and return to the clinic for a final visit on Day 56 from the first dose.""}]",,
Non-Invasive Measurement of Gastrointestinal (GI) Motility in Patients With Amyotrophic Lateral Sclerosis (ALS),2017-01,COMPLETED,2016-11,SPONSOR_INVESTIGATOR,Christine Barr,Christine Barr,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,41.0,ACTUAL,,"['Amyotrophic Lateral Sclerosis', 'Gastric Motility', 'Autonomic Nervous System', 'Neurodegenerative Diseases', 'Movement Disorders', 'Gastrointestinal Motility']",ALS clinic patients at MDA/ALS Center of Hope.
"Cell Signaling, Reinnervation and Metabolism in Kennedy Disease and Amyotrophic Lateral Sclerosis (ALS)",2024-02,RECRUITING,2025-12,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,"['Amyotrophic Lateral Sclerosis', 'Kennedy Disease']",INTERVENTIONAL,40.0,ESTIMATED,"[{'name': 'Muscle biopsy', 'description': 'A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.'}]",,
Tau PET Imaging in Atypical Dementias,2023-11,RECRUITING,2024-02-01,PRINCIPAL_INVESTIGATOR,Emily Rogalski,Northwestern University,"[""Primary Progressive Aphasia With Suspected Alzheimer's Disease""]",INTERVENTIONAL,70.0,ESTIMATED,"[{'name': '18F-AV-1451'}, {'name': 'PET', 'description': 'PET scanner for brain imaging'}]",,
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),2019-04,COMPLETED,2012-03,SPONSOR,,Cytokinetics,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,27.0,ACTUAL,"[{'name': 'CK-2017357', 'description': 'Total daily oral dose of 250 mg (125 mg BID) of CK-2017357 for 7 days followed by total daily oral dose of 375 mg (125 mg AM and 250 mg PM) for 7 days followed by total daily oral dose of 500 mg (250 mg BID) of CK-2017357 for 7 days'}, {'name': 'Placebo', 'description': 'Matching placebo tablets BID for 21 days'}, {'name': 'Riluzole 50 MG'}]",,
Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS),2023-08,RECRUITING,2026-06,SPONSOR,,Stichting TRICALS Foundation,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,171.0,ESTIMATED,"[{'name': 'Lithium Carbonate 400 MG', 'description': 'Lithium carbonate vs placebo (2:1)'}]",,
"Clinical Characteristics, Natural History, Health Care Measures, and Genetic Screening in Patients With ALS",2023-05,RECRUITING,2025-06,SPONSOR,,Ambulanzpartner Soziotechnologie APST GmbH,"['Motor Neuron Disease, Amyotrophic Lateral Sclerosis']",OBSERVATIONAL,2000.0,ESTIMATED,,"['ID-ALS', 'ALSFRS-R-SE', 'ALSFRS-R', 'Neurofilament light chain NfL', 'APST Research', 'ALS-App', 'SOD1', 'C9orf72', 'FUS', 'TARDBP', 'Biomarker']","The enrollment of subjects takes place in specialized ALS outpatient centers in Germany. ALS patients eligible for the investigation will be invited to participate in this cohort study. After obtaining informed consent, subjects will be enrolled in the study."
To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers,2023-09,ACTIVE_NOT_RECRUITING,2025-06-30,SPONSOR,,"Everfront Biotech Co., Ltd.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,56.0,ESTIMATED,"[{'name': 'HK-001', 'description': 'HK-001 is synthesized by PharmaCore Biotech Co., Ltd. Synthetic (Z)-BP with high purity will be used in this proposed study.'}, {'name': 'Placebo control', 'description': 'In order to evaluate the safety and tolerability of HK-001 more accurately, a drug-free placebo control is planned to be utilized for the same administration route in this proposed trial. The placebo control that is identical in appearance, smell, weight, and excipients will be supplied by Everfront Biotech Inc.'}]",,
Social Cognition in Patients With Amyotrophic Lateral Sclerosis,2020-06,UNKNOWN,2023-09,SPONSOR,,"University Hospital, Angers",['Social Cognition'],INTERVENTIONAL,74.0,ESTIMATED,"[{'name': 'neuropsychological test', 'description': 'neuropsychological test'}]",,
"A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)",2023-04,TERMINATED,2023-03-31,SPONSOR,,Cytokinetics,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,72.0,ACTUAL,"[{'name': 'Reldesemtiv', 'description': 'Oral tablet'}]","['Amyotrophic Lateral Sclerosis', 'ALS', 'CK-2127107', 'Reldesemtiv']",
Rehabilitation in SOD1 ALS Treated With Tofersen,2024-01,ENROLLING_BY_INVITATION,2024-12,PRINCIPAL_INVESTIGATOR,Sean E Smith,Washington University School of Medicine,"['Amyotrophic Lateral Sclerosis', 'Lou Gehrig Disease', 'Familial Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease', 'Motor Neuron Disease, Familial']",OBSERVATIONAL,10.0,ESTIMATED,"[{'name': 'Rehabilitation', 'description': 'Particapants currently receiving tofersen treatment will be referred to outpatient physical and/or occupational therapy.'}]",,Patients with SOD1 ALS
CNS10-NPC-GDNF for the Treatment of ALS,2020-07,COMPLETED,2019-10-18,PRINCIPAL_INVESTIGATOR,Robert H. Baloh,Cedars-Sinai Medical Center,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,18.0,ACTUAL,"[{'name': 'Stem cell (HPC) implantation', 'description': 'All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.'}, {'name': 'Stereotactic surgical device', 'description': 'A newly developed stereotactic frame is being evaluated as a part of this trial'}]","['stem cells', 'growth factor', 'ALS']",
"Longitudinal Study of Cognition With Niemann-Pick Disease, Type C",2016-01,COMPLETED,2014-09,PRINCIPAL_INVESTIGATOR,"Marc C. Patterson, M.D.",Mayo Clinic,"['Niemann-Pick Disease, Type C']",OBSERVATIONAL,70.0,ACTUAL,,"['Niemann-Pick disease type C', 'Lysosomal disease']","Longitudinal observational study of cognition in patients with NPC. Subjects will be recruited from participants in an observational study currently in progress at NIH, and from subjects receiving clinical care at Mayo Clinic. Participants will be administered age-and functionally-appropriate neuropsychological test instruments annually to track cognitive changes over time, and to link these data to the subjects' scores on the NIH disability scale."
Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS),2013-08,TERMINATED,2010-06,SPONSOR,,"Teva Branded Pharmaceutical Products R&D, Inc.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,446.0,ACTUAL,"[{'name': 'Talampanel', 'description': '50mg capsules tid'}]","['Talampanel', 'Open-Label Study', 'Amyotrophic Lateral Sclerosis']",
Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-CellsÂ®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS),2023-08,NOT_YET_RECRUITING,2025-12,SPONSOR,,"Q Therapeutics, Inc.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'Q-Cells', 'description': 'cellular therapeutic comprised of human cells of the glial lineage'}]",,
HDtDCS in Logopenic Variant PPA: Effects on Language and Neural Mechanisms,2021-11,ENROLLING_BY_INVITATION,2023-06,PRINCIPAL_INVESTIGATOR,Elias Granadillo Deluque,Medical College of Wisconsin,['Primary Progressive Aphasia'],INTERVENTIONAL,20.0,ESTIMATED,"[{'name': 'HD-tDCS', 'description': 'High-Dose transcranial Direct Current Stimulation'}, {'name': 'Sham', 'description': 'Sham sessions (no electric current)'}]","['Adult', 'Primary Progressive Aphasia', 'High-definition Transcranial Direct Current Stimulation', 'HD-tDCS', 'Language', 'Logopenic', 'Magnetic Resonance Imaging', 'MRI', 'Magnetoencephalography', 'MEG', 'Brain', 'Aphasia']",
National Registry of Veterans With Amyotrophic Lateral Sclerosis and DNA Bank,2014-04,COMPLETED,2009-09,SPONSOR,,US Department of Veterans Affairs,['ALS'],OBSERVATIONAL,2121.0,ACTUAL,,['ALS'],Living veterans with an ALS diagnosis verified by medical records.
A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,2018-08,TERMINATED,2018-07-27,SPONSOR,,"Flex Pharma, Inc.",['Motor Neuron Disease'],INTERVENTIONAL,54.0,ACTUAL,"[{'name': 'FLX-787-ODT (orally disintegrating tablet)', 'description': 'FLX-787-ODT taken three times daily for 28 days'}, {'name': 'Placebo ODT', 'description': 'Placebo ODT taken three times daily for 28 days'}]","['Motor Neuron Disease', 'Neurodegenerative Diseases', 'Nervous System Diseases', 'Neuromuscular Diseases', 'Amyotrophic Lateral Sclerosis', 'Primary Lateral Sclerosis', 'Progressive Muscular Atrophy', 'Muscle cramps', 'Muscle cramping', 'ALS', 'MND', 'PMA', 'PLS', 'FLX-787']",
EMERALD TRIAL Open Label Extension Study,2023-03,ACTIVE_NOT_RECRUITING,2024-01,SPONSOR,,Gold Coast Hospital and Health Service,"['Amyotrophic Lateral Sclerosis', 'Cannabis', 'CBD', 'Motor Neuron Disease']",INTERVENTIONAL,7.0,ACTUAL,"[{'name': 'MediCabilis CBD oil', 'description': 'The investigational product (MediCabilis 5% (50mg/ml) CBD Oil) will be supplied by BOD Australia, an Australian licensed manufacturer of medical grade cannabis.\n\nThe main components of MediCabilis 5% (50 mg/mL) CBD extract in MCT Oil are:\n\n* Cannabis sativa L. dry extract\n* Medium chain triglycerides (Ph Eur 0868) which are added in order to adjust the active constituent (cannabidiol) to the target content.\n\nEach mL of MediCabilis provides:\n\n* 50 mg of Cannabidiol (CBD+CBDA)\n* Less than 2 mg tetrahydrocannabinol (THC)\n* Non-active ingredient: Medium Chain Triglycerides (MCT) oil sourced from coconut'}]",,
Effectiveness of Two Oral Appliances for Managing Oral Self-biting Injuries in Patients With ALS,2021-03,UNKNOWN,2021-12,PRINCIPAL_INVESTIGATOR,Nina Riera-Punet,University of Barcelona,['Satisfaction'],INTERVENTIONAL,31.0,ESTIMATED,"[{'name': 'Hard occlusal splint', 'description': 'Use of a hard occlusal splint at times they considered helpful.'}, {'name': 'Flexible customized mouthguard', 'description': 'Use of a flexible customized mouthguard at times they considered helpful.'}]",,
A Study Evaluating the Safety and Tolerability of QRL-201 in ALS,2023-12,RECRUITING,2025-05-06,SPONSOR,,QurAlis Corporation,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,64.0,ESTIMATED,"[{'name': 'QRL-201 - Dose 1', 'description': 'Drug: Dose 1 of QRL-201 administered via intrathecal injection\n\nDiluent: artificial cerebrospinal fluid (aCSF)\n\nPlacebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator\n\nDiluent: artificial cerebrospinal fluid (aCSF)'}, {'name': 'QRL-201 - Dose 2', 'description': 'Drug: Dose 2 of QRL-201 administered via intrathecal injection\n\nDiluent: artificial cerebrospinal fluid (aCSF)\n\nPlacebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator\n\nDiluent: artificial cerebrospinal fluid (aCSF)\n\nDiluent: artificial cerebrospinal fluid (aCSF)'}, {'name': 'QRL-201 - Dose 3', 'description': 'Drug: Dose 3 of QRL-201 administered via intrathecal injection\n\nDiluent: artificial cerebrospinal fluid (aCSF)\n\nPlacebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator\n\nDiluent: artificial cerebrospinal fluid (aCSF)'}, {'name': 'QRL-201 - Dose 4', 'description': 'Drug: Dose 4 of QRL-201 administered via intrathecal injection\n\nDiluent: artificial cerebrospinal fluid (aCSF)\n\nPlacebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator\n\nDiluent: artificial cerebrospinal fluid (aCSF)'}, {'name': 'QRL-201 - Dose 5', 'description': 'Drug: Dose 5 of QRL-201 administered via intrathecal injection\n\nDiluent: artificial cerebrospinal fluid (aCSF)\n\nPlacebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator\n\nDiluent: artificial cerebrospinal fluid (aCSF)'}, {'name': 'QRL-201 - Dose 6', 'description': 'Drug: Dose 6 of QRL-201 administered via intrathecal injection\n\nDiluent: artificial cerebrospinal fluid (aCSF)\n\nPlacebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator\n\nDiluent: artificial cerebrospinal fluid (aCSF)'}, {'name': 'QRL-201 - Dose 7', 'description': 'Drug: Dose 7 of QRL-201 administered via intrathecal injection\n\nDiluent: artificial cerebrospinal fluid (aCSF)\n\nPlacebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator\n\nDiluent: artificial cerebrospinal fluid (aCSF)'}, {'name': 'QRL-201- Dose 8', 'description': 'Drug: Dose 8 of QRL-201 administered via intrathecal injection\n\nDiluent: artificial cerebrospinal fluid (aCSF)\n\nPlacebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator\n\nDiluent: artificial cerebrospinal fluid (aCSF)'}]","['ALS, Stathmin-2, STMN2, ASO, Antisense Oligonucleotide']",
Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS),2020-08,TERMINATED,2018-12-21,SPONSOR,,Aquestive Therapeutics,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,9.0,ACTUAL,"[{'name': 'Riluzole Oral Soluble film (ROSF) 50 mg', 'description': 'Enrolled subjects underwent an instrumental evaluation of swallowing safety before and after administration of a single dose of the ROSF formulation containing 50 mg of riluzole.'}]",,
Study of ActharÂ® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),2020-09,TERMINATED,2019-11-25,SPONSOR,,Mallinckrodt,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,143.0,ACTUAL,"[{'name': 'Acthar', 'description': 'Repository corticotropin for subcutaneous injection'}, {'name': 'Placebo', 'description': 'Matching placebo for subcutaneous injection'}]",['ALS'],
Reinnervation and Neuromuscular Transmission in ALS,2024-01,RECRUITING,2026-12,SPONSOR,,University of Aarhus,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,120.0,ESTIMATED,"[{'name': 'Observational study', 'description': 'Observational study.'}]",,Patients refered for neurophysiological examination or patients followed at out-patient clinics.
Registration Study of Amyotrophic Lateral Sclerosis (ALS) in Mainland China,2020-03,UNKNOWN,2023-03-20,SPONSOR,,Peking University Third Hospital,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,4752.0,ESTIMATED,,,Patients who meet the criteria will be enrolled from multi-centers in mainland China.
Transcranial Magnetic Stimulation in Primary Progressive Aphasia,2020-05,COMPLETED,2020-03-10,PRINCIPAL_INVESTIGATOR,Jordi A Matias-Guiu,"Hospital San Carlos, Madrid",['Primary Progressive Aphasia'],INTERVENTIONAL,20.0,ACTUAL,"[{'name': 'Transcranial Magnetic Stimulation', 'description': 'Stimulation or inhibition using TMS will be delivered guided by a neuronavigator system in different brain regions.'}]",,
Investigating Speech Sequencing in Neurotypical Speakers and Persons With Disordered Speech,2023-02,NOT_YET_RECRUITING,2026-05,PRINCIPAL_INVESTIGATOR,Frank Guenther,Boston University Charles River Campus,"['Stuttering, Developmental', 'Aphasia, Primary Progressive']",INTERVENTIONAL,315.0,ESTIMATED,"[{'name': 'Learning of non-native phoneme combinations: 6 training sessions', 'description': 'Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During each training session, the participant will practice producing a set of 8 stimuli (the Fully Learned stimuli). Each of the 8 Fully Learned stimuli will be produced 60 times over the 6 training sessions.'}, {'name': 'Learning of non-native phoneme combinations: 1 training session', 'description': 'Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During the training session, the participant will practice producing a set of 3 stimuli (the Fully Learned stimuli). Each of the 3 Fully Learned stimuli will be produced 60 times.'}, {'name': 'Learning of novel multisyllabic nonwords', 'description': 'Each trial of the training sessions (total of 6 training sessions over 2 days) will follow a simple reaction time protocol in which a nonword stimulus formed by 2 or 3 syllables that are legal in American English is presented auditorily to the participant, who then produces the stimulus as quickly and accurately as possible. During training, each participant will repeatedly produce 6 nonwords, with each nonword produced a total of 60 times over the 6 training sessions.'}, {'name': 'Anodal tDCS', 'description': 'Continuous anodal tDCS is delivered to a speech processing area of the brain during a 19-minute speech training session. The tDCS stimulation will ramp up to its maximum value (2 milliamperes) in the minute prior to the training session and maintained at that level throughout the session.'}, {'name': 'Sham tDCS', 'description': 'Sham tDCS stimulation is delivered to a speech processing area of the brain during a 19-minute speech training session. During the minute prior to training onset, the tDCS stimulator is ramped up to 2 milliamperes and then back down to 0.'}, {'name': 'Learning of non-native phoneme combinations: 8 training sessions', 'description': 'Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During each training session, the participant will practice producing a set of 3 stimuli (the Fully Learned stimuli). Each of the 3 Fully Learned stimuli will be produced 120 times over the 8 training sessions.'}]","['Stuttering, Developmental', 'Magnetic Resonance Imaging', 'Transcranial Direct Current Stimulation', 'Speech Motor Learning', 'Speech Disorders', 'Neurocomputational Modeling']",
"Resting Energy Expenditure Equations in Amyotrophic Lateral Sclerosis, Creation of a ALS-specific Equation",2017-12,COMPLETED,2014-11,SPONSOR,,"University Hospital, Limoges",['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,315.0,ACTUAL,[{'name': 'nutritional assessement'}],,ALS diagnosed patients according to Airlie House criteria
Compassionate Treatment : An Exploratory Clinical Trial to Assess Treatment of Amyotrophic Lateral Sclerosis,2016-01,COMPLETED,2016-01,PRINCIPAL_INVESTIGATOR,Shinn-Zong Lin,China Medical University Hospital,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,1.0,ACTUAL,"[{'name': 'Autologous Adipose-Tissue Derived Stem Cells', 'description': '1. Intravenous and Intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells\n2. Patient will receive brain implantation of approximately 100 -400million Autologous Adipose-Tissue Derived Stem Cells.\n\nPatient will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice , before brain implantation, and will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice, after brain implantation .'}]","['Amyotrophic Lateral Sclerosis', 'Autologous Adipose-Tissue Derived Stem Cells (ADSCs)']",
Ultrasonography of the Neuromuscular Degeneration Behavior in Amyotrophic Lateral Sclerosis,2021-10,COMPLETED,2020-03-10,PRINCIPAL_INVESTIGATOR,Antonio TomÃ¡s RÃ­os-CortÃ©s,Hospital General Universitario Santa Lucia,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,26.0,ACTUAL,,,Patient with Amyotrophic Lateral Sclerosis
Establishment of a Human Tissue Bank for Studying the Microbial Etiology of Neurodegenerative Diseases,2019-12,WITHDRAWN,2019-07-02,SPONSOR,,Wake Forest University Health Sciences,"['Neurodegenerative Diseases', 'Amyotrophic Lateral Sclerosis', 'Multiple Sclerosis', 'Parkinson Disease']",OBSERVATIONAL,0.0,ACTUAL,,"['neurodegenerative diseases', 'amyotrophic lateral sclerosis', 'multiple sclerosis', ""Parkinson's Disease""]",Patients at Carolinas Medical Center with and without neurodegenerative disease
Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis,2016-11,UNKNOWN,2019-11,SPONSOR,,"University Hospital, Angers",['Sporadic Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ESTIMATED,[{'name': 'Skin Biopsy'}],"['Bioenergetics', 'Protein Metabolism', 'Sporadic Amyotrophic Lateral Sclerosis']",
Trial of Amivita in Amyotrophic Lateral Sclerosis,2017-04,UNKNOWN,2018-10-20,SPONSOR,,Wujin People's Hospital,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'Amivita', 'description': 'In each course, Amivita solution (500ml) will be administrated i.v. once daily for 4 weeks. After an interval of 2 weeks, the participants will be treated again. A total of 7 courses will be given,'}]","['Amyotrophic lateral sclerosis, survival, adverse event']",
Explore Biomarkers of Motor Neuron Disease/Frontal Dementia Spectrum Disease in China,2021-06,ENROLLING_BY_INVITATION,2030-12-31,SPONSOR,,Peking University Third Hospital,"['Amyotrophic Lateral Sclerosis', 'Frontotemporal Dementia', 'Motor Neuron Disease']",OBSERVATIONAL,2500.0,ESTIMATED,,,MND/FTD patients in China
Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,2013-02,COMPLETED,2007-12,,,Mayo Clinic,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,330.0,ACTUAL,"[{'name': 'Insulin like growth factor, type 1', 'description': '0.05 mg per kg body weight given subcutaneously twice daily'}, {'name': 'Placebo', 'description': 'The placebo represented the inert suspension vehicle for the IGF-1. It was given as equal volume as the active drug based upon body weight, subcutaneously twice daily.'}]","['amyotrophic lateral sclerosis', 'ALS', 'progressive weakness', 'insulin-like growth factor-1', 'IGF-I', 'Myotrophin']",
Induced Pluripotent Stem Cells for Niemann Pick Disease,2020-04,COMPLETED,2019-12-01,SPONSOR,,CENTOGENE GmbH Rostock,['Niemann-Pick Diseases'],OBSERVATIONAL,40.0,ACTUAL,,,The patient has a diagnosis of Niemann Pick disease
EncoreAnywhere Use in Motor Neurone Disease,2017-05,COMPLETED,2017-04-01,SPONSOR,,Sheffield Teaching Hospitals NHS Foundation Trust,['Motor Neuron Disease'],INTERVENTIONAL,19.0,ACTUAL,"[{'name': 'EncoreAnywhere with data available to review', 'description': 'Encore Anywhere will be installed and available for review by the clinical team'}, {'name': 'EncoreAnywhere with no data available to review', 'description': 'Encore Anywhere will be installed but not available for review by the clinical team'}]",,
Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis,2017-11,COMPLETED,2018-10-16,SPONSOR,,"University of North Carolina, Chapel Hill",['ALS'],OBSERVATIONAL,21.0,ACTUAL,,,SALS patients SOD1 associated FALS patients Healthy control
Neuromuscular Ultrasound in ALS,2015-03,COMPLETED,2015-03,SPONSOR,,Duke University,['ALS'],OBSERVATIONAL,40.0,ACTUAL,"[{'name': 'Ultrasound of nerve and muscle', 'description': 'Ultrasound of 6 muscles and 2 nerves will be performed.'}]",,All patients referred to the electromyography laboratory for ALS.
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis,2017-12,COMPLETED,2017-10,SPONSOR,,Duke University,"['Prostate Cancer', 'Renal Cancer', 'Brain Cancer', 'ALS']",OBSERVATIONAL,40.0,ACTUAL,,,"This is a parallel group, single institution, prospective clinical study."
Effect of MD1003 in Amyotrophic Lateral Sclerosis,2019-06,COMPLETED,2017-12,SPONSOR,,MedDay Pharmaceuticals SA,"['ALS', 'Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease']",INTERVENTIONAL,30.0,ACTUAL,"[{'name': 'MD1003', 'description': 'capsules 100mg 3 times per day'}, {'name': 'Placebo oral capsule', 'description': 'capsules 100mg lactose 3 times per day'}]","['Biotin', 'MD1003', 'ALSFRS-R']",
Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day,2012-07,TEMPORARILY_NOT_AVAILABLE,,SPONSOR,,"Bennett, James P., Jr., M.D., Ph.D.",['Amyotrophic Lateral Sclerosis'],EXPANDED_ACCESS,,,"[{'name': 'R(+) pramipexole dihydrochloride monohydrate', 'description': '20 mg tid per day orally'}]",,
Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis,2022-07,COMPLETED,2022-07-08,SPONSOR,,Washington University School of Medicine,"['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease']",INTERVENTIONAL,15.0,ACTUAL,"[{'name': 'carbidopa-levodopa', 'description': ""Motivated by the success of dopaminergic drugs in treating rigidity associated with Parkinson's disease, some neurologists have used carbidopa-levodopa to attempt to improve spasticity in ALS and PLS patients.""}, {'name': 'Placebo Oral Tablet', 'description': 'Placebo will be given to maintain blinding of participants and study team.'}]","['ALS', 'PLS', 'Primary Lateral Sclerosis']",
The Nociceptive Flexion Reflex as a Diagnostic Tool of Central Sensitization,2024-01,RECRUITING,2024-10,SPONSOR,,University Ghent,"['Central Sensitisation', 'Fibromyalgia', 'Neck Pain', 'Low Back Pain', 'Whiplash']",OBSERVATIONAL,240.0,ESTIMATED,,,"* Fibromyalgia patients (n=30) diagnosed according to the 2010 ACR-criteria
* Patients with non-specific, idiopathic neck pain complaints which are acute (n=30) or chronic (n=30)
* Patients with neck pain complaints of traumatic origin type whiplash grade 1 (pain, stiffness or tenderness of the neck and no objective physical abnormalities) and grade 2 (neck complaints and musculoskeletal disorders such as reduced range of motion and tender pain points) according to the Quebec Task Force on Whiplash Associated Disorders which is acute (n=30) or chronic (n=30)
* Patients with non-specific, idiopathic back pain complaints which are acute (n=30) or chronic (n=30)
* Healthy controls (n=30) matched based on age, sex and BMI"
Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis,2011-01,UNKNOWN,,,,"Charite University, Berlin, Germany",['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,20.0,ESTIMATED,"[{'name': 'Anakinra', 'description': 'Open Safety and Tolerability study to evaluate a subcutaneous application 100 mg of Anakinra in combination with Riluzol in Amyotrophic Lateral Sclerosis.'}]","['ALS', 'Anakinra', 'Kineret', 'Progressive Muscular Atrophy', 'PMA', 'Safety Trial', 'Tolerability Trial']",
"A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS",2023-07,ACTIVE_NOT_RECRUITING,2024-11,SPONSOR,,NeuroSense Therapeutics Ltd.,"['Amyotrophic Lateral Sclerosis', 'ALS']",INTERVENTIONAL,69.0,ACTUAL,"[{'name': 'PrimeC', 'description': 'Ciprofloxacin and celecoxib combination extended release formulation'}, {'name': 'Placebo', 'description': 'Placebo matches active drug in size, color and taste'}]",,
"Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis",2003-08,COMPLETED,2003-08,,,National Institute of Neurological Disorders and Stroke (NINDS),"['Primary Lateral Sclerosis', 'Hereditary Spastic Paraplegia', 'Amyotrophic Lateral Sclerosis']",OBSERVATIONAL,55.0,,,"['MRI', 'Neuromuscular Disease', 'N-Acetyl Aspartate', 'Choline', 'Creatine', 'Spasms', 'Spasticity', 'Primary Lateral Sclerosis', 'Hereditary Spastic Paraplegia', 'Spastic Paraparesis', 'Healthy Volunteer', 'HV', 'Normal Control']",
DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS,2020-08,COMPLETED,2017-12-31,SPONSOR,,VA Office of Research and Development,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,34.0,ACTUAL,,"['Amyotrophic Lateral Sclerosis', 'Voice', 'Voice Quality', 'Total Lung Capacity']",A Cohort of Veteran diagnosed with ALS seen at the Tampa VA
sCD163 in ALS Patients,2014-12,COMPLETED,2016-02,SPONSOR,,University of Aarhus,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,20.0,ACTUAL,"[{'name': 'lumbar puncture for spinal fluid and blood sample', 'description': 'lumbar puncture for spinal fluid and blood sample'}]","['Amyotrophic Lateral Sclerosis', 'spinal fluid', 'CD163']","Patients with ALS, treated or newly diagnosed"
Brain and Nerve Stimulation for Hand Muscles in Spinal Cord Injury and ALS,2018-09,COMPLETED,2018-07-31,PRINCIPAL_INVESTIGATOR,"Noam Y. Harel, MD, PhD",Bronx VA Medical Center,"['Spinal Cord Injury (SCI)', 'Amyotrophic Lateral Sclerosis (ALS)']",INTERVENTIONAL,39.0,ACTUAL,"[{'name': 'Transcranial magnetic stimulation', 'description': 'One TMS pulse every 10 seconds for 20 minutes'}, {'name': 'Median nerve stimulation', 'description': 'One median nerve pulse every 10 seconds for 20 minutes'}, {'name': 'Cervical transcutaneous stimulation', 'description': 'One cervical pulse every 10 seconds for 20 minutes'}]","['Spinal Cord Injuries', 'Amyotrophic Lateral Sclerosis', 'Transcranial magnetic stimulation, single pulse', 'non-invasive brain stimulation']",
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease,2021-06,TERMINATED,2021-10-01,SPONSOR,,"AZTherapies, Inc.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,12.0,ACTUAL,"[{'name': 'ALZT-OP1a (cromolyn)', 'description': '1. Mast cell stabilizer\n2. Neuroinflammatory microglial modulator\n3. anti-inflammatory'}]","['ALS', 'Amyotrophic Lateral Sclerosis', ""Lou Gehrig's disease"", 'mild ALS', 'moderate ALS', 'mild to moderate ALS']",
"A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS",2023-07,RECRUITING,2024-12,SPONSOR,,The Florey Institute of Neuroscience and Mental Health,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,50.0,ESTIMATED,"[{'name': 'Ambroxol', 'description': 'Participants in the study will receive varying doses of ambroxol in solution, 3 times per day. Doses will be increased pending a safety review, up to a maximum of 1260mg/day. Blood tests will be conducted weekly to assess tolerance. Compliance will be monitored by returning used bottles. The study will last 32 weeks, including 24 weeks of drug administration and follow-up visits. After the final follow-up, there will be an end of study safety visit occurring 4 weeks later. The total time of participation will be 32 weeks. This includes a screening visit up to 4 weeks prior to Baseline, then a Baseline visit, followed by 24 weeks of follow-up (3x in clinic follow-up visits). These 24 weeks will be the drug administration period, meaning that the total duration of drug administration is 24 weeks. Following this drug administration and follow-up period, there will be an EoS safety-follow up visit that will occur 4 weeks after the final follow-up visit (28 weeks from baseline).'}, {'name': 'Placebo', 'description': 'Participants randomised to the control arm will receive a placebo for the duration of the study. The placebo will look and taste like ambroxol, but will have no active ingredient. Participants will not be told which arm they have been randomised to. The placebo will primarily be a glucose solution, however it will also have flavouring (e.g. bitters) and colouring, so as to make it look and taste like ambroxol, to maintain blinding.'}]",,
Neurofilament Light Chain in Amyotrophic Lateral Sclerosis,2023-12,RECRUITING,2024-12-31,PRINCIPAL_INVESTIGATOR,"Thomas Meyer, MD","Charite University, Berlin, Germany","['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease']",OBSERVATIONAL,3000.0,ESTIMATED,"[{'name': 'Neurofilament light chain', 'description': 'Neurofilament light chain as biomarker for amyotrophic lateral sclerosis'}]","['ALS', 'Amyotrophic lateral sclerosis', 'Neurofilament light chain', 'NfL', 'ALS Funktional Rating Scale', 'Progression', 'biomarker', 'treatment marker', 'therapeutic marker']",patients with clinical diagnosis of amyotrophic lateral sclerosis
Delineating Swallowing Impairment and Decline in ALS,2023-02,COMPLETED,2023-02-16,SPONSOR,,University of Florida,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,109.0,ACTUAL,"[{'name': 'Videofluoroscopic Swallowing Study (VFSS)', 'description': 'Videofluoroscopic swallowing study will be performed to measure oropharyngeal swallowing'}, {'name': 'Voluntary Peak Cough Flow Testing', 'description': 'Voluntary peak cough flow testing will be performed to determine the peak expiratory flow (PEF) and volume of air expelled (FEV1) during voluntary coughing.'}, {'name': 'Iowa Oral Performance Instrument', 'description': 'The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.'}, {'name': 'Capsaicin Challenge', 'description': 'A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 Î¼M capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction ""cough if you need to"" prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds.'}, {'name': 'Pulmonary Function Testing', 'description': 'Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP) expressed as a percentage of predicted values.'}, {'name': 'Eating Assessment Tool 10', 'description': 'The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.'}, {'name': 'The Center for Neurologic Study Bulbar Function Scale', 'description': 'The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.'}]",,Individuals with Amyotrophic Lateral Sclerosis
Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS,2023-10,COMPLETED,2023-06-27,SPONSOR,,Mitsubishi Tanabe Pharma Corporation,['ALS'],INTERVENTIONAL,15.0,ACTUAL,"[{'name': 'MT-1186', 'description': 'Suspension'}]",,
Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia,2021-04,COMPLETED,2018-11-03,PRINCIPAL_INVESTIGATOR,Michela Pievani,IRCCS Centro San Giovanni di Dio Fatebenefratelli,"[""Alzheimer's Disease"", 'Frontotemporal Dementia, Behavioral Variant']",INTERVENTIONAL,45.0,ACTUAL,"[{'name': 'transcranial direct current stimulation (tDCS)', 'description': '10 daily 25-minutes tDCS sessions over two weeks.'}]",,
"A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS)",2021-01,COMPLETED,2020-06-22,SPONSOR,,Kadimastem,['ALS (Amyotrophic Lateral Sclerosis)'],INTERVENTIONAL,16.0,ACTUAL,"[{'name': 'AstroRx', 'description': 'Astrocytes derived from human embryonic stem cells'}]",,
A Mindful Community for People With ALS and Their Primary Caregivers,2024-01,RECRUITING,2024-07-31,PRINCIPAL_INVESTIGATOR,Ellen Langer,Harvard University,"['Amyotrophic Lateral Sclerosis', 'Caregiver Burden']",INTERVENTIONAL,300.0,ESTIMATED,"[{'name': 'Mindfulness', 'description': 'Online non-meditation mindfulness program'}, {'name': 'Mindful Learning', 'description': 'Online learning program'}]","['Mindfulness', 'Quality of Life']",
Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases,2024-01,RECRUITING,2032-07,PRINCIPAL_INVESTIGATOR,Eino Solje,Kuopio University Hospital,"['Alzheimer Disease', 'Frontotemporal Dementia', 'Dementia With Lewy Bodies']",INTERVENTIONAL,200.0,ESTIMATED,"[{'name': 'Gamma tACS (40 Hz) over the superior parietal cortex', 'description': 'Single session of gamma tACS (40 Hz) over the superior parietal cortex'}]",,
Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study,2024-01,ACTIVE_NOT_RECRUITING,2027-12-31,SPONSOR,,Kuopio University Hospital,"['Neurodegenerative Diseases', 'Alzheimer Disease', 'Frontotemporal Dementia', 'Lewy Body Disease', 'Vascular Dementia', 'Parkinson Disease', 'Progressive Supranuclear Palsy', 'Corticobasal Degeneration', 'Multiple System Atrophy', 'Amyotrophic Lateral Sclerosis', 'Huntington Disease']",OBSERVATIONAL,61292.0,ESTIMATED,,,"All consecutive patients admitted to Kuopio University Hospital (KUH) and Oulu University Hospital (OUH) Neurology outpatient clinic with a progressive neurodegenerative disease during 2010-2021 are identified from KUH and OUH data registry with all ICD-10 codes used in the diagnostics of neurodegenerative diseases. Their estimated number is 5572 patients. Clinical data of these patients are retrieved from the corresponding hospital data lakes. The patients will be divided into different diagnostic groups based on the accepted diagnostic criteria in use. Further, a matched control cohort is retrieved from the Finnish Population Information System maintained by the Digital and Population Data Services Agency. Every research patient has 10 controls matched by age, gender, and place of residency (according to the year of diagnosis), and the matching is performed for research patients that were alive at the end of the year of the diagnosis."
Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS,2023-11,NOT_YET_RECRUITING,2026-09,SPONSOR,,Mario Negri Institute for Pharmacological Research,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,246.0,ESTIMATED,"[{'name': 'Acetyl-l-carnitine', 'description': 'Acetyl-l-carnitine'}, {'name': 'Placebo', 'description': 'placebo'}]",,
3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS),2022-09,COMPLETED,2022-09-12,SPONSOR,,"Macquarie University, Australia",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,16.0,ACTUAL,"[{'name': '3K3A-APC Protein', 'description': '3K3A-APC with intravenous dosing of five doses of either 15mg or 30mg at 12 hourly interval. The first 8 patients will receive 15mg dose, and the next 8 patients will receive 30mg dose.'}]","['ALS', 'Amyotrophic Lateral Sclerosis', 'MND', 'Motor Neurone Disease', '3K3A-APC']",
Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia,2023-07,RECRUITING,2025-09,SPONSOR,,"University Hospital, Toulouse",['Primary Progressive Aphasia'],INTERVENTIONAL,15.0,ESTIMATED,"[{'name': 'semantic therapy and semantic re-education', 'description': 'Patients will be followed over two periods ""Phase A (randomized, 6 to 8 weeks) - Phase B (5 weeks)"".\n\nPhase A : Baseline Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 6 to 8 weeks (i.e. 18 to 24 sessions) depending on the randomisation, at the rate of 3 speech therapy sessions of 45 minutes per week.\n\nPhase B : Semantic re-education The sessions will consist of training based on the analysis of semantic traits (Coustaut, 2019). This phase will last 5 weeks (i.e. 15 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week.\n\nIn accordance with the application of the SCED methodology, repeated measurements will be carried out every second session during phases A and B. They will consist of proposing the oral naming task (lasting 10 minutes).'}]","['Semantic primary progressive aphasia', 'semantic variant (svPPA)', 'speech therapy', 'anomia', 'metacognition', 'Single Case Experimental Design', 'technology', 'naming', 'speed of lexical access']",
Continuation Study for Latozinemab,2024-01,ENROLLING_BY_INVITATION,2027-11-30,SPONSOR,,Alector Inc.,['Neurodegenerative Diseases'],INTERVENTIONAL,35.0,ESTIMATED,"[{'name': 'Latozinemab', 'description': 'All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks'}]","['Frontotemporal Dementia (FTD)', 'Amyotrophic Lateral Sclerosis (ALS)']",
Molecular Imaging Modality by Positron Emission Tomography Using 18F-X : Study of Microglial Activation in Amyotrophic Lateral Sclerosis,2010-03,UNKNOWN,2010-12,,,"University Hospital, Tours","['Amyotrophic Lateral Sclerosis', 'Bulbar Disease', 'Spinal Disease']",INTERVENTIONAL,30.0,ESTIMATED,"[{'name': '18F-X PET SCAN', 'description': '18F-X PET Scan : Injection of 7.8 mSv for 370 MBq of dose (0.021 mSv / MBq)'}]","['neurology', 'sclerosis', 'imaging', 'tomography']",
Olfactory Deficits in Neurologic Disease,2021-08,COMPLETED,2020-07-03,PRINCIPAL_INVESTIGATOR,Mark William Albers,Massachusetts General Hospital,"['Alzheimer Disease', 'Traumatic Brain Injury', 'Amyotrophic Lateral Sclerosis', 'Frontotemporal Dementia', 'Lewy Body Disease', 'Mild Cognitive Impairment']",OBSERVATIONAL,201.0,ACTUAL,,,"1. Diagnosis of Probable Alzheimer's Disease, prodromal Alzheimer's Disease, Frontotemporal Dementia, Mild Cognitive Impairment, or Dementia with Lewy Bodies or mild and moderate/severe TBI.
2. Diagnosis of familial or sporadic ALS per El Escorial Criteria or individuals with known gene mutations associated with ALS (regardless of clinical phenotype).
3. Age-matched controls
4. Males and females with a minimum age of enrollment of 18 years. There is no maximum age of enrollment."
Clinical Research in ALS Study,2023-03,RECRUITING,2027-12,PRINCIPAL_INVESTIGATOR,Michael Benatar,University of Miami,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,10000.0,ESTIMATED,,"['genetics', 'biomarkers', 'pre-symptomatic', 'natural history']","The CRiALS research program aims to recruit three types of participants:

* Individuals affected with ALS or a related neurodegenerative disease
* Unaffected individuals from pedigrees in which the genetic cause of ALS is known
* Healthy controls"
Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells,2016-06,COMPLETED,2015-08,PRINCIPAL_INVESTIGATOR,Hisham Abdel-Azim,Children's Hospital Los Angeles,"['Sickle Cell Disease', 'Thalassemia', 'Anemia', 'Granuloma', 'Wiskott-Aldrich Syndrome', 'Chediak Higashi Syndrome', 'Osteopetrosis', 'Neutropenia', 'Thrombocytopenia', 'Hurler Disease', 'Niemann-Pick Disease', 'Fucosidosis']",INTERVENTIONAL,25.0,ACTUAL,"[{'name': 'Hematopoietic stem cell transplantation', 'description': 'hematopoietic stem cell transplantation conditioning regimen depending on graft source'}]","['unrelated', 'BMT', 'HSCT', 'bone marrow transplantation', 'sickle cell disease', 'thalassemia', 'CGD', 'HLH', 'Blackfan-Diamond anemia', 'Hurler', 'leukodystrophy', 'LAD I', 'Genetic diseases', 'Red blood cell defects', 'Leukocyte defects and immune deficiencies', 'Hereditary Lymphohistiocytosis', 'chronic granulomatous disease', 'Wiskott-Aldrich syndrome', 'Chediak Higashi syndrome', 'CD40 ligand deficiency', 'Hyper IgM syndrome', 'leucocytes adhesion defect type 1', 'Osteopetrosis', 'congenital neutropenia', 'X-linked lymphoproliferative disease', 'Platelets defects', 'Congenital amegakaryocytic thrombocytopenia', 'Metabolic and storage disorders', 'Hurler disease', 'leukodystrophies', 'Niemann-Pick disease', 'Fucosidosis', 'Stem cell defects', 'reticular agenesis']",
Oxytocin and Social Cognition in Frontotemporal Dementia,2014-03,COMPLETED,2010-11,PRINCIPAL_INVESTIGATOR,Elizabeth Finger,Lawson Health Research Institute,"['Frontotemporal Dementia', ""Pick's Disease""]",INTERVENTIONAL,24.0,ACTUAL,"[{'name': 'intranasal oxytocin', 'description': 'Participants will receive 24 IU of oxytocin or placebo (Salinex saline nasal spray) intranasally 30 minutes prior to completing the experimental tasks. Two weeks later participants will return for a second visit and receive the alternate drug (either intranasal oxytocin or Salinex) prior to completing the experimental tasks.'}]","['Social Cognition', 'Oxytocin']",
Digital Smartwatch Measurements as Potential Biomarkers for Remote Disease Tracking in ALS,2024-02,WITHDRAWN,2024-02-06,SPONSOR,,University of Alberta,"['Amyotrophic Lateral Sclerosis', 'Primary Lateral Sclerosis', 'Muscular Atrophy, Progressive', 'Frontotemporal Dementia', 'Healthy']",OBSERVATIONAL,0.0,ACTUAL,,,"People living with ALS and related motor neuron diseases including ALS-Frontotemporal Dementia (ALS-FTD), Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA) and asymptomatic individuals with a known ALS mutation

AND

Healthy controls that are age and sex matched to patients"
Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS,2017-11,WITHDRAWN,2018-08,SPONSOR,,"Flex Pharma, Inc.","['Amyotrophic Lateral Sclerosis', 'Fasciculation']",INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'FLX-787-ODT (orally disintigrating tablet)', 'description': 'Oral Disintegrating Tablet'}]","['ALS', 'Amyotrophic Lateral Sclerosis', 'Fasciculation', 'FLX-787']",
"Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1",2021-10,TERMINATED,2021-10-25,SPONSOR,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),"['Niemann-Pick Disease, Type C1']",INTERVENTIONAL,2.0,ACTUAL,"[{'name': 'VTS-270', 'description': 'Intravenous VTS-270 was administered on a monthly dosing schedule for 12 months. Each participant received one of two doses (500 or 1000mg/kg). Participants also received monthly 900 mg intrathecal VTS-270 therapy.'}]",['2-Hydroxypropyl-B-Cyclodextrin'],
Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells,2023-02,RECRUITING,2025-12,PRINCIPAL_INVESTIGATOR,Benjamin Reubinoff,Hadassah Medical Organization,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,25.0,ESTIMATED,,['ALS'],We will use human somatic cells from existing collections.
SWITCH II Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis,2023-03,WITHDRAWN,2022-11-30,SPONSOR,,"Synchron Medical, Inc.","['Neurologic Disorder', 'Paralysis', 'Paralysis; Stroke', 'Amyotrophic Lateral Sclerosis', 'Muscular Dystrophies', 'Spinal Cord Injury', 'Stroke, Lacunar', 'Stroke, Brainstem', 'Upper Limb Injury', 'Spinal Muscular Atrophy']",INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Motor Neuroprosthesis', 'description': 'Type of implantable brain computer interface'}]",,
Monitoring of Non-invasive Ventilation During Sleep in ALS,2015-12,COMPLETED,,PRINCIPAL_INVESTIGATOR,Dr. Dries Testelmans,Universitaire Ziekenhuizen KU Leuven,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,40.0,ACTUAL,,"['Amyotrophic Lateral Sclerosis', 'Noninvasive Ventilation', 'Polysomnography']","Amyotrophic lateral sclerosis patients, which are followed at the Neuromuscular Reference Centre UZ Leuven, in need for NIV treatment"
French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis,2023-06,NOT_YET_RECRUITING,2028-03-31,SPONSOR,,"University Hospital, Limoges",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,1000.0,ESTIMATED,"[{'name': 'Blood sample', 'description': 'Blood sample will be taken to identify Genomic, metabolomic, metabolic, neurofilaments, and inflammation markers associated to weight loss'}]","['Amyotrophic lateral sclerosis', 'Weight Loss', 'Genetics', 'Nutrition', 'Prognosis', 'Metabolomics', 'Inflammation']",
Quality of Life Evaluation With the SRI Questionnaire of ALS Patient With Non-invasive Ventilation,2023-09,RECRUITING,2024-09-13,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,48.0,ESTIMATED,"[{'name': 'Score completion', 'description': 'completion of the SRI score'}]","['amyotrophic lateral sclerosis', 'quality of life evaluation', 'SRI questionnaire', 'Zarit Burden interview']",
Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS),2019-07,NO_LONGER_AVAILABLE,,SPONSOR,,"Biohaven Pharmaceuticals, Inc.","['Amyotrophic Lateral Sclerosis', 'ALS', 'Lou Gehrig Disease', ""Lou Gehrig's Disease"", 'Lou-Gehrigs Disease', 'Motor Neuron Disease, Amyotrophic Lateral Sclerosis']",EXPANDED_ACCESS,,,"[{'name': 'Riluzole', 'description': 'For adult patients, one 40mg of BHV-0223, administered sublingually, on a twice daily basis (approximately every 12 hours).'}]","['Amyotrophic Lateral Sclerosis', 'ALS', 'Lou Gehrig Disease', ""Lou Gehrig's Disease"", 'Lou-Gehrigs Disease', 'Motor Neuron Disease, Amyotrophic Lateral Sclerosis', 'Riluzole', 'RilutekÂ®', 'Sublingual', 'Oral formulation', 'Neuroprotective Agents', 'Administration, Sublingual', 'Administration, Oral', 'Biological Availability']",
"Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C",2024-01-23,RECRUITING,2024-09-30,SPONSOR,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),"['Niemann-Pick Disease, Type C']",OBSERVATIONAL,100.0,ESTIMATED,,"['Genetic', 'Clinical', 'DNA', 'Medical', 'History', 'Natural History']","Individuals with Niemann-Pick Disease, type C"
"A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS",2024-01,NOT_YET_RECRUITING,2026-06,PRINCIPAL_INVESTIGATOR,Oliver Blanchard,McGill University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'Darifenacin 7.5 MG Extended Release Oral Tablet', 'description': 'During the first two weeks (titration period), patients in the treatment arm will receive a daily dose of 7.5 mg darifenacin extended-release tablet. After the titration period, the dose will be increased to 15 mg once daily, which consists of two 7.5 mg tablets together for a period of 22 weeks.'}, {'name': 'Placebo', 'description': 'During the first two weeks (titration period), patients in the placebo arm will receive a daily dose of 1 placebo tablet. After the titration period, the dose will be increased to two placebo tablets taken together, for a period of 22 weeks.'}]","['Amyotrophic lateral sclerosis', 'Darifenacin', 'Neuromuscular junction']",
Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants,2023-03,COMPLETED,2021-07-20,SPONSOR,,Sanofi,['Amyotrophic Lateral Sclerosis (Healthy Volunteers)'],INTERVENTIONAL,84.0,ACTUAL,"[{'name': 'SAR443820', 'description': 'Capsule / Oral'}, {'name': 'Placebo', 'description': 'Matching Capsule / Oral'}]",,
Development of iPS From Donated Somatic Cells of Patients With Neurological Diseases,2022-08,RECRUITING,2025-12,SPONSOR,,Hadassah Medical Organization,['Neurodegenerative Disorders'],OBSERVATIONAL,120.0,ESTIMATED,,"['Amyotrophic Lateral Sclerosis', 'Familial Dysautonomia', ""Parkinson's Disease"", ""Alzheimer's Disease"", 'Age Related Macular Degeneration', 'Retinitis Pigmentosa', ""Huntington's Disease"", 'Machado - Joseph Disease', 'SMA - Spinal Muscular Atrophy', 'Ataxia Telangiectasia']",120 donors to cover 10 different neurodegenerative disorders (previously specified) based on 10 donors per disorder and 20 healthy control donors.
Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis,2016-08,COMPLETED,2017-06,SPONSOR,,"Orion Corporation, Orion Pharma",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,66.0,ACTUAL,"[{'name': 'ODM-109', 'description': 'ODM-109 1 mg capsule for oral administration.'}, {'name': 'Placebo for ODM-109', 'description': 'Placebo capsule for oral administration.'}]",,
"Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1",2018-01-13,COMPLETED,2016-12-13,SPONSOR,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),['Neimann-Pick Disease'],INTERVENTIONAL,12.0,ACTUAL,"[{'name': 'Vorinostat', 'description': 'Histone deactylase inhibitor'}]","['Niemann Pick Disease, Type C1', 'Phase I, Phase 2', 'Vorinostat']",
"A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",2020-08,COMPLETED,2020-03-16,SPONSOR,,"Genentech, Inc.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,54.0,ACTUAL,"[{'name': 'GDC-0134', 'description': 'GDC-0134 capsule will be administered orally at various doses, depending on the cohort and treatment period.'}, {'name': 'Placebo', 'description': 'Placebo matching to GDC-0134'}, {'name': 'Rabeprazole', 'description': 'Rabeprazole 20 mg twice daily orally'}, {'name': 'Midazolam', 'description': '2mg of liquid formulation of midazolam orally'}, {'name': 'Caffeine', 'description': '100 mg tablet or solution of caffeine orally'}]",,
Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia,2012-06,COMPLETED,2012-06,SPONSOR_INVESTIGATOR,"Tiffany Chow, MD","Tiffany Chow, MD",['Frontotemporal Dementia'],INTERVENTIONAL,17.0,ACTUAL,"[{'name': 'memantine hydrochloride', 'description': 'memantine hydrochloride oral tablets, 10mg po bid'}]","['PET', 'frontotemporal dementia', 'memantine', ""Pick's disease""]",
SSRIs vs. TCAs for Depression in ALS Patients,2020-01,COMPLETED,2019-05-30,PRINCIPAL_INVESTIGATOR,Ghazala Hayat,St. Louis University,"['Depression', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,2.0,ACTUAL,"[{'name': 'Tricyclic Antidepressants (""TCA"")', 'description': 'if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.'}, {'name': 'Selective Serotonin Uptake Inhibitors (""SSRI"")', 'description': 'if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.'}]",,
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),2021-07,COMPLETED,2019-11-24,SPONSOR,,Amylyx Pharmaceuticals Inc.,"['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease', 'Neuromuscular Diseases', 'Neurodegenerative Diseases', 'Spinal Cord Diseases', 'TDP-43 Proteinopathies', 'Nervous System Diseases', 'Central Nervous System Diseases']",INTERVENTIONAL,137.0,ACTUAL,"[{'name': 'AMX0035', 'description': 'AMX0035'}, {'name': 'Placebo', 'description': 'Matching Placebo Comparator'}]","['Randomized', 'Double-blind', 'Placebo-controlled', 'Amyotrophic Lateral Sclerosis', 'Sodium Phenylbutyrate', 'Tauroursodeoxycholic Acid']",
Intermediate Expanded Access Protocol for ALS,2024-02,AVAILABLE,,SPONSOR,,Clene Nanomedicine,['Amyotrophic Lateral Sclerosis'],EXPANDED_ACCESS,,,"[{'name': 'CNM-Au8', 'description': 'CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bipyramid, tetrahedron, decahedron, planar spheroids). Highly pure elemental Au nanocrystals are suspended in USP purified deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) nominally concentrated to 0.5 mg/L (500 ppm). CNM-Au8 will be administered orally in volumes of 60 mL from single-dose HDPE containers. Participants will orally receive 30 mg of CNM-Au8 once daily.'}]","['ALS', 'Gold', 'Nanoparticle', 'Expanded access', 'Au8', 'CNMAu8']",
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis,2021-05,COMPLETED,2019-10-30,SPONSOR,,ACADIA Pharmaceuticals Inc.,['Dementia-related Psychosis'],INTERVENTIONAL,392.0,ACTUAL,"[{'name': 'Placebo', 'description': 'Placebo, tablets, once daily by mouth'}, {'name': 'Pimavanserin 34 mg', 'description': 'Pimavanserin 34 mg total daily dose, tablets, once daily by mouth'}, {'name': 'Pimavanserin 20 mg', 'description': 'Pimavanserin 20 mg total daily dose, tablets, once daily by mouth'}]","['Dementia', 'Dementia-related psychosis', ""Dementia associated with Parkinson's disease"", 'Dementia with Lewy bodies', ""Alzheimer's disease"", 'Behavioral variant frontotemporal dementia', 'Progressive supranuclear palsy', 'Corticobasal degeneration', 'Vascular dementia', 'Hallucinations', 'Delusions', 'Psychosis']",
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS),2024-01,ACTIVE_NOT_RECRUITING,2025-02,PRINCIPAL_INVESTIGATOR,Nathan P. Staff,Mayo Clinic,"['ALS', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,75.0,ACTUAL,"[{'name': 'Autologous Adipose-derived Mesenchymal Stromal Cells', 'description': ""The investigational product consists of autologous adipose-derived Mesenchymal Stromal Cells (MSCs), suspended in 5-10 mL Lactated Ringer's. The MSC are provided in a sterile syringe labelled with appropriate patient and product identifiers ready for intrathecal injection.""}]",,
Noninvasive Examination of the Work of Breathing in Patients With Amyotrophic Lateral Sclerosis (ALS).,2013-03,TERMINATED,2013-02,SPONSOR,,Drexel University College of Medicine,"['Amyotrophic Lateral Sclerosis', 'Neurodegenerative Disease', 'Motor Neuron Disease']",OBSERVATIONAL,10.0,ACTUAL,,"['Amyotrophic Lateral Sclerosis', 'Cerebrospinal Fluid', 'Neurodegenerative Disease', 'Motor Neuron Disease', 'Autonomic Nervous System', 'Neurodegenerative Diseases', 'Movement Disorders']",ALS clinic patients at MDA/ALS Center of Hope.
Nightime NIV Initiation in Amyotrophic Lateral Sclerosis in an Outpatient Setting,2016-04,COMPLETED,2014-03,PRINCIPAL_INVESTIGATOR,Enrica Bertella,Fondazione Salvatore Maugeri,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,50.0,ACTUAL,"[{'name': 'Nightime NIV initiation', 'description': 'In-hospital vs home'}]",,
Exogenous Toxicants and Genetic Susceptibility in ALS,2006-03,COMPLETED,2002-08,,,National Institute of Environmental Health Sciences (NIEHS),['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,525.0,,,,
Early Access Program With Arimoclomol in US Patients With NPC,2023-11,AVAILABLE,,SPONSOR,,ZevraDenmark,"['Niemann-Pick Disease, Type C']",EXPANDED_ACCESS,,,"[{'name': 'Arimoclomol', 'description': 'Participants receive prescribed arimoclomol by oral administration'}]",,
Stem Cell Therapy for Amyotrophic Lateral Sclerosis,2018-10,WITHDRAWN,2013-08,SPONSOR,,Neurogen Brain and Spine Institute,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Stem cell', 'description': 'Autologous bone marrow derived mononuclear cells were administered via intrathecal and intramuscular routes.'}]",,
The E-health Application To Modify ORal Energy Intake and Measure Outcomes REmotely in ALS Clinical Trial (EAT MORE2),2022-02,COMPLETED,2021-12-31,PRINCIPAL_INVESTIGATOR,"Anne-Marie Alexandra Wills, MD",Massachusetts General Hospital,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,87.0,ACTUAL,"[{'name': 'ALS Nutrition App (MyDataHelps platform)', 'description': 'We have designed a mobile health app to provide nutritional counseling and to measure disease outcomes both through self-reported questionnaires and through passive data collection.'}]",,"Adults with ALS without dysphagia, diabetes or cardiovascular disease"
ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases,2014-07,TERMINATED,2011-11,SPONSOR,,Aldagen,"['Inherited Metabolic Diseases', 'Lysosomal Storage Disorders', 'Peroxisomal Storage Diseases', 'Inborn Errors of Metabolism', 'Mucopolysaccharidosis']",INTERVENTIONAL,40.0,ESTIMATED,"[{'name': 'ALD-101', 'description': 'A subpopulation of cord blood cells composed of cells that express a high level of the intracellular enzyme aldehyde dehydrogenase (ALDH).'}]","['Hurler Syndrome', 'MPS I', 'Hurler-Scheie Syndrome', 'Hunter Syndrome', 'MPS II', 'Sanfilippo Syndrome', 'MPS III', 'Maroteaux-Lamy Syndrome', 'MPS VI', 'Krabbe Disease', 'Globoid Leukodystrophy', 'Metachromatic Leukodystrophy', 'MLD', 'Adrenoleukodystrophy', 'ALD', 'Adrenomyeloneuropathy', 'AMN', 'Sandhoff Disease', 'Tay Sachs Disease', 'Pelizaeus Merzbacher', 'PMD', 'Niemann-Pick Disease A', 'Niemann-Pick Disease B', 'Alpha-mannosidosis', 'Inherited metabolic diseases', 'Inborn errors of metabolism', 'Lysosomal storage diseases', 'Peroxisomal storage diseases', 'Hematopoietic stem cell transplantation', 'Umbilical cord blood transplantation', 'Mucopolysaccharidosis', 'Mucopolysaccharidosis I', 'Mucopolysaccharidosis II', 'Mucopolysaccharidosis III', 'Mucopolysaccharidosis VI', 'I Cell disease', 'Fucosidosis', 'GM1 Gangliosidosis', 'Canavan Disease']",
rTMS for the Treatment of Primary Progressive Aphasia: A Randomized Controlled Trial,2020-06,WITHDRAWN,2021-12-31,SPONSOR,,Peking Union Medical College Hospital,"['Aphasia, Primary Progressive', 'Repetitive Transcranical Magnetic Stimulation']",INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Magstim rTMS', 'description': 'The device is made in London,UK'}]",,
"Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders",2023-11,RECRUITING,2030-01,PRINCIPAL_INVESTIGATOR,Bjorn E. Oskarsson,Mayo Clinic,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,100.0,ESTIMATED,,,Subjects with ALS and similar neurodegenerative disorders and their family members will be identified from patients seen in the Department of Neurology at Mayo Clinic Florida on the basis of a diagnosis of ALS or a similar neurodegenerative disorder.
"Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C",2023-10,RECRUITING,2024-06,SPONSOR,,Washington University School of Medicine,"['Niemann-Pick Disease, Type C']",INTERVENTIONAL,12.0,ESTIMATED,"[{'name': 'adrabetadex (2-Hydroxypropyl-Beta-Cyclodextrin)', 'description': 'VTS-270 (2-Hydroxypropyl-Beta-Cyclodextrin) will be administered intravenously to specifically target liver disease. In the first phase of the study, dosing frequency will be twice a week with IV adrabetadex (VTS-270) for six weeks for a total of 12 administrations. Subjects will be evaluated at each study visit for evidence of adverse effects.\n\nDoses to be studied are 500, and 1000 mg/kg. Six subjects will be studied at each dose level. Cohort 1: Subjects 1-6, 500 mg/kg Cohort 2: Subjects 7-12, 1000 mg/kg'}]",,
Geometrical Facial Deformation According to Posture in Amyotrophic Lateral Sclerosis,2021-03,UNKNOWN,2021-04-30,PRINCIPAL_INVESTIGATOR,Sungchul Huh,Pusan National University Yangsan Hospital,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,20.0,ESTIMATED,"[{'name': '3-dimensional scan', 'description': 'Facial 3-dimensional scan according to posture'}]",,Patient: a patient who visit out- or inpatient clinic at rehabilitation hospital Healthy volunteer: community dwelling volunteer
Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD),2017-08,WITHDRAWN,2007-07-26,SPONSOR,,Johns Hopkins University,['Dementia'],INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Amantadine'}, {'name': 'Placebo'}]","['Behavioral disturbance', 'Frontotemporal dementia', 'Dementia', 'Amantadine', 'Behavioral disturbance due to frontotemporal dementia']",
Dietary Approach to Improving Quality of Life in Amyotrophic Lateral Sclerosis,2019-06,WITHDRAWN,2021-07-01,SPONSOR_INVESTIGATOR,Terry L. Wahls,Terry L. Wahls,"['Diet Modification', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Modified Paleolithic diet', 'description': 'The diet eliminates legumes, grains and nightshades (as opposed to the Paleolithic diet) and is higher in vegetable and fruit intake and in omega-3 fatty rich foods.'}]",,
An In-home Study of Brain Computer Interfaces,2017-03,COMPLETED,2011-05,PRINCIPAL_INVESTIGATOR,"Jane Huggins, PhD",University of Michigan,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,1.0,ACTUAL,"[{'name': 'Brain Computer Interface for Wheelchair Tilt Control', 'description': 'Patients will be given the BCI for use in-home, as long as they use the BCI at least 10 hours per week and complete monthly performance assessment sessions.'}]",,
"Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease",2023-12,ACTIVE_NOT_RECRUITING,2024-12,SPONSOR,,Azafaros A.G.,"['GM2 Gangliosidosis', 'Niemann-Pick Disease, Type C']",INTERVENTIONAL,13.0,ACTUAL,"[{'name': 'AZ-3102 (Dose 1)', 'description': 'Pharmaceutical form: capsule\n\nRoute of administration: oral'}, {'name': 'Placebo', 'description': 'Pharmaceutical form: capsule\n\nRoute of administration: oral'}, {'name': 'AZ-3102 (Dose 2)', 'description': 'Pharmaceutical form: capsule\n\nRoute of administration: oral'}]",,
Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation,2003-10,UNKNOWN,,,,Fairview University Medical Center,"['I Cell Disease', 'Fucosidosis', 'Globoid Cell Leukodystrophy', 'Adrenoleukodystrophy', 'Mannosidosis', 'Niemann-Pick Disease', 'Pulmonary Complications', 'Mucopolysaccharidosis I', 'Mucopolysaccharidosis VI', 'Metachromatic Leukodystrophy', ""Gaucher's Disease"", 'Wolman Disease']",OBSERVATIONAL,10.0,,,"[""Gaucher's disease"", 'I cell disease', 'Niemann-Pick disease', 'Wolman disease', 'adrenoleukodystrophy', 'disease-related problem/condition', 'fucosidosis', 'genetic diseases and dysmorphic syndromes', 'globoid cell leukodystrophy', 'inborn errors of metabolism', 'mannosidosis', 'metachromatic leukodystrophy', 'mucopolysaccharidosis', 'mucopolysaccharidosis I', 'mucopolysaccharidosis VI', 'oncologic disorders', 'pulmonary complications', 'rare disease', 'sphingolipidoses']",
Amyotrophic Lateral Sclerosis (ALS) Gulf War Study,2009-10,COMPLETED,2003-03,,,US Department of Veterans Affairs,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,135.0,ACTUAL,,"['ALS', 'amyotrophic lateral sclerosis', 'Gulf War Veterans']",Living and deceased veterans with an ALS diagnosis who served in the military between 8/2/1990 and 7/31/1991.
TMS for the Treatment of Primary Progressive Aphasia,2023-10,RECRUITING,2025-01-31,PRINCIPAL_INVESTIGATOR,Alexandra Touroutoglou,Massachusetts General Hospital,"['Logopenic Variant Primary Progressive Aphasia', 'Non-fluent Variant Primary Progressive Aphasia', 'Semantic Variant Primary Progressive Aphasia']",INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'ACTIVE rTMS', 'description': 'All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).'}, {'name': 'SHAM rTMS', 'description': 'All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).'}]",,
Human Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis (ALS),2015-12,COMPLETED,2015-12,PRINCIPAL_INVESTIGATOR,Angelo Luigi Vescovi,"Azienda Ospedaliera Santa Maria, Terni, Italy",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,18.0,ACTUAL,"[{'name': 'Human Neural Stem Cells', 'description': 'Surgical microinjection of human neural stem cells on spinal cord of ALS patients'}]","['amyotrophic lateral sclerosis', 'motor neuron disease', 'stem cells', 'safety', 'ALS-FRS-Functional scale R and FVC (%) variation', 'Survival analysis', 'Changes in quality of life scales']",
Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS),2012-05,COMPLETED,2011-04,,,Mayo Clinic,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,1.0,ACTUAL,"[{'name': 'autologous mesenchymal stem cells', 'description': 'single intrathecal dose of 10x6 cells by lumbar puncture.'}]",,
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,2020-08,COMPLETED,2017-09-27,SPONSOR,,Cytokinetics,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,744.0,ACTUAL,"[{'name': 'Tirasemtiv'}, {'name': 'Placebo tablets'}]","['fast skeletal troponin activator', 'tirasemtiv', 'CK-2017357', 'double-blind', 'randomized', 'placebo-controlled']",
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL),2021-05,COMPLETED,2020-09,SPONSOR,,"University of California, San Francisco","['FTLD', 'Progressive Supranuclear Palsy (PSP)', 'Frontotemporal Dementia (FTD)', 'Corticobasal Degeneration (CBD)', 'PPA Syndrome', 'Behavioral Variant Frontotemporal Dementia (bvFTD)', 'Semantic Variant Primary Progressive Aphasia (svPPA)', 'Nonfluent Variant Primary Progressive Aphasia (nfvPPA)', 'FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)', 'Amyotrophic Lateral Sclerosis (ALS)', 'Oligosymptomatic PSP (oPSP)', 'Corticobasal Syndrome (CBS)']",OBSERVATIONAL,1489.0,ACTUAL,,"['FTLD, PSP, CBD, PPA, FTD, FTD-ALS, CBS, ALS, svPPA, nfvPPA, oPSP']","Patients with a diagnosis of a frontotemporal lobar degeneration (FTLD) syndrome, including progressive supranuclear palsy (PSP), semantic variant primary progressive aphasia (svPPA), and frontotemporal dementia with amyotrophic lateral sclerosis (FTD-ALS). Family members of patients with FTLD syndromes."
EH301 for the Treatment of ALS,2018-05,COMPLETED,2017-06,SPONSOR,,Elysium Health,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,32.0,ACTUAL,"[{'name': 'EH301', 'description': ""1-(beta-D-Ribofuranosyl)nicotinamide chloride and 3,5-Dimethoxy-4'-hydroxy-trans-stilbene""}, {'name': 'Placebo', 'description': 'No intervention- placebo'}]",,
Clinical Trial on the Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis,2010-12,COMPLETED,2010-02,,,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,11.0,ACTUAL,"[{'name': 'Laminectomy and bone marrow stem cells transplantation', 'description': 'T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation'}, {'name': 'Autologous bone marrow cells collection', 'description': 'Autologous bone marrow cells collection under sedation. Sixty mL are obtained and processed through a ficoll gradient.'}]","['Amyotrophic Lateral Sclerosis', 'Bone marrow', 'Stem cells', 'Autologous', 'Safety']",
Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI),2020-07,COMPLETED,2018-01-28,SPONSOR,,"Centre Hospitalier Universitaire, Amiens","['Frontotemporal Dementia', 'Huntington Disease', 'Alzheimer Disease', 'Semantic Dementia', 'Dementia, Vascular']",OBSERVATIONAL,49.0,ACTUAL,"[{'name': 'prevalence of behavioural dysexecutive syndrome', 'description': 'Behavioural Dysexecutive Syndrome Inventory (ISDC)'}]",['behavioural disorders'],"French-speaking subjects between the ages of 40 and 85 years with an MMSE score \> 15/30, followed for AD or MCI or VaD or FTD or SD or HD will be selected by their neurologist during a routine memory assessment visit."
Study of Standard Noninvasive Positive Pressure Ventilation (NIPPV) and Low Expiratory Pressure NIPPV in ALS Patients,2016-11,COMPLETED,2011-10,SPONSOR_INVESTIGATOR,Kirsten Gruis,Kirsten Gruis,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,28.0,ACTUAL,"[{'name': 'ViasysÂ® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)', 'description': 'Noninvasive positive airway pressure ventilation'}]",,
The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules,2021-06,UNKNOWN,2022-12-31,SPONSOR,,Peking University Third Hospital,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,144.0,ESTIMATED,"[{'name': 'Huolingshengji Granules', 'description': '1 bag of Huolingshengji Granules each time + 1 tablet of Riluzole tablet simulation agent each time, twice a day, orally;'}, {'name': 'Riluzole tablet', 'description': 'Huolingshengji granules simulation agent 1 bag each time + Riluzole tablet 1 tablet each time, 2 times a day, orally.'}]",,
Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS,2023-07,TERMINATED,2023-03-30,SPONSOR,,Johns Hopkins University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,4.0,ACTUAL,"[{'name': '[11C]CPPC Injection', 'description': 'A single dose of \\[11C\\]CPPC (370 megabecquerel (MBq) (XÂ±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.'}]",['Positron Emission Tomography'],
Speech-Language Treatment With Remotely Supervised Transcranial Direct Current Stimulation in Primary Progressive Aphasia,2023-07,ACTIVE_NOT_RECRUITING,2024-06-30,PRINCIPAL_INVESTIGATOR,Maya Henry,University of Texas at Austin,['Primary Progressive Aphasia'],INTERVENTIONAL,10.0,ESTIMATED,"[{'name': 'Remotely supervised Transcranial Direct Current Stimulation (RS-tDCS)', 'description': ""tDCS is a type of non-invasive brain stimulation. 1.5 milliamp (mA) of current will be delivered via electrodes in saline-soaked sponges placed on the left side of the head and right upper arm. The stimulation will be delivered for 20 minutes, 5 times weekly, in the participant's home setting while the participant engages in computer-delivered speech-language training. Sessions are monitored by study personnel.""}, {'name': 'Remotely supervised sham tDCS (RS-sham-tDCS)', 'description': ""tDCS is a type of non-invasive brain stimulation. During sham stimulation 1.5 milliamp (mA) of current will be delivered for a brief period and then turned off. Current will be delivered via electrodes in saline-soaked sponges placed on the left side of the head and right upper arm. Sham will be delivered for 20 minutes, 5 times weekly, in the participant's home setting while the participant engages in computer-delivered speech-language training. Sessions are monitored by study personnel.""}, {'name': 'Lexical Retrieval Training (LRT)', 'description': 'Participants work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) teletherapy sessions per week with a clinician plus 30 minutes of additional independent, computer-based practice exercises 3 times per week.'}, {'name': 'Video Implemented Script Training in Aphasia (VISTA)', 'description': 'Participants work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes two (one hour each) teletherapy sessions per week with a clinician targeting clear and accurate script production, script memorization, and conversational usage of scripts. The participant completes 30 minutes of independent, computer-based practice 3 times per week, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts.'}]","['Speech-Language Pathology', 'Primary Progressive Aphasia', 'Fronto-Temporal Dementia', ""Alzheimer's Disease"", 'Neurodegenerative Disease', 'Logopenic', 'Semantic', 'Nonfluent', 'Logopenic Variant Primary Progressive Aphasia', 'Semantic Variant Primary Progressive Aphasia', 'Nonfluent Variant Primary Progressive Aphasia', 'Semantic Dementia', 'Speech Entrainment', 'Script Training', 'Teletherapy', 'Transcranial Direct Current Stimulation', 'Remotely-Supervised Transcranial Direct Current Stimulation', 'Lexical Retrieval', 'Noninvasive Brain Stimulation', 'Telehealth']",
Evaluation of a Transcranial Stimulation With Direct Current on Language Disorders in Semantic Dementia,2023-03,RECRUITING,2024-09,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,['Semantic Dementia'],INTERVENTIONAL,80.0,ESTIMATED,"[{'name': 'Transcranial stimulation', 'description': '1. 10 days of stimulation (20min, 1.59mA) in double-blind sham-controlled. 3 arms (N=20 in each arm):\n\n   * left-excitatory tDCS (N=20)\n   * right-inhibitory tDCS (N=20)\n   * sham tDCS (N=20)\n2. 4 language/semantic evaluations: base-line; 3 days; 2 weeks; 4 months post-tDCS\n3. 2 MRI/PET acquisitions: pre-stimulation (base-line); 2 weeks post-tDCS'}]",,
Safety and Tolerability Ultra-high-caloric Food Supplements in Amyotrophic Lateral Sclerosis (ALS),2021-04,COMPLETED,2021-04-05,SPONSOR_INVESTIGATOR,"Albert Christian Ludolph, Prof.","Albert Christian Ludolph, Prof.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,64.0,ACTUAL,"[{'name': 'high-caloric fatty diet', 'description': 'see arm/group description'}, {'name': 'ultra-high-caloric fatty diet', 'description': 'see arm/group description'}, {'name': 'ultra-high-caloric carbohydrate-rich diet', 'description': 'see arm/group description'}]",,
A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C,2017-05,COMPLETED,2017-05,SPONSOR,,ZevraDenmark,"['Niemann-Pick Disease, Type C']",OBSERVATIONAL,35.0,ACTUAL,,"['NP-C', 'LSD', 'lysosomal storage disorder', 'lysosomal storage disease', 'NPC2', 'NPC1', 'Niemann-Pick Type C', 'Niemann-Pick,', 'Arimoclomol']",NPC1 and NPC2 patients aged 2-18 years
Pre-hospital ECMO in Advanced Resuscitation in Patients With Refractory Cardiac Arrest. ( SUB30 ),2020-11,UNKNOWN,2021-12-31,SPONSOR,,Barts & The London NHS Trust,"['Death, Sudden, Cardiac', 'Out-Of-Hospital Cardiac Arrest', 'Ventricular Fibrillation', 'Cardiopulmonary Arrest With Successful Resuscitation']",INTERVENTIONAL,6.0,ESTIMATED,"[{'name': 'ECMO resuscitation', 'description': 'Extracorporeal Cardio-Pulmonary Resuscitation (ECPR) using ECMO within 30 minutes of cardiac arrest'}]","['Advanced life support (ALS)', 'Extra-corporeal Membrane Oxygenation Resuscitation (ECMO)']",
Dementias and Microbiota Composition: Is Possible to Revert the Dementia Symptoms Reverting the Microbiota Composition?,2023-06,RECRUITING,2025-02-01,PRINCIPAL_INVESTIGATOR,Margarita Torrente,University Rovira i Virgili,"['Dementia Alzheimers', 'Dementia With Lewy Bodies', 'Parkinson Disease Dementia', 'Dementia Frontotemporal', 'Mild Cognitive Impairment']",OBSERVATIONAL,240.0,ESTIMATED,"[{'name': 'No intervention', 'description': 'no intervention'}, {'name': 'Probiotic supplement', 'description': 'A total of 60 Alzheimer Disease (AD) patients will be recruited, 30 will ingest the probiotic mixture and 30 will ingest placebo (randomized assignment to the groups will be done). The experimental group will take the probiotic ingest daily: Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, and Lactobacillus fermentum (2 Ã— 109 colony forming units (CFU)/g of each). This mixture of bacteria has been showed to have positive results with 12 weeks treatment.'}]","['cognitive status', 'functional status', 'neuropsychiatric status', 'microbiota']",Clinic patients from hospitals and other diagnostic medical centers.
Quantitative Analysis of Precise Brain Volume in Amyotrophic Lateral Sclerosis,2021-06,COMPLETED,2021-01-31,SPONSOR,,Peking University Third Hospital,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,32.0,ACTUAL,"[{'name': 'Diagnostic criteria', 'description': 'Diagnostic criteria of ALS'}]",,32
Spinal Interneuron Excitability in ALS,2021-08,UNKNOWN,2021-11,SPONSOR,,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",['ALS'],INTERVENTIONAL,120.0,ESTIMATED,"[{'name': 'Electrophysiology', 'description': 'EMG recordings conditioned by electrical peripheral nerve stimulation and/or transcranial magnetic stimulation'}]","['Pathophysiology', 'Spinal interneurons', 'Electrophysiology', 'EMG', 'transcranial magnetic stimulation (TMS)']",
Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS),2015-04,COMPLETED,2014-06,PRINCIPAL_INVESTIGATOR,David Gomez Almaguer,Hospital Universitario Dr. Jose E. Gonzalez,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,14.0,ACTUAL,"[{'name': 'Intrathecal autologous stem cell', 'description': 'Mobilization and collection of stem cells for intravenous and intrathecal administration'}]","['ALS, stem cells']",
Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),2023-03,COMPLETED,2017-04,PRINCIPAL_INVESTIGATOR,Jeremy Shefner,Barrow Neurological Institute,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,52.0,ACTUAL,"[{'name': 'NeuRxÂ® Diaphragm Pacing Systemâ„¢ (DPS)', 'description': ""The NeuRxÂ® Diaphragm Pacing Systemâ„¢ (DPS) is a four channel, implanted percutaneous diaphragm muscle stimulation system. Pictures of the device are provided in the Clinician's Manual for the NeuRxÂ® DPS procedure and technique guide from the manufacture Synapse Biomedical, Inc. Under general anesthesia, the intramuscular electrodes are laparoscopically implanted in the diaphragm. The ends of the implanted electrodes are tunneled subcutaneously to an exit site on the chest or abdominal wall and connected to an external stimulator.""}]","['ALS', 'DPS', 'Diaphragm Pacing']",
A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain,2024-01,RECRUITING,2025-03-31,SPONSOR,,AbbVie,['Chronic Lymphocytic Leukemia'],OBSERVATIONAL,132.0,ESTIMATED,,"['Chronic Lymphocytic Leukemia', 'Bruton Tyrosine Kinase Inhibitor', 'Patient-Reported Outcomes Measure', 'Patient-Reported Experience Measure', 'Venetoclax', 'Venclexta', 'Venclyxto', 'ABT-199', 'Patient Preferences', 'Cancer', 'PROVIDENCE']",Adult participants diagnosed with chronic lymphocytic leukemia (CLL) treated with fixed-time duration (FTD) or continuous oral regimens who attend to a regular follow up visit at a Spanish participating hospital will be eligible to participate in the study.
A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS),2011-11,COMPLETED,2005-02,SPONSOR,,Novartis,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,350.0,ACTUAL,[{'name': 'TCH346'}],['Amyotrophic Lateral Sclerosis; ALS'],
Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS],2003-12,COMPLETED,,,,National Center for Research Resources (NCRR),['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,,,[{'name': 'Creatine'}],,
Molecular Neuroimaging of Neuroinflammation in Neurodegenerative Dementias,2023-03,RECRUITING,2025-08,SPONSOR,,Lawson Health Research Institute,['Frontotemporal Dementia'],INTERVENTIONAL,40.0,ESTIMATED,"[{'name': '(18F)-FEPPA', 'description': 'PET ligand that binds to activated microglia, a marker of neuroinflammation'}]","['PET', 'MRI', 'Inflammation', 'Microglia', 'FEPPA']",
Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol),2023-10,RECRUITING,2025-01,SPONSOR,,InFlectis BioScience,"['Amyotrophic Lateral Sclerosis', 'ALS']",INTERVENTIONAL,50.0,ESTIMATED,"[{'name': 'IFB-088 50mg/day', 'description': 'Tested product'}, {'name': 'Placebo', 'description': 'Placebo'}, {'name': 'Riluzole 100mg/day', 'description': 'Standard of care treatment, co-administered with tested product (IFB-088 50mg/day) or placebo'}]","['IFB-088', 'Icerguastat', 'ALS', 'Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease', 'Neurodegenerative Disease']",
Life Enhancing Activities for Family Caregivers,2019-08,COMPLETED,2019-06-30,PRINCIPAL_INVESTIGATOR,Glenna Dowling,"University of California, San Francisco","['Stress', 'Dementia', 'Affect']",INTERVENTIONAL,175.0,ACTUAL,"[{'name': 'Positive Affect', 'description': 'Six-session skill-building program designed to raise levels of positive emotion when skills are practiced over the duration of the program.'}]","['positive affect', 'caregivers', 'caregiving', 'stress', 'mood', 'dementia', ""Alzheimer's"", 'FTD', 'Lewy', 'mindfulness', 'help']",
China Amyotrophic Lateral Sclerosis Registry of Patients With Traditional Chinese Medicine,2021-05,RECRUITING,2028-03-01,PRINCIPAL_INVESTIGATOR,Ying Gao,"Dongzhimen Hospital, Beijing",['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,2000.0,ESTIMATED,,,Patients who meet the criteria will be enrolled from multi-centers in China.
Explore Neuroprotective Effect of Lipoic Acid in Amyotrophic Lateral Sclerosis,2020-08,UNKNOWN,2022-10-01,SPONSOR,,"Second Affiliated Hospital, School of Medicine, Zhejiang University",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,150.0,ESTIMATED,"[{'name': 'lipoic acid group', 'description': 'The patients will take lipoic acid for 6 course, the first course of treatment is 14 days with 14 days of rest, and the following course is the first for 10 days, with 14 days interval.The patients will use 600mg domestic lipoic acid in 250ml normal saline by intravenous, once a day.\n\nAt the same time, the patients will take domestic riluzole tablets 50mg orally, twice a day.'}, {'name': 'control group', 'description': 'The patients will take domestic riluzole tablets 50mg orally, twice a day.'}]",,
Open-label Clinical Trial of Lacosamide in ALS,2020-07,COMPLETED,2020-05-31,PRINCIPAL_INVESTIGATOR,Satoshi Kuwabara,Chiba University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,7.0,ACTUAL,"[{'name': 'Lacosamide', 'description': 'Sodium channel blocker'}]",,
Open Label Extension Study of AMX0035 in Patients With ALS,2022-01,COMPLETED,2021-11-01,SPONSOR,,Amylyx Pharmaceuticals Inc.,"['Amyotrophic Lateral Sclerosis', 'ALS']",INTERVENTIONAL,95.0,ACTUAL,"[{'name': 'AMX0035', 'description': 'A combination therapeutic of TUDCA and Sodium Phenylbutyrate'}]",,
Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS),2016-05,COMPLETED,2012-05,PRINCIPAL_INVESTIGATOR,Robert Welsh,University of Michigan,"['ALS', 'Amyotrophic Lateral Sclerosis']",OBSERVATIONAL,92.0,ACTUAL,,"['ALS', 'amyotrophic lateral sclerosis', 'brain-computer interface', 'functional magnetic resonance imaging', 'radiology', 'fMRI']",All are able to participate.
Transcranial Magnetic Stimulation in Nonfluent/Agrammatic Variant Primary Progressive Aphasia,2022-02,TERMINATED,2022-02-14,PRINCIPAL_INVESTIGATOR,Fidel Vila-Rodriguez,University of British Columbia,['Primary Progressive Nonfluent Aphasia'],INTERVENTIONAL,2.0,ACTUAL,"[{'name': 'Active iTBS', 'description': 'Intermittent theta burst transcranial magnetic stimulation'}, {'name': 'Sham iTBS', 'description': 'Sham intervention'}]","['Aphasia', 'Agrammatism', 'Frontotemporal Dementia', 'Tauopathies', 'Neurodegenerative Diseases', 'Language Disorders', 'Frontotemporal Lobar Degeneration']",
"Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers",2024-02,RECRUITING,2024-06-30,SPONSOR,,"Ashvattha Therapeutics, Inc.","['Amyotrophic Lateral Sclerosis (ALS)', 'Parkinson Disease (PD)', 'Alzheimer Disease (AD)', 'Multiple Sclerosis (MS)']",INTERVENTIONAL,65.0,ESTIMATED,"[{'name': '18F-OP-801', 'description': '18F Hydroxyl Dendrimer'}]",,
Communication Bridge Pilot Study,2024-01,NOT_YET_RECRUITING,2024-09-01,SPONSOR,,University of Chicago,['Primary Progressive Aphasia'],INTERVENTIONAL,12.0,ESTIMATED,"[{'name': 'Communication Bridge', 'description': 'Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.'}]","['Aphasia', 'Dementia', 'Communication', 'Frontotemporal Dementia', 'Alzheimer Disease']",
Telespirometry in Amyotrophic Lateral Sclerosis (ALS),2023-06,ENROLLING_BY_INVITATION,2024-12-30,PRINCIPAL_INVESTIGATOR,Eufrosina I. Young,State University of New York - Upstate Medical University,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,100.0,ESTIMATED,"[{'name': 'Spirometry', 'description': 'All study participants will undergo pulmonary function testing using conventional spirometry in clinic and portable spirometry in clinic and at home. In-clinic conventional laboratory spirometry is compared with portable spirometry and Slow vital capacity is obtained in upright and supine positions.'}]","['Pulmonary Function Test', 'Amyotrophic Lateral Sclerosis', 'Slow Vital Capacity']",Subjects are invited to volunteer and recruited from ALS specialty care outpatient clinics at SUNY Upstate and Atrium Health.
Impact of Nuedexta on Bulbar Physiology and Function in ALS,2023-02,COMPLETED,2021-11-22,SPONSOR,,University of Florida,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,28.0,ACTUAL,"[{'name': 'dextromethorphan HBr and quinidine sulfate', 'description': 'All eligible and enrolled study participants will be administered the study drug, Nuedexta, as recommended by their treating neurologists.The drug will be administered per the efficacy and safety protocol, with no changes in administration method or recommended dose for individuals with ALS. Prior to commencing treatment with Nuedexta, participants will undergo a comprehensive bulbar evaluation of swallowing, airway protection, speech functions, and complete validated patient-reported surveys. Following 30 days of Nuedexta treatment, participants will be e-evaluated using the same battery of assessments.'}]",['bulbar dysfunction'],
RAPA-501 Therapy for ALS EAP,2023-12,AVAILABLE,,SPONSOR,,Rapa Therapeutics LLC,['Amyotrophic Lateral Sclerosis'],EXPANDED_ACCESS,,,"[{'name': 'RAPA-501 Autologous T cells', 'description': 'Experimental: Intermediate size expanded access cohort. Single-agent RAPA-501 T cells, 80 x 10EE6 cells per infusion.'}]","['Amyotrophic Lateral Sclerosis', 'Autologous TREG/Th2 cell therapy', 'RAPA-501']",
Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis,2017-03,UNKNOWN,2017-12,SPONSOR,,Red de Terapia Celular,['ALS (Amyotrophic Lateral Sclerosis)'],INTERVENTIONAL,20.0,ESTIMATED,"[{'name': 'MNC (Mononuclear cells)', 'description': 'The cells are infused into the TA muscle of the lower limb randomized as Group A (experimental) intramuscularly. The infusion is made with a needle, 26 gauge, at 4 points of the TA muscle a specific depth given by the neurophysiological study. The total volume infused will be 2 ml, 0.5 ml at each point.\n\nFor infusion is as painless as possible for the patient to comply exactly with stereotactic indications of neurophysiology, the infusion was made at a uniform controlled rate and for this, the syringe is placed on a Yesargil arm, equipped with a microinjector and controlled infusion device.'}, {'name': 'Saline', 'description': 'The placebo, 2ml of saline, will be infused like in the experimental arm.'}]",,
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),2019-05,COMPLETED,2012-03,SPONSOR,,Cytokinetics,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,49.0,ACTUAL,"[{'name': 'Placebo (Part A)', 'description': 'Placebo tablets once daily for 14 days (Part A)'}, {'name': 'CK-2017357 (Part A)', 'description': 'One 125 mg CK-2017357 tablet once daily for 14 days (Part A)'}, {'name': 'CK-2017357 (Part A)', 'description': 'Two 125 mg CK-2017357 tablets once daily for 14 days (Part A)'}, {'name': 'CK-2017357 (Part A)', 'description': 'Three 125 mg CK-2017357 tablets once daily for 14 days (Part A)'}, {'name': 'Riluzole 50 MG (Part B)', 'description': 'One 50 mg tablet once daily for 14 days (Part B)'}, {'name': 'Placebo (Part B)', 'description': 'Placebo tablets once daily for 14 days (Part B)'}, {'name': 'CK-2017357 (Part B)', 'description': 'One 125 mg tablet once daily for 14 days (Part B)'}, {'name': 'CK-2017357 (Part B)', 'description': 'Two 125 mg tablets once daily for 14 days (Part B)'}, {'name': 'CK-2017357 (Part B)', 'description': 'Three 125 mg tablets once daily for 14 days (Part B)'}]",,
Neurofilament Surveillance Project (NSP),2023-11,ACTIVE_NOT_RECRUITING,2026-12,SPONSOR,,The Bluefield Project to Cure Frontotemporal Dementia,"['Frontotemporal Dementia', 'Frontotemporal Lobar Degeneration', 'FTD-GRN']",OBSERVATIONAL,335.0,ESTIMATED,,"['C9orf72', 'GRN', 'MAPT']","This study is an ancillary study to ALLFTD. Thus, all NSP participants will be recruited directly from the longitudinal arm of ALLFTD.

Roughly equivalent numbers of participants will be enrolled from each of the following groups:

* Members of families with known mutations in C9orf72
* Members of families with known mutations in GRN
* Members of families with known mutations in MAPT

Although participant must be from a family with a known mutation, the participant themselves need not know their personal mutation status."
Evaluation of Metabolomic Analysis in Early Diagnosis of ALS,2019-07,COMPLETED,2018-02,SPONSOR,,"University Hospital, Tours",['ALS'],INTERVENTIONAL,82.0,ACTUAL,"[{'name': 'lumbar puncture', 'description': 'lumbar puncture at enrollment in study'}]","['ALS', 'Spinal Cerebrospinal Fluid', 'Urine', 'SERUM', 'Diagnosis']",
New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis,2023-07,RECRUITING,2026-12-31,SPONSOR,,Assistance Publique Hopitaux De Marseille,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,160.0,ESTIMATED,"[{'name': 'Muscular MRI', 'description': 'MRI (1.5T)'}, {'name': 'Electrophysiological exam', 'description': 'MUNIX'}, {'name': 'Brain MRI', 'description': 'MRI (7T)'}, {'name': 'Spinal cord MRI', 'description': '7T and 3T MRI'}]",,
Escalated Application of Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis Patients,2017-08,COMPLETED,2017-04-05,SPONSOR,,Hospital e Maternidade Dr. ChristÃ³vÃ£o da Gama,['Motor Neuron Disease'],INTERVENTIONAL,3.0,ACTUAL,"[{'name': 'Autologous Mesenchymal stem cells (MSCs)', 'description': '2 intrathecal autologous MSCs infusions (1x10\\^8 cells) will be performed, escalated from 30 days apart'}]",['Amyotrophic Lateral Sclerosis'],
Quantitative Neuromuscular Ultrasonography in Amyotrophic Lateral Sclerosis (ALS),2015-07,COMPLETED,,PRINCIPAL_INVESTIGATOR,Jacinto MartÃ­nez-PayÃ¡,Universidad CatÃ³lica San Antonio de Murcia,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,60.0,ACTUAL,,"['Amyotrophic lateral sclerosis', 'Ultrasonography', 'Motor neurons', 'Neuromuscular diseases', 'Fasciculation']",Patient with Amyotrophic Lateral Sclerosis.
A Study to Evaluate the Performance of a Diagnostic Test in ALS,2016-04,UNKNOWN,2016-12,PRINCIPAL_INVESTIGATOR,Andreas Jeromin,"Iron Horse Diagnostics, Inc.",['Amyotrophic Lateral Sclerosis (ALS)'],OBSERVATIONAL,300.0,ESTIMATED,"[{'name': 'Lumbar puncture', 'description': 'Collection of biofluids to determine the accuracy, sensitivity and specificity of a diagnostic test developed by Iron Horse Diagnostics'}]",['neuromuscular diseases'],ALS and other motoneuron diseases (ALS mimics)
Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis,2020-05,COMPLETED,2019-06-28,PRINCIPAL_INVESTIGATOR,Suma Babu,Massachusetts General Hospital,['Amyotrophic Lateral Sclerosis (ALS)'],OBSERVATIONAL,86.0,ACTUAL,"[{'name': '[18F] GE-180', 'description': 'PET Tracer Ligand'}]","['Biofluid', 'ALS', 'MRI', 'PET', 'Imaging', 'Biomarkers', 'Amyotrophic Lateral Sclerosis', 'TRACK ALS', 'pathology']","Approximately 200 subjects will be screened and approximately 100 subjects will be enrolled. Fifty (50) subjects will be diagnosed with possible, probable, probable-lab supported, or definite ALS, fifty (50) subjects will have no known neurological disease."
Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis,2022-11,ACTIVE_NOT_RECRUITING,2023-11,SPONSOR,,"University Hospital, Lille",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,372.0,ACTUAL,"[{'name': 'Deferiprone', 'description': 'One 600 mg delayed-release tablets of deferiprone twice a day, for at 30 mg/kg/day'}, {'name': 'Placebo Oral Tablet', 'description': 'the placebo twice daily morning and evening.'}]","['Conservative Iron Chelation', 'Disease-modifying Strategy']",
Brain Function in Primary Lateral Sclerosis,2006-02,COMPLETED,2006-02,,,National Institute of Neurological Disorders and Stroke (NINDS),['Motor Neuron Disease'],OBSERVATIONAL,36.0,,,"['EEG', 'Voluntary Movement', 'Motor Cortex', 'Reaction Time', 'Corticospinal', 'Primary Lateral Sclerosis', 'PLS', 'Healthy Volunteer', 'HV']",
A Trial of Tocilizumab in ALS Subjects,2019-12,COMPLETED,2018-07-11,PRINCIPAL_INVESTIGATOR,"Shafeeq Ladha, MD",Barrow Neurological Institute,"['ALS', 'Amyotrophic Lateral Sclerosis', ""Lou Gehrig's Disease"", 'Motor Neuron Disease']",INTERVENTIONAL,22.0,ACTUAL,"[{'name': 'Tocilizumab', 'description': 'IV Infusion'}, {'name': 'Placebo', 'description': 'IV Infusion'}]","['ALS', 'tocilizumab', 'biomarker']",
Direct Current Brain Polarization in Frontotemporal Dementia,2005-08,COMPLETED,2005-08,,,National Institute of Neurological Disorders and Stroke (NINDS),['Pick Disease of the Brain'],INTERVENTIONAL,6.0,,[{'name': 'Direct Current Polarization'}],"['Treatment', 'Transcranial Stimulation', 'Frontal Lobe', ""Pick's Disease"", 'Cognitive Impairment', 'Dementia', 'Frontotemporal Dementia', 'FTD']",
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2),2023-07,ACTIVE_NOT_RECRUITING,2026-06-02,SPONSOR,,Alector Inc.,['Frontotemporal Dementia'],INTERVENTIONAL,40.0,ESTIMATED,"[{'name': 'AL001', 'description': '60 mg/kg of AL001 every 4 weeks'}]",,
Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),2021-03,COMPLETED,2009-09-04,SPONSOR,,Knopp Biosciences,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,194.0,ACTUAL,"[{'name': 'Placebo', 'description': 'Placebo: 2 tablets taken orally twice daily'}, {'name': 'Dexpramipexole 50 mg/day', 'description': 'Dexpramipexole: 2 x 12.5 mg tablets taken orally twice daily'}, {'name': 'Dexpramipexole 150 mg/day', 'description': 'Dexpramipexole: 2 x 37.5 mg tablets taken orally twice daily'}, {'name': 'Dexpramipexole 300 mg/day', 'description': 'Dexpramipexole: 2 x 75 mg tablets taken orally twice daily'}]","['ALS', 'Amyotrophic Lateral Sclerosis', 'Lou Gehrig', ""Lou Gehrig's"", ""Lou Gehrig's disease"", 'Motor Neuron Disease', 'Nervous System Diseases', 'KNS-760704', 'BIIB050']",
Biomarkers of Synaptic Damage in Multiple Sclerosis,2022-10,RECRUITING,2027-09-30,PRINCIPAL_INVESTIGATOR,Mario Stampanoni Bassi,Neuromed IRCCS,"['Multiple Sclerosis', 'Parkinson Disease', 'Amyotrophic Lateral Sclerosis', 'Alzheimer Disease']",OBSERVATIONAL,300.0,ESTIMATED,"[{'name': 'lumbar puncture', 'description': 'lumbar puncture performed to detect OCB for diagnostic purposes'}]","['synaptic plasticity', 'neuroinflammation', 'neurodegeneration']","patients recruited within the Neurology Unit, IRCCS Neuromed. Subjects with other chronic neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD), and healthy subjects subjected to blood sampling and / or lumbar puncture for clinical reasons will be recruited as control group."
Neurofilament Assay for the Diagnosis of ALS,2021-09,UNKNOWN,2023-11-01,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,['Progressive Motor Neuron Disease Without Definite Diagnosis'],OBSERVATIONAL,100.0,ESTIMATED,"[{'name': 'Drawing a tube of blood (serum)', 'description': 'dosage of neurofilaments and comparison with a final diagnosis one year after sampling.'}]","['ALS', 'Neurofilaments', 'NFL', 'pNFH', 'Amyotrophic Lateral Sclerosis', 'progressive motor neuron disease']",Patients with progressive motor neuron disease without a definite diagnosis.
A Study for Patients Who Completed VITALITY-ALS (CY 4031),2021-05,COMPLETED,2018-10-26,SPONSOR,,Cytokinetics,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,280.0,ACTUAL,"[{'name': 'tirasemtiv', 'description': 'Oral'}]","['Amyotrophic Lateral Sclerosis', 'ALS', 'tirasemtiv']",
Connectomics in Psychiatric Classification,2020-05,COMPLETED,2019-09-05,SPONSOR,,Washington University School of Medicine,"['Dementia', 'Dementia Alzheimers', 'Frontotemporal Dementia', ""Pick's Disease With Dementia""]",OBSERVATIONAL,30.0,ACTUAL,"[{'name': 'MRI Brain Imaging', 'description': 'Up to two Magnetic Resonance Imaging (MRI) scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.'}, {'name': 'Mental Health Assessment and Computerized Cognitive Test', 'description': 'Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.'}]",,Individuals between the ages of 45-85 with a diagnosis of Dementia.
Digital Tools for Assessment of Motor Functions and Falls in ALS,2024-01,RECRUITING,2025-09-30,PRINCIPAL_INVESTIGATOR,Andrew Geronimo,Milton S. Hershey Medical Center,"['ALS', 'PLS', 'PMA']",OBSERVATIONAL,20.0,ESTIMATED,"[{'name': 'PAMSys Activity Monitoring System', 'description': 'This system is composed of a Study Tablet running custom fall detection and reporting software and PAMSys sensors. PAMSys provides clinical-grade physical activity monitoring, storing the raw accelerometer data that can be used for analyzing activity parameters such as those listed in Table 3. Sensor data will be downloaded manually upon receipt of the study device by Biosensics, the study sponsor. Sensors can be worn during all activities including while showering and sleeping. The rated battery life is 3-6 months for the fall sensor, and 4 weeks for the activity sensors. This system is not classified as a medical device. Reports of sensor use, step number, battery level, and memory availability are sent hourly to a secured and HIPAA compliant back-end server provided by BioSensics. The Study Tablet also contains modules for performing speech, handwriting, and pattern tracing tasks.'}, {'name': 'Motor, Speech, and Handwriting Assessment', 'description': 'These assessments occur at each study visit. After equipping the subject with 3 activity sensors (1 on pendant around neck and 2 on wrists).\n\n* 10-meter walk task (5 minutes) - The subject starts from a standing position and walks a length of 10 meters. The best time of three trials is used.\n* Timed Up and Go (TUG) test (5 minutes) - Subjects stand, walk to a marker on the floor 3 meters ahead, turn around the marker, walk back to the chair, and sit. The best time of three trials is used.\n* Handwriting Assessment Battery (HAB) (15 minutes) \\[Faddy2008\\] - The subject is seated at a table with a pencil and paper and performs a series of writing tasks.\n* Speech Assessment Battery (SAB)(10 minutes) - The participant will perform a set of audio recordings using the study tablet while sitting in a quiet room.'}]",,Patients with motor neuron disease experiences changes in their walking.
Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS),2023-03,RECRUITING,2024-01,SPONSOR,,"Annexon, Inc.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,24.0,ESTIMATED,"[{'name': 'ANX005', 'description': 'IV Infusion'}]",,
Assessment of Postural Orientation and Equilibrium In Early Amyotrophic Lateral Sclerosis (ALS),2013-07,COMPLETED,2011-02,SPONSOR,,Wake Forest University Health Sciences,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,35.0,ACTUAL,,"['fall', 'balance']",Patients diagnosed with Amyotrophic Lateral Sclerosis
Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS),2012-10,COMPLETED,2010-06,SPONSOR,,Sangamo Therapeutics,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,45.0,ACTUAL,"[{'name': 'SB-509', 'description': 'Intramuscular injection of 60 mg of SB-509. Two doses on Day 0 and Day 90.'}]","['Amyotrophic Lateral Sclerosis,', 'ALS,', ""Lou Gehrig's Disease""]",
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND,2020-03,COMPLETED,2020-01-30,SPONSOR,,Collaborative Medicinal Development Pty Limited,"['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease']",INTERVENTIONAL,50.0,ESTIMATED,"[{'name': 'Cu(II)ATSM', 'description': 'copper-containing synthetic small molecule'}]",,
Influence of the Vitamin D Blood Levels on the Amyotrophic Lateral Sclerosis Phenotype,2015-09,COMPLETED,2015-09,SPONSOR,,"University Hospital, Montpellier",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,127.0,ACTUAL,"[{'name': 'Blood test', 'description': 'Blood test'}]","['Amyotrophic lateral sclerosis', 'Vitamin D', 'Blood Levels']",
Intraspinal Transplantation of Autologous ADRC in ALS Patients,2020-04,UNKNOWN,2022-10-31,PRINCIPAL_INVESTIGATOR,Anna Sarnowska,Mossakowski Medical Research Centre Polish Academy of Sciences,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients', 'description': '3 injections of ADRC: 1 intraspinal and 2 intrathecal'}]","['ALS', 'ADRC', 'adipose derived regenerative cells', 'intraspinal transplantation', 'mesenchymal cells']",
Complement Activation in the Lysosomal Storage Disorders,2021-05,WITHDRAWN,2021-04-30,SPONSOR,,Melbourne Health,"['Fabry Disease', 'Gaucher Disease', 'Niemann-Pick Disease, Type C', 'Lysosomal Storage Diseases']",OBSERVATIONAL,0.0,ACTUAL,"[{'name': 'Complement measurements', 'description': 'Blood and urine tests to assess the complement activation state'}]",['complement'],"Consenting patients with FD, GD or NPC, and age and sex-matched controls"
The Clinical Trial on the Use of Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis,2012-06,UNKNOWN,2015-04,SPONSOR,,General Hospital of Chinese Armed Police Forces,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'stem cell transplantation', 'description': 'after stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.'}]","['ALS', 'stem cell']",
Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS (Part 2),2018-09,UNKNOWN,2020-09-01,SPONSOR,,"Taipei Veterans General Hospital, Taiwan",['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,20.0,ESTIMATED,,"['Amyotrophic lateral sclerosis, ALS, communication, needs']","Participants with ALS were recruited from ALS clinics(Taipei Veterans General Hospital, Taiwan, R.O.C),20 participants. Participants were eligible for this study if they were diagnosed with definite, probable, probable laboratory-supported, or possible ALS according to the criteria (Brooks et al., 2000)."
Virtual Individual Cognitive Stimulation Therapy: a Proof of Concept Study,2022-03,ACTIVE_NOT_RECRUITING,2025-09-01,SPONSOR,,"University College, London","['Dementia', 'Dementia, Vascular', 'Dementia, Mixed', 'Dementia With Lewy Bodies', 'Dementia Frontal', 'Dementia, Mild', 'Dementia Moderate', 'Dementia Alzheimers', 'Dementia of Alzheimer Type', 'Dementia, Multi-Infarct', 'Dementia Frontotemporal']",INTERVENTIONAL,34.0,ACTUAL,"[{'name': 'Virtual Individual Cognitive Simulation Therapy', 'description': 'Virtual Individual Cognitive Stimulation Therapy (V-iCST) is an individual and virtual adaptation of Cognitive Stimulation Therapy (CST), a routine psychosocial treatment for people with mild to moderate dementia in the UK.'}]","['Dementia', 'Randomized Controlled Trial', 'Cognitive Stimulation', 'Mild to Moderate Dementia', 'Teletherapy', 'Psychosocial Interventions']",
Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD,2022-08,COMPLETED,2021-06-22,SPONSOR,,"AngioLab, Inc.",['Age-Related Macular Degeneration'],INTERVENTIONAL,126.0,ACTUAL,"[{'name': 'ALS-L1023', 'description': 'ALS-L1023 is an active fraction extracted from Melissa officinalis L. (Labiatae; lemon balm) leaves.'}, {'name': 'Ranibizumab', 'description': 'LUCENTISÂ® (an anti-neovascular VEGF-A inhibitor) 0.5 mg, intravitreal injection'}, {'name': 'Placebo', 'description': 'Control group for comparison with oral administration of ALS-L1023'}]",,
Brain Computer Interface Complete locked-in State Communication,2019-04,UNKNOWN,2022-04,PRINCIPAL_INVESTIGATOR,Dr. Ujwal Chaudhary,University Hospital Tuebingen,['Complete Locked-in State'],OBSERVATIONAL,15.0,ESTIMATED,"[{'name': 'Non-invasive brain computer interface', 'description': 'The hemodynamic change in the motor cortex of the CLIS patient will be recorded across many sessions spread over more than a year and will be used to train a classifier to predict the ""yes"" and ""no"" answering pattern of the CLIS patient. For patient who can still open their eyes but cannot use any other means of communication will control an EEG based BCI for communication.'}]","['non-invasive brain computer interface', 'communication', 'amyotrophic lateral sclerosis', 'complete locked-in state']",Amyotrophic lateral sclerosis patients in complete locked-in state without any eye movement
Adenosine 2A Receptor Antagonism and AIH in ALS,2023-11,RECRUITING,2024-12-31,SPONSOR,,University of Florida,['ALS'],INTERVENTIONAL,40.0,ESTIMATED,"[{'name': 'Consume 20mg of istradefylline', 'description': 'Consume a single 20 mg istradefylline tablet'}, {'name': 'Low Oxygen therapy', 'description': 'Breathing short periods of low oxygen, consisting of 15 episodes of 1 minute of breathing 10% oxygen, with 2 minutes of breathing 21% oxygen. 45 minutes total.'}, {'name': 'Placebo counterpart to the istradefylline drug', 'description': 'Consume a single microcrystalline cellulose'}, {'name': 'SHAM counterpart to low oxygen therapy.', 'description': 'Breathing short periods of sham low oxygen, consisting of 15 episodes of 1 minute of breathing 21% oxygen, separated by 2 minutes of breathing 21% oxygen. 45 minutes total.'}]","['ALS', 'hypoxia', 'breathing', 'istradefylline']",
Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,2023-07,ACTIVE_NOT_RECRUITING,2023-12-31,SPONSOR,,Humanitas Mirasole SpA,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,337.0,ACTUAL,"[{'name': 'Tauroursodeoxycholic Acid', 'description': '* Tauroursodeoxycholic acid (TUDCA) 250 mg capsules\n* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal\n* Mode of administration: orally\n* Duration: 18 months'}, {'name': 'Placebo', 'description': '* Placebo 250 mg capsules\n* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal\n* Mode of administration: orally\n* Duration: 18 months'}]",,
Remote Pulmonary Function Testing in Amyotrophic Lateral Sclerosis (Pilot),2020-07,COMPLETED,2019-09-30,PRINCIPAL_INVESTIGATOR,Zachary Simmons,Milton S. Hershey Medical Center,['ALS'],INTERVENTIONAL,49.0,ACTUAL,"[{'name': 'remote pulmonary function testing', 'description': 'Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)'}, {'name': 'standard pulmonary function testing', 'description': 'Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)'}]","['Telemedicine', 'Pulmonary Function Testing', 'Telehealth']",
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter),2016-07,COMPLETED,2007-06,,,Avanir Pharmaceuticals,"[""Alzheimer's Disease"", 'Stroke', ""Parkinson's Disease"", 'Traumatic Brain Injury']",INTERVENTIONAL,600.0,ESTIMATED,[{'name': 'AVP-923'}],"['ALS', 'MS', 'CNS', 'AD', 'TBI', 'Dextromethorphan', 'IEED', 'Emotional']",
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis,2024-01,RECRUITING,2024-11,SPONSOR,,Corcept Therapeutics,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,198.0,ESTIMATED,"[{'name': 'Dazucorilant 300 mg', 'description': '300 mg of dazucorilant will be administered once daily in 4 softgel capsules of 75 mg dazucorilant/capsule.'}, {'name': 'Dazucorilant 150 mg', 'description': 'Dazucorilant and placebo will be administered once daily in 4 softgel capsules, 2 capsules with 75 mg dazucorilant/capsule and 2 capsules of placebo equivalent.'}, {'name': 'Placebo', 'description': 'Placebo will be administered once daily in 4 softgel capsules of placebo equivalent.'}]","['ALS, Amyotrophic Lateral Sclerosis']",
Magnetic Stimulation of the Human Nervous System,2005-11,COMPLETED,2005-11,,,National Institute of Neurological Disorders and Stroke (NINDS),"['Demyelinating Disease', 'Healthy', 'Lysosomal Storage Disease', 'Motor Neuron Disease', 'Movement Disorder']",OBSERVATIONAL,450.0,,,"['Myelopathy', 'Demyelination', 'Leukodystrophy', 'Motor Neuron Disease', 'Movement Disorders', 'Normal Volunteer']",
Effect of Functional Exercise in Patients With Spinal Bulbar Muscular Atrophy,2018-02-28,COMPLETED,2018-02-28,,,National Institute of Neurological Disorders and Stroke (NINDS),['Motor Neuron Disease'],INTERVENTIONAL,61.0,ACTUAL,"[{'name': 'A functional exercise program'}, {'name': 'A stretching exercise program'}]","['Exercise', 'Spinal Bulbar Muscular Atrophy', 'Spinal and Bulbar Muscular Atrophy', 'SBMA', 'Motor Neuron Disease']",
Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS),2007-01,TERMINATED,2006-08,,,"Charite University, Berlin, Germany",['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,40.0,,[{'name': 'Thalidomide (drug)'}],"['ALS, motor neuron disease']",
Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral Sclerosis,2020-07,COMPLETED,2019-05-01,SPONSOR,,Peking University Third Hospital,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,20.0,ACTUAL,"[{'name': 'Plasma from healthy young people treatment + Riluzole', 'description': 'Intravenous injection: the subjects received 400ml of intravenous plasma infusion every 2 weeks, with a continuous course of 2 treatments and a course of treatment every 3 months. The course of treatment lasted 10 months, with a total of 3200ml of plasma infusion.'}, {'name': 'Riluzole', 'description': 'The basic treatment is Riluzole 25\\~50mg twice daily'}]",['Amyotrophic lateral sclerosis; Plasma infusion'],
"Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)",2024-02-07,RECRUITING,2027-02-28,SPONSOR,,National Institute of Neurological Disorders and Stroke (NINDS),"['Spinal and Bulbar Muscular Atrophy', 'Kennedys Disease', 'Motor Neuron Disease']",OBSERVATIONAL,70.0,ESTIMATED,,"['Motor Neuron Disease', 'Spinal and Bulbar Muscular Atrophy', 'Kennedys disease', 'Androgen Receptor', 'Natural History Study', 'Natural History']",Primary Clinical with a confirmatory genetic testing result that is consistent with a diagnosis of spinal and bulbar muscular atrophy.
Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone,2017-09,COMPLETED,2016-06,SPONSOR,,"Taiho Oncology, Inc.",['Advanced Solid Tumors'],INTERVENTIONAL,44.0,ACTUAL,"[{'name': 'TAS-102', 'description': '35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.'}, {'name': 'Trifluridine', 'description': '35 mg/m2, orally, single dose'}]",['Advanced solid tumors (excluding breast cancer) for which no standard therapy exists'],
EEG Biofeedback to Improve Memory in Adults With Dementia,2018-03,COMPLETED,2008-06,PRINCIPAL_INVESTIGATOR,"Marvin H. Berman, Ph.D.",Quietmind Foundation,['Dementia'],INTERVENTIONAL,37.0,ACTUAL,"[{'name': 'QEEG-based Neurofeedback Training', 'description': 'EEG amplitude is measured and visual and auditory rewards are given when amplitude at specific locations is modified to meet preset threshholds.'}]","['Frontotemporal Lobar Degeneration', 'EEG Biofeedback', 'Cerebral oxygenation biofeedback', 'Frontotemporal Dementia', 'Peak Alpha Amplitude', 'Quantitative EEG Assessment']",
Remote Pulmonary Function Testing and Nurse Coaching in ALS,2023-03,RECRUITING,2024-06-30,PRINCIPAL_INVESTIGATOR,"Zachary Simmons, MD",Milton S. Hershey Medical Center,['ALS'],INTERVENTIONAL,40.0,ESTIMATED,"[{'name': 'remote pulmonary function testing', 'description': 'Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)'}, {'name': 'standard pulmonary function testing', 'description': 'Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)'}, {'name': 'Nurse Respiratory Health Coaching (NRHC)', 'description': 'Nurse Respiratory Health Coaching - The NRHC intervention follows the ""teamlet"" model described by Bennett et al. \\[Bennett2010\\], made up of the research coordinator who performs respiratory testing, and the nurse practitioner who coaches using the GROW (goals, realities, options, wrap-up) model.'}]","['Telemedicine', 'Pulmonary Function Testing', 'Telehealth']",
Optimizing INITIation of Non-invasive Ventilation in ALS Patients,2021-08,NOT_YET_RECRUITING,2025-10-01,PRINCIPAL_INVESTIGATOR,Peter Wijkstra,University Medical Center Groningen,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,250.0,ESTIMATED,"[{'name': 'Standard care', 'description': 'Both groups: standard care+ questionnaires'}]","['Noninvasive ventilation', 'Quality of life']","Patients must be diagnosed with Amyotrophic Lateral Sclerosis (ALS), Progressive Spinal Muscular Atrophy (PSMA) or Primary Lateral Sclerosis (PLS) by a neurologist.

The patients will be included (after signing informed consent) during the first visit to one of the HMV centres in the Netherlands. Patients must to be able to participate and at least 18 years old"
Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors,2017-06,COMPLETED,2015-06-17,SPONSOR,,"Taiho Oncology, Inc.",['Advanced Solid Tumors'],INTERVENTIONAL,8.0,ACTUAL,"[{'name': 'TAS-102 with a light tracer dose of [14C]FTD', 'description': 'A single dose of 60 mg TAS-102 with a light tracer dose (200 nCi, approximately 1.2 Î¼g) of \\[14C\\]FTD administered as an oral solution on Day 1 (mass balance part)'}, {'name': 'TAS-102 with a light tracer dose of [14C] TPI', 'description': 'A single dose of 60 mg TAS-102 with a light tracer dose (1000 nCi, approximately 5.6 Î¼g) of \\[14C\\]TPI administered as an oral solution on Day 1 (mass balance part)'}, {'name': 'TAS-102 tablets', 'description': '35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met. Treatment starts during study extension part (day 9 of the study).'}]",['Advanced solid tumors'],
Feasibility of Passive Data Collection in Dementia Subjects With Agitation,2021-12,COMPLETED,2021-12-06,SPONSOR,,HealthMode Inc.,"['Dementia', 'Alzheimer Disease', 'Vascular Dementia', 'Frontotemporal Dementia', 'Lewy Body Dementia', 'Mixed Dementia']",OBSERVATIONAL,1.0,ACTUAL,,,"Eligible individuals who have a diagnosis of dementia and a recent history of agitation will sign an informed consent, with a legally authorized representative (LAR) when necessary, to enroll in the study."
"Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS",2016-07,COMPLETED,2016-07,SPONSOR,,Brainstorm-Cell Therapeutics,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,48.0,ACTUAL,"[{'name': 'Autologous MSC-NTF cells', 'description': 'Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration'}, {'name': 'Placebo', 'description': 'Excipient administration by combined intramuscular and intrathecal administration'}]","['Mesenchymal Stromal cells', 'MSC-NTF', 'Cell therapy', 'ALS']",
"DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida",2022-02,COMPLETED,2014-12,PRINCIPAL_INVESTIGATOR,Bjorn E. Oskarsson,Mayo Clinic,['Amyotrophic Lateral Sclerosis (ALS)'],OBSERVATIONAL,33.0,ACTUAL,,,"Eligible patients will be female or male, \> or = 18 years of age. ALS and control subjects will meet eligibility criteria. Control subjects will be similar in age to ALS patients. No special classes of subjects are specifically sought or excluded from the protocol."
Rural Dementia Caregiver Project,2023-11,COMPLETED,2023-10-16,SPONSOR,,"University of California, San Francisco","['Depression', 'Stress, Psychological', 'Self Efficacy', 'Loneliness', 'Social Isolation', 'Health Care Utilization', 'Dementia', 'Dementia Alzheimers', 'Dementia of Alzheimer Type', 'Dementia, Vascular', 'Dementia Frontal', 'Dementia, Lewy Body', 'Dementia, Mixed', 'Dementia in Parkinsons Disease', 'Dementia, HIV', 'Dementia Frontotemporal', 'Dementia, Multi-Infarct']",INTERVENTIONAL,418.0,ACTUAL,"[{'name': 'Building Better Caregivers Workshop', 'description': 'Workshops consist of small group or about 20-25 persons. Two peer co-facilitators (caregiver themselves) will guide workshop activities. Participants will receive a workshop booklet. Each week, participants will log on at least 2-3 times for a total time of approximately two hours. Participants do not require ""real time"" attendance at pre-determined times.'}, {'name': 'Attention Control', 'description': 'Participants will receive two brief 15-30 minutes phone calls by study staff, and will receive a handbook on dementia and caregiver resources while they wait for the workshop.'}]","['Caregiver', 'Caregiving']",
The Importance of Positive Expiratory Pressure Associated With the In-exsufflator in ALS Patients,2024-02,NOT_YET_RECRUITING,2026-03-01,SPONSOR,,Groupe Hospitalier du Havre,['Amyotrophic Lateral Sclerosis ALS7'],INTERVENTIONAL,11.0,ESTIMATED,"[{'name': 'MI-E with PEP function activated during the pause', 'description': 'PEP function will be activated during the pause when using the EOVE-70. The PEP function in cmH2O will start at 8 cmH2O; the PEP setting can be decreased or increased at the discretion of the practitioner to optimize. The other therapeutic settings (positive pressure, negative pressure, inspiratory time, expiratory time and pause time) will be set individually for each patient by an experienced physiotherapist in order to reach the best clinical efficacy (usual clinical care)'}, {'name': 'MI-E without PEP function activated during the pause', 'description': 'The PEP function will not be activated during the pause when using the EOVE-70. The other therapeutic settings (positive pressure, negative pressure, inspiratory time, expiratory time and pause time) will be set individually for each patient by an experienced physiotherapist in order to reach the best clinical efficacy (usual clinical care)'}]","['ALS', 'Amyotrophic Lateral Sclerosis', 'MI-E therapy', 'INEX therapy', 'Airway clearance technics', 'Neuromuscular disease', 'Cough assit']",
Combination Therapy in Amyotrophic Lateral Sclerosis (ALS),2012-11,COMPLETED,2012-03,SPONSOR,,"Phoenix Neurological Associates, LTD",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,28.0,ACTUAL,"[{'name': 'Pioglitazone and Tretinoin', 'description': 'Tretinoin: 1 pill twice a day (10 mg/bid) Pioglitazone HCL: 1 pill once a day (30 mg/qd)'}, {'name': 'Tretinoin and Pioglitazone HCL', 'description': 'Tretinoin 10 mg 1 pill po twice a day Pioglitazone HCL 30 mg 1 pill po once a day'}, {'name': 'Placebo', 'description': 'Placebo'}]","['ALS Treatment', 'Tretinoin', 'Pioglitazone HCL', 'Actos', 'Tau levels', 'ALS']",
Mitochondrial Functions and Oxidative Stress in ALS Patients,2011-01,UNKNOWN,2008-02,,,"University Hospital, Clermont-Ferrand",['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,40.0,ESTIMATED,[{'name': 'Mitochondrial functions and oxidative stress'}],"['Hypermetabolism', 'Mitochondrial abnormalities', 'Oxidant/antioxidant status']","Three groups of patients will be studied : 20 hypermetabolic ALS patients, 20 normometabolic ALS patients and 20 healthy volunteers paired for age and sex."
Staging System in Amyotrophic Lateral Sclerosis,2023-06,RECRUITING,2024-12-02,SPONSOR,,"University Hospital, Limoges",['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,50.0,ESTIMATED,,"['Amyotrophic Lateral Sclerosis', 'ALS', 'Staging', 'Biomarker']","patients with ALS, followed-up in the ALS expert center of Limoges university Hospital (France)."
"Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency",2019-01,COMPLETED,2018-01-03,SPONSOR,,"Alexion Pharmaceuticals, Inc.","['Lysosomal Acid Lipase Deficiency', 'Wolman Disease']",INTERVENTIONAL,9.0,ACTUAL,"[{'name': 'Sebelipase alfa (SBC-102)', 'description': 'Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL Deficiency. Dosing occurred qw for up to 5 years.'}]","['LIPA', 'Wolman Disease', 'Wolman Phenotype', 'Acid Lipase Deficiency', 'Acid Cholesteryl Hydrolase', 'Acid Lipase Disease Deficiency, type 2', 'Cholesteryl Ester Storage Disease (CESD)', 'Cholesteryl Ester Hydrolase Deficiency', 'Early Onset Lysosomal Acid Lipase Deficiency (Wolman Disease)', 'LAL Deficiency', 'Late Onset Lysosomal Acid Lipase Deficiency (CESD)', 'Wolman Disease (early onset LAL Deficiency)', 'Related Disorders:', 'Non-alcoholic Fatty Liver Disease (NAFLD)', 'Non-alcoholic Steatohepatitis (NASH)', 'Alcoholic Liver Disease', 'Cryptogenic Cirrhosis', 'Niemann-Pick Disease (NPD) Type C', 'Chanarin Dorfman Syndrome']",
F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis,2020-09,COMPLETED,2020-06-10,SPONSOR_INVESTIGATOR,"Tammie L. S. Benzinger, MD, PhD","Tammie L. S. Benzinger, MD, PhD",['Amyotrophic Lateral Sclerosis (ALS)'],OBSERVATIONAL,9.0,ACTUAL,"[{'name': 'Drug: F 18 T807', 'description': 'Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.'}]","['fronto-temporal dementia', 'Tauopathies', 'Nervous System Diseases', 'Neurodegenerative Diseases']","Collaborating neuromuscular physicians will refer participants for MR and PET imaging to evaluate tau distribution in the brain of subjects with ALS, or ALS with frontotemporal dementia caused by different genetic mutations, or any mutation carrier (with or without symptoms), or normal controls."
Safety and Efficacy of Miglustat in Chinese NPC Patients,2022-05,COMPLETED,2022-03-25,SPONSOR,,Actelion,"['Niemann-Pick Disease, Type C']",INTERVENTIONAL,17.0,ACTUAL,"[{'name': 'Miglustat', 'description': 'capsule, oral use'}]",,
Venous Disease Thromboembolic and Amyotrophic Lateral Sclerosis,2020-09,COMPLETED,2020-05-01,SPONSOR,,"University Hospital, Brest","['Lateral Amyotrophic Sclerosis', 'Venous Thrombo-embolic Desease']",OBSERVATIONAL,227.0,ACTUAL,,"['lateral amyotrophic sclerosis', 'venous thrombo-embolic desase', 'pulmonary embolism', 'deep venous thrombosis']",patients with amyotrophic lateral sclerosis defined by revised El Escorial score criteria followed in competence centre of brest universitary hospital during 2000 to 2019
Assessment of Social-emotional Functioning in Neurological Diseases,2015-09,COMPLETED,2013-06,SPONSOR,,"Centre Hospitalier Universitaire, Amiens","['Alzheimer Disease', 'Stroke', ""Parkinson's Disease"", 'Lewy Body Dementia', 'Huntington Disease']",INTERVENTIONAL,177.0,ACTUAL,"[{'name': 'Computerized tests and Electrophysiological measurements', 'description': '* Computerized tests: used to evaluate the empathy The participant observes a computer screen on which appears different types of images or words that can evoke an emotion. The participant responds by pressing the screen with his finger. This is a choice between several answers and respond as quickly as possible.\n* Electrophysiological measurements: provide a measure of autonomic response to emotional stimuli: galvanic response (GSR) and electromyographic activity (EMG) of facial muscles (corrugator supercilii and zygomatic major).\n* Neuropsychological assessment includes an assessment of intellectual efficiency, perceptual and visual-constructive abilities, memory, executive and an assessment of behavior and mood from questionnaires.'}]","['Alzheimer disease', 'Stroke', 'Frontotemporal Lobar Degeneration', 'Lewy Body Dementia', 'Huntington Disease', 'mild cognitive impairment', 'vascular injury', ""Parkinson's disease""]",
Virtual Task in Amyotrophic Lateral Sclerosis,2017-04,COMPLETED,2016-10-04,PRINCIPAL_INVESTIGATOR,Carlos Bandeira de Mello Monteiro,University of Sao Paulo,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,60.0,ACTUAL,"[{'name': 'Acquisition on TouchScreen', 'description': 'Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.'}, {'name': 'Acquisition on Kinect', 'description': 'Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.'}, {'name': 'Acquisition on LeapMotion', 'description': 'Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.'}, {'name': 'Acquisition on TouchScreen Control Group', 'description': 'Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.'}, {'name': 'Acquisition on Kinect Control Group', 'description': 'Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.'}, {'name': 'Acquisition on LeapMotion Control Group', 'description': 'Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.'}]","['Amyotrophic Lateral Sclerosis', 'Virtual Reality Exposure Therapy', 'User-Computer Interface', 'Rehabilitation', 'Motor Activity']",
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial,2022-03,RECRUITING,2023-12,SPONSOR,,Dallas VA Medical Center,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,60.0,ESTIMATED,"[{'name': 'Antioxidants', 'description': 'Over-the-counter anti-oxidants, namely vitamin E, NAc cysteine, L-cystine, Nicotinamide and Taurursodiol at defined doses'}]",,
Ambulatory Versus Inpatient Initiation of Home Mechanical Ventilation,2023-09,RECRUITING,2024-11,SPONSOR_INVESTIGATOR,Anne Kathrine Staehr-Rye,Anne Kathrine Staehr-Rye,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,46.0,ESTIMATED,"[{'name': 'Outpatient', 'description': 'Outpatient Initiation of noninvasive mechanical ventilation'}, {'name': 'Hospitalization', 'description': 'Initiation of non-invasive mechanical ventilation during hospitalization'}]",,
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for ALS,2022-10,SUSPENDED,2025-09,SPONSOR,,The Foundation for Orthopaedics and Regenerative Medicine,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,20.0,ESTIMATED,"[{'name': 'AlloRx', 'description': 'cultured allogeneic adult umbilical cord derived mesenchymal stem cells'}]","['Amyotrophic Lateral Sclerosis', 'ALS', 'Stem cells']",
Subgenual Cingulate Deep Brain STIMulation for Apathetic Behavioral Variant FRONtotemporal Dementia,2023-05,RECRUITING,2026-01-12,PRINCIPAL_INVESTIGATOR,Andres M. Lozano,"University Health Network, Toronto","['Frontotemporal Dementia', 'Deep Brain Stimulation']",INTERVENTIONAL,6.0,ESTIMATED,"[{'name': 'Bilateral subgenual cingulate deep brain stimulation (SGC DBS)', 'description': ""Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone. All patients will receive deep brain stimulation (DBS) targeting the subgenual cingulate (SGC) bilaterally. No other changes to pre-existing treatment will be made. This is the only arm in this experiment.""}]","['Subgenual cingulate', 'Deep brain stimulation', 'Apathy', 'Behavioral variant']",
Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS),2022-08,COMPLETED,2008-06-17,SPONSOR,,"Teva Pharmaceutical Industries, Ltd.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,366.0,ACTUAL,"[{'name': '40 mg glatiramer acetate', 'description': 'parenteral drug'}, {'name': 'Placebo'}]",,
A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS,2016-10,UNKNOWN,2021-12,PRINCIPAL_INVESTIGATOR,DR. LAWRENCE KORNGUT,University of Calgary,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,25.0,ESTIMATED,"[{'name': 'Pimozide 2 mg per day'}, {'name': 'Pimozide 4 mg per day'}, {'name': 'Placebo (Lactose tablet)'}]",,
The Use of Airway Clearance Devices in ALS,2020-08,COMPLETED,2018-12,PRINCIPAL_INVESTIGATOR,Ashraf Elsayegh,Cedars-Sinai Medical Center,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,5.0,ACTUAL,"[{'name': 'High Frequency Chest Compression Device (HFCC)', 'description': 'A vest designed to help clear the airway of mucus and other secretions through mechanical knocking of the chest area.'}, {'name': 'Cough Assist', 'description': 'A device that aids patients to clear mucus and secretions that they would otherwise be unable to clear with coughing.'}]","['Airway Clearance Devices', 'High Frequency Chest Compression Devices', 'Cough Assist']",
Volume Mode Non-invasive Ventilation in Amyotrophic Lateral Sclerosis,2023-05,RECRUITING,2024-03-15,SPONSOR,,University Hospitals Coventry and Warwickshire NHS Trust,"['Amyotrophic Lateral Sclerosis', 'Respiratory Failure', 'Respiratory Insufficiency', 'Sleep-Disordered Breathing', 'Neuro-Degenerative Disease', 'Neuron Disease, Motor', 'Nervous System Diseases', 'Neuromuscular Diseases']",INTERVENTIONAL,40.0,ESTIMATED,"[{'name': 'iVAPS-AE', 'description': 'Patients randomised to this intervention will commence home NIV in iVAPS-AE mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.'}, {'name': 'ST-mode', 'description': 'Patients randomised to this intervention will commence home NIV in ST-mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.'}]","['Non-invasive ventilation', 'Home ventilation', 'iVAPS-AE']",
Imaging of Brain Amyloid Plaques in the Aging Population,2023-06,ENROLLING_BY_INVITATION,2024-06,PRINCIPAL_INVESTIGATOR,Val Lowe,Mayo Clinic,"[""Alzheimer's Disease"", 'Dementia With Lewy Bodies', 'Frontotemporal Dementia', 'Vascular Dementia']",INTERVENTIONAL,8000.0,ESTIMATED,"[{'name': 'Pittsburgh Compound B (C-11 PiB)', 'description': 'Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.'}, {'name': 'F-18 FDG', 'description': 'Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.'}, {'name': 'Tau (18-F-AV-1451)', 'description': '1. PIB PET scan, Tau PET scan and/or FDG PET scan\n2. Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss. ECG will be performed on subjects who have not had previous ECG test at Mayo to rule out prolonged QT interval prior to PET TAU scan.'}]","['Imaging', 'PET', 'PiB', 'FDG', 'MCI', 'Dementia', ""Alzheimer's Disease"", 'Brain Amyloid']",
Longitudinal Study of Outcomes Measures in ALS Trials,2015-09,COMPLETED,2016-03,PRINCIPAL_INVESTIGATOR,Patricia L. Andres,Massachusetts General Hospital,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,100.0,ACTUAL,,"['outcomes measures', 'strength measurement', 'disease progression']",Adults with ALS
Hypermetabolism in ALS Using Six REE Formulas,2017-12,COMPLETED,2014-11,SPONSOR,,"University Hospital, Limoges",['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,449.0,ACTUAL,[{'name': 'Assesment of REE in ALS patients compared to control populations and to compare six formulas commonly used to predict REE.'}],"['Amyotrophic lateral sclerosis,', 'Resting energy expenditure', 'Predictive equation']",ALS patients
Technical Evaluation of Earswitch Phase B,2023-12,NOT_YET_RECRUITING,2025-04,PRINCIPAL_INVESTIGATOR,Dario Cazzola,University of Bath,['Motor Neuron Disease'],INTERVENTIONAL,150.0,ESTIMATED,"[{'name': 'EarSwitch device', 'description': 'The Earswitchâ„¢ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.'}]","['Assistive Technology', 'Ear rumble', 'Tensor Tympani']",
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis,2018-06,COMPLETED,2014-10,SPONSOR,,Mitsubishi Tanabe Pharma Corporation,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,137.0,ACTUAL,"[{'name': 'MCI-186', 'description': ""Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).""}, {'name': 'Placebo', 'description': ""Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).""}, {'name': 'MCI-186 in open label phase', 'description': ""All patients after the double blind phase may receive MCI-186 in 7th until 12th treatment - observation cycles at the patients' will.""}]",['Amyotrophic Lateral Sclerosis (ALS)'],
Hyperkinetic Movements in Patients With Disease of Motor Neurons and Their Response to Treatment With Nusinersen,2021-03,UNKNOWN,2021-07-30,PRINCIPAL_INVESTIGATOR,Maja KojoviÄ‡,University Medical Centre Ljubljana,"['Tremor', 'Involuntary Movements', 'SMA', 'MND (Motor Neurone DIsease)']",OBSERVATIONAL,110.0,ESTIMATED,"[{'name': 'Nusinersen', 'description': 'Patients with SMA who will be treated with nusinersen will be included.'}]","['Tremor', 'Minipolymyoclonus', 'Nusinersen', 'SMA', 'MND', 'ALS']","Consecutive patients with ALS, PMA, or PLS followed in MND outpatient clinic will be included in the study. Consecutive SMA patients treated with Nusinersen and followed in MND outpatient clinic will be included."
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III,2017-11,COMPLETED,2008-07,SPONSOR,,Mitsubishi Tanabe Pharma Corporation,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,25.0,ACTUAL,"[{'name': 'MCI-186', 'description': ""Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).""}, {'name': 'Placebo of MCI-186', 'description': ""Two ampoules of Placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).""}]","['Amyotrophic lateral sclerosis', 'free radical scavenger']",
Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001,2022-02,COMPLETED,2022-02-15,SPONSOR,,Collaborative Medicinal Development Pty Limited,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,55.0,ACTUAL,"[{'name': 'Cu(II)ATSM', 'description': 'cooper-containing synthetic small molecule'}]",,
Long-Term Evaluation of BIIB067 (Tofersen),2023-05,ACTIVE_NOT_RECRUITING,2024-06-13,SPONSOR,,Biogen,['ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation'],INTERVENTIONAL,138.0,ACTUAL,"[{'name': 'Tofersen', 'description': 'Participants will receive a loading dose regimen followed by maintenance dosing.'}]",,
Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease),2015-03,TERMINATED,2009-04,SPONSOR,,"Genzyme, a Sanofi Company","['Acid Sphingomyelinase Deficiency', 'Niemann-Pick Disease']",INTERVENTIONAL,11.0,ACTUAL,"[{'name': 'rhASM', 'description': 'Single dose of 0.03mg/kg body weight IV'}, {'name': 'rhASM', 'description': 'Single dose of 0.1mg/kg body weight IV'}, {'name': 'rhASM', 'description': 'Single dose of 0.3mg/kg body weight IV'}, {'name': 'rhASM', 'description': 'Single dose of 0.6mg/kg body weight IV'}, {'name': 'rhASM', 'description': 'Single dose of 1.0mg/kg body weight IV'}]","['Acid sphingomyelinase deficiency', 'Niemann-Pick disease', 'Lysosomal storage disorder', 'Enzyme replacement therapy', 'Treatment']",
Neuromuscular Magnetic Stimulation in ALS Patients,2018-08,COMPLETED,2017-11-01,PRINCIPAL_INVESTIGATOR,Maurizio Inghilleri,University of Roma La Sapienza,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,22.0,ACTUAL,"[{'name': 'Neuromuscular magnetic stimulation (NMMS)', 'description': 'It is a non-invasive, stimulation technique that does not induce high-intensity cutaneous electric fields and does not activate skin nociceptors, thus resulting in a painless and better-tolerated procedure. rNMMS is delivered through a high-frequency magnetic stimulator connected to a conventional circular cooled coil. Magnetic stimulator is placed above the flexor muscles of the forearm. rNMMS is delivered at a 5-Hz frequency and with a 100% stimulation intensity of 100% of the maximum intensity in 140 trains of 50 stimuli. sNMMS is delivered with a sham coil producing similar acoustic sensations and mechanical skin perceptions.'}]","['Amyotrophic lateral sclerosis', 'Muscle disease', 'Neuromuscular magnetic stimulation']",
Effects of tDCS on Apraxia of Speech in Non-Fluent Primary Progressive Aphasia,2023-06,RECRUITING,2025-04,SPONSOR,,Johns Hopkins University,['Primary Progressive Aphasia'],INTERVENTIONAL,60.0,ESTIMATED,"[{'name': 'Active tDCS plus Speech-Language Therapy', 'description': 'Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2 mA (estimated current density 0.04 mA/cm\\^2; estimated total charge 0.048 C/cm\\^2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will target apraxia of speech (AOS).'}, {'name': 'Sham plus Speech-Language Therapy', 'description': 'Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will target apraxia of speech (AOS).'}]","['transcranial direct current stimulation (tDCS)', 'neurodegeneration', 'language therapy', 'primary progressive aphasia (PPA)', 'apraxia of speech (AOS)']",
A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives,2022-11,RECRUITING,2023-10,SPONSOR,,Sanguine Biosciences,"['Age-Related Macular Degeneration', 'Allergies', 'Alpha-Gal Syndrome', 'Alzheimer Disease', 'Amyloidosis', 'Ankylosing Spondylitis', 'Arthritis', 'Alopecia Areata', 'Asthma', 'Atopic Dermatitis', 'Autism', 'Autoimmune Hepatitis', ""Behcet's Disease"", 'Beta-Thalassemia', 'Cancer', 'Celiac Disease', 'Kidney Diseases', 'COPD', 'Crohn Disease', 'Cystic Fibrosis', 'Diabetes', 'Dravet Syndrome', 'DMD', 'Fibromyalgia', 'Graves Disease', 'Thyroid Diseases', 'Hepatitis', 'Hidradenitis Suppurativa', 'ITP', 'Leukemia', 'ALS', 'Lupus or SLE', 'Lymphoma', 'Multiple Sclerosis', 'Myasthenia Gravis', 'Heart Diseases', 'Parkinson Disease', 'Pemphigus Vulgaris', 'Cirrhosis', 'Psoriasis', 'Schizophrenia', 'Scleroderma', 'Sickle Cell Disease', 'Stroke', 'Ulcerative Colitis', 'Vasculitis', 'Vitiligo']",OBSERVATIONAL,20000.0,ESTIMATED,"[{'name': 'Specimen sample', 'description': 'The study may require a tissue collection and/or a participant survey for participation. Most tissue collected will come from a blood draw; up to 100mL for the health condition group, 60mL for the exceptive condition group, and up to 180mL for the control group (if determined safe for the participant). Participant surveys may involve participant reported outcomes (PROs) or custom participant surveys.'}]",,"Health condition, exceptive condition, and control participants will be recruited by one or any of the following resources, but not limited to:

* Use of online marketing where potential participants receive study information from the Sanguine's website or online participant referral program;
* In the site investigators (or PI's) clinic; and/or
* Through community advocacy programs.
* Participant Referral"
Enhancing Neuroplasticity and Frontal Lobe Function in Patients With Mild Alzheimer's Disease,2018-01,COMPLETED,2017-10,PRINCIPAL_INVESTIGATOR,Tarek Rajji,Centre for Addiction and Mental Health,"[""Alzheimer's Disease""]",INTERVENTIONAL,49.0,ACTUAL,"[{'name': 'Paired Associative Stimulation', 'description': 'PAS simulates in humans the induction of long-term potentiation (LTP), a prototype of synaptic neuroplasticity. PAS involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC. As such, these two stimulations arrive simultaneously in the DLPFC and result in potentiation of TMS induced cortical evoked potential, analogous to in vitro LTP.'}, {'name': 'Paired Associative Stimulation-Control', 'description': 'PAS-C is a control PAS paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.'}]","[""Alzheimer's Disease"", 'Brain stimulation', 'transcranial magnetic stimulation']",
Music Intervention in the Treatment of Sleep Disorders for Depressed Patients,2023-02,COMPLETED,2023-02,SPONSOR,,Sanatorium Kilchberg AG,"['Insomnia', 'Depression']",INTERVENTIONAL,30.0,ACTUAL,"[{'name': 'Music intervention', 'description': 'Patient receives Music Intervention before going to sleep. It is composed Music which the Patient hear with maysound Music player.'}]","['sleep Quality', 'Depression', 'Music', 'quality of life']",
Improving Self-Care of Behavioral Variant Frontotemporal Dementia Caregivers,2022-01,COMPLETED,2021-11-03,SPONSOR,,University of Pennsylvania,"['Behavioral Variant of Frontotemporal Dementia', 'Caregiver Stress Syndrome']",INTERVENTIONAL,30.0,ACTUAL,"[{'name': 'Health Information + Health Coaching', 'description': 'Virtual Health Coaching for You: The focus of these sessions is helping caregivers take care of themselves. These are virtual health coaching sessions by trained Health Coaches over 6 months with content based on the theoretical framework from our prior research'}]",,
Magnetic Resonance Spectroscopy in Acid Sphingomyelinase Deficiency,2023-06,RECRUITING,2024-09-01,SPONSOR_INVESTIGATOR,Eline C. B. Eskes,Eline C. B. Eskes,"['Asmd, Visceral Type']",INTERVENTIONAL,34.0,ESTIMATED,"[{'name': 'MR Spectroscopy (MRS)', 'description': 'MR Spectroscopy (MRS)'}, {'name': 'MR Elastography (MRE)', 'description': 'MR Elastography (MRE) with a device that induces shear waves in the body. This device is placed upon the abdomen of the subject and is hold in place by straps. The device will produce low-frequency vibrations (e.g. 30-60 Hz) which are not painful to the participant. A declaration of conformity and a safety document are provided in the study dossier.'}]",,
PST for Care Partners of Adults With Alzheimer's and Alzheimer'S-related Dementia,2023-07,COMPLETED,2023-07-20,PRINCIPAL_INVESTIGATOR,Shannon Juengst,University of Texas Southwestern Medical Center,"['Alzheimer Disease', 'Frontotemporal Degeneration (FTD)', 'Lewy Body Dementia (LBD)', 'Vascular Contributions to Cognitive Impairment and Dementia (VCID)', 'Mixed Etiology Dementias (MED)', 'Mild Cognitive Impairment (MCI)']",INTERVENTIONAL,94.0,ACTUAL,"[{'name': 'Problem Solving Training', 'description': 'Problem Solving Training (PST) is a metacognitive strategy training approach, grounded in self-management theory, that teaches a simple, systematic method for evaluating problems, generating and selecting solutions, developing specific goals and action plans, and evaluating and revising plans as needed.'}]","['Alzheimer Disease', 'Frontotemporal Degeneration', 'Lewy Body Dementia', 'Vascular contributions to cognitive impairment and dementia', 'Mixed etiology dementias', 'Mild Cognitive Impairment', 'Care partner', 'Caregiver', ""Alzheimer's-related Dementia""]",
"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",2012-02,WITHDRAWN,,SPONSOR,,CytRx,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Placebo', 'description': 'Placebo t.i.d.'}, {'name': 'Arimoclomol', 'description': 'capsule, 400 mg t.i.d.'}]","['ALS', ""Lou Gehrig's disease""]",
Safety and Tolerability of High Dose Biotin in Patients With Amyotrophic Lateral Sclerosis,2021-08,COMPLETED,2021-05-10,PRINCIPAL_INVESTIGATOR,Johnny Salameh,American University of Beirut Medical Center,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,12.0,ACTUAL,"[{'name': 'Biotin', 'description': 'High dose biotin'}, {'name': 'Placebo Oral Tablet', 'description': 'Placebo tablet similar in shape and size to the biotin tablet'}]","['Amyotrophic lateral sclerosis', 'Biotin']",
Respiratory Complications in ALS,2021-09,COMPLETED,2021-09-01,SPONSOR,,Liverpool University Hospitals NHS Foundation Trust,"['Motor Neuron Disease', 'Pneumonia']",OBSERVATIONAL,300.0,ACTUAL,"[{'name': 'Questionaires', 'description': 'Any validated functional rating scale, such as the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) or the ALSFRS-Revised (if available)'}]",,Patient population with ALS
Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS),2009-03,UNKNOWN,2009-10,,,Synapse Biomedical,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,100.0,ESTIMATED,"[{'name': 'Intramuscular diaphragm electrodes', 'description': 'Conditioning of the diaphragm'}]","['ALS', 'Amyotrophic Lateral Sclerosis', ""Lou Gehrig's disease"", 'Diaphragm for Ventilatory Assist', 'Diaphragm Pacing']",
Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS),2021-01,COMPLETED,2020-12-23,SPONSOR,,Tokyo Medical University,['ALS'],INTERVENTIONAL,66.0,ACTUAL,"[{'name': 'Perampanel', 'description': '4mg/d or 8mg/d'}, {'name': 'placebo', 'description': 'placebo'}]","['sporadic ALS', 'perampanel']",
Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis,2005-04,UNKNOWN,2005-04,,,The Avicena Group,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,107.0,,[{'name': 'Creatine Monohydrate'}],"['Amyotrophic Lateral Sclerosis', 'ALS', 'Creatine', 'Creatine Monohydrate', 'Muscle Strength']",
The Clinical Impact of the Novel Alzheimer's Blood-based Biomarkers,2024-02,ENROLLING_BY_INVITATION,2025-12-31,PRINCIPAL_INVESTIGATOR,Marc Suarez-Calvet,Hospital del Mar Research Institute (IMIM),"['Alzheimer Disease', 'Cognitive Impairment', 'Dementia', 'Neurodegenerative Diseases', 'Frontotemporal Dementia', 'Lewy Body Disease', 'Vascular Dementia']",OBSERVATIONAL,200.0,ESTIMATED,"[{'name': ""Early adoption of blood-based biomarkers for Alzheimer's disease"", 'description': 'A blood test will be performed to obtain plasma measures of Amyloid-Î² (AÎ²) 42/40, phosphorylated tau (p-tau) 181, p-tau217, p-tau231 and Glial fibrillary acidic protein (GFAP) and Neurofilament light chain (NfL) and results will be disclosure to the early and late arms at different time points.'}]","['Blood-biomarkers', 'Alzheimer Disease', 'Diagnosis', 'Dementia', 'Cognitive impairment']","PLASMAR is prospective, unicentric, unblinded and randomized controlled study with blinded outcome ascertainment. Two hundred new patients will be consecutively recruited. All consecutive new patients who are visited for the first time to the outpatients' Memory Clinic at the Neurology Service (Hospital del Mar, Barcelona, Spain) will be considered for the study. Each patient will name a study partner to participate in this study, who will be considered for the study as well. In case the patient is diagnosed with dementia, a caregiver will be considered."
Environmental Exposure and Neurological Diseases Questionnaire,2023-09,RECRUITING,2025-12,PRINCIPAL_INVESTIGATOR,Elijah W. Stommel,Dartmouth-Hitchcock Medical Center,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,2000.0,ESTIMATED,"[{'name': 'Patient Registry', 'description': 'Patient Registry'}]",,"1. ALS patients in case-control at CCF
2. Non-neurodegenerative patients in case control at CCF
3. Non-neurodegenerative general population in Ohio
4. ALS patient registry in Ohio"
Fecal Microbiota Transplantation Effect on Amyotrophic Lateral Sclerosis Patients,2024-02,ACTIVE_NOT_RECRUITING,2025-02,PRINCIPAL_INVESTIGATOR,JESSICA MANDRIOLI,Azienda Ospedaliero-Universitaria di Modena,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,42.0,ACTUAL,"[{'name': 'Fecal microbiota transplantation', 'description': 'Fecal microbiota transplantation will be performed during two endoscopic procedures (baseline and at 6 months) by allogenic infusion of collected feces in the duodenum-jejunum.'}, {'name': 'Placebo', 'description': 'patients will undergo endoscopic procedure with biopsy during sedation but without any kind of intervention'}]","['microbiota', 'fecal transplantation', 'adaptive immunity', 'T regulatory lymphocytes']",
Evaluation of Usability and Human Factors in the Novus System,2016-03,UNKNOWN,2017-01,SPONSOR,,Bioness Neuromodulation,"['Drop Foot', 'Muscle Weakness', 'Motor Neuron Disease, Upper']",INTERVENTIONAL,16.0,ESTIMATED,"[{'name': 'Novus system', 'description': 'The Novus system is a FES based neuroprosthesis, which intended to provide ankle dorsiflexion and knee flexion or extension in individuals with foot drop and thigh muscle weakness, following an upper motor neuron injury or disease.'}]","['Functional Electrical Stimulation', 'Upper motor neuron injury or disease', 'Drop foot', 'Thigh muscle weakness']",
Breathing With Amyotrophic Lateral Sclerosis,2023-09,RECRUITING,2026-12-31,SPONSOR,,"University Hospital, Toulouse",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,36.0,ESTIMATED,"[{'name': 'Mechanical In-Exsufflator treatment', 'description': 'The Mechanical In-Exsufflator (MIE) is a device that alternately inhales and exhales air and amplifies the respiratory cycles in flow and pressure. 15 breathing cycles (about 3 minutes) are recommended each day.\n\nPatients will practice the MIE daily independently and/or carried out by his physiotherapist (PT) during PT sessions.\n\nThe MIE is prescribed by the neurologist or pulmonologist and is covered by social security in France. It is gifted by an external service provider.\n\nThe Peak-Flow Cough is considered as the standardized score retaining the best of 3 consecutive measurements by Peak-Flow, a small portable device for personal use, which measures the maximum expiratory flow reached by the patient at the moment when the breath is most powerful.\n\nThe patient is his own control. At baseline, the patient will be treated as usual. He will be asked to read the Peak-Flow Cough measures. The PT will also perform the Peak flow measurement at each patient visit.'}]","['Mechanical In-Exsufflator', 'Physiotherapy', 'Cough', 'peak expiratory flow on cough']",
Home Use of Cupping Massage in Chronic Neck Pain,2013-10,COMPLETED,2012-05,PRINCIPAL_INVESTIGATOR,Romy Lauche,UniversitÃ¤t Duisburg-Essen,['Neck Pain'],INTERVENTIONAL,84.0,ACTUAL,"[{'name': 'cupping massage', 'description': 'the upper back is covered in massage oil the cupping glass is drawn along the back muscles'}, {'name': 'Progressive muscle relaxation', 'description': 'standardized programme on muscle relaxation according to Jacobson'}]",,
Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD),2021-04,RECRUITING,2026-12,SPONSOR,,"University of California, Irvine","['Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia', 'Paget Disease of Bone', 'Frontotemporal Dementia', 'Myopathy']",OBSERVATIONAL,50.0,ESTIMATED,,"['IBMPFD - Inclusion Body Myopathy associated with', ""Paget's disease of bone and Frontotemporal Dementia"", 'VCP gene - Valosin-containing protein gene']",Individuals with a personal or family history of VCP associated disease.
Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS,2020-02,COMPLETED,2011-09-30,SPONSOR,,Hoffmann-La Roche,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,512.0,ACTUAL,"[{'name': 'Olesoxime', 'description': '2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid'}, {'name': 'Placebo Comparator', 'description': '2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid'}, {'name': 'Riluzole', 'description': 'Riluzole given as add-on therapy 50mg bid'}]","['Amyotrophic Lateral Sclerosis', 'TRO19622', 'Trophos']",
Human Placental-Derived Stem Cell Transplantation,2022-10,COMPLETED,2022-09,SPONSOR,,New York Medical College,"['Mucopolysaccharidosis I', 'Mucopolysaccharidosis VI', 'Adrenoleukodystrophy', 'Niemann-Pick Disease', 'Metachromatic Leukodystrophy', 'Wolman Disease', ""Krabbe's Disease"", ""Gaucher's Disease"", 'Fucosidosis', 'Batten Disease', 'Severe Aplastic Anemia', 'Diamond-Blackfan Anemia', 'Amegakaryocytic Thrombocytopenia', 'Myelodysplastic Syndrome', 'Acute Myelogenous Leukemia', 'Acute Lymphocytic Leukemia']",INTERVENTIONAL,43.0,ACTUAL,"[{'name': 'Human Placental Derived Stem Cell', 'description': 'Infusions of thawed HPDSC to be given following UCB infusion.'}]","['umbilical cord blood', 'stem cell transplantation', 'placental stem cell', 'inborn errors of metabolism', 'marrow failure', 'Severe Combined Immunodeficiency Disease', 'AML', 'ALL', 'MDS']",
Autobiographical Specificity,2023-02,RECRUITING,2025-02-28,SPONSOR,,Nantes University Hospital,"['Memory', 'Alzheimer Disease', 'Frontotemporal Dementia']",OBSERVATIONAL,62.0,ESTIMATED,"[{'name': 'Autobiographical reminder', 'description': 'The analysis of the specificity of Autobiographical Recall will be done through the following scale, developed for the study:\n\n* 6 points for a recall involving a single personal event located in space AND time (e.g.,""I remember when my parents took me to the sea for the first time..in 1962..in Dunkerque"")\n* 5 points for a recall involving a single personal event located in space OR time (""I remember when my parents first took me to the sea...in 1962"")\n* 4 points for a recall involving a single personal event but without spatial/temporal details (""I remember when my parents took me to the sea for the first time"")\n* 3 points for a recall involving a general personal event but located in space AND time (""we used to go to Dunkerque in the summer"")\n* 2 points for a recall involving a general personal event but located in space OR time (""we used to go to Dunkerque"")\n* 1 point for a recall involving a general personal event without spatial/temporal details (""we used to go on vacation"")'}]","['Autobiographical memory', ""Alzheimer's disease"", 'with behavioral variant of frontotemporal dementia']","All participants will be recruited through the active file of memory consultations of the ""memory resource and research center"" (CMRR) of the Nantes University Hospital."
A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS),2024-01,RECRUITING,2026-06,SPONSOR,,Verge Genomics,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,50.0,ESTIMATED,"[{'name': 'VRG50635', 'description': 'Specified dose on specified days'}]","['VRG50635', 'Familial Amyotrophic Lateral Sclerosis', 'Sporadic Amyotrophic Lateral Sclerosis', 'ALS']",
Confirmation of Self-Reported Incident ALS Cases in the AARP-Diet and Health (AARP-DH) Cohort,2010-08-03,COMPLETED,2010-08-03,,,National Institute of Environmental Health Sciences (NIEHS),['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,21.0,ACTUAL,,"['Public Health', 'Elderly Population', 'Neurodegenerative Diseases', 'Exposure', 'Lifestyle']",
Treatment Study of Frontotemporal Dementia,2009-06-01,COMPLETED,2009-06-01,,,National Institute of Neurological Disorders and Stroke (NINDS),['Frontotemporal Lobar Degeneration'],OBSERVATIONAL,20.0,,,"['Frontotemporal Dementia', ""Alzheimer's Disease"", 'Atypical Antipsychotic', 'Stimulant', 'Apathy', 'Disinhibition', 'Antipsychotic', 'Biomarkers', 'Dementia', 'FTD']",
Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis,2016-03,UNKNOWN,2016-12,SPONSOR,,Neuralstem Inc.,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,18.0,ESTIMATED,"[{'name': 'surgical implantation', 'description': 'human spinal cord stem cell implantation in ALS patients'}]","['Human spinal cord derived neural stem cell transplantation', 'ALS']",
Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS),2008-11,COMPLETED,2008-04,,,Cantonal Hospital of St. Gallen,"['Cramps', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,24.0,ACTUAL,[{'name': 'Dronabinol'}],"['ALS', 'cramps', 'THC', 'Dronabinol']",
Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome,2021-06,UNKNOWN,2022-12-31,SPONSOR,,Peking University Third Hospital,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,13.0,ESTIMATED,"[{'name': 'IL-2', 'description': 'The administration period was divided into 6 courses. 6 cycles of IL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks, followed by a 2-week break in treatment. The adminstration course was 24 weeks.. The 24-week follow-up period was followed after the treatment.'}]",,
Frequency of SOD1 and C9orf72 Gene Mutations in French ALS,2023-11,COMPLETED,2023-05-15,SPONSOR,,"University Hospital, Tours",['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,1000.0,ACTUAL,"[{'name': 'Blood', 'description': 'a blood sample will be taken during hospitalisation for diagnostic confirmation or during the quarterly multidisciplinary consultations scheduled as part of the standard follow-up set up for these patients in the ALS centres of the FILSLAN network. If the genetic status is not yet known, this sample will be taken (1 tube of 7mL EDTA) and then sent within 24-48 hours at room temperature to one of the 3 participating molecular biology laboratories according to the criteria defined in the manual of samples being taken in the 3 laboratories.'}]","['Blood sample', 'Genetic features']",incident population of ALS patients followed in the FILSLAN centres.
"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis",2022-01,COMPLETED,2021-11-17,SPONSOR,,Biogen,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,106.0,ACTUAL,"[{'name': 'BIIB078', 'description': 'Administered as specified in the treatment arm.'}, {'name': 'Placebo', 'description': 'Administered as specified in the treatment arm.'}]",,
Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.,2017-10,COMPLETED,2015-10-02,SPONSOR,,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France","['Apathy', 'Behavior', 'Frontotemporal Dementia']",INTERVENTIONAL,14.0,ACTUAL,"[{'name': 'Evaluation of Apathy Close to Real Life Situation', 'description': 'Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.'}]","['Apathy', 'Goal-directed behavior', 'Quantitative evaluation', 'Sensor', 'Ethogram']",
SOD1 Kinetics Measurements in ALS Patients,2023-04,SUSPENDED,2024-12,PRINCIPAL_INVESTIGATOR,"Timothy M. Miller, MD, PhD",Washington University School of Medicine,"['Amyotrophic Lateral Sclerosis, Familial', 'Amyotrophic Lateral Sclerosis, Sporadic']",OBSERVATIONAL,86.0,ESTIMATED,,"['SOD1', 'Amyotrophic Lateral Sclerosis', 'ALS', 'Kinetics', 'Amyotrophic Lateral Sclerosis, Familial', 'Amyotrophic Lateral Sclerosis, Sporadic']","Known SOD1 positive ALS status, sporadic ALS and SOD1 positive carriers (non-ALS)."
A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers,2022-03,RECRUITING,2022-07,SPONSOR,,ProJenX,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,32.0,ESTIMATED,"[{'name': 'prosetin', 'description': 'oral solution'}, {'name': 'placebo', 'description': 'oral solution'}]",,
Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases,2022-02,UNKNOWN,2022-12-31,PRINCIPAL_INVESTIGATOR,Piu Chan,"Xuanwu Hospital, Beijing","['Alzheimer Disease', 'Progressive Supranuclear Palsy', 'Frontotemporal Dementia']",OBSERVATIONAL,155.0,ESTIMATED,,"['Tau', 'SV2A', 'PET imaging']","Subjects will be separated into two groups: AD group and Non-AD group. Among them, AD group will include cognitive normal controls, prodromal Alzheimer's disease patients and mild Alzheimer's disease patients. Non-AD group will include patients with progressive supranuclear palsy (PSP) , patients with frontotemporal dementia (FTD) carrying MAPT gene, patients with FTD without MAPT gene (carrying other FTD related genes such as C9Orf, Progranulin, CHCHD10 or svPPA with TDP43 gene), non-symptomatic carriers with MAPT mutation and normal controls."
CARE Canadian ALS Riluzole Evaluation,2007-10,COMPLETED,2004-12,,,Sanofi,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,414.0,ACTUAL,[{'name': 'Riluzole'}],,
NF-ÎºB Inhibition in Amyotrophic Lateral Sclerosis,2022-06,RECRUITING,2022-09,SPONSOR,,Sunnybrook Health Sciences Centre,['ALS'],INTERVENTIONAL,75.0,ESTIMATED,"[{'name': 'Withania somnifera', 'description': 'Nuclear Factor Kappa Beta Inhibitor'}, {'name': 'Placebo', 'description': 'Placebo Comparator'}]","['Withania somnifera', 'Ashwagandha', 'Nuclear Factor Kappa Beta Inhibition', 'Amyotrophic Lateral Sclerosis']",
"EEG and TMS-based Biomarkers of ALS, MS and FTD",2021-06,UNKNOWN,2023-04,PRINCIPAL_INVESTIGATOR,Orla Hardiman,"University of Dublin, Trinity College","['Amyotrophic Lateral Sclerosis', 'Frontotemporal Dementia', 'Multiple Sclerosis']",OBSERVATIONAL,400.0,ESTIMATED,"[{'name': '128 electrode electroencephalography (EEG)', 'description': '128 electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting or performing tasks designed to engage specific cortical motor networks of interest (cognitive, behavioural, motor and sensory)'}, {'name': 'Transcranial magnetic stimulation (TMS)', 'description': 'Single and paired pulse TMS protocol will be delivered while surface bipolar EMG is recorded over hand muscles to interrogate corticospinal tract function and cortical motor network component functions'}]","['EEG', 'TMS', 'Neurodegeneration', 'Network', 'Electrophysiology', 'Biomarkers', 'Cognitive', 'Behavioural', 'Motor']","Healthy controls and patients diagnosed with ALS, FTD or MS"
An Online Mindfulness Intervention for People With ALS and Their Caregivers,2019-02,COMPLETED,2019-02,PRINCIPAL_INVESTIGATOR,Francesco Pagnini,Harvard University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,100.0,ACTUAL,"[{'name': 'Mindfulness', 'description': ""The structure of the protocol incorporates key features of Langer's mindfulness theory. Many of the tasks and exercises have demonstrated increased mindfulness in the general population and have been modified to incorporate ALS-specific exercises that make sense from patients and caregivers' points of view. The intervention provides easily understood multimedia (video and written) presentations of the framework of mindfulness and the aims of the planned tasks. The general structure of the protocol mixes different mindfulness elements; for every week there is a specific topic examined in depth. These topics are: Attention to variability; Positive and negative events; Unpredictability; Sense Making; and Novelty seeking / novelty producing. The overall duration of the protocol is 5 weeks.""}]",['mindfulness'],
ALS/MND Natural History Study Data Repository,2023-07,RECRUITING,2030-12-31,PRINCIPAL_INVESTIGATOR,Alexander Sherman,Massachusetts General Hospital,"['ALS', 'PLS', 'MND (Motor Neurone DIsease)', 'Kennedy Disease', 'PMA - Progressive Muscular Atrophy', 'PBP - Progressive Bulbar Palsy']",OBSERVATIONAL,5000.0,ESTIMATED,,,All people living with ALS/MND at participating multidisciplinary ALS/MND clinics
Identification of Graphic Markers of Neurocognitive Disorders (MG),2022-09,RECRUITING,2023-08-27,PRINCIPAL_INVESTIGATOR,Olivier Beauchet,Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'ÃŽle-de-MontrÃ©al,"['Alzheimer Disease', 'Primary Progressive Aphasia', 'Neurocognitive Disorders']",OBSERVATIONAL,75.0,ESTIMATED,"[{'name': 'Identification of Graphic Markers', 'description': ""The study consists of a single physical visit to the research team's site.\n\nParticipants will take a graphic task included in a validated test for language impairment in adults and older adults (DTLA). This test with writing data has a maximum completion time of 15 minutes. Diagnostic data will be collected from the patient's chart, frailty data and socio-demographic data will be collected by self-questionnaires.\n\nParticipants will be evaluated by the principal investigator or his or her representatives from the research team.""}]",['Graphic markers'],Participants will be selected from the patient files of the principal investigator.
Systematic Laryngoscopic Evaluation of Upper Airways in Ventilated ALS Patients in Portugal and in Norway,2021-03,UNKNOWN,2022-12-31,SPONSOR_INVESTIGATOR,Tiina Maarit Andersen,Tiina Maarit Andersen,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,60.0,ESTIMATED,"[{'name': 'Transnasal Fiberoptic Laryngoscopy', 'description': 'Use of Transnasal Fiberoptic Laryngoscopy during NIV titration to optimalize the NIV settings to laryngeal responses during the NIV treatment.'}]","['Noninvasive Ventilation', 'Laryngoscopy']",
The Swedish BioFINDER 2 Study,2023-11,RECRUITING,2028-12-31,PRINCIPAL_INVESTIGATOR,Oskar Hansson,Skane University Hospital,"['Dementia', 'Alzheimer Disease', 'Parkinson Disease', 'Lewy Body Disease', 'Parkinson-Dementia Syndrome', 'Frontotemporal Degeneration', 'Semantic Dementia', 'Progressive Nonfluent Aphasia', 'Progressive Supranuclear Palsy', 'Corticobasal Degeneration', 'Multiple System Atrophy', 'Mild Cognitive Impairment']",INTERVENTIONAL,1505.0,ESTIMATED,"[{'name': 'Flutemetamol F18 Injection', 'description': 'PET imaging of Abeta amyloid'}, {'name': '[18F]-RO6958948', 'description': 'PET imaging of Tau aggregates'}, {'name': 'Elecsys (Roche) Abeta42, Ttau and Ptau', 'description': 'Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid'}, {'name': 'Lumipulse (Fujirebio) Abeta42, Ttau and Ptau', 'description': 'Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid'}]","['Early diagnosis, biomarker, PET, MRI, Î²-amyloid, tau, CSF, cognitive test']",
"ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program",2023-05,ENROLLING_BY_INVITATION,2026-07-31,PRINCIPAL_INVESTIGATOR,Melissa Wasserstein,Albert Einstein College of Medicine,"['Acid Sphingomyelinase Deficiency', 'Ceroid Lipofuscinosis, Neuronal, 2', 'Cerebrotendinous Xanthomatosis', 'Fabry Disease', 'GM1 Gangliosidosis', 'Gaucher Disease', 'Lysosomal Acid Lipase Deficiency', 'Metachromatic Leukodystrophy', 'Mucopolysaccharidosis II', 'Mucopolysaccharidosis III-B', 'Mucopolysaccharidosis IV A', 'Mucopolysaccharidosis VI', 'Mucopolysaccharidosis VII', 'Niemann-Pick Disease, Type C']",OBSERVATIONAL,175000.0,ESTIMATED,"[{'name': 'Confirmatory Testing', 'description': ""All positive screens will be referred using standard notification procedures, where the New York State NBS reporting team contacts the ScreenPlus site medical geneticist, who will contact the newborn's pediatrician and family. The initial evaluation will include a clinical examination and confirmatory molecular studies, enzymatic and biomarker studies, when available. All aspects of the confirmatory testing will be at no cost to the participants. If confirmed to have a ScreenPlus disorder, the investigators will counsel the family and help connect them with treatment, clinical trials and disease specialists. The investigators will also provide emotional and social support resources to help in this journey.""}]","['Newborn Screening', 'Rare Diseases', 'Families', 'Genetics', 'ELSI']",Newborns born at a ScreenPlus pilot hospital who are less than four weeks old.
The Effect of GCSF in the Treatment of ALS Patients,2013-11,COMPLETED,2013-11,SPONSOR,,Tehran University of Medical Sciences,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,40.0,ACTUAL,"[{'name': 'Granulocyte Colony Stimulating Factor'}, {'name': 'Placebo'}]","['Amyotrophic Lateral Sclerosis', 'Granulocyte Colony Stimulating Factor']",
P300 Brain Computer Interface Keyboard to Operate Assistive Technology,2015-05,COMPLETED,2012-05,PRINCIPAL_INVESTIGATOR,"Jane Huggins, PhD",University of Michigan,"['Healthy', 'Amyotrophic Lateral Sclerosis', 'Neuromuscular Disease', 'Spinal Cord Injury', 'Cerebral Palsy']",INTERVENTIONAL,29.0,ACTUAL,"[{'name': 'Brain Computer Interface Keyboard', 'description': 'Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.'}]",['Normal'],
Neurofeedback Rehabilitation Based on Motor Imaging in Patients in the Immobilization Phase,2018-05,UNKNOWN,2021-06,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,"['Healthy Subjects, Patients With Amyotrophic Lateral Sclerosis, Patients With Shoulder Surgery']",INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'Videogames', 'description': 'Videogames'}]","['EEG, neurofeedback, fMRI, ALS, surgery, upper limbs']",
Telehealth in Motor Neurone Disease,2017-04,COMPLETED,2016-04,SPONSOR,,Sheffield Teaching Hospitals NHS Foundation Trust,['Motor Neuron Disease'],INTERVENTIONAL,77.0,ACTUAL,[{'name': 'TiM telehealth arm'}],,
Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia,2009-11,COMPLETED,2009-09,,,Sunnybrook Health Sciences Centre,['Frontotemporal Dementia'],INTERVENTIONAL,22.0,ESTIMATED,"[{'name': 'Citalopram', 'description': 'Titrates from 10mg/day to 40mg/day, increases 10mg per week.'}]","['frontotemporal lobar degeneration', 'frontotemporal dementia', 'serotonin', 'dementia', 'behavioural disturbances']",
Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis,2021-03,TERMINATED,2020-06-18,SPONSOR,,Sanofi,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,15.0,ACTUAL,"[{'name': 'DNL747', 'description': 'Repeating oral dose'}, {'name': 'Placebo', 'description': 'Repeating oral dose'}]",,
A Composite MR Neuroimaging Marker for Alzheimer's Disease,2016-01,WITHDRAWN,2016-01,SPONSOR,,Medical College of Wisconsin,"[""Alzheimer's Disease"", 'Mild Cognitive Impairment', 'Frontotemporal Dementia']",OBSERVATIONAL,0.0,ACTUAL,,"[""Alzheimer's disease"", 'Mild Cognitive Impairment', 'Frontotemporal dementia', 'fMRI', 'functional neuroimaging', 'Memory']","* Alzheimer's, non-Alzheimer's dementia, and mild cognitive impairment (MCI) participants recruited from the Medical College of Wisconsin/Froedtert Hospital Memory Disorders Clinic
* MCI and healthy volunteers recruited from the community"
Amyotrophic Lateral Sclerosis and the Innate Immune System,2017-10,RECRUITING,2026-06,PRINCIPAL_INVESTIGATOR,Anne-Lene KjÃ¦ldgaard,"Rigshospitalet, Denmark","['Amyotrophic Lateral Sclerosis', 'Neurodegenerative Disease', 'Motor Neuron Disease']",OBSERVATIONAL,375.0,ESTIMATED,,"['Biological Specimen Banks', 'Innate Immunity', 'Clinical Study', 'Complement system proteins', 'Amyotrophic lateral sclerosis', 'Neurodegenerative disease', 'Motor neuron disease']","ALS group: Patients diagnosed with certain or likely ALS

Neurological control group:

Patients being examined for cronical headache or being referred to hospital to get a lumbar perfusion test performed.

Neurologically healthy control group:

Clinical study 1: Healty employees from Rigshospitalet Clinical study 2: Neurologically healthy patients having planned orthopaedic surgery performed in spinal anaestesia."
Effects of Remote Ischemic Conditioning on Hand Use in Individuals With Spinal Cord Injury and Amyotrophic Lateral Sclerosis,2023-04,COMPLETED,2022-10-31,PRINCIPAL_INVESTIGATOR,Noam Y. Harel,Bronx VA Medical Center,"['Spinal Cord Injuries', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,21.0,ACTUAL,"[{'name': 'Active Remote Ischemic Conditioning', 'description': 'The active RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The active RIC will be achieved via blood pressure cuff inflation to 200 mmHg.'}, {'name': 'Sham Remote Ischemic Conditioning', 'description': ""The sham RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The sham RIC will be achieved via blood pressure cuff inflation to 10 mmHg below the subjects' diastolic blood pressure which would not cause the blood occlusion.""}, {'name': 'Isometric hand exercise', 'description': 'Participants will be instructed to pinch a dynamometer with thumb and index finger at different intensities and durations. The intensities of pinch force will be 10%, 25%, and 50% of the maximal voluntary contraction (MVC). For each intensity, durations of 2, 4, and 6 s will be employed, which resulted in nine different combinations delivered in pseudorandom order. Participants will perform 2 sets of the isometric hand exercise (18 pinches in total). The interval between each pinch will be 2 seconds, with 30 second intervals between each set.'}]","['Remote ischemic conditioning', 'Neuroplasticity', 'transcranial magnetic stimulation']",
Clinical Trial - Analyzing Participation Experiences Of Amyotrophic Lateral Sclerosis Patients,2023-12,NOT_YET_RECRUITING,2026-07,SPONSOR,,Power Life Sciences Inc.,"['ALS', 'Amyotrophic Lateral Sclerosis']",OBSERVATIONAL,500.0,ESTIMATED,,"['als', 'als clinical trials', 'als diversity studies', 'amyotrophic lateral sclerosis']","Amyotrophic Lateral Sclerosis patients who are actively considering enrolling in an interventional clinical trial, but have not yet completed enrollment and registration."
The National Amyotrophic Lateral Sclerosis Registry,2024-02,RECRUITING,2030-12,SPONSOR,,Centers for Disease Control and Prevention,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,30000.0,ESTIMATED,,"['Amyotrophic Lateral Sclerosis', ""Lou Gehrig's Disease"", 'Motor Neuron Disease']",ALS cases in the United States
A New Eye-based Communication Device for ALS Patients,2015-07,COMPLETED,2015-04,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,12.0,ACTUAL,"[{'name': 'EOL (Eye On Line)', 'description': 'the intervention consists in training program allowing a gradual acquisition of the eye-writing'}]",,
Identification of Diagnostic And Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples,2019-12,COMPLETED,2017-04-04,SPONSOR,,Wake Forest University Health Sciences,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,132.0,ACTUAL,,"['Amyotrophic Lateral Sclerosis', 'motor neuron disease', 'biological markers', 'biomarkers']",Patients at the Carolinas Neuromuscular/ALS-MDA Center and patients at Carolinas Medical Center.
A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS),2013-09,UNKNOWN,2015-05,PRINCIPAL_INVESTIGATOR,Fan Dongsheng,Peking University Third Hospital,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,10.0,ESTIMATED,"[{'name': 'Fasudil', 'description': 'All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.'}]",,
Clinical Procedures to Support Research in ALS,2023-08,RECRUITING,2024-06,PRINCIPAL_INVESTIGATOR,Michael Benatar,University of Miami,"['Amyotrophic Lateral Sclerosis', 'ALS-Frontotemporal Dementia', 'Primary Lateral Sclerosis', 'Progressive Muscular Atrophy']",OBSERVATIONAL,1200.0,ESTIMATED,,,Affected patients receiving care at a clinical center that uses Epic as EHR.
Efficacy and Tolerability of Beta Hydroxybutyrate Ester in Patients With Amyotrophic Lateral Sclerosis (ALS),2023-03,RECRUITING,2023-10-01,PRINCIPAL_INVESTIGATOR,"Albert Christian Ludolph, Prof.",University of Ulm,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,76.0,ESTIMATED,"[{'name': 'Beta Hydroxybutyrate Ester (KetoneAid KE4)', 'description': 'see arm/group description'}, {'name': 'Placebo', 'description': 'see arm/group description'}]","['nutrition', 'beta hydroxybutyrate ester', 'high-caloric', 'ketone ester', 'ketone monoester']",
Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis,2020-06,COMPLETED,2016-06,SPONSOR,,"Instituto Grifols, S.A.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,13.0,ACTUAL,"[{'name': 'Albumin', 'description': '27 plasma exchange procedures using Albumin 5% (estimated 3000 mL per plasma exchange) as replacement solution:\n\n* three weeks of intensive treatment with two plasma exchanges per week\n* twenty-one weeks of maintenance treatment with one weekly plasma exchange'}]","['plasma exchange', 'albumin']",
Study of the Neural Basis of Analogical Reasoning,2017-03,COMPLETED,2021-02,SPONSOR,,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France","['Frontotemporal Dementia', 'Progressive Supranuclear Palsy', 'Healthy Subjects']",INTERVENTIONAL,130.0,ACTUAL,"[{'name': 'transcranial magnetic stimulation'}, {'name': 'MRI imaging'}, {'name': 'EEG recording'}, {'name': 'Neuropsychological examination'}]",,
Longitudinal Study of Innate Lymphoid Cells in Peripheral Blood in ALS,2021-12,TERMINATED,2020-11-13,PRINCIPAL_INVESTIGATOR,Benjamin Murdock,University of Michigan,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,66.0,ACTUAL,"[{'name': 'Blood draw', 'description': 'Research subjects will have two tubes of blood drawn, approximately 20mL.'}]",,ALS patients (200) and matched controls (75)
Biomarkers in Neurodegenerative Diseases,2019-11,WITHDRAWN,2025-10-01,SPONSOR,,University of Minnesota,"['Mild Cognitive Impairment (MCI)', 'Alzheimer Disease (AD)', 'Dementia With Lewy Bodies (DLB)', 'Frontotemporal Lobar Degeneration (FTLD)', 'Parkinsons Disease With Dementia (PDD)', 'Transient Epileptic Amnesia (TEA)', 'Temporal Lobe Epilepsy (TLE)', 'Spinocerebellar Ataxias (SCA)', 'HIV Associated Neurocognitive Disorder (HAND)', 'Amyotrophic Lateral Sclerosis (ALS)', 'Primary Lateral Sclerosis (PLS)']",OBSERVATIONAL,0.0,ACTUAL,"[{'name': 'Neuraceq', 'description': 'Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.'}]",,"* Adults lacking capacity to consent and/or adults with diminished capacity to consent, including, but not limited to, those with acute medical conditions, psychiatric disorders, neurologic disorders, developmental disorders, and behavioral disorders.
* Individual or group with a serious health condition for which there are no satisfactory standard treatments."
Sertraline for the Treatment of Patients With Frontal Lobe Dementia (FLD),1998-11,COMPLETED,2000-05,,,National Institute of Neurological Disorders and Stroke (NINDS),['Dementia'],INTERVENTIONAL,30.0,,[{'name': 'Sertraline'}],"['Frontal Lobe Dementia', 'Serotonergic Transmission']",
Triumeq in Amyotrophic Lateral Sclerosis,2023-06,RECRUITING,2026-07-01,SPONSOR,,"Macquarie University, Australia",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,390.0,ESTIMATED,"[{'name': 'Dolutegravir, Abacavir and Lamivudine', 'description': 'Dolutegravir 50mg, Abacavir 600mg and Lamivudine 300mg.'}, {'name': 'Placebo', 'description': 'Matching placebo.'}]",['ALS'],
Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS),2023-09,COMPLETED,2018-03,SPONSOR,,AB Science,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,394.0,ACTUAL,"[{'name': 'Masitinib (4.5)', 'description': '4.5 mg/kg/day'}, {'name': 'Riluzole'}, {'name': 'Placebo'}, {'name': 'Masitinib (3.0)', 'description': '3 mg/kg/day'}]",['Amyotrophic Lateral Sclerosis (ALS) - masitinib'],
Talampanel for Amyotrophic Lateral Sclerosis (ALS),2011-10,COMPLETED,2010-05,SPONSOR,,"Teva Branded Pharmaceutical Products R&D, Inc.",['ALS'],INTERVENTIONAL,559.0,ACTUAL,"[{'name': 'Talampanel', 'description': 'capsules Talampanel, 3 times per day, 52 weeks'}, {'name': 'Talampanel', 'description': 'capsules Talampanel, 3 times per day, 52 weeks'}, {'name': 'placebo', 'description': 'capsules, placebo, 3 times a day, for 52 weeks'}]",['ALS'],
Investigating Genetic Status in Patients Presenting to Clinic,2023-12,RECRUITING,2043-08,PRINCIPAL_INVESTIGATOR,Elizabeth Finger,Lawson Health Research Institute,"['Dementia, Frontotemporal', 'Alzheimer Dementia (AD)', 'Lewy Body Dementia (LBD)']",OBSERVATIONAL,1000.0,ESTIMATED,"[{'name': 'Biosample collection.', 'description': 'Blood draw.'}]",['Neurodegenerative disorders'],"Persons presenting to the cognitive clinic with a neurodegenerative disorder (for example, AD, FTD, LBD, ALSP, and related conditions);

Biological family members of someone diagnosed with a neurodegenerative disorder, presenting to clinic;"
Efficacy and Safety Evaluation of PC-SOD for Injection in Reducing Myocardial Reperfusion Injury,2019-09,UNKNOWN,2021-03-30,SPONSOR,,"Beijing Tide Pharmaceutical Co., Ltd",['Myocardial Reperfusion Injury'],INTERVENTIONAL,120.0,ESTIMATED,"[{'name': 'PC-SOD', 'description': 'PC-SOD will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.'}, {'name': 'placebo', 'description': 'Placebo will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.'}]",,
Clinical Trial of High Dose CoQ10 in ALS,2013-02,COMPLETED,2008-03,PRINCIPAL_INVESTIGATOR,Hiroshi Mitsumoto,Columbia University,"['Amyotrophic Lateral Sclerosis', ""Lou Gehrig's Disease""]",INTERVENTIONAL,185.0,ACTUAL,"[{'name': 'coenzyme Q10', 'description': 'antioxidant and mitochondrial cofactor, given in capsules three times daily'}, {'name': 'Placebo', 'description': 'Placebo capsules, indistinguishable from CoQ10 capsules, given three times daily'}]","['amyotrophic lateral sclerosis', 'ALS', ""Lou Gehrig's disease"", 'CoQ10', 'coenzyme Q10', 'antioxidants', 'free radicals', 'mitochondrial dysfunction']",
CuATSM Compared With Placebo for Treatment of ALS/MND,2019-11,UNKNOWN,2020-12-30,SPONSOR,,Collaborative Medicinal Development Pty Limited,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,80.0,ESTIMATED,"[{'name': 'Cu(II)ATSM', 'description': 'oral suspension'}, {'name': 'Placebos', 'description': 'oral suspension'}]",,
Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS),2009-04,UNKNOWN,,,,Yoshino Neurology Clinic,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,25.0,ESTIMATED,"[{'name': 'YAM80', 'description': 'Oral administration, 2 to 6 mg, once a day.'}]",['ALS'],
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS),2019-07,COMPLETED,2014-07,SPONSOR,,"Genervon Biopharmaceuticals, LLC",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,12.0,ACTUAL,"[{'name': 'GM604', 'description': 'GM604 treated group subject will receive a slow IV bolus injection (\\~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).'}, {'name': 'Placebo comparator', 'description': 'Placebo comparator group subject will receive a slow IV bolus injection (\\~1min) of 6.4 mL bacteriostatic saline for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).'}]","['ALS', 'motorneuron disease', 'Central Nervous System (CNS) disease', 'neurodegeneration', 'neuroprotective', 'mechanisms of action', 'pathways', 'biomarkers', 'Cerebral Spinal Fluid (CSF)', 'blood biomarkers', 'multi-factorial', 'multisystem', 'single target', 'pathogenic mechanisms', 'Protein Bands Selection by Function', 'in silico analysis', 'active site', 'protein', 'peptide', 'embryonic stage', 'endogenous', 'master regulators', 'fetal development', 'embryonic development', 'common pathways', 'Blood Brain Barrier (BBB)', 'anti-inflammatory', 'anti-apoptotic', 'anti-oxidative', 'regenerative', 'distress signals', 'neurotrophin', 'Motoneuronotrophic factor (MNTF)', 'ALS model', 'life span', 'disease onset', 'grip strength', 'protein expression', 'DNA microarray', 'differential expression', 'Phase 1 clinical trial', 'rare disease', 'common underlying pathogenic mechanisms', 'neurological deficits', 'gene mutation', 'misfolded proteins', 'inadvertent errors', 'modulation of genes', 'master regulator peptide drug', 'ALS related genes', 'mitochondria dysfunction', 'excitotoxicity', 'axonal transport', 'oxidative stress', 'protein aggregation', 'pathogenesis', 'target biomarkers', 'efficacy biomarkers']",
iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study,2023-02,RECRUITING,2024-03-31,PRINCIPAL_INVESTIGATOR,Haruhisa Inoue,Kyoto University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,49.0,ESTIMATED,"[{'name': 'Bosutinib (Phase 1 part)', 'description': 'Subjects will receive 100 mg, 200mg, 300mg or 400 mg of bosutinib once daily, orally.'}, {'name': 'Bosutinib (Phase 2 part)', 'description': 'Subjects will receive 200mg/day or 300mg/day of bosutinib once daily, orally.'}]","['sporadic ALS, SOD1']",
Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD),2022-09,APPROVED_FOR_MARKETING,,SPONSOR,,Sanofi,['Sphingomyelin Lipidosis'],EXPANDED_ACCESS,,,"[{'name': 'olipudase alfa (GZ402665)', 'description': 'Patients will receive intravenous (IV) infusion of olipudase alfa'}]",,
Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers,2024-01-17,RECRUITING,2024-12-01,SPONSOR,,National Institute of Neurological Disorders and Stroke (NINDS),"['Neuromuscular Disease', 'Motor Neuron Disease', 'Inherited Neuromuscular Conditions', 'Inherited Neuropathies']",INTERVENTIONAL,275.0,ESTIMATED,"[{'name': 'EIM testing', 'description': 'EIM device is placed on the muscle and a high frequency current is delivered to the skin.'}, {'name': 'Nerve &amp; muscle ultrasonography', 'description': 'Ultrasound waves to examine the muscles and nerves'}, {'name': 'Nerve conduction studies', 'description': 'Small metal disk electrodes attached to wires onto skin to measure how fast nerves conduct electrical impulses and the strength of the connection between nerves and muscles.'}, {'name': 'Electromyography (EMG)', 'description': 'Thin needle placed into muscles to record electrical activity-adults only'}]","['Electrophysiology', 'Neuromuscular Disease']",
Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS),2023-12,NOT_YET_RECRUITING,2025-03,SPONSOR,,Arrowhead Pharmaceuticals,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,32.0,ESTIMATED,"[{'name': 'ARO-SOD1 Injection', 'description': 'single doses of ARO-SOD1 Injection by IT infusion'}]",,
Genetics of Familial and Sporadic ALS,2023-01,COMPLETED,2023-01,PRINCIPAL_INVESTIGATOR,Teepu Siddique,Northwestern University,"['Amyotrophic Lateral Sclerosis (ALS)', 'Familial Amyotrophic Lateral Sclerosis', 'ALS With Frontotemporal Dementia (ALS/FTD)', ""Lou Gehrig's Disease"", 'Motor Neuron Disease (MND)', 'Primary Lateral Sclerosis (PLS)', 'Sporadic ALS (SALS)']",OBSERVATIONAL,13521.0,ACTUAL,"[{'name': 'Genetic study of ALS families', 'description': 'Collection and analysis of genetic material, medical and family histories from families with ALS'}]","['FALS', 'ALS', 'ALS/FTD', 'SALS', 'MND', 'PLS']",Open to all ALS patients and selected family members
GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma,2023-08,RECRUITING,2026-03,SPONSOR,,FundaciÃ³n EspaÃ±ola de HematologÃ­a y HemoterapÃ­a,"['Gaucher Disease', 'Acid SphingoMyelinase Deficiency']",OBSERVATIONAL,210.0,ESTIMATED,,"['Gaucher disease', 'Acid sphingomyelinase deficiency', 'GD', 'ASMD', 'DBS', 'Splenomegaly', 'monoclonal gammopathies', 'multiple myeloma']","* Adult patients of both sexes.
* Patients who present signs, assessed instrumentally or with laboratory tests, of unknown splenomegaly, defined as a palpable spleen â‰¥ 1cm from the costal margin or diagnosed by ultrasound, magnetic resonance imaging (MRI) or computed tomography (CT) of the spleen.
* Splenectomy patient with no diagnosis of the origin of the splenomegaly of unknown origin.
* Patients with splenomegaly or splenectomy without diagnosis but identified with ITP (Idiopathic Thrombocytopenic Purpura)"
Revealing Engagement Dynamics Among Semantic Dementia Patients,2024-01,NOT_YET_RECRUITING,2027-02,SPONSOR,,Power Life Sciences Inc.,['Semantic Dementia'],OBSERVATIONAL,500.0,ESTIMATED,,['Semantic Dementia'],"Patients with semantic dementia who are actively considering enrolling in a clinical trial for said condition, but have not yet completed enrollment and randomization phases."
Pleiotropy and Mechanism of Peripheral Nerve Related Genes in the Progression of Amyotrophic Lateral Sclerosis,2021-07,UNKNOWN,2022-12-31,SPONSOR,,Peking University Third Hospital,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,300.0,ESTIMATED,"[{'name': 'Patient information collection, exon sequencing and follow-up.', 'description': 'Clinical baseline data, disease characteristics, auxiliary examination results, EMG examination results, drug use and other information were collected. 4-6ml peripheral blood was collected for exon sequencing. The patients were followed up every three months by a specialist in the form of outpatient or telephone.'}]",,Amyotrophic lateral sclerosis patients in Peking University Third Hospital
Reducing Disparities in the Quality of Advance Care Planning for Older Adults,2024-01,ENROLLING_BY_INVITATION,2024-05-01,SPONSOR,,Duke University,"['Metastatic Cancer', 'Congestive Heart Failure', 'Chronic Obstructive Pulmonary Disease', 'Parkinson Disease', 'Interstitial Lung Disease', 'Amyotrophic Lateral Sclerosis', 'End Stage Liver Disease', 'End Stage Renal Disease', 'Diabetes Complications']",INTERVENTIONAL,800.0,ESTIMATED,"[{'name': 'Respecting Choices First Steps', 'description': 'Advance Care Planning Approach'}, {'name': 'Five Wishes Form', 'description': 'Advance Care Planning Approach'}]","['Advance Care Planning', 'Disparities', 'Palliative Care', 'End of Life Care', 'African Americans']",
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects,2016-12,COMPLETED,2016-09,PRINCIPAL_INVESTIGATOR,Danna Jennings,Molecular NeuroImaging,"[""Alzheimer's Disease (AD)"", ""Parkinson's Disease (PD)"", 'Chronic Traumatic Encephalopathy (CTE)', 'Progressive Supranuclear Palsy (PSP)', 'Frontal Temporal Dementia (FTD)', ""Pick's Disease"", 'Tauopathies']",INTERVENTIONAL,16.0,ACTUAL,"[{'name': '[18F]T807 ([18F]MNI-777)', 'description': 'All enrolled subjects will undergo an \\[18F\\]MNI-777 PET imaging visit. For individuals with AD or CTE, \\[18F\\]florbetapir imaging may also be performed to serve as a means of correlating disease severity by evaluating the relationship of Î²-amyloid uptake (measured by \\[18F\\]florbetapir imaging) and tau protein uptake (measured by \\[18F\\]MNI-777 PET imaging). For individuals with Parkinsonian symptoms, \\[123I\\]Î²-CIT SPECT imaging may be performed to evaluate for a reduction in dopamine transporter uptake.'}]","[""Alzheimer's disease (AD)"", ""Parkinson's disease (PD)"", 'Progressive supranuclear palsy (PSP)', 'Chronic traumatic encephalopathy (CTE)', 'Frontal temporal dementia (FTD)', ""Pick's disease"", 'tauopathies']",
Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia,2024-02,NOT_YET_RECRUITING,2027-12-01,SPONSOR,,Johns Hopkins University,"['Primary Progressive Aphasia', 'Logopenic Progressive Aphasia', 'Non-Fluent Primary Progressive Aphasia']",INTERVENTIONAL,120.0,ESTIMATED,"[{'name': 'Active tDCS + Language Therapy', 'description': 'Active tDCS stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 milliamps (mA)/cm2; estimated total charge 0.048 Coulombs (C)/cm2) in a ramp-like fashion for a maximum of 20 minutes. Language therapy will be conducted in conjunction with stimulation and will target oral and written naming.'}, {'name': 'Sham tDCS + Language Therapy', 'description': 'During sham stimulation, current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Language therapy targeting oral and written naming will be administered during sham tDCS stimulation.'}]","['transcranial direct current stimulation', 'language treatment', 'primary progressive aphasia']",
A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients,2015-01,COMPLETED,2014-08,SPONSOR,,US Department of Veterans Affairs,['ALS (Amyotrophic Lateral Sclerosis)'],OBSERVATIONAL,27.0,ACTUAL,"[{'name': 'BCI Device', 'description': 'A Brain Computer interface or BCI records brain signals and analyzes them to derive device commands. BCIs give their users communication and control channels that do not depend on peripheral nerves and muscles.'}]","['Amyotrophic Lateral Sclerosis', 'Brain Computer Interface (BCI)', ""Lou Gehrig's disease""]",The subjects were patients at five VA medical centers who were severely disabled by amyotrophic lateral sclerosis (ALS).
Health Insurance Literacy and Challenges in Accessing Health Services in Niemann-Pick,2020-10,COMPLETED,2020-09-21,SPONSOR,,National Niemann-Pick Disease Foundation,['Niemann-Pick Diseases'],OBSERVATIONAL,76.0,ACTUAL,,,"Within the United States, patients or the parent/caregiver of patients who have been diagnosed with any of the 7 known subtypes of Niemann-Pick disease"
Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis,2018-06,TERMINATED,2015-09-30,SPONSOR,,University of Michigan,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,6.0,ACTUAL,"[{'name': 'MRI', 'description': 'Subjects will have an MRI that lasts approximately 60 minutes at the same time points as during the stem cell study schedule; once before the stem cell surgery, and again at 1, 6, 12, 18, 24, 36, and 48 months after receiving stem cells. This magnetic resonance imaging(MRI)scan will be of the cervical spine and brain.'}]",,
Longitudinal Cognitive Assessment by BoCA,2023-01,RECRUITING,2029-10-01,SPONSOR,,Alzheimer's Light LLC,"['Alzheimer Disease', 'Mild Cognitive Impairment', 'Vascular Dementia', 'Frontotemporal Dementia', 'Parkinson Disease', 'Multiple Sclerosis', 'TBI']",OBSERVATIONAL,10000.0,ESTIMATED,"[{'name': 'Boston Cognitive Assessment (BoCA)', 'description': 'The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.\n\nBoCA includes eight subtests in the following domains: Memory/Immediate Recall, Memory/Delayed Recall, Executive function/ Visuospatial, Executive function/ Mental rotation, Attention, Mental math, Language/Prefrontal Synthesis, and Orientation. The maximum total score is 30. Higher score indicates better cognitive performance.\n\nAfter BoCA is completed, the domain scores and total score are provided immediately. Users will also receive an email with the link to the full report with progress charts.'}]",,"According to the American Academy of Neurology, nearly 7% of people in their early 60s worldwide have mild cognitive impairment, while the condition affects 38% of people ages 85 and older.

The BoCA evaluation can help doctors figure out if an underlying condition is causing a patient's cognitive decline. Many treatable conditions such as sleep disorders, mood problems, heavy metal accumulation, as well as lack of movement and social interactions can affect memory and thinking.

Our goal is to reduce barriers for patients to receive the testing that may benefit their treatment and health through the use of digital technology."
Brain Excitability and Connectivity in Sensory-motor Pathways in ALS,2018-09,UNKNOWN,2022-04-06,SPONSOR,,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,52.0,ESTIMATED,"[{'name': 'functional MRI', 'description': 'conditioning brain activity with peripheral stimulations'}, {'name': 'structural MRI', 'description': 'diffusion MRI and tractography for evaluating the brain structures'}, {'name': 'EEG/MEG', 'description': 'conditioning brain activity with peripheral stimulations'}]","['Brain excitability', 'Brain connectivity', 'Motor cortex', 'Somatosensory cortex']",
Interactions Between Neurostimulation and Physical Exercise,2017-09,WITHDRAWN,2017-09-26,PRINCIPAL_INVESTIGATOR,"Noam Y. Harel, MD, PhD",Bronx VA Medical Center,"['Spinal Cord Injuries', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Cervical plus transcranial stimulation', 'description': 'Conditioning pulses of cervical electrical stimulation will be delivered before or after test pulses of transcranial magnetic stimulation.'}, {'name': 'Cervical stimulation plus hand/wrist exercise', 'description': 'Pulses of cervical stimulation will be delivered while the subject performs finger and wrist motor tasks.'}, {'name': 'Electromyographic (EMG)-triggered (closed-loop) stimulation', 'description': 'Force and EMG activity of specific hand muscles will be used to trigger peripheral nerve electrical stimulation or transcranial magnetic stimulation.'}]","['transcranial magnetic stimulation', 'neurostimulation', 'non-invasive stimulation', 'closed-loop stimulation']",
"""New Perspectives of Adaptation to NIV in ALS""",2018-07,COMPLETED,2018-01,SPONSOR,,Fondazione Don Carlo Gnocchi Onlus,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,48.0,ACTUAL,"[{'name': 'Adaptation and training to Non Invasive Ventilation (NIV)', 'description': ""Each person recruited after a respiratory evaluation (baseline spirometry and supine, maximal inspiratory and expiratory pressures (MIP / MEP) or sniff nasal inspiratory pressure (SNIP), 6 Minute Walking Test (6MWT) -if still ambulatory, arterial blood gas, nocturnal polygraphy) will be adapted to Non Invasive Ventilation (NIV). Moreover, the subject will be brought to the management of bronchial secretions (under the terms set out herein) during not less than five outpatient or house accesses, depending on who is randomly assigned to the experimental group or the control group. These accesses will take place weekly, for a period of two months, considering both the needs and the patient's clinical condition.""}]","['Non Invasive Ventilation (NIV)', 'Amyotrophic Lateral sclerosis (ALS)', 'adaptation', 'home care']",
Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain,2020-12,COMPLETED,2019-07-31,PRINCIPAL_INVESTIGATOR,Jae Seung Kim,Asan Medical Center,"['Healthy Volunteer', 'Alzheimer Disease', 'Frontotemporal Dementia', 'Parkinson Disease']",INTERVENTIONAL,20.0,ACTUAL,"[{'name': '[18F]PI-2620', 'description': 'Imaging for evaluating the accumulation of abnormal tau protein in the brain'}]","['[18F]PI-2620, tauopathy, positron emission computed tomography']",
Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS),2017-12,COMPLETED,2017-12-19,SPONSOR,,University of Florida,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,21.0,ACTUAL,"[{'name': 'Micro Mouth Pressure Meter', 'description': 'The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flanged rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) used.'}, {'name': 'Iowa Oral Performance Instrument', 'description': 'The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.'}, {'name': 'Electrical Impedance Myography', 'description': ""The SFB7 Bioimpedance device measures the function of the tongue by calculating measures of reactance, resistance and phase once a custom electrode array is placed on the midline of the subject's tongue for approximately 2 seconds.""}, {'name': 'Capsaicin', 'description': 'A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 Î¼M capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction ""cough if you need to"" prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds.'}, {'name': 'Videofluoroscopic Swallowing Study', 'description': 'Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.'}, {'name': 'Pulmonary Function Testing', 'description': 'Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.'}, {'name': 'Swallowing Related Quality of Life Questionnaire', 'description': 'Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.'}, {'name': 'Functional Oral Intake Scale', 'description': 'The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.'}, {'name': 'Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised', 'description': 'The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) will be used to track global disease progression in participants.'}, {'name': 'Eating Assessment Tool-10', 'description': 'The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.'}, {'name': 'Communicative Effectiveness Survey', 'description': 'The Communication Effectiveness Survey (CES) will be used for participant reporting of communication abilities across different speech contexts.'}, {'name': 'The Center for Neurologic Studies Bulbar Function Scale', 'description': 'The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.'}]",,
An Intermediate Size Expanded Access Protocol of AMX0035 for ALS,2022-10,APPROVED_FOR_MARKETING,,SPONSOR,,Amylyx Pharmaceuticals Inc.,['Amyotrophic Lateral Sclerosis'],EXPANDED_ACCESS,,,"[{'name': 'AMX0035', 'description': 'Proprietary formulation of sodium phenylbutyrate and taurursodiol'}]",,
Molecular and Cellular Mechanisms of Lysosomal Storage Diseases,2021-02,UNKNOWN,2022-12,SPONSOR,,O & O Alpan LLC,['Lysosomal Storage Disorders'],OBSERVATIONAL,80.0,ESTIMATED,,"['Gaucher disease', 'Fabry disease', 'Pompe disease', 'Niemann-Pick disease']",Patients or suspected carriers of a lysosomal storage disorders.
A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),2019-05,COMPLETED,2010-11,SPONSOR,,Cytokinetics,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,67.0,ACTUAL,"[{'name': 'Placebo', 'description': 'Matching placebo in capsules administered as a single oral dose.'}, {'name': '250 mg CK-2017357', 'description': '250 mg CK-2017357 in capsules administered as a single oral dose.'}, {'name': '500 mg CK-2017357', 'description': '500 mg CK-2017357 in capsules administered as a single oral dose.'}]",,
Collection of Blood Samples for DNA in Motor Neuron Disease,2013-09-09,COMPLETED,2013-09-09,,,National Institute of Neurological Disorders and Stroke (NINDS),['Motor Neuron Diseases'],OBSERVATIONAL,23.0,ACTUAL,,"['Amyotrophic Lateral Sclerosis', 'Primary Lateral Sclerosis', 'Genetics', 'Blood Sample', 'PLS', 'ALS']",
Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS],2008-08,COMPLETED,2005-01,SPONSOR,,"University of Wisconsin, Madison",['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,100.0,,[{'name': 'Tamoxifen'}],,
Early Feasibility Study of the MyoRegulatorÂ® for Treatment of ALS,2023-12,RECRUITING,2024-07-31,SPONSOR,,PathMaker Neurosystems Inc.,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,5.0,ESTIMATED,"[{'name': 'MyoRegulatorÂ®', 'description': 'Study participants will receive treatment using the MyoRegulatorÂ® device 3 times a week for 2 x 30 minutes per session. The first week of treatment will be followed by a 1-week rest period with no treatments. Treatment sessions will then resume for 4 consecutive weeks, 3 times per week. A follow-up visit will be scheduled 4 weeks after the last treatment session.'}]","['amyotrophic lateral sclerosis', 'neuromodulation', 'motor neuron hyperexcitability suppression', 'non-invasive']",
Multidisciplinary Follow-up of Patients With Amyotrophic Lateral Sclerosis,2018-04,UNKNOWN,2018-10-01,SPONSOR_INVESTIGATOR,Ruxandra Iancu Ferfoglia,Ruxandra Iancu Ferfoglia,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,60.0,ACTUAL,"[{'name': 'no intervention', 'description': 'no intervention'}]",,Patients living in the Geneva area suffering from Amyotrophic Lateral Sclerosis or related disorders
Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System,2023-12,TERMINATED,2021-11-02,SPONSOR,,Mandos LLC,['Niemann-Pick Type C Disease'],INTERVENTIONAL,27.0,ACTUAL,"[{'name': 'Adrabetadex', 'description': 'Administered via lumbar puncture (LP) and IT infusion'}]","['Niemann-Pick', 'NPC', 'NPC Type 1 (NPC1)']",
Analysis of Capillary Retinal and Papillary Vascularization in Patients With Amyotrophic Lateral Sclerosis - CAPISLA,2021-10,UNKNOWN,2023-02,SPONSOR,,"University Hospital, Angers",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,94.0,ESTIMATED,"[{'name': 'angiographic optical coherence tomography', 'description': 'angiographic optical coherence tomography'}]",,
Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia,2023-11,COMPLETED,2022-11-20,PRINCIPAL_INVESTIGATOR,"Edward D Huey, MD",Columbia University,['Frontotemporal Dementia (FTD)'],INTERVENTIONAL,17.0,ACTUAL,"[{'name': 'Lithium Carbonate', 'description': 'Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.'}, {'name': 'Placebo', 'description': 'Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels.'}]","['Lithium', 'Lithium Carbonate']",
HEALEY ALS Platform Trial - Regimen B Verdiperstat,2023-05,COMPLETED,2022-12-06,SPONSOR_INVESTIGATOR,"Merit E. Cudkowicz, MD","Merit E. Cudkowicz, MD",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,167.0,ACTUAL,"[{'name': 'Matching Placebo', 'description': 'Drug: Matching Placebo\n\nAdministration: Oral\n\nDose: two tablets twice daily'}, {'name': 'Verdiperstat', 'description': 'Drug: Verdiperstat\n\nAdministration: Oral\n\nDose: 600mg twice daily'}]","['ALS', 'Placebo-Controlled', 'Double-Blind', 'Regimen Specific Appendix', ""Lou Gehrig's Disease"", 'Verdiperstat', 'Biohaven Pharmaceuticals']",
PatientSpot Formerly Known as ArthritisPower,2023-12,RECRUITING,2025-03-01,PRINCIPAL_INVESTIGATOR,Shilpa Venkatachalam,Global Healthy Living Foundation,"['Rheumatoid Arthritis', 'Ankylosing Spondylitis', 'Fibromyalgia', 'Gout', 'Crohn Disease', 'Juvenile Idiopathic Arthritis', 'Lupus Erythematosus', 'Myositis', 'Osteoarthritis', 'Osteoporosis', 'Psoriasis', 'Psoriatic Arthritis', 'Scleroderma', 'Dermatomyositis', 'Inflammatory Bowel Diseases', 'Polymyositis', 'Axial Spondyloarthritis', 'Diffuse Idiopathic Skeletal Hyperostosis', 'Polymyalgia Rheumatica', 'Giant Cell Arteritis', 'Temporal Arteritis', 'Wegener', 'Relapsing Polychondritis', 'Undifferentiated Connective Tissue Disease', 'Spinal Cord Injuries', 'Alzheimer Disease', 'Amyotrophic Lateral Sclerosis', 'Ataxia', 'Bell Palsy', 'Brain Tumor', 'Cerebral Aneurysm', 'Epilepsy', 'Guillain-Barre Syndrome', 'Headache', 'Head Injury', 'Hydrocephalus', 'Lumbar Disc Disease', 'Meningitis', 'Multiple Sclerosis', 'Muscular Dystrophy', 'Neurocutaneous Syndromes', 'Parkinson Disease', 'Stroke', 'Cluster Headache', 'Tension-Type Headache', 'Chronic Obstructive Pulmonary Disease', 'Asthma', 'Lung Cancer', 'Cystic Fibrosis', 'Sleep Apnea', 'Eczema', 'Alopecia', 'Chronic Inflammation', 'Unstable Angina', 'Heart Attack', 'Heart Failure', 'Arrythmia', 'Valve Heart Disease', 'High Blood Pressure', 'Congenital Heart Disease', 'Peripheral Arterial Disease', 'Diabetes', 'Chronic Liver Disease', 'Obesity']",OBSERVATIONAL,40000.0,ESTIMATED,,,Participants will be derived from the population of people who indicate that they have been diagnosed by a physician with a chronic condition. al conditions will be invited to join the ArthritisPower research registry and download the PatientSpot App.
Sensorimotor Imaging for Brain-Computer Interfaces,2024-01,RECRUITING,2025-12,PRINCIPAL_INVESTIGATOR,"Jennifer Collinger, PhD",University of Pittsburgh,['Functional Neuroimaging'],INTERVENTIONAL,15.0,ESTIMATED,"[{'name': 'Motor or sensory imagery', 'description': 'Brain activity will be measured using fMRI while participants imagine different movements or sensations in order to assess the organization of sensorimotor cortical activity after injury'}]","['tetraplegia', 'ALS', 'amyotropic lateral sclerosis']",
Atalante Exoskeleton in the Rehabilitation of Patients With Amyotrophic Lateral Sclerosis,2023-12,RECRUITING,2026-12,SPONSOR,,Institut de Recherche sur la Moelle Ã©piniÃ¨re et l'EncÃ©phale,['ALS - Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,20.0,ESTIMATED,"[{'name': 'Atalante exoskeleton', 'description': 'The gait training program using Atalante exoskeleton consisted of 3 sessions per week for 6 weeks. For each participant, the assistance of the exoskeleton can be specifically adjusted and can be set symmetrically or asymmetrically bases on his capabilities.'}]","['Atalante exoskeleton', 'Gait training', 'Amyotrophic lateral sclerosis']",
Ciprofloxacin/Celecoxib Combination in Patients With ALS,2022-01,COMPLETED,2022-01-20,SPONSOR,,NeuroSense Therapeutics Ltd.,['ALS (Amyotrophic Lateral Sclerosis)'],INTERVENTIONAL,10.0,ACTUAL,"[{'name': 'Fixed dose combination Ciprofloxacin/Celecoxib', 'description': 'Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day'}]",,
Validation Of Tidal/End -Tidal CO2 in ALS,2021-03,UNKNOWN,2021-06-04,SPONSOR,,Papworth Hospital NHS Foundation Trust,"['Motor Neuron Disease', 'Amyotrophic Lateral Sclerosis']",OBSERVATIONAL,200.0,ESTIMATED,,"['PaCO2', 'N-Tidal C Device', 'Self-monitoring', 'CO2 waveforms']",Participants will have previously been diagnosed with Motor Neurone Disease by a neurologist. Study participants will be recruited from patients attending weekly Motor Neurone Disease clinics within the RSSC at Royal Papworth Hospital.
Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS,2023-10,TERMINATED,2023-09-29,SPONSOR,,Mitsubishi Tanabe Pharma America Inc.,['ALS'],INTERVENTIONAL,384.0,ACTUAL,"[{'name': 'MT-1186', 'description': 'Oral edaravone'}, {'name': 'Placebo', 'description': 'Oral'}]",,
Intermediate Expanded Access Protocol (EAP) CNMAu8.EAP02,2023-10,AVAILABLE,,SPONSOR,,Clene Nanomedicine,['Amyotrophic Lateral Sclerosis'],EXPANDED_ACCESS,,,"[{'name': 'CNM-Au8', 'description': 'CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bipyramid, tetrahedron, decahedron, planar spheroids).\n\nHighly pure elemental Au nanocrystals are suspended in USP purified deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) nominally concentrated to up to 0.5 mg/mL (500 ppm).'}]","['Expanded access', 'ALS', 'Amyotrophic Lateral Sclerosis', 'CNM Au8', 'Au8']",
G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical Response,2007-11,COMPLETED,2007-08,,,Peking University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,40.0,ACTUAL,"[{'name': 'Granulocyte Colony Stimulating Factor', 'description': 'Granulocyte Colony Stimulating Factor,5ug/kg/day iH Qd\\*5 days,3 months interval for 4 times'}, {'name': 'NS', 'description': 'NS 1ml iH Qd\\*5 days, 3 months interval for 4 times'}]","['Amyotrophic Lateral Sclerosis', 'Granulocyte Colony Stimulating Factor', 'Randomized Control Trial Study']",
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS),2023-04,TERMINATED,2023-03-31,SPONSOR,,Cytokinetics,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,486.0,ACTUAL,"[{'name': 'Reldesemtiv', 'description': 'Reldesemtiv Oral Tablet'}, {'name': 'Placebo', 'description': 'Placebo Oral Tablet'}]","['Amyotrophic Lateral Sclerosis', 'ALS', 'CK-2127107', 'Reldesemtiv', 'COURAGE-ALS']",
Impact of Early Non Invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Patients,2016-02,COMPLETED,2015-12,PRINCIPAL_INVESTIGATOR,Eva Farrero Munoz,Hospital Universitari de Bellvitge,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,42.0,ACTUAL,"[{'name': 'Home pressure ventilator model Vivo 40 (BREAS Medical AB)', 'description': 'Nocturnal non invasive ventilation (Vivo 40)with minimum pressure support of 10 cm H2O (IPAP 14, EPAP 4). Parameters will be adjusted according to tolerance and to achieve PaCO2 \\< 45 mmHg and improve symptoms.'}]",,
Trial of Oxaloacetate in ALS,2019-12,UNKNOWN,2021-02,SPONSOR_INVESTIGATOR,Omar Jawdat,Omar Jawdat,['ALS'],INTERVENTIONAL,24.0,ESTIMATED,"[{'name': 'Oxaloacetic Acid', 'description': 'The first 3 patients will receive 500 mg twice daily, and subsequent cohorts will increase by 500 mg per dose to a maximum of 2500 mg twice daily.'}]",,
Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),2011-03,TERMINATED,2009-10,,,Massachusetts General Hospital,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,84.0,ACTUAL,"[{'name': 'Lithium Carbonate', 'description': 'Participants will receive capsules that contain 150 milligrams (mg) lithium carbonate. Participants will be randomized to lithium/riluzole or placebo/riluzole and treated for 52 weeks. Participants originally randomized to placebo who fail (progress) will crossover to lithium for the remainder of the trial.'}, {'name': 'Riluzole', 'description': 'All participants enrolled in this study will be taking a stable dose of riluzole 50 milligrams (mg) by mouth (PO) twice per day (BID) for at least 30 days prior to screening.'}, {'name': 'placebo', 'description': 'an inactive substance'}]","['Amyotrophic lateral sclerosis', 'ALS', ""Lou Gehrig's disease"", 'riluzole', 'lithium', 'neurodegeneration']",
Magnetic Imaging for Diagnostic of Amyotrophic Lateral Sclerosis,2023-07,RECRUITING,2024-12,SPONSOR,,"University Hospital, Toulouse",['Amyotrophic Lateral Sclerosis With Dementia'],INTERVENTIONAL,50.0,ESTIMATED,"[{'name': 'Whole Body MRI and ENMG', 'description': 'Whole body muscle MRI lasting 30 to 45 min without injection of contrast medium an ENMG'}]","['Amyotrophic', 'Sclerosis']",
Rehabilitative Trial With tDCS in Amyotrophic Lateral Sclerosis,2020-03,COMPLETED,2018-07-01,PRINCIPAL_INVESTIGATOR,Barbara Borroni,Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ACTUAL,"[{'name': 'Anodal bilateral motor cortex and cathodal spinal tDCS', 'description': '10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)'}, {'name': 'Sham bilateral motor cortex and sham spinal tDCS', 'description': '10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)'}]","['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease', 'Transcranial Direct Current Stimulation']",
"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)",2024-01,ACTIVE_NOT_RECRUITING,2025-11,SPONSOR,,Denali Therapeutics Inc.,['Frontotemporal Dementia'],INTERVENTIONAL,106.0,ESTIMATED,"[{'name': 'DNL593', 'description': 'Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)'}, {'name': 'Placebo', 'description': 'Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)'}]","['FTD', 'FTD-GRN', 'granulin']",
"Screening of Niemann-Pick Disease, Type C in a Psychiatric Population",2017-01,TERMINATED,2016-12,SPONSOR,,"University Hospital, Grenoble",['Psychiatric Adults Patients'],INTERVENTIONAL,22.0,ACTUAL,"[{'name': 'Blood sampling'}, {'name': 'Biopsy'}]","['Niemann-Pick Disease, Type C', 'Psychiatric', 'Psychotic disorders']",
Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone,2023-12,RECRUITING,2024-09,SPONSOR,,Loma Linda University,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,160.0,ESTIMATED,"[{'name': 'Sample Collection', 'description': 'The investigators will be collecting blood, urine, and spinal fluid samples.'}]",,Anyone who meets the Inclusion/Exclusion Criteria
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD),2018-03,COMPLETED,2016-02,SPONSOR,,TauRx Therapeutics Ltd,['Behavioral Variant Frontotemporal Dementia (bvFTD)'],INTERVENTIONAL,220.0,ACTUAL,"[{'name': 'TRx0237', 'description': 'TRx0237 100 mg tablet will be administered twice daily.'}, {'name': 'Placebo', 'description': 'Placebo tablets will be administered twice daily. The placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.'}]","['Behavioral Variant Frontotemporal Dementia', 'bvFTD', 'Frontotemporal Dementia']",
Double Blind Trial of DC Polarization in FTD,2007-05-10,COMPLETED,2007-05-10,,,National Institute of Neurological Disorders and Stroke (NINDS),['Dementia'],INTERVENTIONAL,20.0,,[{'name': 'Anodal DC polarization of left prefrontal cortex'}],"['Frontal Lobe', 'Language', 'Behavior', 'Degenerative Diseases', ""Pick's Disease"", 'Frontotemporal Dementia', 'FTP']",
Feasibility of an Electrical Impedance Tomography Device for Pulmonary Function Testing in ALS Patients,2023-04,RECRUITING,2023-12-30,PRINCIPAL_INVESTIGATOR,Seward Rutkove,Beth Israel Deaconess Medical Center,['ALS'],OBSERVATIONAL,60.0,ESTIMATED,"[{'name': 'EIT', 'description': 'EIT comprises a chest belt that is connected to a computer via a universal serial bus (USB) or an Ethernet cable. The chest belt captures EIT data, which is transmitted via the USB or Ethernet cable to the computer. Tomography-like impedance images of the lungs are computed and displayed on the computer. The impedance images will be used to evaluate lung recruitment and other pulmonary function parameters that are currently measured using standard-of-care PFT devices.'}]",,Patients clinically diagnosed with ALS
Contribution of Diaphragmatic Ultrasound for Monitoring Diaphragmatic Function in Patients With Amyotrophic Lateral Sclerosis,2023-11,RECRUITING,2026-11,SPONSOR,,Centre Hospitalier Universitaire Dijon,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,50.0,ESTIMATED,"[{'name': 'Diaphragmatic ultrasound', 'description': 'duration 15 minutes, performed at M0, M3, M6 and M9'}, {'name': 'Electro-physiological exploration of the diaphragm', 'description': 'duration between 30 and 60 minutes performed at M0'}]",,Patients with Amyotrophic Lateral Sclerosis with no indication for non-invasive ventilation
Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients,2024-01,NOT_YET_RECRUITING,2027-02,SPONSOR,,Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM),['ALSFTD'],INTERVENTIONAL,150.0,ESTIMATED,"[{'name': 'Probiotic', 'description': 'Participants will be taking 1 sachet a day containing 15 billion CFU.'}, {'name': 'Placebo', 'description': 'Participants will be taking 1 sachet a day.'}]","['ALS', 'FTD', 'motor function', 'probiotics', 'lipidomics', 'metabolites', 'neurofilament', 'microbiome']",
Physiological Flow of Liquids Used in Dysphagia Management (Neuro),2021-03,COMPLETED,2020-12-31,SPONSOR,,"University Health Network, Toronto","['Amyotrophic Lateral Sclerosis', 'Parkinson Disease', 'Dysphagia']",OBSERVATIONAL,40.0,ACTUAL,"[{'name': 'Videofluoroscopic Swallowing Examination', 'description': 'During the videofluoroscopy, subjects will take up to 21 sips of liquid, ranging in thickness from thin (like water), to extremely-thick (like pudding or custard). The liquids will be mixed with E-Z-Paque barium sulfate, to allow it to be visible on the x-ray.'}, {'name': 'Tongue Strength Measurement', 'description': 'We will measure tongue strength using a tongue pressure measurement system called the Iowa Oral Performance Instrument (IOPI). A small disposable bulb filled with air will be placed in the mouth, just behind the front teeth. Participants will be asked to press their tongue upwards against the bulb as hard as they can, three (3) times at the front of the tongue and three (3) times at the back of the tongue (i.e., total of six (6) maximum isometric tongue presses). Participants will also be asked to swallow their saliva with the bulb placed in their mouth, three (3) times.\n\nTongue pressure measurement will be completed twice in the data collection session - once at the beginning, and once at the end (following the videofluoroscopy).'}]","['Thickened Liquids', 'Dysphagia Management', 'Videofluoroscopy', 'Swallowing Physiology']",Participants with ALS will be recruited from the multidisciplinary ALS clinics at the University of Florida during regularly scheduled care visits. Participants with Parkinson's disease will be recruited from the University of Florida Center for Movement Disorders.
Stories in the Moment: Dance Program for People Living With Dementia,2024-01,RECRUITING,2024-10-31,PRINCIPAL_INVESTIGATOR,Magda Kaczmarska,DanceStream Projects,"['Dementia', 'Mild Cognitive Impairment', 'Alzheimer Disease', 'Lewy Body Disease', 'Frontotemporal Dementia', 'Vascular Dementia']",INTERVENTIONAL,72.0,ESTIMATED,"[{'name': 'Stories in the Moment Dance Program - Online', 'description': 'Stories in the Moment is a co-creative dance, movement and storytelling program for persons living with dementia and care partners.'}]","['Dance', 'Wellbeing', 'Belonging', 'Non-pharmacological intervention']",
"Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders",2022-05,ENROLLING_BY_INVITATION,2024-10,PRINCIPAL_INVESTIGATOR,Robert Brown,"University of Massachusetts, Worcester","['Amyotrophic Lateral Sclerosis', 'Frontotemporal Dementia', 'PLS', 'Motor Neuron Disease', 'Lou Gehrigs Disease', 'Familial Disease', 'Amyotrophic Lateral Sclerosis, Sporadic', 'Muscular Dystrophy', 'Miyoshi Myopathy', 'Amyotrophic Lateral Sclerosis With Dementia']",OBSERVATIONAL,6000.0,ESTIMATED,,"['FALS', 'ALS', 'SALS', 'MND', 'SOD1', 'ALS GENES', 'PLS', 'PMA', 'ALS/FTD', 'FAMILIAL ALS', 'SPORADIC ALS', 'GENETICS', 'FTD', 'Miyoshi myopathy']","Individuals diagnosed with ALS, motor neuron disease, PLS, ALS with dementia, Miyoshi Myopathy, some muscular dystrophies and spouse/population controls. Some family members may be eligible to participate as well."
EEG-Based Brain-Computer Interface Project for Individuals With Amyotrophic Lateral Sclerosis (ALS),2017-03,COMPLETED,2016-12,SPONSOR,,Drexel University College of Medicine,"['Amyotrophic Lateral Sclerosis', 'Neurodegenerative Disease', 'Motor Neuron Disease']",OBSERVATIONAL,102.0,ACTUAL,,"['Amyotrophic Lateral Sclerosis', 'Cerebrospinal Fluid', 'Neurodegenerative Disease', 'Motor Neuron Disease', 'Autonomic Nervous System', 'Neurodegenerative Diseases', 'Movement Disorders']",ALS clinic patients at MDA/ALS Center of Hope.
Enhancing Language Function in Primary Progressive Aphasia,2023-09,RECRUITING,2026-06-15,SPONSOR,,University of Arizona,['Primary Progressive Aphasia'],INTERVENTIONAL,20.0,ESTIMATED,"[{'name': 'tDCS + language therapy', 'description': 'In this study fMRI-guided noninvasive neuromodulation will be applied, called Transcranial Direct Current Stimulation (tDCS) to the frontal and parietal brain regions that show reduced activation but still are structurally intact. TDCS will be paired with personalized speech-language therapy to enhance language functions.'}, {'name': 'sham TDCS + language therapy', 'description': 'sham control will be applied with language therapy to the same regions as active TDCS.'}]",,
Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis,2019-02,COMPLETED,2017-08-18,SPONSOR,,"Bioinova, s.r.o.","['Motor Neuron Disease, Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,26.0,ACTUAL,"[{'name': 'Suspension of human autologous MSC 3P in 1.5 ml', 'description': 'Intrathecal application of Autologous Multipotent Mesenchymal Stromal Cells 3P suspension'}]",,
A Non-Interventional National Study in Pediatric Patients With Unexplained Enlarged Spleen,2024-01,RECRUITING,2024-09-30,SPONSOR,,Sanofi,"['Gaucher Disease, Splenomegaly', 'Acid SphingoMyelinase Deficiency']",OBSERVATIONAL,150.0,ESTIMATED,,,"Patient under 18 year-old with unexplained SMG (SMG defined as a palpable spleen, already known or discovered for the first time) and who has undergone tests to eliminate obvious causes of SMG including: hemolytic anemia, hematological malignancy, portal hypertension, infectious disease associated with SMG"
Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis,2023-06,NOT_YET_RECRUITING,2026-03-01,PRINCIPAL_INVESTIGATOR,Annemarie HÃ¼bers,"University Hospital, Geneva",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,98.0,ESTIMATED,"[{'name': 'Tideglusib', 'description': '1000 mg/day per os'}]",,
Open Label Study: Treatment of ALS Fatigue With PolyMVA,2021-04,COMPLETED,2021-05-25,PRINCIPAL_INVESTIGATOR,Raghav Govindarajan,University of Missouri-Columbia,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,12.0,ACTUAL,"[{'name': 'PolyMVA', 'description': 'One-half teaspoon of PolyMVA contains the following:\n\n* Daily Value Thiamin (B-1) 23mg 1,533 Riboflavin (B-2) 0.45mg 26 Vitamin B-12 460mcg 7,666 Proprietary Blend 32mg - contains the following ingredients (no FDA value has been established on any of the following): Palladium, Alpha Lipoic Acid, Molybdenum, Rhodium, Ruthenium, Formyl Methionine, N-acetyl Cysteine.\n\nFor each ml of Poly-MVA, the exact dosages are as follows:\n\nPalladium: 3.97mg Molybdenum: 0.044mg Ruthenium: 0.0014mg Rhodium: 0.014mg Lipoic Acid: 7.68mg Thiamine (B1): 9.26mg Riboflavin (B2): 0.174mg B12: 0.185mg Formyl Methionine: 0.026mg N-Acetyl cysteine: 0.185mg Vitamin A acetate 100 IU\n\nOther Ingredients: Distilled water, purified water, thiamine hydrochloride, Vitamin B12 as cyanocobalamin.'}]",,
"Establishment of a Tissue Bank (Blood, CSF) for the Understanding of Motor Neuron Disease (MND)",2022-07,TERMINATED,2020-10-29,SPONSOR,,Wake Forest University Health Sciences,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,766.0,ACTUAL,,"['Amyotrophic lateral sclerosis', 'motor neuron disease', 'biological markers', 'biomarkers']","ALS patients in the Charlotte, NC, area."
A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS),2019-12,COMPLETED,2019-03-28,SPONSOR_INVESTIGATOR,"Richard Bedlack, M.D., Ph.D.","Richard Bedlack, M.D., Ph.D.",['ALS'],INTERVENTIONAL,15.0,ACTUAL,"[{'name': 'Triheptanoin', 'description': ""Triheptanoin is a medium chain triglyceride (MCT) that can improve mitochondrial function and energy production and therefore has potential for slowing ALS progression. Indeed, triheptanoin slowed motor neuron loss and delayed the onset of weakness in a mutant SOD1 model of ALS. The Triheptanoin we will use is a colorless to light yellow oil. The target triheptanoin dose for this study is 1g/kg/d. This target dose was selected because it was safe and tolerable and altered brain MR spectroscopy in patients with Huntington's Disease.""}]",,
"Tolerability, Safety and Efficacy of Sigh Breaths During NIMV in Motor Neuron Disease",2022-03,ACTIVE_NOT_RECRUITING,2022-12-31,PRINCIPAL_INVESTIGATOR,Nilo Riva,Ospedale San Raffaele,"['Motor Neuron Disease', 'Respiratory Failure', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,44.0,ESTIMATED,"[{'name': 'NIMV with sigh breaths', 'description': 'Sigh breaths: Maximal Inspiratory pressure (IPAPmax) increased of at least 25% ( â‰¥ 125%) with a frequency of at least 1/200 breaths. The sigh breaths will be delivered as part of the standard NIMV protocol'}, {'name': 'Standard NIMV', 'description': 'Will be treated by standard NIMV with no sigh'}]",,
Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN),2024-01,RECRUITING,2029-08-31,SPONSOR,,Prevail Therapeutics,['Frontotemporal Dementia'],INTERVENTIONAL,23.0,ESTIMATED,"[{'name': 'LY3884963', 'description': 'Participants will receive a single dose of LY3884963, administered intra cisterna magna'}, {'name': 'Methylprednisolone', 'description': 'IV pulses every 2 weeks in the first 3 months.'}, {'name': 'Optional Sirolimus', 'description': 'At the investigators discretion following steroid tolerability issues, patients may receive a loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication'}, {'name': 'Optional Prednisone', 'description': 'If needed and at the investigator discretion, Oral Prednisone may be added to the immunosuppression regimen'}]","['Fronto-Temporal Dementia', 'Frontotemporal Dementia', 'Progranulin Mutations', 'FTD-GRN', 'Gene Therapy', 'Dementia Gene Therapy', 'AAV9']",
A Speech Sound and Phonemic Awareness Intervention in Flemish Early Childhood Education,2014-12,UNKNOWN,2015-12,PRINCIPAL_INVESTIGATOR,Lieve Van Severen,KU Leuven,['Other Developmental Disorders of Speech and Language'],INTERVENTIONAL,200.0,ESTIMATED,"[{'name': 'speech sound intervention', 'description': 'An intervention that stimulates speech sound perception and production in four-year-olds.\n\nEach day at preschool the children receive a 15 to 20 minutes intervention, for 12 weeks'}, {'name': 'World-project', 'description': 'An intervention that stimulates vocabulary development in four-year-olds. Each day at preschool the children receive a 120 minutes intervention, for 10 weeks'}]",,
Young Onset Dementia - the Difficult Diagnosis and the Stressful Life for the Whole Family,2021-03,COMPLETED,2020-07,SPONSOR,,Norwegian Centre for Ageing and Health,"['Frontotemporal Dementia', 'Alzheimer Disease']",OBSERVATIONAL,250.0,ACTUAL,,"['Young onset dementia', 'Quality of life', 'Specific needs', 'Healthcare resources in dementia', 'Frontotemporal dementia', ""Alzheimer's disease"", 'Healthcare services']","YOD participants are community residing persons recruited from memory clinics in Norway and Nordic countries (Iceland, Sweden and Denmark)."
Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis,2022-11,COMPLETED,2022-08-31,SPONSOR,,"Helixmith Co., Ltd.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,18.0,ACTUAL,"[{'name': 'Engensis', 'description': 'Lyophilized biologic to be reconstituted containing Engensis'}, {'name': 'Placebo', 'description': 'Injectable liquid'}]",,
Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS),2020-06,RECRUITING,2030-12-01,SPONSOR,,Peking University Third Hospital,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,3000.0,ESTIMATED,"[{'name': 'Amyotrophic lateral sclerosis', 'description': 'AMYOTROPHIC lateral sclerosis (ALS) is a degenerative disorder of motor neurons in the cortex, brainstem and spinal cord1,2. Its cause is unknown and it is uniformly fatal, typically within five years3'}]",['amyotrophic lateral sclerosis; Epidemiology'],ALS patients in mainland China.
The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALS,2022-04,ACTIVE_NOT_RECRUITING,2023-04,SPONSOR,,Polski Bank Komorek Macierzystych JSC (PBKM),['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,20.0,ACTUAL,"[{'name': ""Mesenchymal stem cells isolated from Wharton's jelly"", 'description': 'Intrathecal administration of mesenchymal stem cells'}]","['Amyotrophic Lateral Sclerosis', 'Stem Cells']",
A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD,2023-03,ACTIVE_NOT_RECRUITING,2023-09-01,SPONSOR,,"Transposon Therapeutics, Inc.","['Amyotrophic Lateral Sclerosis', 'Frontotemporal Dementia']",INTERVENTIONAL,42.0,ACTUAL,"[{'name': 'TPN-101, 400 mg/day', 'description': '400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).'}, {'name': 'Placebo', 'description': 'Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).'}]","['ALS', 'FTD']",
Innovative Ultrasound Technology in Neuromuscular Disease,2022-03,COMPLETED,2020-03-01,PRINCIPAL_INVESTIGATOR,Seward Rutkove,Beth Israel Deaconess Medical Center,"['Amyotrophic Lateral Sclerosis', 'Muscular Dystrophy', 'Radiculopathy', 'Myopathy', 'Polyneuropathy and Mononeuropathies', 'Trauma Injury', 'Orthopedic Disorder']",OBSERVATIONAL,223.0,ACTUAL,,,"Patients with any neuromuscular disorder (i.e. primary nerve or muscle disease), both localized and generalized, producing some degree of weakness or disability."
Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD,2023-10,ACTIVE_NOT_RECRUITING,2024-05-22,SPONSOR,,University of Florida,"['C9orf72 Amyotrophic Lateral Sclerosis (ALS)', 'Frontotemporal Dementia']",INTERVENTIONAL,18.0,ACTUAL,"[{'name': 'Metformin', 'description': 'Metformin is a widely used, well-tolerated drug that has been used for decades as a first-line defense for treating type 2 diabetes. Its safety has been well established. Subjects will begin treatment with Metformin at a dosage of 500mg with an escalation of dosage by 500mg every week to a maximal dosage of 2000mg. Dosing will be twice daily.'}]","['ALS', 'FTD', 'Lou Gehrigs Disease']",
Deep Phenotyping in Patients With ALS,2021-12,COMPLETED,2021-11-09,SPONSOR,,Barrow Neurological Institute,"['ALS', 'Motor Neuron Disease']",OBSERVATIONAL,32.0,ACTUAL,,,ALS patient volunteers will be invited to participate in this study by their neurologists either in clinic or at a regular scheduled appointment visit.
Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders,2017-10,COMPLETED,2016-07,SPONSOR_INVESTIGATOR,"MinYoung Kim, M.D.","MinYoung Kim, M.D.","['Brain Injury', 'Cerebral Palsy', 'Amyotrophic Lateral Sclerosis', ""Parkinson's Disease""]",INTERVENTIONAL,10.0,ACTUAL,"[{'name': 'Umbilical cord blood therapy'}, {'name': 'Filgrastim'}]","['Umbilical cord blood', 'Granulocyte-colony stimulating factor', 'Brain injury', 'Neurodegenerative disorder', 'Efficacy', 'Safety']",
Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Patients With Amyotrophic Lateral Sclerosis,2016-08,UNKNOWN,2018-12,PRINCIPAL_INVESTIGATOR,Wojciech Maksymowicz,University of Warmia and Mazury,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'Biological: Cell-based therapy', 'description': 'Human autologous bone marrow-derived mesenchymal stem cell transplantation in ALS patients.'}]",,
Phase 3 Study of Dexpramipexole in ALS,2021-05,COMPLETED,2012-11,SPONSOR,,Knopp Biosciences,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,942.0,ACTUAL,"[{'name': 'Dexpramipexole', 'description': 'Oral tablet 150mg twice daily for up to 18 months.'}, {'name': 'Placebo', 'description': 'Oral tablet twice daily for up to 18 months.'}]","['Amyotrophic Lateral Sclerosis', 'ALS', 'Motor Neurone Disease', 'Motor Neuron Disease', ""Lou Gehrig's disease""]",
Study of the Effects Strengthening Exercises in Individuals With ALS,2004-12,COMPLETED,2004-12,,,University of Saskatchewan,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,40.0,,[{'name': 'Exercise'}],"['Amyotrophic Lateral Sclerosis', 'Exercise']",
Efficacy Study of Kinto Care Coaching for Dementia Family Caregivers,2024-01,ACTIVE_NOT_RECRUITING,2024-08-31,SPONSOR,,Kinto,"['Dementia', 'Alzheimer Disease', 'Lewy Body Disease', 'Vascular Dementia', 'Frontotemporal Dementia', 'Mixed Dementia']",INTERVENTIONAL,495.0,ACTUAL,"[{'name': 'Kinto Care Coaching', 'description': 'Describe the basics of the intervention'}]","['Caregiving', 'Financial Education', 'Technology', 'Behavioral Intervention', 'Caregiver Support Intervention', 'Financial Literacy', 'Financial Preparedness', 'Caregiver Well Being', 'Caregiver Stress', 'Caregiver Burden']",
Pupillography as Screening Tool for Brain Insulin Resistance,2018-07,COMPLETED,2019-01-07,SPONSOR,,University Hospital Tuebingen,['Obesity'],INTERVENTIONAL,22.0,ACTUAL,"[{'name': 'human insulin', 'description': 'human insulin administered as nasal spray'}, {'name': 'placebo', 'description': 'placebo administered as nasal spray'}, {'name': 'Pupillography', 'description': 'Autonomic tone will be adressed by pupillography using the F2D2 (Amtech Germany) device.'}]",,
Acoustic and Perceptual Markers of Dysarthria in Amyotrophic Lateral Sclerosis (ALS),2020-01,COMPLETED,2019-12-23,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,"['Amyotrophic Lateral Sclerosis', 'Primary Lateral Sclerosis', ""Kennedy's Disease""]",OBSERVATIONAL,71.0,ACTUAL,,"['Acoustic and perceptual markers', 'Dysarthria', 'Amyotrophic lateral sclerosis', 'Primitive lateral sclerosis', ""Kennedy's disease""]","We will recruit 80 patients (40 ALS patients, 20 PLS patients and 20 KD patients). They will be recruited at the ""centre de rÃ©fÃ©rence pour les maladies du motoneurone (PitiÃ©-SalpÃªtriÃ¨re). An initial EMG will be achieved during the usual diagnostic management"
HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose,2023-10,COMPLETED,2023-08-25,SPONSOR_INVESTIGATOR,"Merit E. Cudkowicz, MD","Merit E. Cudkowicz, MD",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,161.0,ACTUAL,"[{'name': 'SLS-005', 'description': 'Administration: Infusion Dose: 0.75 g/kg weekly'}, {'name': 'Matching Placebo', 'description': 'Administration: Infusion Dose: equivalent weight-based volume as described for trehalose'}]","['ALS', 'Placebo-Controlled', 'Double-Blind', 'Regimen Specific Appendix', ""Lou Gehrig's Disease"", 'Trehalose', 'Seelos Therapeutics']",
Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis,2013-09,COMPLETED,2012-03,PRINCIPAL_INVESTIGATOR,Maysam Ghovanloo,Georgia Institute of Technology,"['Quadriplegia', 'Spinal Cord Injury', 'ALS']",INTERVENTIONAL,61.0,ACTUAL,"[{'name': 'Tongue Piercing', 'description': 'Subjects brush their teeth, and then swish and spit with chlorhexidine mouthwash for 30-60s. Subjects would be placed in a semirecumbent position in a procedure chair. After marking the piercing site using a sterilized surgical marking pen the protruded tongue would be pierced. Anesthesia may be used during the piercing at the discretion of the operator and the subject. A sterilized titanium or surgical grade stainless steel piercing tongue stud would be placed in an appropriate position on the tongue to minimize complications from the piercing but also facilitate good functionality of the TDS.'}, {'name': 'Usability assessment', 'description': 'Computer access: Subjects wear the TDS and get trained. Then they sit 1.5 m from a 22"" LCD monitor. Then they use TDS to conduct several tasks using their tongues, such as clicking on target objects and navigating through on-screen maze, while the computer registers their tongue commands and measures their performance.\n\nWheelchair control: Subjects wear the TDS and use it to drive an electrically powered wheelchair through an obstacle course using their tongues. The operator measured the time it takes for the subjects to drive through the course as well as the number of collisions.'}]","['Disability', 'Quadriplegia', 'Paralysis', 'Assistive technology', 'Quality of life', 'Computer access', 'Wheeled mobility']",
"Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System",2019-03,UNKNOWN,2022-02-28,SPONSOR,,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France","['Apathy', 'Frontotemporal Dementia', 'Parkinson Disease', 'Depressive Symptoms']",INTERVENTIONAL,135.0,ESTIMATED,"[{'name': 'ECOCAPTURE', 'description': '45 minutes observational session for tracking goal directed behavior into a waiting room equipped with video and sensor-based data acquisition system'}, {'name': 'Cognitive and Behavioral experimental tasks', 'description': 'Cognitive and Behavioral experimental tasks to explore additional frontal cognitive and behavioral dimensions and functions'}, {'name': 'Neuropsychological assessment', 'description': 'MMS / MADRS / EBI / NART / Mini-SEA / BREF / HAD / MATTIS / HAYLING / STROOP / STARKSTEIN / DAS'}, {'name': 'ICM_APATHY_TASKS', 'description': 'Apathy experimental task'}, {'name': 'MRI', 'description': 'T1 MRI / T2 MRI / Resting state fMRI / Multi-shell diffusion-weighted MRI'}, {'name': 'Neurohormonal mechanisms', 'description': 'Hormonal dosage / Diabetic dosage / Ionogramme dosage / Inflammatory dosage / Hepatic dosage / Lipidic dosage / Thyroid dosage'}, {'name': ""Supplementary Neuropsychological Assessment - Parkinson's Disease"", 'description': 'ACDD / QUIP / BIS-11 / ECMP / QUIP-RS'}]","['Apathy', 'Goal-directed behavior', 'Assessment', 'Diagnosis', 'Sensor', 'Ecological condition', 'Neurological disease']",
Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis,2013-07,COMPLETED,2010-09,SPONSOR,,Wake Forest University Health Sciences,"['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease', ""Lou Gehrig's Disease""]",INTERVENTIONAL,9.0,ACTUAL,"[{'name': 'Treadmill Exercise', 'description': ""The intervention will consist of 30 minutes of exercise, performed 3 times per week for 8 weeks (24 sessions). Patient will walk on a treadmill with up to 40% of their body weight supported by a body weight support system with an overhead harness. The training session duration will be 60 minutes consisting of six intervals of 5 minutes exercise, interspersed with 6 intervals of 5 minutes rest to avoid overwork weakness and fatigue. Five minute exercise intervals should be sufficient for patients to reach a steady state. Patients will build up their endurance to this training level at their own pace as tolerated. Walking speed will be determined as tolerated by each patient. Exercise intensity will be guided by each patient's own perception of exertion, but not to exceed level 12-13 (mild to moderate) on the modified Borg perceived exertion scale, and by oxygen saturation (Sa O2) â‰¥ 90% monitor by handheld pulse Oximeter.""}]",['Exercise for Amyotrophic lateral sclerosis'],
Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS Patients,2023-10,COMPLETED,2023-02-04,PRINCIPAL_INVESTIGATOR,"JosÃ© Enrique de la Rubia OrtÃ­, Ph",FundaciÃ³n Universidad CatÃ³lica de Valencia San Vicente MÃ¡rtir,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,90.0,ACTUAL,"[{'name': 'Liposomed polyphenols resveratrol and curcumin', 'description': 'Combination of resveratrol (75mg) and curcumin (200mg) liposomed'}, {'name': 'Placebo for liposomed resveratrol and curcumin', 'description': 'Water with sucrose replacing the liposomed polyphenols'}, {'name': 'Isocaloric Diet', 'description': '40% carbohydrates, 40% lipids and 20% proteins'}, {'name': 'G04CB02', 'description': 'G04CB02, in a single daily dose for 4 months'}, {'name': 'Placebo microcrystalline methylcellulose', 'description': 'Placebo replacing G04CB02'}]",,
Yogic Breathing Exercise for People With Amyotrophic Lateral Sclerosis,2023-11,RECRUITING,2025-08-28,PRINCIPAL_INVESTIGATOR,"Hon K. Yuen, PhD",University of Alabama at Birmingham,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'yogic breathing exercise', 'description': 'A typical session will begin with the yoga instructor demonstrating a breathing exercise technique. The participants will learn and practice each technique.'}]",['Amyotrophic Lateral Sclerosis'],
Phase 3 Extension Study of Dexpramipexole in ALS,2022-04,TERMINATED,2013-02,SPONSOR,,Knopp Biosciences,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,616.0,ACTUAL,"[{'name': 'Dexpramipexole', 'description': 'Oral tablet 150 mg given twice daily (BID)'}]","['ALS, Motor Neuron Disease, Amyotrophic Lateral Sclerosis']",
Chewing Efficiency Measured by a Two Colour Chewing Gum Test in Amyotrophic Lateral Sclerosis (ALS) Patients?,2020-03,COMPLETED,2019-07,PRINCIPAL_INVESTIGATOR,Genton Graf Laurence,"University Hospital, Geneva",['Amyotrophic Lateral Sclerosis 11'],OBSERVATIONAL,25.0,ACTUAL,,,ALS patients participating in the cohort study of the University Hospital Geneva
Effects of Long Term Ventilation Support on the Quality of Life of ALS Patients and Their Families,2023-03,RECRUITING,2032-08-21,SPONSOR,,Haukeland University Hospital,"['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease', 'Nervous System Diseases', 'Spinal Cord Diseases', 'Neurodegenerative Diseases', 'TDP-43 Proteinopathies']",INTERVENTIONAL,200.0,ESTIMATED,"[{'name': 'Long term mechanical ventilation support', 'description': 'Patients that choose life prolonging treatment with long term mechanical ventilation support'}, {'name': 'No long term mechanical ventilation support', 'description': 'Patients that decline life prolonging treatment with long term mechanical ventilation support'}]","['Quality of life', 'Overall quality of life', 'Health related quality of life', 'Disease specific quality of life', 'Ventilation support', 'Non-invasive ventilation support', 'Invasive ventilation support']",
Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis,2023-01,ACTIVE_NOT_RECRUITING,2024-06-20,SPONSOR,,Ferrer Internacional S.A.,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,300.0,ESTIMATED,"[{'name': 'FAB122', 'description': 'Daily dose 100 mg'}, {'name': 'Placebo', 'description': 'Daily dose'}]",,
Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS),2020-01,COMPLETED,2019-02-07,SPONSOR,,University of Florida,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,50.0,ACTUAL,"[{'name': 'PowerLung trainer', 'description': 'PowerLung trainer will be utilized which has both an inspiratory and expiratory loading capacity for training. A single daily training session will consist of three sets of 10 repetitions for a total of 30 inspiratory repetitions and 30 expiratory repetitions (i.e. 60 repetitions) for 5 days a week, for 3 months.'}, {'name': 'Micro Mouth Pressure Meter', 'description': 'The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flange rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest Maximum Inspiratory Pressures (MIP) and Maximal Expiratory Pressure (MEP) used.'}, {'name': 'Pulmonary Function Testing', 'description': 'Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.'}, {'name': 'Videofluoroscopic swallowing study', 'description': 'Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.'}, {'name': 'Swallowing Quality of Life Questionnaire', 'description': 'Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.'}, {'name': 'Iowa Oral Pressure Instrument', 'description': 'The IOPI is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.'}, {'name': 'Capsaicin', 'description': 'A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 Î¼M capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction ""cough if you need to"" prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds.'}]",,
HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS),2022-12,COMPLETED,2023-05-09,SPONSOR,,National Institute of Neurological Disorders and Stroke (NINDS),['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,122.0,ACTUAL,"[{'name': 'Darunavir', 'description': 'Orally-administered medication approved for HIV treatment. MOA is as a protease inhibitor. Dose is 600mg twice daily.'}, {'name': 'Ritonavir', 'description': 'Orally-administered, FDA-approved medication for HIV treatment. Used in combination with darunavir. Dose is 100mg twice daily.'}, {'name': 'Dolutegravir', 'description': 'Orally-administered, FDA-approved medication to treat HIV. It acts as an integrase inhibitor. Dose is 50mg once daily.'}, {'name': 'Tenofovir alafenamide (TAF)', 'description': 'Orally-administered, FDA-approved medication used to treat HIV. It acts as a nucleoside reverse transcriptase inhibitor. Dose is 25mg once daily.'}]","['Amyotrophic Lateral Sclerosis', 'Antiretroviral Therapy', 'Virus']",
WeCareAdvisor Study for Caregivers of People Living With Dementia,2024-01,RECRUITING,2025-10,SPONSOR,,Drexel University,"['Dementia', 'Caregiver Burnout', 'Caregiver Stress Syndrome', 'Alzheimer Disease', 'Frontotemporal Dementia', 'Vascular Dementia', 'Dementia With Lewy Bodies']",INTERVENTIONAL,326.0,ESTIMATED,"[{'name': 'Immediate treatment group with High-Intensity Prompts', 'description': 'Caregivers in the immediate treatment group with high-intensity prompts will use the WeCareAdvisor tool for 6 months. Caregivers will receive telephone and email prompts to use the tool.'}, {'name': 'Immediate treatment group with Low-Intensity Prompts', 'description': 'Caregivers in the immediate treatment group with low-intensity prompts will use the WeCareAdvisor tool for 6 months. Caregivers will receive email prompts to use the tool.'}, {'name': 'Waitlist Control after three months with High-Intensity Prompts', 'description': 'After 3 months, caregivers will use the WeCareAdvisor tool for 3 months. Caregivers will receive telephone and email prompts. Once the caregiver receives the WeCareAdvisor tool, they will receive a weekly automated email as well as a weekly telephone call from study staff to prompt them to use the tool.'}, {'name': 'Waitlist Control after three months with Low-Intensity Prompts', 'description': 'After 3 months, caregivers will use the WeCareAdvisor tool for 3 months. Caregivers will receive email prompts.'}]","['dementia', 'caregiver', ""alzheimer's disease"", 'memory loss']",
Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders,2023-05,ENROLLING_BY_INVITATION,2050-11,PRINCIPAL_INVESTIGATOR,Keith A. Josephs,Mayo Clinic,"['PSP', 'CBD', 'PCA', 'LPA', 'Semantic Dementia', 'Semantic Aphasia', 'Behavioral Variant of Frontotemporal Dementia', 'FTD', 'PPA', 'Apraxia of Speech', 'MSA - Multiple System Atrophy', 'Parkinson Disease']",OBSERVATIONAL,500.0,ESTIMATED,"[{'name': 'C-11 PiB', 'description': 'Completing PET scan looking for amyloid protein'}, {'name': 'AV1451 Tau', 'description': 'Completing PET scan looking for tau protein'}, {'name': 'C-11 ER176', 'description': 'Completing PET scan looking for neuroinflammation'}]",,Symptoms of neurodegenerative disease
Spinal Cord Associative Plasticity for ALS,2024-01,NOT_YET_RECRUITING,2028-02-29,SPONSOR,,VA Office of Research and Development,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,32.0,ESTIMATED,"[{'name': 'Spinal Cord Associative Plasticity (SCAP)', 'description': 'Paired non-invasive brain and spinal cord stimulation.'}, {'name': 'Upper extremity task-oriented exercise', 'description': 'Participants will perform a range of exercises composed of tasks resembling daily home/community activities such as stacking and sorting small objects, manipulating writing utensils, keys, buttons, etc.'}]","['neuromodulation', 'spinal cord stimulation', 'task-oriented exercise', 'transcranial magnetic stimulation']",
The General Breathing Record Study,2018-09,COMPLETED,2018-07-04,SPONSOR,,TidalSense,"['Asthma', 'Heart Failure', 'Pneumonia', 'Motor Neuron Disease', 'Vocal Cord Dysfunction', 'Breathlessness']",OBSERVATIONAL,70.0,ACTUAL,,"['Capnography, Diagnosis. Breathlessness, Exacerbations, Device']",The healthy Cohort will be made up of healthy volunteers. The Disease Cohorts will be selected from hospital outpatient clinic lists and inpatient wards.
Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation,2015-04,TERMINATED,2015-11,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,"['Amyotrophic Lateral Sclerosis', 'Respiratory Insufficiency']",INTERVENTIONAL,74.0,ACTUAL,"[{'name': 'phenique nerve stimulation NeurXâ„¢ (Synapse Biomedical)', 'description': 'phenique nerve stimulation NeurXâ„¢ (Synapse Biomedical)'}, {'name': 'sham phrenic nerve stimulation', 'description': 'sham phenic nerve stimulation'}]","['Amyotrophic lateral sclerosis,', 'Diaphragm', 'Mechanical ventilation', 'Phrenic nerve stimulation', 'Respiratory insufficiency']",
Circuitry Assessment and Reinforcement Training Effects on Recovery,2023-09,SUSPENDED,2025-09-01,SPONSOR,,Johns Hopkins University,"['Aphasia', 'Primary Progressive Aphasia', 'Stroke']",INTERVENTIONAL,80.0,ESTIMATED,"[{'name': 'EEG Neurofeedback', 'description': 'Active EEG neurofeedback'}, {'name': 'Sham Feedback', 'description': ""Sham EEG feedback sessions identical to active sessions except that the feedback given to the participant will not be based on the individual's live EEG activity.""}]","['communication', 'language', 'speech', 'anxiety', 'sleep', 'neurofeedback']",
A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C,2023-09,ACTIVE_NOT_RECRUITING,2024-11,SPONSOR,,IntraBio Inc,"['Niemann-Pick Disease, Type C']",INTERVENTIONAL,53.0,ESTIMATED,"[{'name': 'N-Acetyl-L-Leucine', 'description': 'N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)'}, {'name': 'Placebo', 'description': 'Matching Placebo Sachet'}]",,
RadicavaÂ® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS),2023-08,ACTIVE_NOT_RECRUITING,2024-03,SPONSOR,,Mitsubishi Tanabe Pharma America Inc.,"['Amyotrophic Lateral Sclerosis', 'ALS']",OBSERVATIONAL,300.0,ESTIMATED,"[{'name': 'Edaravone (RadicavaÂ®/Radicava ORSÂ®)', 'description': 'Participants will be followed from enrollment up to 24 weeks after treatment initiation (6 treatment cycles - 28 days per cycle, corresponding to a treatment period of approximately 24 weeks) or premature study discontinuation.\n\nBiomarker testing and clinical assessments will be performed at baseline (at enrollment or before the start of cycle 1), and at cycles 1, 3, and 6. Dosing is 60 mg daily by intravenous infusion for 14 days for the initial treatment cycle, followed by daily dosing on 10 out of 14 days in subsequent treatment cycles.'}]","['biomarkers', 'edaravone', 'RadicavaÂ®', 'Radicava ORSÂ®', 'motor neuron disease']","This study will be conducted in participants who have sporadic or familial amyotrophic lateral sclerosis (ALS) as defined by revised El Escorial criteria. Participants must provide written informed consent prior to screening. At screening, eligible patient must be at least 18 years old with a decision made to prescribe Edaravone prior to consenting. Participants who are either Edaravone naÃ¯ve or who did not receive any Edaravone dose within one month of consenting are eligible for inclusion given they meet all other protocol requirements."
Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1,2023-12,TERMINATED,2021-10-18,SPONSOR,,Mandos LLC,"['Niemann-Pick Disease, Type C']",INTERVENTIONAL,2.0,ACTUAL,"[{'name': 'VTS-270', 'description': 'Administered IT via LP infusion of VTS-270'}]","['Niemann-Pick', 'NPC']",
Mexiletine for the Treatment of Muscle Cramps in ALS,2017-07,COMPLETED,2016-05,SPONSOR_INVESTIGATOR,"Bjorn Oskarsson, MD","Bjorn Oskarsson, MD",['Muscle Cramps in Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,23.0,ACTUAL,"[{'name': 'Mexiletine', 'description': 'Sodium channel blocker'}, {'name': 'Placebo', 'description': 'Placebo'}]","['Muscle cramps', 'Cramp', 'ALS', 'Amyotrophic Lateral Sclerosis', ""Lou Gehrig's disease"", 'Motor Neuron Disease', 'MND']",
Surface EMG and Ultrasound in MND,2022-03,COMPLETED,2019-12-01,SPONSOR,,King's College Hospital NHS Trust,['Motor Neuron Disease'],INTERVENTIONAL,25.0,ACTUAL,"[{'name': 'High-density surface EMG', 'description': 'High-density surface EMG for fasciculation detection'}, {'name': 'Ultrasound', 'description': 'Ultrasound for fasciculation detection'}]",,
Gamma-Induction in FrontoTemporal Dementia Trial,2024-02,RECRUITING,2025-12,PRINCIPAL_INVESTIGATOR,Emiliano Santarnecchi,Massachusetts General Hospital,['Frontotemporal Dementia'],INTERVENTIONAL,70.0,ESTIMATED,"[{'name': 'Transcranial Alternating Current Stimulation (tACS)', 'description': 'tACS is a noninvasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head.'}, {'name': 'Sham Transcranial Alternating Current Stimulation (sham tACS)', 'description': 'Sham (placebo) simulation of transcranial alternating current stimulation without receiving any real stimulation.'}]",['FTD'],
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS),2022-05,ACTIVE_NOT_RECRUITING,2024-03,SPONSOR,,"Apellis Pharmaceuticals, Inc.","['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease']",INTERVENTIONAL,249.0,ACTUAL,"[{'name': 'Pegcetacoplan (APL-2)', 'description': 'Complement (C3) Inhibitor'}, {'name': 'Placebo', 'description': 'Sterile solution of equal volume to active arm'}]","['Amyotrophic Lateral Sclerosis', 'ALS', 'Motor Neuron Disease', 'APL-2', 'APL2', 'Pegcetacoplan']",
Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis,2003-12,COMPLETED,,,,National Center for Research Resources (NCRR),['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,,,[{'name': 'Creatinine'}],['ALS'],
Polysomnography-directed Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS),2020-11,TERMINATED,2010-07,SPONSOR,,Columbia University,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,25.0,ACTUAL,"[{'name': 'Sleep study-guided adjustment of NIV', 'description': 'Sleep studies will be performed at baseline, within 2 weeks to initially titrate NIV, and at 1, 3 and 6 months to assess NIV performance and adjust it as necessary based on oxygenation and ventilation parameters.'}, {'name': 'Standard initiation of NIV', 'description': ""NIV will be initiated and managed as per current standard of practice. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months to gather data but will not influence NIV management. NIV will be adjusted by a respiratory therapist or the subject's primary physician per waking symptoms.""}]","['Amyotrophic Lateral Sclerosis', 'Noninvasive Ventilation', 'Respiratory Dysfunction', 'Positive Pressure Ventilation']",
Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy,2023-04,COMPLETED,2022-03-30,SPONSOR,,Johns Hopkins University,"['Primary Progressive Aphasia', 'PPA']",INTERVENTIONAL,8.0,ACTUAL,"[{'name': 'Active tDCS plus Speech-Language Therapy', 'description': '1-2 milliamps (mA) of Anodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge is placed on the left inferior frontal gyrus (IFG). The stimulation will be delivered at an intensity of 1-2 mA in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be verb naming therapy in a sentence context.'}, {'name': 'Sham tDCS plus Speech-Language Therapy', 'description': 'Sham tDCS stimulation is provided to the left inferior frontal gyrus (IFG) using a tDCS device. Speech-language therapy will be verb naming therapy in a sentence context.'}]","['Aphasia', 'Language therapy', 'Neurocognitive Disorders', 'Frontotemporal Dementia', 'Dementia', 'Anomia']",
"Phenotype, Genotype and Biomarkers 2",2023-08,RECRUITING,2024-06,PRINCIPAL_INVESTIGATOR,Michael Benatar,University of Miami,"['Amyotrophic Lateral Sclerosis', 'Hereditary Spastic Paraplegia', 'Primary Lateral Sclerosis', 'Progressive Muscular Atrophy', 'Frontotemporal Dementia']",OBSERVATIONAL,300.0,ESTIMATED,,"['ALS', 'PLS', 'PMA', 'HSP', 'FTD', 'MSP']","Primary participants - patients that have or are suspected to have ALS or a related disease.

Secondary participants - family members of primary participants enrolled in the study"
Dual Treatment With Lithium and Valproate in ALS.,2019-02,COMPLETED,2019-08,PRINCIPAL_INVESTIGATOR,Marie Catherine Boll Woehrlen,El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez,"['Amyotrophic Lateral Sclerosis', 'Amyotrophic Lateral Sclerosis, Sporadic']",INTERVENTIONAL,43.0,ACTUAL,"[{'name': 'Active treatment with dual therapy', 'description': 'Blue pills ( 200 mg of magnesium valproate ) and white pills ( 300 mg of lithium carbonate) are administered orally with meals.'}, {'name': 'Placebos', 'description': 'Administered orally under the same conditions'}]","['Amyotrophic lateral sclerosis', 'Dual therapy', 'Randomized controlled trial', 'ALSFRS-R']",
"A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects",2019-05,COMPLETED,2019-10-09,SPONSOR,,Neuropore Therapies Inc.,['Healthy Volunteers'],INTERVENTIONAL,49.0,ACTUAL,"[{'name': 'NPT520-34 (125 mg)', 'description': 'NPT520-34, 125 mg oral capsules (size 1)'}, {'name': 'Placebos (125 mg)', 'description': 'Placebo, 125 mg oral capsules'}]","['Phase 1', 'Safety', 'Tolerability', 'Pharmacokinetics', ""Parkinson's Disease"", 'Amyotrophic Lateral Sclerosis']",
Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2,2016-05,COMPLETED,2016-05,SPONSOR,,Centre Hospitalier Universitaire de NÄ«mes,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,36.0,ACTUAL,"[{'name': 'Placebo', 'description': 'Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).'}, {'name': '1.0 MIU IL-2 per day', 'description': 'Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).'}, {'name': '2.0 MIU IL-2 per day', 'description': 'Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).'}]",['low-dose interleukin 2'],
Far Infrared Radiation Treatment of Dementia and Other Mental Illness,2009-08,UNKNOWN,2009-03,,,GAAD Medical Research Institute Inc.,['Dementia'],INTERVENTIONAL,4.0,ACTUAL,"[{'name': 'Far Infrared', 'description': 'Far infrared radiation (5 Î¼m to 20 Î¼m wavelength) for 30 to 40 minutes per treatment session.'}]","['Familial Dementia', 'Semantic Dementia', 'Senile Paranoid Dementia']",
Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS,2018-04,TERMINATED,2018-08-23,SPONSOR,,"Flex Pharma, Inc.","['Amyotrophic Lateral Sclerosis', 'Fasciculation']",INTERVENTIONAL,3.0,ACTUAL,"[{'name': 'FLX-787-ODT', 'description': 'Oral Disintegrating Tablet'}]","['ALS', 'Amyotrophic Lateral Sclerosis', 'Fasciculation', 'FLX-787']",
Auditory Beat Stimulation and Behavioural Variant of Frontotemporal Dementia,2023-06,COMPLETED,2021-09-01,PRINCIPAL_INVESTIGATOR,Dr. Juergen Fell,"University Hospital, Bonn","['Anxiety', 'bvFTD']",INTERVENTIONAL,11.0,ACTUAL,"[{'name': 'Auditory beat stimulation: 8Hz monaural beat stimulation', 'description': 'Auditory beat stimulation is a reversible, non-invasive application of sound to the ears.'}]",,
Ocular Surface Metabolo-lipidomics in Lateral Amyotrophic Sclerosis,2023-11,COMPLETED,2023-09-30,SPONSOR,,"University Hospital, Tours",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,55.0,ACTUAL,"[{'name': 'Measure of visual acuity', 'description': 'ETDRS and Parinaud scale'}, {'name': 'Interferometry', 'description': 'Non-contact exam measuring N.I.B.U.T (Non-invasive break-up time), quantitative and qualitative evaluation of the meibomian glands and quantitative evaluation of the tear meniscus'}, {'name': 'Samples of basal tears', 'description': 'Collection of basal tears without instillation of anesthetic with a Schirmer strip for 5 minutes and by microcapillary'}, {'name': 'Central corneal sensitivity', 'description': 'Central corneal sensitivity using a Cochet-Bonnet esthesiometer (LuneauÂ©)'}, {'name': 'Slit lamp examination and undilated fundus', 'description': 'Slit lamp examination and undilated fundus'}, {'name': 'Conjunctival impression', 'description': 'Conjunctival impression with anesthetic instillation'}, {'name': 'Evaluation of the corneal innervation', 'description': 'Contact corneal confocal microscopy'}]","['Amyotrophic Lateral Sclerosis', 'Biomarkers', 'Ocular Surface', 'Tear']",
TRIAL READY (Clinical Trial Readiness),2023-08,ACTIVE_NOT_RECRUITING,2024-06,PRINCIPAL_INVESTIGATOR,Michael Benatar,University of Miami,"['Amyotrophic Lateral Sclerosis', 'Frontotemporal Dementia', 'ALS-Frontotemporal Dementia', 'Primary Lateral Sclerosis', 'Progressive Muscular Atrophy']",OBSERVATIONAL,610.0,ESTIMATED,,,"Patients with ALS or a related neurodegenerative disorder, including FTD, ALS-FTD, PLS and PMA. Individuals never diagnosed with and not at particular risk of developing ALS or a related disorder."
Pharyngeal Electrical Stimulation in Amyotrophic Lateral Sclerosis,2021-03,COMPLETED,2020-07-21,PRINCIPAL_INVESTIGATOR,"Albert Christian Ludolph, Prof.",University of Ulm,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,20.0,ACTUAL,"[{'name': 'Pharyngeal Electrical Stimulation', 'description': 'Pharyngeal Electrical Stimulation is applied at the pharynx via a nasogastral tube for 10 minutes per day on 3 consecutive days.'}]",,
Inspiratory Muscle Training With Powerbreath Device in Patients With ALS,2022-05,COMPLETED,2021-11-12,SPONSOR,,Universidad Francisco de Vitoria,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,20.0,ACTUAL,"[{'name': 'Inspiratory Muscle Training with Powerbreath IMT device.', 'description': 'Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks.\n\nEach day, each subject perform 15 repetitions in the morning and evening, from Monday to Friday, resting on weekends.\n\nThe endurance of the device increases along the study, initiating with the 30% of their own maximum inspiratory pressure (PImax) during the first week and increasing a 10% every other week, till reach the goal of 60% PImax.'}]","['Amyotrophic lateral sclerosis', 'Maximum Inspiratory Pressure', 'Diaphragm']",
Home-Based Exercise in Primary Progressive Aphasia (HEPPA),2023-12,ACTIVE_NOT_RECRUITING,2024-08-31,PRINCIPAL_INVESTIGATOR,Louis Bherer,Montreal Heart Institute,"['Primary Progressive Aphasia', 'Neurodegenerative Diseases', 'Logopenic Progressive Aphasia', 'Semantic Dementia', 'Non-fluent Aphasia']",INTERVENTIONAL,13.0,ACTUAL,"[{'name': 'Home-based multicomponent exercise intervention program', 'description': 'A novel home-based multicomponent exercise intervention program was designed using a multimodal training circuit. This 24-week circuit program was created to improve functional (resistance) and aerobic health. Participants will be asked to train two to three times a week for 45 minutes. They will be supervised via videoconference by a trained kinesiologist from the EPIC Center at the Montreal Heart Institute. If desired, participants can complete their exercises with a partner, friend, or relative to facilitate communication. Participants will be asked to document the perceived intensity of their exercises in a booklet after each workout. The perceived intensity of their exercises will be measured by a validated effort perception scale graduated from 0 to 10 (Borg scale; Williams, 2017). Progressions will increase every five weeks and will be subject to modification if not properly tolerated or if found to be below a 3 on the Borg rate of perceived exertion scale (moderate intensity).'}]","['Primary Progressive Aphasia', 'Home-Based Exercise Intervention', 'Pilot Study']",
Amyotrophic Lateral Sclerosis Registry,2023-05,NOT_YET_RECRUITING,2024-12-31,SPONSOR_INVESTIGATOR,yilong Wang,yilong Wang,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,1000.0,ESTIMATED,"[{'name': 'Amyotrophic Lateral Sclerosis', 'description': 'All ALS patients included in this group.'}]",['Amyotrophic lateral sclerosis'],The study aims to include an estimated 1000 ALS patients in China.
Presymptomatic Neuromuscular Junction Defects and Compensatory Mechanisms in ALS,2022-02,UNKNOWN,2023-05-25,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,10.0,ACTUAL,"[{'name': 'Muscle biopsy', 'description': 'A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.'}]","['ALS', 'Motor Neuron', 'Neuromuscular Junction']",
Transcranial Direct Current Stimulation for Primary Progressive Aphasia,2021-06,COMPLETED,2020-03-13,SPONSOR,,University of Pennsylvania,['Primary Progressive Aphasia'],INTERVENTIONAL,16.0,ACTUAL,"[{'name': 'transcranial direct current stimulation', 'description': 'Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.'}]",,
Effects of Nocturnal Non-invasive Ventilation in Patients With Amyotrophic Lateral Sclerosis,2013-08,COMPLETED,2013-04,SPONSOR,,National Taiwan University Hospital,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,70.0,ACTUAL,"[{'name': 'non-invasive ventilation', 'description': 'CPAP, BiPAP'}]","['Amyotrophic Lateral Sclerosis', 'hypoventilation']",
Communication by Brain - Computer Interface in Amyotrophic Lateral Sclerosis:Feasibility Study,2013-05,UNKNOWN,,SPONSOR,,Centre Hospitalier Universitaire de Nice,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,20.0,ESTIMATED,[{'name': 'communication system P300 Speller'}],,
Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders,2023-03,COMPLETED,2022-09-15,SPONSOR,,Novoic Limited,"['Alzheimer Disease', 'Mild Cognitive Impairment', 'Dementia With Lewy Bodies', 'Dementia, Vascular', 'Frontotemporal Dementia', 'Primary Progressive Aphasia', 'Parkinson Disease', 'Motor Neuron Disease', 'Major Depressive Disorder', 'Bipolar Disorder', 'Amyotrophic Lateral Sclerosis']",OBSERVATIONAL,172.0,ACTUAL,,"['Speech', 'Acoustic', 'Language', 'Linguistic', 'Machine Learning', 'Artificial Intelligence']",Study population is UK-based.
R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis,2008-01,COMPLETED,2006-12,,,"Bennett, James P., Jr., M.D., Ph.D.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ACTUAL,"[{'name': 'R(+) pramipexole dihydrochloride monohydrate', 'description': '10 mg tid oral'}]","['amyotrophic lateral sclerosis', 'pramipexole', 'oxidative stress', 'neuroprotection']",
"Registry Study of Assistive Devices, Medicines and Healthcare Measures in ALS, SMA and Other Neurological Diseases.",2023-05,RECRUITING,2025-06,SPONSOR,,Ambulanzpartner Soziotechnologie APST GmbH,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,25000.0,ESTIMATED,,"['ALS Registry study', 'SMA Registry study', 'ALS medication and care registry study', 'SMA medication and care registry study', 'NfL', 'Neurofilament light chain', 'ALSFRS-R', 'ALS-App', 'ALS', 'APST Research', 'Biomarker', 'Tofersen', 'Nusinersen', 'Risdiplam']","The cohort includes patients with ALS, SMA and other chronic neurological conditions who received care with assistive devices, remedies, medications, or nursing interventions."
Expanded Access Protocol: Repeated Administration of NurownÂ® (Autologous MSC-NTF Cells) for the Treatment of ALS,2022-09,NO_LONGER_AVAILABLE,,SPONSOR,,Brainstorm-Cell Therapeutics,['Amyotrophic Lateral Sclerosis'],EXPANDED_ACCESS,,,"[{'name': 'NurOwn (MSC-NTF cells)', 'description': 'Intrathecal administration'}]",,
Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,2015-05,TERMINATED,2010-06,PRINCIPAL_INVESTIGATOR,"Albert Christian Ludolph, Prof.",University of Ulm,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,219.0,ACTUAL,"[{'name': 'pioglitazone', 'description': '45 mg/day, 18 months'}, {'name': 'placebo', 'description': 'once daily, 18 months'}]","['amyotrophic lateral sclerosis', 'survival time', 'ALS functioning Rating Scale', 'quality of life', 'non-invasive ventilation', 'clinical tolerability', 'survival']",
An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS,2024-02,ACTIVE_NOT_RECRUITING,2024-12,SPONSOR,,Clene Nanomedicine,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,40.0,ESTIMATED,"[{'name': 'CNMAu8', 'description': 'CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bi-pyramid, tetrahedron, decahedron, planar spheroids). Those choosing to participate in the OLE period will orally receive 30 mg of CNM-Au8, once daily.'}]","['ALS', 'Open-label extension']",
COMMAND Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis,2022-12,ACTIVE_NOT_RECRUITING,2024-08,SPONSOR,,"Synchron Medical, Inc.","['Neurologic Disorder', 'Paralysis', 'Paralysis; Stroke', 'Amyotrophic Lateral Sclerosis', 'Muscular Dystrophies', 'Spinal Cord Injuries', 'Stroke, Lacunar', 'Stroke Brainstem', 'Cervical Spinal Cord Injury', 'Spinal Muscular Atrophy', 'Tetraplegic; Paralysis', 'Quadriplegia/Tetraplegia']",INTERVENTIONAL,6.0,ACTUAL,"[{'name': 'Motor Neuroprosthesis (MNP)', 'description': 'Type of implantable brain computer interface'}]",,
Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients,2016-10,COMPLETED,2016-12,SPONSOR,,"University Hospital, Lille","['ALS (Amyotrophic Lateral Sclerosis)', 'Iron Overload']",INTERVENTIONAL,23.0,ACTUAL,"[{'name': 'Deferiprone', 'description': '30 mg/kg per day, oral use'}]",,
The Safety and The Efficacy Evaluation of ET-STEM in Patients With Frontotemporal Dementia,2022-10,RECRUITING,2026-12-31,PRINCIPAL_INVESTIGATOR,Hee Jin Kim,Samsung Medical Center,['Frontotemporal Dementia'],INTERVENTIONAL,12.0,ESTIMATED,"[{'name': 'ET-STEM', 'description': 'mesenchymal stem cells preconditioned with ethionamide'}]",,
Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD,2015-12,COMPLETED,2015-03,PRINCIPAL_INVESTIGATOR,Jennifer Whitwell,Mayo Clinic,"['Atypical Alzheimers Disease', 'Logopenic Variant of Primary Progressive Aphasia (LPA)', 'Posterior Cortical Atrophy (PCA)']",INTERVENTIONAL,27.0,ACTUAL,"[{'name': 'C-11 PiB', 'description': ""One time intravenous administration of \\~740 megabecquerel (MBq) of \\[N-methyl-C-11\\]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).""}]","['aphasia', 'logopenic', 'PCA', 'LPA']",
Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy,2017-11,UNKNOWN,2019-10-01,PRINCIPAL_INVESTIGATOR,Shirley Wray,Massachusetts General Hospital,"['PSP - Progressive Supranuclear Palsy', ""PD - Parkinson's Disease"", ""AD - Alzheimer's Disease"", 'ALS (Amyotrophic Lateral Sclerosis)']",OBSERVATIONAL,56.0,ESTIMATED,"[{'name': 'Pupillometry', 'description': 'Use of pupillometry to assess melanopsin-light pathway in patients with neurodegenerative diseases'}]",,Subjects diagnosed with PSP and age-matched control subjects
Support Via Technology: Living and Learning With Advancing FTD,2022-04,COMPLETED,2022-03-04,SPONSOR,,Oregon Health and Science University,"['Caregivers Burnout', 'Frontotemporal Dementia']",INTERVENTIONAL,16.0,ACTUAL,"[{'name': 'STELLA-FTD', 'description': 'Behavioral intervention for caregivers for those with FTD'}]",,
Validation of a New Device to Measure Neuromuscular Disease Progression,2011-05,COMPLETED,2010-09,,,Massachusetts General Hospital,['Amyotrophic Lateral Sclerosis & Other Neuromuscular Disorders'],OBSERVATIONAL,120.0,ESTIMATED,,"['Strength testing', 'Disease progression', 'ALS', 'Healthy Adults']",Individuals with ALS
Aerobic Exercise Training in Amyotrophic Lateral Sclerosis,2013-09,UNKNOWN,2014-06,PRINCIPAL_INVESTIGATOR,Alessandro Mezzani,Fondazione Salvatore Maugeri,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,40.0,ESTIMATED,"[{'name': 'Aerobic exercise training', 'description': 'Intensity: heart rate corresponding to 40% peak VO2. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month'}, {'name': 'Standard physical therapy (Stretching/Range-of-motion)', 'description': 'Intensity: N/A. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month'}]","['Amyotrophic lateral sclerosis', 'Aerobic training', 'Peak oxygen consumption', 'Quality of life']",
Minocycline to Treat Amyotrophic Lateral Sclerosis,2007-12,COMPLETED,2007-01,,,National Institute of Neurological Disorders and Stroke (NINDS),['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,400.0,,[{'name': 'minocycline'}],"['ALS', 'amyotrophic lateral sclerosis', 'minocycline']",
Enoxacin for Amyotrophic Lateral Sclerosis (ALS),2024-01,COMPLETED,2023-11-15,PRINCIPAL_INVESTIGATOR,Angela Genge,McGill University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,8.0,ACTUAL,"[{'name': 'Enoxacin', 'description': 'Oral 200mg tablet'}, {'name': 'Placebo', 'description': 'Oral tablet'}]",['Enoxacin'],
RT001 in Amyotrophic Lateral Sclerosis,2021-06,UNKNOWN,2022-09-30,SPONSOR,,"Retrotope, Inc.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,40.0,ESTIMATED,"[{'name': 'RT001', 'description': 'RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 5 months'}, {'name': 'Placebo', 'description': 'Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.'}]",,
"Effects of Remote-based Resistance Training on Cardiometabolic Risk Factors, Cognitive Function, and Quality of Life in Adults Living With Alzheimer's Disease and/or Related Dementias",2021-08,UNKNOWN,2022-06,PRINCIPAL_INVESTIGATOR,Michael Bruneau,Drexel University,"['Dementia', 'Alzheimer Disease', 'Dementia, Vascular', 'Lewy Body Disease', 'Frontotemporal Dementia', 'Mild Cognitive Impairment', 'Aging', 'Hypertension', 'Obesity, Abdominal', 'Obesity', 'Body Weight', 'Blood Pressure', 'Blood Glucose, High', 'Blood Glucose, Low', 'Dyslipidemias', 'Quality of Life', 'Cognitive Impairment']",INTERVENTIONAL,36.0,ESTIMATED,"[{'name': 'Remote-based Resistance Exercise Training', 'description': 'All participants enrolled in the trial will receive supervised remote-based resistance exercise training. The exercises will be performed with the use of Therabands and will include 8-10 exercises performed for 1 set of 15 repetitions, performed 3 days per week for 24 weeks.'}]",,
Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea,2015-08,COMPLETED,2014-03,SPONSOR,,Hospices Civils de Lyon,"['Sialorrhea', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,18.0,ACTUAL,"[{'name': 'Botox injection', 'description': 'Local ultrasound-guided bilateral injection of botulinum toxin type A in parotid (35 UI/gland) and submandibular (15 UI/gland) glands.'}, {'name': 'Placebo injection', 'description': 'A local ultrasound-guided bilateral injection of placebo (NaCl 0.9 %) in parotid (0.7 ml/gland) and submandibular (0.3 ml/gland) glands.'}]","['Sialorrhea', 'Amyotrophic lateral sclerosis', 'Botulinum toxin']",
Differential Study of Muscle Transcriptome,2014-06,COMPLETED,2015-01,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,"['ALS', 'SMA', 'SBMA']",INTERVENTIONAL,42.0,ACTUAL,"[{'name': 'Muscle biopsy', 'description': 'open muscular biopsy of the deltoid under local anaesthesia'}]","['ALS', 'Motor neuron diseases', 'Transcriptome']",
Intermediate-Sized Expanded Access Study,2023-06,AVAILABLE,,SPONSOR,,"Seelos Therapeutics, Inc.",['Amyotrophic Lateral Sclerosis'],EXPANDED_ACCESS,,,"[{'name': 'Trehalose', 'description': 'Once weekly 0.75g/kg administration'}]","['ALS', ""Lou Gehrig's Disease"", 'Trehalose', 'Seelos Therapeutics', 'SLS-005']",
Cerebrospinal Fluid Repository,2017-03,COMPLETED,2008-10,SPONSOR,,Drexel University College of Medicine,"['Amyotrophic Lateral Sclerosis', 'Cerebrospinal Fluid', 'Neurodegenerative Disease', 'Motor Neuron Disease']",OBSERVATIONAL,11.0,ACTUAL,,"['Amyotrophic Lateral Sclerosis', 'Cerebrospinal Fluid', 'Neurodegenerative Disease', 'Motor Neuron Disease', 'Autonomic Nervous System', 'Neurodegenerative Diseases', 'Movement Disorders']",Those undergoing a lumbar puncture for reasons unrelated to this study.
Anticipated Patient and Caregiver Burden,2024-01,RECRUITING,2025-06-22,SPONSOR,,Assistance Publique Hopitaux De Marseille,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,126.0,ESTIMATED,"[{'name': 'Psychological assessments', 'description': 'The visit will take place during a multidisciplinary assessment in the ALS Center at the Timone Hospital, Neuromuscular Disease and ALS Department. The patient will be accompanied by his/her caregiver. During this multidisciplinary assessment, the patient is present at the hospital between 8am and 4pm. The various scales and self-questionnaires can be completed during this time. The time required to complete these scales and self-questionnaires is estimated to be about 90 minutes.'}]","['amyotrophic lateral sclerosis', 'caregiver', 'burden', 'depression']",
Effects of Direct Current Brain Stimulation on Cognition,2005-10,COMPLETED,2005-10,,,National Institute of Neurological Disorders and Stroke (NINDS),['Electrical Stimulation of the Brain'],INTERVENTIONAL,170.0,,"[{'name': 'TMS'}, {'name': 'EEG'}]","['Frontal Lobe', 'Motor Cortex', 'Dementia', 'Cognition', 'Healthy Volunteer', 'HV']",
Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS,2012-05,COMPLETED,2014-12,SPONSOR,,Royan Institute,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,8.0,ACTUAL,"[{'name': 'intrathecal injection', 'description': 'Intrathecal injection of mesenchymal stem cells in patients with ALS'}]",['ALS intrathecal injection bone marrow mesenchymal stem cell'],
Remote Speech and Swallowing Assessment in ALS,2023-10,RECRUITING,2024-09,PRINCIPAL_INVESTIGATOR,Andrew Geronimo,Milton S. Hershey Medical Center,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,170.0,ESTIMATED,"[{'name': 'Digital recording of speech and swallow sounds using the Beiwe Digital Health App on a personal smartphone', 'description': '\\[Patients only\\] Weekly completion of audio recordings of speech and swallowing performed at home by the subject using the study smartphone application on their personal device.'}, {'name': 'Modified Barium Swallow Study (MBSS)', 'description': '\\[Patients only\\] MBSS is an instrumented evaluation of oropharyngeal swallowing function that is performed using videofluoroscopy.'}, {'name': 'Speech Intelligibility Test (SIT)', 'description': '\\[Patients only\\] The SIT is a standardized test for measuring speech intelligibility.'}, {'name': 'SIT Scoring', 'description': '\\[Listeners only\\] Listeners will judge the intelligibility of speech recordings made by patients in the study.'}]","['telemonitoring', 'digital health', 'mobile health', 'dysphagia', 'dysarthria']",Population 1: Patients with ALS Population 2: Healthy Listeners
Determinants of Disease Severity in Amyotrophic Lateral Sclerosis,2001-01,UNKNOWN,,,,National Institute of Neurological Disorders and Stroke (NINDS),['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,75.0,,,"['amyotrophic lateral sclerosis', 'motor neuron disease', 'neurologic and psychiatric disorders', 'rare disease']",
Nabilone for Agitation in Frontotemporal Dementia,2023-10,ACTIVE_NOT_RECRUITING,2025-12,SPONSOR_INVESTIGATOR,"Simon Ducharme, MD","Simon Ducharme, MD","['Frontotemporal Dementia', 'Frontotemporal Dementia, Behavioral Variant', 'Primary Progressive Aphasia', 'bvFTD', 'PPA', 'FTD']",INTERVENTIONAL,45.0,ESTIMATED,"[{'name': 'Nabilone', 'description': ""Nabilone is a synthetic cannabinoid that has shown benefit for agitation in Alzheimer's disease. Nabilone further has potentially beneficial properties on oxidative stress and inflammation in neurodegenerative diseases, mechanisms that have been linked to the pathophysiology of frontotemporal dementia.""}, {'name': 'Placebo', 'description': 'The placebo is a capsule identical to the nabilone capsules that will be used in this clinical trial.'}]","['Nabilone', 'Nabilone FTD', 'Agitation', 'TEVA Nabilone', 'Dementia', 'BvFTD', 'FTD']",
The Association Between Technical and Non-technical Skills in Real-life ALS Situations. Impact of Pit Crew Model on the Resuscitation Skills.,2021-06,COMPLETED,2020-09,SPONSOR,,Turku University Hospital,['Cardiac Arrest'],OBSERVATIONAL,37.0,ACTUAL,"[{'name': 'Pit crew model education', 'description': 'A pit crew model for resuscitation is educated to all resuscitation team members.'}]","['non-technical skills (NTS)', 'human factors', 'team work', 'Crew Resource Management / Crisis Resource Management (CRM)', 'technical skills (TS)', 'Cardiopulmonary resuscitation', 'Advanced cardiac life support', 'Pit Crew Model']","The target group of this study is the resuscitation team of the adult ICU of Turku University Central Hospital. This team consists of an ICU doctor (most commonly an anaesthesiologist specialized for intensive care), two ICU nurses and one medical technician."
A Study of Monepantel in Individuals With Motor Neurone Disease,2023-12,COMPLETED,2023-11-29,SPONSOR,,PharmAust Ltd,['Motor Neuron Disease'],INTERVENTIONAL,12.0,ACTUAL,"[{'name': 'Monepantel', 'description': 'Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals'}]",,
"A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS",2012-02,COMPLETED,2007-01,SPONSOR,,CytRx,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,80.0,,[{'name': 'arimoclomol'}],,
Study of Hepatic Function in Patients With Spinal and Bulbar Muscular Atrophy,2022-08,COMPLETED,2020-11-19,SPONSOR,,National Institute of Neurological Disorders and Stroke (NINDS),"['Spinal and Bulbar Muscular Atrophy (SBMA)', 'Motor Neuron Disease']",OBSERVATIONAL,71.0,ACTUAL,,"['Liver', 'Motor Neuron Disease', 'Natural History']","We plan to enroll men with genetically confirmed SBMA, age-matched healthy control men, SBMA carrier women, age-matched healthy control women and males with other motor neuron disease patients as disease controls."
Neurobiological and Immunological Mechanisms of Dyspnea in ALS (BIOPNEA),2022-02,NOT_YET_RECRUITING,2024-10,SPONSOR,,Association pour le DÃ©veloppement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil,"['Shortness of Breath', 'Dyspnea', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'biological test', 'description': 'dyspnea evaluation, ventilatory evaluation and biological test before and after non invasive ventilation'}]",,
Italian Validation of the Beaumont Behavioural Inventory (BBI),2021-10,COMPLETED,2020-11-30,SPONSOR,,Istituti Clinici Scientifici Maugeri SpA,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,190.0,ACTUAL,"[{'name': 'BBI', 'description': 'administration of psychometric test'}]",['ALS; frontotemporal degeneration; behavioural changes.'],Subject with amyotrophic lateral sclerosis
Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,2018-05,COMPLETED,2017-12-12,SPONSOR,,"Neuraltus Pharmaceuticals, Inc.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,138.0,ACTUAL,"[{'name': 'NP001'}, {'name': 'Placebo'}]","['ALS', 'Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease', 'Central Nervous System Diseases', 'Nervous System Diseases', 'Neurodegenerative Diseases', 'Neuromuscular Diseases', 'Inflammation', 'C-Reactive Protein']",
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease,2018-06,UNKNOWN,2019-08,SPONSOR,,Stem Cells Arabia,"['Motor Neuron Disease', 'Amyotrophic Lateral Sclerosis', 'Primary Lateral Sclerosis', 'Progressive Muscular Atrophy', 'Progressive Bulbar Palsies']",INTERVENTIONAL,40.0,ESTIMATED,"[{'name': 'Stem Cells', 'description': 'Autologous bone marrow-derived stem cell populations injected via the intravenous and intrathecal routes.'}]",,
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation,2023-05-25,COMPLETED,,SPONSOR,,National Institute of Neurological Disorders and Stroke (NINDS),"['Amyotrophic Lateral Sclerosis', 'Frontotemporal Lobar Degeneration']",OBSERVATIONAL,50.0,ACTUAL,,"['Motor Neuron Disease', 'Frontotemporal Dementia', 'Cognitive Testing', 'Magnetic Resonance Imaging (MRI)', 'Transcranial Magnetic Stimulation (TMS)', 'Natural History']",Participants with C9ORF72 mutation
A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia,2011-01,COMPLETED,2004-07,,,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","['Frontotemporal Dementia', 'Pick Complex']",INTERVENTIONAL,41.0,ACTUAL,[{'name': 'galantamine hydrobromide'}],"['Frontotemporal Dementia', 'Pick Complex', 'galantamine hydrobromide']",
Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients,2015-11,UNKNOWN,2018-11,SPONSOR,,Assistance Publique Hopitaux De Marseille,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,100.0,ESTIMATED,"[{'name': 'ALS Functional rating Scale-revised (ALS FRS-R)'}, {'name': 'slow vital capacity'}, {'name': 'Blood sample'}, {'name': 'Cerebrospinal Fluid (CSF) sample'}]",,
Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen in Norway: A Prospective Cohort Study,2022-03,RECRUITING,2022-12-31,SPONSOR,,Haukeland University Hospital,"['Amyotrophic Lateral Sclerosis', 'Cognitive Impairment']",OBSERVATIONAL,50.0,ESTIMATED,"[{'name': 'ECAS-N', 'description': 'assessing ALS-specific cognitive impairment'}, {'name': 'MoCA', 'description': 'assessing cognitive impairment'}, {'name': 'CDR', 'description': 'assessing global cognitive impairment, as well as possible diagnosis- and Level of dementia'}, {'name': 'Questionnaire', 'description': 'Questions related to work situation and car driving'}]","['Amyotrophic Lateral Sclerosis', 'Cognitive', 'Predictor']",Patients who fullfill the inclusion criteria and attending to the ALS-clinic at HUH within 4 months after being diagnosed with ALS.
A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS),2022-10,COMPLETED,2023-01-31,SPONSOR,,Amylyx Pharmaceuticals Inc.,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,28.0,ACTUAL,"[{'name': 'AMX0035', 'description': 'Tauroursodeoxycholic Acid and Sodium Phenylbutyrate orally given twice a day'}]",,
"BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES",2019-12,TERMINATED,2019-12-13,PRINCIPAL_INVESTIGATOR,Adam Boxer,"University of California, San Francisco","['Primary Tauopathies', 'Corticobasal Degeneration Syndrome', 'Frontotemporal Lobar Degeneration With Tau Inclusions', 'MAPT Mutation Carriers, Symptomatic', 'Traumatic Encephalopathy Syndrome', 'Nonfluent Aphasia, Progressive']",INTERVENTIONAL,22.0,ACTUAL,"[{'name': 'BIIB092', 'description': 'BIIB092 is an investigational monoclonal antibody directed at tau protein'}, {'name': 'Placebo', 'description': 'Inactive ingredient'}]","['CBS, CBD, nfvPPA, FTD, sMAPT, TES']",
Relationship Between Respiratory Functional Tests and Image Thoracic Techniques in Patients With Neuromuscular Diseases,2014-02,COMPLETED,2013-07,SPONSOR,,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,5.0,ACTUAL,"[{'name': 'No intervention', 'description': 'We perform in all patients respiratory functional tests, thoracic x-ray, SNIF test and diaphragmatic magnetic resonance imaging.'}]","['Diaphragmatic force', 'mobility']",Patients with amyotrophic lateral sclerosis.
A Relational Research Recruitment and Engagement Intervention for Cognitive Aging Research,2024-01,COMPLETED,2023-05-31,SPONSOR,,"University of Wisconsin, Madison","['Dementia', 'Cognitive Dysfunction', 'Alzheimer Disease', 'Lewy Body Disease', 'Frontotemporal Dementia']",INTERVENTIONAL,182.0,ACTUAL,"[{'name': 'Relational Research Recruitment and Engagement Intervention', 'description': '* Specified recruiter/point of contact\n* Flexibility in study time, place, method of recruitment (preferred participant email, phone), and follow-up (in registry, if participant calls back at all restart 3 failed phone contacts)\n* Resource matching (financial, transportation constraints)'}]","['Recruitment Intervention', 'Recruitment Science', ""Alzheimer's Disease Research Participation""]",
Clinical Trial Nuedexta in Subjects With ALS,2017-02,COMPLETED,2015-03,PRINCIPAL_INVESTIGATOR,"Richard A. Smith, MD","Center for Neurologic Study, La Jolla, California,",['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,90.0,ACTUAL,"[{'name': 'Nuedexta', 'description': 'Nuedexta PO (by mouth) for 28 Â± 3 days'}, {'name': 'Matching Placebo', 'description': 'matching placebo PO (by mouth) for 28 Â± 3 days'}]","['Amyotrophic lateral sclerosis', 'ALS', 'Nuedexta', 'Bulbar function', 'motor neurons']",
"Far Infrared Irradiation for Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS)",2009-08,UNKNOWN,2010-06,,,GAAD Medical Research Institute Inc.,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,7.0,ACTUAL,"[{'name': 'Far Infrared Radiation (5Î¼m to 20Î¼m wavelength)', 'description': 'Radiation: Far Infrared Radiation (5Î¼m to 20Î¼m wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.'}, {'name': 'Far infrared radiation', 'description': 'Far infrared radiation at a frequency of 5 microns to 20 microns for 30 to 40 minutes per session.'}]","['ALS (Amyotrophic Lateral Sclerosis)', 'Amyotrophic Lateral Sclerosis With Dementia', 'Amyotrophic Lateral Sclerosis, Guam Form', 'Dementia With Amyotrophic Lateral Sclerosis', ""Gehrig's Disease"", 'Guam Form of Amyotrophic Lateral Sclerosis', 'Lou Gehrig Disease']",
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS,2023-11,RECRUITING,2024-12,SPONSOR,,MediciNova,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,230.0,ESTIMATED,"[{'name': 'MN-166', 'description': 'Subjects will take MN-166 for 12 months followed by a 6-month open-label extension phase.'}, {'name': 'placebo', 'description': 'Subjects will take matching placebo for 12 months followed by a 6-month open-label extension phase.'}]","['ALS', 'MN-166', 'ibudilast', 'amyotrophic lateral sclerosis']",
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,2024-02-07,RECRUITING,2025-10-30,SPONSOR,,National Institute of Neurological Disorders and Stroke (NINDS),"['Frontotemporal Dementia', 'Amyotrophic Lateral Sclerosis', 'Progressive Supranuclear Palsy']",OBSERVATIONAL,300.0,ESTIMATED,,"['TDP-43', 'Progressive Supranuclear Palsy', 'Motor Neuron Disease', 'Frontotemporal Dementia', 'Corticobasal Syndrome', 'Natural History']","Adults with a diagnosis of ALS, FTD, or a related adult-onset neurodegenerative disorder"
Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials,2014-09,COMPLETED,2012-03,PRINCIPAL_INVESTIGATOR,Seward Rutkove,Beth Israel Deaconess Medical Center,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,89.0,ACTUAL,,"['amyotrophic lateral sclerosis', 'motor neuron disease', 'outcome measure', 'biomarker', 'impedance']",Patients with amyotrophic lateral sclerosis (ALS)
VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease,2023-02,COMPLETED,2018-03-28,SPONSOR,,Mandos LLC,"['Niemann-Pick Disease, Type C']",INTERVENTIONAL,56.0,ACTUAL,"[{'name': 'Parts A/B: Adrabetadex', 'description': '900 - 1800 milligram (mg) of adrabetadex administered every 2 weeks via lumbar intrathecal infusion'}, {'name': 'Parts A/B: Sham Control', 'description': 'No experimental drug is administered to participants - intrathecal administrations are simulated by skin prick'}]","['Niemann-Pick Type C1 (NPC1) Disease', 'neurologic disease', 'gross motor dysfunction', 'fine motor dysfunction', 'dysphagia', 'swallowing problems', 'cognitive dysfunction', 'gait abnormalities', 'pediatrics']",
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,2008-09,TERMINATED,2007-06,,,Assistance Publique - HÃ´pitaux de Paris,"['Frontotemporal Dementia', 'Amyotrophic Lateral Sclerosis']",OBSERVATIONAL,400.0,ACTUAL,,"['Amyotrophic lateral sclerosis', 'Frontotemporal dementia', 'Mutations spectrum', 'Linkage studies', 'Genetic epidemiology']",Patients and relatives coming in outcome clinics. They are all volunteers and agree to give a blood sample and signing an informed consent explaining the study.
Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease,2007-08-15,COMPLETED,2007-08-15,,,National Eye Institute (NEI),['Niemann Pick Diseases'],INTERVENTIONAL,30.0,,[{'name': 'OGT918'}],"['Eye Movement', 'Niemann Pick C']",
Study of Safety and of the Mechanism of BLZ945 in ALS Patients,2023-07,RECRUITING,2026-05-08,SPONSOR,,Novartis Pharmaceuticals,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,56.0,ESTIMATED,"[{'name': 'BLZ945', 'description': 'Investigational drug'}]","['PET', 'ALS', 'Microglia', 'CSF']",
Communication Bridge 3 Study,2024-01,NOT_YET_RECRUITING,2028-09,SPONSOR,,University of Chicago,['Primary Progressive Aphasia'],INTERVENTIONAL,200.0,ESTIMATED,"[{'name': 'Communication Bridgeâ„¢', 'description': 'Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.'}, {'name': 'Evidence-Based Impairment Focused', 'description': 'Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.'}]","['Aphasia', 'Dementia', 'Communication', 'Frontotemporal Dementia', 'Alzheimer Disease']",
Amyotrophic Lateral Sclerosis Web Based Patient Care Database: ALSConnection.Org,2010-02,COMPLETED,2010-02,,,Forbes Norris MDA/ALS Research Center,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,15000.0,ESTIMATED,[{'name': 'ALS Registry'}],['Amyotrophic Lateral Sclerosis'],Any patient diagnosed with ALS by a licensed physician.
Methodology Study of Novel Outcome Measures to Assess Progression of ALS,2019-10,COMPLETED,2019-08-01,SPONSOR,,Biogen,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,138.0,ACTUAL,,,Participants suffering from ALS are recruited by participating physicians in a standard clinical practice setting.
Gilenya in Amyotrophic Lateral Sclerosis (ALS),2016-06,COMPLETED,2015-05,PRINCIPAL_INVESTIGATOR,James D. Berry MD,Massachusetts General Hospital,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ACTUAL,"[{'name': 'Gilenya', 'description': '0.5mg Gilenya orally by mouth once daily for approximately 28 days'}, {'name': 'Placebo', 'description': '0.5mg placebo (sugar pill) orally by mouth once daily for approximately 28 days'}]","['ALS', 'Gilenya', 'Fingolimod']",
Screening and Natural History: Primary Lateral Sclerosis and Related Disorders,2019-04-24,COMPLETED,2019-04-24,SPONSOR,,National Institute of Neurological Disorders and Stroke (NINDS),['Primary Lateral Sclerosis'],OBSERVATIONAL,189.0,ACTUAL,,"['Apparently Sporadic Spastic Paraplegia', 'Spasticity', 'Motor Neuron Disease', 'Amyotrophic Lateral Sclerosis', 'Primary Lateral Sclerosis', 'Muscle Stiffness', 'Involuntary Muscle Contraction', 'Isaacs Syndrome']",
Multimodal Ocular Imaging in Neurodegeneration,2022-03,COMPLETED,2019-04-03,PRINCIPAL_INVESTIGATOR,Cagri Besirli,University of Michigan,"['Alzheimer Disease', 'Alzheimer Dementia', 'Frontotemporal Dementia']",OBSERVATIONAL,16.0,ACTUAL,"[{'name': 'Spectral-Domain Optical Coherence Tomography (SD-OCT)', 'description': 'Each participant in this study will undergo Optical coherence tomography (OCT), a non-invasive imaging test of the eye, one time. OCT uses light waves to take cross-section pictures of the retina, which are generated using scattered light waves.'}, {'name': 'Magnetic Resonance Imaging (MRI)', 'description': 'Each participant in this study will undergo a single Magnetic resonance imaging (MRI) scan, a scanning technique for creating detailed images of the human body. The scan uses a magnetic field and radio waves to generate images of the brain.'}, {'name': 'Positron Emission Tomography (PET)', 'description': 'Each participant in this study will undergo a single Positron emission tomography (PET) scan of the brain. PET is a nuclear medicine functional imaging technique that is used to observe metabolic processes in the brain as an aid to the diagnosis of disease using the combination of a radioactive tracer, camera, and a computer.'}, {'name': 'Comprehensive Ophthalmic Examination', 'description': ""Each participant in this study will receive one comprehensive eye examination which will be performed by a licensed ophthalmologist at the University of Michigan. This examination will include the assessment of the participant's visual acuity, a slit lamp examination which will look at the anterior and posterior tissues of the eye including the retina using various lights and lenses, and intraocular pressures.""}, {'name': 'Fundus Photography', 'description': 'Each participant in this study will undergo fundus photography of each eye. Fundus photography involves the use of a retinal camera coupled with a low power microscope to capture photographs of the retina.'}]","['FTD', 'Dementia', 'Retina']","Patients are recruited with mid-to-late stage AD and FTD, as well as age-matched healthy controls, using the extensive database of research participants maintained by the Michigan Alzheimer's Disease Center (MADC)."
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients,2023-02,NOT_YET_RECRUITING,2025-07,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,"['Walking Capacity', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,36.0,ESTIMATED,"[{'name': 'Salbutamol', 'description': 'Salbutamol for 6 months'}, {'name': 'Placebo', 'description': 'Placebo Syrup for 6 months'}]","['Amyotrophic Lateral Sclerosis', 'Walking capacity', 'Salbutamol', 'Ventolin']",
Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases,2023-03,RECRUITING,2025-12,PRINCIPAL_INVESTIGATOR,"Matthew E. R. Butchbach, Ph.D.",Nemours Children's Clinic,"['Spinal Muscular Atrophy', 'Charcot-Marie-Tooth Disease', 'Muscular Dystrophy', 'Spinal Muscular Atrophy With Respiratory Distress 1', 'Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease', 'Neuromuscular Disease', 'Peroneal Muscular Atrophy']",OBSERVATIONAL,300.0,ESTIMATED,"[{'name': 'sample collection', 'description': 'collection of blood'}]",['distal hereditary motor neuronopathy'],This study will enroll children diagnosed with a motor neuron or neuromuscular disease as well as their parents and/or siblings as well as adults with childhood-onset motor neuron or neuromuscular diseases.
Breath Stacking Technique Associated With Expiratory Muscle Training in Amyotrophic Lateral Sclerosis Patients,2023-04,TERMINATED,2022-12-01,PRINCIPAL_INVESTIGATOR,Vinicius Zacarias Maldaner da silva,Escola Superior de Ciencias da Saude,"['Amyotrophic Lateral Sclerosis', 'Neuromuscular Diseases']",INTERVENTIONAL,50.0,ACTUAL,"[{'name': 'Breath Stacking Group', 'description': 'Lung recruitment technique using manual bag resuscitation with oronasal mask interface'}, {'name': 'Breath stacking and EMT', 'description': 'Lung recruitment technique with one way valve with counter resistance during all expiratory phase'}]","['respiratory function tests', 'deglution disorders']",
ECoG Direct Brain Interface for Individuals With Upper Limb Paralysis,2016-10,COMPLETED,2015-04,PRINCIPAL_INVESTIGATOR,"Jennifer Collinger, PhD",University of Pittsburgh,"['Tetraplegia', 'Spinal Cord Injury', 'Brachial Plexus Injury', 'Muscular Dystrophy', 'ALS', 'Brainstem Stroke']",INTERVENTIONAL,6.0,ACTUAL,"[{'name': 'Implantation of ECoG sensors on the brain surface', 'description': 'One ECoG sensor will be implanted over the motor cortex of study participants'}]","['Electrocorticography', 'Tetraplegia', 'Spinal cord injury', 'Brainstem stroke', 'Neuroprosthetic', 'Brain-computer interface', 'Direct brain interface', 'Neural activity', 'Motor cortex']",
Tamoxifen Treatment in Patients With Motor Neuron Disease,2014-06,COMPLETED,2019-09-18,SPONSOR,,Taipei Medical University Shuang Ho Hospital,"['Amyotrophic Lateral Sclerosis', 'ALS Functional Ration Scale', 'TAR-DNA-binding Protein-43', 'Tamoxifen', 'mTOR']",INTERVENTIONAL,20.0,ACTUAL,"[{'name': 'tamoxifen 40 mg daily for one year', 'description': 'both arms with riluzole daily'}]","['amyotrophic lateral sclerosis', 'ALS functional ration scale', 'TAR-DNA-binding protein-43', 'tamoxifen', 'mTOR']",
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS,2023-06,TERMINATED,2022-10-28,SPONSOR,,Alector Inc.,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,5.0,ACTUAL,"[{'name': 'AL001', 'description': 'Administered via intravenous (IV) infusion'}, {'name': 'Placebo', 'description': 'Administered via intravenous (IV) infusion'}]",,
Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease,2021-07,COMPLETED,2017-03,SPONSOR,,"Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company","['Niemann-Pick Disease, Type C1']",INTERVENTIONAL,14.0,ACTUAL,[{'name': 'VTS-270'}],"['2-Hydroxypropyl-B-Cyclodextrin', 'Niemann-Pick Disease, Type C1', 'Neurodegeneration']",
Lower Extremity Fixation In Neuropathic Patients Study,2023-06,TERMINATED,2022-10-28,SPONSOR,,Stryker Trauma GmbH,"['Neuropathy', 'Charcot; Disease (Etiology)']",OBSERVATIONAL,41.0,ACTUAL,"[{'name': 'SALVATIONâ„¢ EXTERNAL FIXATION', 'description': ""Wright Medical's lower extremity devices used to treat neuropathic patients""}]",,"Neuropathic Patients treated/implanted with SALVATIONâ„¢ External Fixation, SALVATIONâ„¢ Fusion Bolts and Beams, SALVATIONâ„¢ Midfoot Nail, The SALVATIONâ„¢ 3Di Plating System, and/or VALORâ„¢ NAIL"
"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",2021-07,COMPLETED,2013-07,SPONSOR,,Knopp Biosciences,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,74.0,ACTUAL,"[{'name': 'KNS-760704', 'description': '150 mg Q12H KNS-760704 given orally (300 mg total daily dose)'}]","['ALS', 'Amyotrophic Lateral Sclerosis', 'Lou Gehrig', ""Lou Gehrig's"", ""Lou Gehrig's disease"", 'Motor Neuron Disease', 'Nervous System Diseases', 'KNS-760704', 'RTPB']",
CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS,2024-02,RECRUITING,2025-09,PRINCIPAL_INVESTIGATOR,Clive Svendsen,Cedars-Sinai Medical Center,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,16.0,ESTIMATED,"[{'name': 'CNS10-NPC-GDNF', 'description': 'Unilateral injections of CNS10-NPC-GDNF into the motor cortex'}]","['ALS', 'Stem cells', 'Growth Factor', 'Regenerative', 'Neural Progenitor Cells', 'NPC', 'Transplantation']",
"The Music, Sleep and Dementia Study",2021-01,COMPLETED,2021-01-12,PRINCIPAL_INVESTIGATOR,"Darina Petrovsky, PhD, RN",University of Pennsylvania,"['Dementia', 'Alzheimer Disease', 'Circadian Rhythm Disorders', 'Circadian Rhythm Sleep Disorder', 'Insomnia', 'Hypersomnia', 'Cognitive Impairment', 'Cognitive Decline', 'Mild Cognitive Impairment', 'Frontotemporal Dementia', 'Neurocognitive Disorders', 'Vascular Dementia', 'Sleep Disorder', 'Memory Impairment']",INTERVENTIONAL,32.0,ACTUAL,"[{'name': 'Tailored music listening intervention', 'description': 'The music intervention consists of listening to preferred soothing music at bedtime for 30 minutes every night for four weeks (28 sessions total). This theory based caregiver-assisted intervention builds on the evidence-based protocol of using individualized music to decrease agitation in nursing home residents. It also accounts for sleep-inducing properties of music.'}]",,
"Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis",2023-07,RECRUITING,2024-09-30,SPONSOR,,Zydus Lifesciences Limited,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,24.0,ESTIMATED,"[{'name': 'ZYIL1 capsules 25 mg and 50 mg Placebo', 'description': 'ZYIL1 capsules 25 mg for oral administration + matching placebo of 50 mg ZYIL1 capsule'}, {'name': 'ZYIL1 capsules 50 mg and 25 mg Placebo', 'description': 'ZYIL1 capsules 50 mg for oral administration + matching placebo of 25 mg ZYIL1 capsule'}, {'name': 'ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg', 'description': 'ZYIL1 capsules 25 mg for oral administration + ZYIL1 capsules 50 mg for oral administration'}, {'name': 'Matching placebo 25 mg and Matching placebo 50 mg', 'description': 'Matching placebo of 25 mg ZYIL1 capsule + Matching placebo of 50 mg ZYIL1 capsule'}]",,
"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",2020-08,COMPLETED,2019-03-07,SPONSOR,,Cytokinetics,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,458.0,ACTUAL,"[{'name': 'Reldesemtiv', 'description': 'Oral tablet'}, {'name': 'Placebo', 'description': 'Oral tablet'}]","['Amyotrophic Lateral Sclerosis', 'ALS', 'CK-2127107', 'Reldesemtiv']",
Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,2011-01,COMPLETED,2007-05,,,Columbia University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,86.0,ACTUAL,"[{'name': 'Celecoxib', 'description': 'Celecoxib 400 mg BID with creatine 10 g BID if randomized to the Celecoxib + Creatine study arm.'}, {'name': 'Creatine', 'description': '10 g BID for either study arm'}, {'name': 'Minocycline', 'description': 'Minocycline 100 mg BID with creatine 10 g BID if randomized to the Minocycline + Creatine study arm'}]","['Amyotrophic Lateral Sclerosis', 'Celecoxib', 'Creatine', 'Minocycline', 'Combination', 'Selection', 'ALS', 'Motor Neuron Disease']",
Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS),2011-07,COMPLETED,2008-10,PRINCIPAL_INVESTIGATOR,Michele Vitacca,Fondazione Salvatore Maugeri,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,40.0,ACTUAL,"[{'name': 'telesurveillance', 'description': 'A telesurveillance program for cough assistance will be approched by the use of an in-exoflator device. Measurement of oxygen saturation (SpO2) will be performed by a Nonin 9500 oxymeter (Minneapolis Plymouth USA).'}]","['home care', 'home rehabilitation', 'telemedicine', 'ALS']",
Safety and Tolerability Study of VTS-270 in Pediatric Participants With Niemann-Pick Type C (NPC) Disease,2020-07,WITHDRAWN,2022-10-30,SPONSOR,,"Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company","['Niemann-Pick Disease, Type C']",INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'VTS-270', 'description': 'VTS-270 200 mg/mL administered as described in the arm group description.'}]",,
Non-invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Using the iVAPS Mode,2020-02,COMPLETED,2019-12,SPONSOR_INVESTIGATOR,Marta Kaminska,Marta Kaminska,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,30.0,ACTUAL,"[{'name': 'Non-invasive home ventilation', 'description': 'A ventilator and mask will be provided to patients according to standard procedures used at the National Program of Home Ventilatory Assistance of the Montreal Chest Institute, adjusted during a daytime outpatient trial, with close follow-up as described in study protocol.'}]","['amyotrophic lateral sclerosis', 'non-invasive ventilation', 'home ventilation', 'IVAPS', 'neuromuscular diseases']",
Remote Home Assessment of Patients With Amyotrophic Lateral Sclerosis,2023-08,RECRUITING,2024-02-01,SPONSOR,,King's College London,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,20.0,ESTIMATED,,,Patients with a diagnosis of amyotrophic lateral sclerosis recruited through King's College Hospital's Motor Nerve Clinic
Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA,2023-11,RECRUITING,2027-10-31,SPONSOR,,Johns Hopkins University,"['Logopenic Progressive Aphasia', 'Primary Progressive Aphasia']",INTERVENTIONAL,60.0,ESTIMATED,"[{'name': 'High-definition active tDCS (HD-tDCS) + ""Repeat After Me"" (RAM) Treatment', 'description': 'Device: Active HD-tDCS \\& ""Repeat After Me"" (RAM) Treatment\n\nStimulation will be delivered by a battery-driven constant current stimulator. Electrical current will be administered to left supramarginal gyrus (L_SMG). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.\n\nParticipants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay.'}, {'name': 'Sham + ""Repeat After Me"" (RAM) Treatment', 'description': 'Device: Sham Current will be administered in a ramp-like fashion but after the ramping phase the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.\n\nParticipants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay.'}]","['transcranial direct current stimulation (tDCS)', 'neurodegeneration', 'verbal short-term memory', 'non-fluent variant', 'logopenic variant', 'primary progressive aphasia']",
Home Care Needs and Current Nursing Status of Patients With Amyotrophic Lateral Sclerosis,2021-07,UNKNOWN,2022-12-31,SPONSOR,,Peking University Third Hospital,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,252.0,ESTIMATED,"[{'name': 'survey', 'description': 'The general information, home care status and functional status of ALS patients and family caregivers were collected.'}]",,"The outpatients, inpatients, discharged patients and their caregivers of ALS in a general hospital in Beijing."
Optimizing NIPPV Use for Patients With ALS,2016-01,COMPLETED,2011-12,PRINCIPAL_INVESTIGATOR,Steven M. Albert,University of Pittsburgh,['ALS'],INTERVENTIONAL,31.0,ACTUAL,"[{'name': 'Data Card Report', 'description': 'Patients received detailed report of acceptance and adherence base don data card information, with linked recommendations, to optimize use.'}]","['ALS', 'nasal ventilation', 'data card recording']",
A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD),2023-12,NOT_YET_RECRUITING,2029-01-02,SPONSOR,,Sanofi,"['Niemann-Pick Diseases', 'Acid Sphingomyelinase Deficiency']",OBSERVATIONAL,10.0,ESTIMATED,"[{'name': 'Olipudase alfa', 'description': 'This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.'}]",,"All children under the age of 2 years with a documented ASMD diagnosis as shown by ASM deficiency in a cell-based assay (peripheral leukocytes, cultured fibroblasts, or lymphocytes) and/or by genotype determination will be considered for enrollment into this ASMD study."
Therapeutic Treatment of Amyotrophic Lateral Sclerosis,2016-08,UNKNOWN,2018-12,PRINCIPAL_INVESTIGATOR,Wojciech Maksymowicz,University of Warmia and Mazury,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'Biological: Cell-based therapy', 'description': ""Human allogeneic Wharton's jelly-derived mesenchymal stem cell transplantation in ALS patients.""}]",,
Effects of Brain Stimulation on Learning and Reasoning,2003-12,COMPLETED,2003-12,,,National Institute of Neurological Disorders and Stroke (NINDS),"['Cerebellar Disease', 'Dementia', 'Healthy', ""Parkinson's Disease""]",OBSERVATIONAL,122.0,,[{'name': 'Cadwell Rapid Rate Magnetic Stimulator'}],"['Magnetic Stimulation', 'Plasticity', 'SRTT', 'Sequence', 'Implicit Memory', 'Explicit Memory', 'Memory', ""Parkinson's Disease"", 'Cerebellar Deficit', 'Frontal Lobe Lesions', 'Frontal Lobe Dementia', 'Normal Volunteer']",
Colchicine for Amyotrophic Lateral Sclerosis,2023-02,COMPLETED,2023-01-03,PRINCIPAL_INVESTIGATOR,JESSICA MANDRIOLI,Azienda Ospedaliero-Universitaria di Modena,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,54.0,ACTUAL,"[{'name': 'Colchicine 1 MG Oral Tablet', 'description': 'Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (\\>70 kg or \\<71 kg) for 30 weeks of duration.'}, {'name': 'Colchicine 1 MG Oral Tablet', 'description': 'Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (\\>70 kg or \\<71 kg) for 30 weeks of duration.'}, {'name': 'Placebo Oral Tablet', 'description': 'Corresponding tablets for 30 weeks'}]","['amyotrophic lateral sclerosis', 'stress granules', 'HSPB8', 'protein quality control', 'colchicine', 'ALSFRS-r', 'survival', 'safety']",
Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study,2020-02,COMPLETED,2019-01-10,SPONSOR_INVESTIGATOR,Edward Kasaraskis,Edward Kasaraskis,['Familial Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,6.0,ACTUAL,"[{'name': 'Betamethasone sodium phosphate/betamethasone acetate (CelestoneÂ® SoluspanÂ®), 30 mg IM once a day for four days', 'description': 'Participants will be given four IM injections throughout the study'}]",,
Predictive Factors for the Diagnosis of Early Noninvasive Ventilation Equipment,2021-08,UNKNOWN,2022-12-14,SPONSOR,,"University Hospital, Toulouse",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,100.0,ESTIMATED,"[{'name': 'diagnosis variables', 'description': ""The study compare the diagnostic variables in patients who received Non invasive ventilation equipment one year after diagnosis with the patient who don't need it. For the independent variables, the present study determine a threshold at the diagnosis for which an early fitting risk appears\n\nThe diagnostic variable are :\n\n* Age of the patient\n* Sex\n* Presence of bulbar involvement or not\n* Time from onset of first symptoms to diagnosis of ALS\n* Score ALSFRS-R\n* Presence of another underlying respiratory pathology (COPD, asthma ...)\n* FVC measurement (Forced vital capacity)\n* PaCO2 measurement\n* Measure SNIP (Sniff nasal inspiratory pressure)\n* Measure of Pimax (Pressure inspiratory maximal)\n* Measurement of the nocturnal desaturation index (number of desaturation less than 90% per hour of sleep)""}]",['diagnostic criteria'],
Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension,2023-02,TERMINATED,2020-11-18,SPONSOR,,"Orion Corporation, Orion Pharma",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,227.0,ACTUAL,"[{'name': 'Levosimendan', 'description': 'Levosimendan 1 mg capsule for oral administration'}]",,
Brain Study of Patients With Frontal Lobe Dementia and Parkinsonian Disorders,2012-12-17,TERMINATED,2012-12-17,,,National Institute of Neurological Disorders and Stroke (NINDS),"[""Alzheimer's Disease"", 'Dementia', ""Down's Syndrome""]",OBSERVATIONAL,597.0,ACTUAL,,"[""Alzheimer's Disease"", 'Cerebral Metabolism', 'Cerebrospinal Fluid', 'Dementia of the Alzheimer Type', '18-F-Fluoro-2-Deoxy-D-Glucose (FDG)', 'Magnetic Resonance Imaging', 'Positron Emission Tomography', 'X-Ray Computed Tomography (CT)', 'Senile Dementia', 'Down Syndrome', 'Trisomy 21']",
Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation,2019-07,COMPLETED,2012-01,SPONSOR_INVESTIGATOR,Edward Kasaraskis,Edward Kasaraskis,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,153.0,ACTUAL,"[{'name': 'Early NIPPV', 'description': 'Early intervention with non-invasive positive pressure ventilation (NIPPV) at 80% forced vital capacity (FVC).'}, {'name': 'Standard NIPPV', 'description': 'Standard of care non-invasive positive pressure ventilation (NIPPV) at 50% forced vital capacity (FVC).'}]","['amyotrophic lateral sclerosis', 'ALS', ""Lou Gehrig's disease"", 'nutrition', 'NIPPV', 'non-invasive positive pressure ventilation', 'percutaneous endoscopic gastrostomy', 'PEG']",
Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis,2022-11,WITHDRAWN,2025-01,SPONSOR,,"Samus Therapeutics, Inc.",['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'PU-AD', 'description': 'active vs placebo'}, {'name': 'Placebo', 'description': 'active vs placebo'}]",,
Effects of Gastrostomy on Amyotrophic Lateral Sclerosis,2006-06,COMPLETED,2005-06,,,"University Hospital, Clermont-Ferrand",['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,380.0,,,"['Gastrostomy', 'Quality of life']",
Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET,2019-03,COMPLETED,2018-02-07,SPONSOR,,Molecular NeuroImaging,"['Healthy Volunteers', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,23.0,ACTUAL,"[{'name': '[18F]PBR06', 'description': 'Subjects will undergo PET imaging using 1 single intravenous (IV) injection of \\[18F\\]PBR06, a PET radioligand for evaluation of microglial activation in the brain. PBR06 will be injected intravenously as a bolus at a dose of no more than 5.5mCi (millicurie).'}]","['HV', 'ALS']",
Novel MRI Biomarkers for Monitoring Disease Progression in ALS,2022-08,RECRUITING,2023-12,SPONSOR,,University of Alberta,"['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease']",OBSERVATIONAL,700.0,ESTIMATED,,"['Magnetic Resonance Imaging', 'MRI', 'Biomarker']","1. Patients with a diagnosis of motor neuron disease (MND). This includes the diagnoses of amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), and progressive muscular atrophy (PMA).
2. Patients with frontotemporal dementia (FTD) with or without motor neuron signs."
Better Living With Non-memory-led Dementia,2022-08,COMPLETED,2023-02-09,SPONSOR,,"University College, London","['Primary Progressive Aphasia', 'Frontotemporal Dementia', 'Alzheimer Disease']",INTERVENTIONAL,31.0,ACTUAL,"[{'name': 'Better living with non-memory led dementia course', 'description': 'Caregivers online training and educational phenotype-specific programme on how to support people with non-memory-led dementia.'}]","['""Posterior Cortical Atrophy""']",
MN4000 for Treatment of CF and MND Patients in the Home Setting,2019-01,COMPLETED,2017-11-30,SPONSOR,,Hill-Rom,"['Cystic Fibrosis', 'Motor Neuron Disease', 'Airway Clearance Impairment']",INTERVENTIONAL,10.0,ACTUAL,"[{'name': 'MN 4000', 'description': 'Patients who required regular home airway clearance therapy were enrolled in the study and were prescribed therapy with the MN4000. Adherence to the prescribed therapy regimen and patient/caregiver satisfaction with the therapy was assessed. Pulmonary function, was assessed for each subject at baseline, after 1 month and after 3 months of home therapy. Results from the therapy period was compared to the baseline period, during which the subject received their regular airway clearance regimen. Airway Clearance Satisfaction surveys were conducted at baseline, after 1 month, and after 3 months of therapy. Results from the MN4000 therapy period were compared to the baseline period, during which the subject received their regular regimen'}]","['Airway Clearance', 'Cystic Fibrosis', 'Motor Neuron Disease', 'Home care']",
Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis,2012-10,UNKNOWN,2016-04,PRINCIPAL_INVESTIGATOR,Alessandra Lugaresi,UniversitÃ  degli Studi 'G. d'Annunzio' Chieti e Pescara,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,54.0,ESTIMATED,"[{'name': 'transcranial direct current stimulation', 'description': 'transcranial direct current stimulation applied to the motor cortex of both sides (1 mA, 20 minutes) for five consecutive days every month for 12 months'}, {'name': 'Sham stimulation', 'description': '1 mA stimulation for 30 seconds every 900 seconds per session'}]",,
A Prospective Study to Evaluate the Correlation Between Oculometric Measurements and Clinical Endpoints in ALS Patients,2023-11,RECRUITING,2023-12-31,SPONSOR,,NeuraLight,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,45.0,ESTIMATED,"[{'name': 'NeuraLight software-based platform', 'description': 'NeuraLight is an investigational software-based platform that is used for assessment and evaluation of neurological conditions including ALS patients'}]",,"About 45 ALS patients, ages 18-75 years with familial or sporadic ALS, according to the Gold Coast Criteria, who are recruited and participating in the PrimeC drug study (NCT05357950)"
Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis,2012-05,COMPLETED,2011-09,PRINCIPAL_INVESTIGATOR,Sharon Halton,The Methodist Hospital Research Institute,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,267.0,ACTUAL,,"['lipid lowering therapy', 'survival', 'ALSFRS', 'age', 'BMI', 'weight']",the Methodist Neurological Institute
Intraventricular Transplantation of Mesenchymal Stem Cell in Patients With ALS,2012-05,WITHDRAWN,,SPONSOR,,Royan Institute,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Intraventricular injection', 'description': 'intraventricular injection of mesenchymal stem cell by stereo taxi in patients with ALS'}]",['mesenchymal stem cell intraventricular injection ALS'],
"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",2012-06,COMPLETED,,SPONSOR,,Ono Pharmaceutical Co. Ltd,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,15.0,ACTUAL,"[{'name': 'ONO-2506PO', 'description': '1200mg QD / 5 years'}]","['ONO-2506PO', 'Amyotrophic Lateral Sclerosis', 'ALS']",
Imaging Biomarkers in ALS,2023-03,ACTIVE_NOT_RECRUITING,2025-09,SPONSOR,,University of Minnesota,"['Amyotrophic Lateral Sclerosis', 'Primary Lateral Sclerosis']",OBSERVATIONAL,30.0,ESTIMATED,,,This study will enroll ALS patients seeking care at the University of Minnesota and age-matched healthy control volunteers.
Efficacy of Web-Based Social-Cognitive Interventions in Right Hemisphere Stroke and Frontotemporal Dementia,2019-02,COMPLETED,2017-05,SPONSOR,,Johns Hopkins University,"['Frontotemporal Dementia', 'Right Sided Cerebral Hemisphere Cerebrovascular Accident']",INTERVENTIONAL,6.0,ACTUAL,"[{'name': 'Brain HQ', 'description': 'Brain HQ is a web application that will be used to provide patients with a training intervention that addresses deficits in social-emotional functions. These include areas such as identifying facial expression, understanding tone of voice, and predicting how people may react in certain situations. The training will take about 30 hours over the course of 4-6 weeks and is done at home.'}]","['Treatment', 'Social-Cognitive Training', 'Web-based', 'Right Hemisphere Stroke', 'Frontotemporal Dementia', 'Right Sided Cerebral Hemisphere Cerebrovascular Accident']",
The Efficacy and Safety of Vitamin E Mixed Tocotrienols In Patients With Amyotrophic Lateral Sclerosis (ALS),2019-10,UNKNOWN,2020-09-01,PRINCIPAL_INVESTIGATOR,Professor Nortina Shahrizaila,University of Malaya,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,20.0,ESTIMATED,"[{'name': 'Tocotrienols', 'description': 'Tocotrienols as a potent antioxidant to modulate oxidative stress and inflammatory response'}, {'name': 'Placebo', 'description': 'The placebo is similar in appearance, but does not contain tocotrienols and consist of palm oil'}]",['ALS'],
F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD),2020-07,WITHDRAWN,2020-12,SPONSOR_INVESTIGATOR,"Tammie L. S. Benzinger, MD, PhD","Tammie L. S. Benzinger, MD, PhD",['Alzheimer Disease'],INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'F 18 T807', 'description': 'Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.'}]","['Dementia', 'Brain Diseases', 'Central Nervous System Diseases', 'Mild Cognitive Impairment', 'tauopathies', 'Neurodegenerative Disease']",
NuroSleeve Powered Brace & Stimulation System to Restore Arm Function,2023-04,RECRUITING,2025-12,PRINCIPAL_INVESTIGATOR,Mijail Demian Serruya,Thomas Jefferson University,"['Neurologic Diseases', 'Hemiparesis', 'Quadriplegia', 'Muscular Dystrophies', 'Arthrogryposis', 'Spinal Cord Injuries', 'Charcot-Marie-Tooth', 'Stroke', 'Weakness of Extremities as Sequela of Stroke', 'Weakness Due to Upper Motor Neuron Dysfunction', 'Amyotrophic Lateral Sclerosis', 'Spinal Muscular Atrophy', 'Arm Paralysis', 'Cerebral Palsy']",INTERVENTIONAL,20.0,ESTIMATED,"[{'name': 'Neurosleeve', 'description': 'Myoelectric devices for restoration of independent arm function'}]","['Arm weakness, paralysis', 'orthosis', 'functional electrical stimulation', 'brace']",
iBCI Optimization for Veterans With Paralysis,2023-08,NOT_YET_RECRUITING,2026-06-30,SPONSOR,,VA Office of Research and Development,"['Spinal Cord Injury', 'Amyotrophic Lateral Sclerosis', 'Brain Stem Infarctions', 'Locked-in Syndrome', 'Muscular Dystrophy']",INTERVENTIONAL,2.0,ESTIMATED,"[{'name': 'Mobile neural decoding platform (mobile iBCI)', 'description': 'An embedded neural signal processor device will be evaluated for its ability to provide accurate and reliable closed-loop control in a home-based brain-computer interface.'}]",,
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia,2023-09,RECRUITING,2025-07-01,SPONSOR_INVESTIGATOR,David Wilson,David Wilson,"['Alzheimer Disease', 'Frontotemporal Dementia', 'Dementia']",INTERVENTIONAL,102.0,ESTIMATED,"[{'name': '[18F]RP-115 PET/MRI or PET/CT and MRI', 'description': 'An I.V. bolus injection of up to 10 millicurie (mCi) \\[18F\\]RP-115 will be administered, followed by a PET/MRI scan or by a combination of PET/CT and MRI'}]","['Alzheimer Disease', 'Nuclear medicine', 'Positron emission tomography', 'Magnetic resonance imaging', 'Frontotemporal Dementia']",
Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer,2013-07,COMPLETED,2012-05,SPONSOR,,Apeiron Biologics,['Radiation Induced Dermatitis'],INTERVENTIONAL,20.0,ACTUAL,"[{'name': 'APN201', 'description': 'All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.\n\nStudy treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area â‰¥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size).'}, {'name': 'Placebo', 'description': 'All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.\n\nStudy treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area â‰¥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size).'}]",,
A Patient Centric Motor Neuron Disease Activities of Daily Living Scale,2019-10,COMPLETED,2019-09-13,SPONSOR,,University of South Florida,"['Amyotrophic Lateral Sclerosis', 'Progressive Muscular Atrophy', 'Primary Lateral Sclerosis', 'Hereditary Spastic Paraplegia']",OBSERVATIONAL,410.0,ACTUAL,"[{'name': 'Web-based Survey', 'description': 'This is a prospective 12-month study of patients with motor neuron disease enrolled in CReATe Connect, an RDCRN Contact Registry.'}]","['Amyotrophic Lateral Sclerosis', 'ALS', 'motor neuron diseases', 'Progressive Muscular Atrophy', 'Primary Lateral Sclerosis', 'Hereditary Spastic Paraplegia']","Patients with motor neuron disease enrolled in CReATe Connect, an RDCRN Contact Registry"
A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,2016-11,COMPLETED,2014-12,SPONSOR,,Mallinckrodt,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,43.0,ACTUAL,"[{'name': 'Repository corticotropin injection', 'description': 'Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks'}]","['H.P. Acthar Gel', 'Acthar', 'amyotrophic lateral sclerosis', 'ALS']",
Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS),2019-03,UNKNOWN,2019-09-16,PRINCIPAL_INVESTIGATOR,Alireza Eishi Oskouei,Isfahan University of Medical Sciences,['Neuromuscular Diseases'],INTERVENTIONAL,20.0,ESTIMATED,"[{'name': 'Edaravone', 'description': 'Edaravone is a free radical scavenger. this drug showed desirable effects like slowing decline of physical function by 33 percent in previous studies.'}, {'name': 'Riluzole', 'description': 'Riluzole is a treatment option for amyotrophic lateral sclerosis. The occurrence of ventilator-dependence or tracheostomy is delayed in selected patients who treated with this drug.'}]","['Amyotrophic Lateral Sclerosis', 'Edaravone']",
Dexpramipexole SAD/MAD Study,2014-11,COMPLETED,2012-01,SPONSOR,,Knopp Biosciences,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,63.0,ACTUAL,"[{'name': 'Dexpramipexole', 'description': 'Oral Tablet at varying doses'}, {'name': 'Dexpramipexole Placebo', 'description': 'Oral tablet at varying doses'}]",,
Intranasal Insulin in Frontotemporal Dementia (FTD),2023-04,TERMINATED,2023-05-15,SPONSOR,,HealthPartners Institute,"['Frontotemporal Dementia, Behavioral Variant']",INTERVENTIONAL,3.0,ACTUAL,"[{'name': 'Novolin-R insulin', 'description': 'Insulin (Novolin-R) 20 IU/IN (0.1ml/10 units IN in each nostril), twice per day, once in the morning and again in the evening (at least 8 hours between doses) for 4 weeks.'}]","['intranasal', 'insulin']",
PiB PET Scanning in Speech and Language Based Dementias,2015-12,COMPLETED,2015-01,PRINCIPAL_INVESTIGATOR,Keith A. Josephs,Mayo Clinic,"['PPA', 'Primary Progressive Aphasia', 'Aphasia', 'Non-fluent Aphasia', 'Semantic Dementia', 'Apraxia of Speech', 'Primary Progressive Nonfluent Aphasia', 'Progressive Aphasia']",INTERVENTIONAL,168.0,ACTUAL,"[{'name': 'C-11 PiB', 'description': ""One time intravenous administration of 740 megabecquerel (MBq) of \\[N-methyl-11C\\]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).""}, {'name': 'F-18 FDG', 'description': 'One time intravenous administration of 629 megabecquerel (MBq) of \\[18-F\\]-fluoro-deoxy-glucose (FDG) (range 555 - 740 MBq).'}]","['aphasia', 'apraxia of speech', 'language']",
Efficacy of Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS),2015-07,COMPLETED,2011-06,SPONSOR,,Columbia University,"['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease']",OBSERVATIONAL,25.0,ACTUAL,,['noninvasive ventilation'],Patients with ALS who are using nocturnal noninvasive ventilation to treat respiratory insufficiency will be screened for eligibility as below.
Exploring Accessible Beauty for Individuals With Upper Extremity Deficits,2023-12,COMPLETED,2023-09-29,PRINCIPAL_INVESTIGATOR,Emily Rosario,Casa Colina Hospital and Centers for Healthcare,"['Stroke, Ischemic', 'Stroke Hemorrhagic', 'Stroke (CVA) or TIA', 'Stroke, Acute', 'Traumatic Brain Injury', 'SCI - Spinal Cord Injury', 'Ehlers-Danlos Syndromes (EDS)', 'Lupus Erythematosus', 'Guillain-Barre Syndrome', 'Multiple Sclerosis', 'Myasthenia Gravis', 'Amyotrophic Lateral Sclerosis', 'Graves Disease', 'Muscular Dystrophies']",OBSERVATIONAL,57.0,ACTUAL,"[{'name': 'Use of Rare Beauty makeup products', 'description': 'Participants will be provided with a selection of beauty products items including foundation, concealer, blush, highlighter, and lipstick, specifically chosen for their potential accessibility features. They will have a specified trial period during which they can use the products as part of their regular beauty routines.'}]","['upper extremity disabilities', 'limited mobility', 'dexterity impairments', 'muscle weakness']","A convenience sample of individuals aged 18 and above, with upper extremity deficits, will be recruited for this study. Efforts will be made to include participants with a range of upper extremity deficits and experiences with beauty products."
Virtual Seating Coach on Power Wheelchairs of Persons With Amyotrophic Lateral Sclerosis (ALS),2023-02,COMPLETED,2020-03-31,SPONSOR,,Wake Forest University Health Sciences,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,39.0,ACTUAL,"[{'name': 'Virtual Seating Coach', 'description': 'Power wheelchair intervention'}]","['Power wheelchairs', 'pressure injuries', 'pain']",
T-Regulatory Cells in Amyotrophic Lateral Sclerosis,2018-03,UNKNOWN,2018-03,SPONSOR_INVESTIGATOR,"Stanley H. Appel, MD","Stanley H. Appel, MD",['ALS (Amyotrophic Lateral Sclerosis)'],INTERVENTIONAL,4.0,ESTIMATED,"[{'name': 'Autologous T-regulatory lymphocytes', 'description': 'intravenous administration of Autologous T-regulatory lymphocytes at a dose of 1x10 to the sixth /kg.'}, {'name': 'Interleukin-2', 'description': 'Subcutaneous Interleukin-2 at a dose of 2x10 to the fifth IU/m2, three times a week.'}]","['ALS', 'T-Regulatory Cells']",
Memory and Social Interactions,2022-12,RECRUITING,2026-12-31,SPONSOR,,"University Hospital, Caen","['Alzheimer Disease', 'Semantic Dementia']",OBSERVATIONAL,192.0,ESTIMATED,"[{'name': 'Learning new information', 'description': 'The purpose of this study is to test the effects of different social contexts when learning new information. Participants in the AD, SPPA, and HC experimental groups will be given tests to learn verbal information (location of drawings in a grid). The learning phases of these tests are presented in the form of a memory game in which participants are asked to make pairs of drawings by finding the second copy of the proposed pair by trial and error in a grid. After learning, a task of recognizing the position of the drawings in the grid is performed. Each participant will carry out this learning in three different conditions: 1) learning alone, 2) learning by observation of the reconstruction of the pairs of images by a partner, and 3) collaborative learning in which the two game partners discover and reconstruct the pairs together.'}]","['Memory', 'Social Interaction', 'Personality', 'Alzheimer Disease', 'Aphasia, Primary Progressive']",AD group SPPA group HC group Partners
Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders,2023-04,TERMINATED,2016-04,SPONSOR,,Talaris Therapeutics Inc.,"['Hurler Syndrome (MPS I)', 'Hurler-Scheie Syndrome', 'Hunter Syndrome (MPS II)', 'Sanfilippo Syndrome (MPS III)', 'Krabbe Disease (Globoid Leukodystrophy)', 'Metachromatic Leukodystrophy (MLD)', 'Adrenoleukodystrophy (ALD and AMN)', 'Sandhoff Disease', 'Tay Sachs Disease', 'Pelizaeus Merzbacher (PMD)', 'Niemann-Pick Disease', 'Alpha-mannosidosis']",INTERVENTIONAL,3.0,ACTUAL,"[{'name': 'hematopoietic stem cell infusion', 'description': 'Enriched hematopoetic stem cell infusion'}]","['hematopoietic stem cell Tx, chimerism, leukodystrophy']",
Development of Targeted RNA-Seq for Amyotrophic Lateral Sclerosis Diagnosis,2024-01,RECRUITING,2025-05,SPONSOR,,Centre Hospitalier Universitaire de NÄ«mes,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,192.0,ESTIMATED,"[{'name': 'RNA sequencing', 'description': 'RNA-Seq (Sureselect XT HS2 RNA) from patient blood sample'}]",,"Patients will be recruited during a consultation for a clinical diagnosis of ALS for which a request for a genetic diagnosis has been made in one of the prescribing centers: CHU Lyon, Montpellier University Hospital, Marseille University Hospital, Clermont-Ferrand University Hospital, Bordeaux University Hospital, Toulouse University Hospital."
The Relationship Between Arterial Stiffness and Respiratory Failure in Motor Neurone Disease,2021-09,COMPLETED,2021-06-30,SPONSOR,,Guy's and St Thomas' NHS Foundation Trust,"['Motor Neurone Disease', 'Hypoxemia and/or Hypercapnia']",OBSERVATIONAL,13.0,ACTUAL,"[{'name': 'Non Invasive Ventilation', 'description': 'Assessments for those participants who are being set up onto NIV'}, {'name': 'Without Non Invasive Ventilation', 'description': 'Assessments for those participants who are not being set up onto NIV'}]",,Patients with Motor Neurone Disease
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3),2023-11,ACTIVE_NOT_RECRUITING,2027-10-11,SPONSOR,,Alector Inc.,['Frontotemporal Dementia'],INTERVENTIONAL,110.0,ESTIMATED,"[{'name': 'AL001', 'description': 'Administered via intravenous (IV) infusion'}, {'name': 'Placebo', 'description': 'Administered via intravenous (IV) infusion'}, {'name': 'Open label - AL001', 'description': 'Administered via intravenous (IV) infusion'}]",,
A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS),2020-07,UNKNOWN,2020-11-02,SPONSOR,,AL-S Pharma,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,18.0,ESTIMATED,"[{'name': 'AP-101', 'description': 'Administered by intravenous infusion (IV)'}]","['Familial Amyotrophic Lateral Sclerosis', 'Sporadic Amyotrophic Lateral Sclerosis']",
[BrainConnexion] - Neurodevice Phase I Trial,2022-11,ACTIVE_NOT_RECRUITING,2023-08-27,SPONSOR,,National Neuroscience Institute,"['Tetraplegia', 'Tetraplegia/Tetraparesis', 'Spinal Cord Injuries', 'Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease', 'Locked-in Syndrome', 'Muscular Dystrophies']",INTERVENTIONAL,5.0,ACTUAL,"[{'name': 'BrainConnexion', 'description': 'A 4.4mm by 4.2mm electrode array is placed onto the surface of the motor cortex which is then connected to a miniaturized neural recording microsystem that transmits signals wirelessly to control an external assistive device. Neural signals are recorded at least once every week for 12 months or longer.'}]",,
Florbetaben PET Imaging in PPA,2022-02,COMPLETED,2021-02-26,PRINCIPAL_INVESTIGATOR,Emily Rogalski,Northwestern University,"['Primary Progressive Aphasia', 'Alzheimer Disease']",OBSERVATIONAL,1.0,ACTUAL,"[{'name': 'Florbetaben F18', 'description': 'A single injection of 8.1mCi of florbetaben F18 will be administered by intravenous bolus injection'}, {'name': 'PET', 'description': 'PET Scan for brain imaging'}]","[""Alzheimer's Disease"", 'Dementia', 'Primary Progressive Aphasia', 'Neurocognitive Disorders', 'Speech Disorders']","Participants will be recruited from other research projects at Northwestern's Mesulam Center. Some of these projects recruit participants from the local Chicagoland area and others recruit participants from across the United States. As Primary Progressive Aphasia is an uncommon syndrome, participant recruitment is not focused on a specific demographic area."
A Pilot Study of the Utility of 3D Printed Masks for ALS Subjects,2021-04,TERMINATED,2020-03-14,PRINCIPAL_INVESTIGATOR,Stephen Goutman,University of Michigan,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,5.0,ACTUAL,"[{'name': 'Custom Mask Interface', 'description': 'Subjects enrolled in the study will received a custom designed, 3D printed, non-invasive ventilation mask interface.'}]","['amyotrophic lateral sclerosis, non-invasive ventilation, mask, custom, 3D-printing']",
A P300 Brain Computer Interface Keyboard to Control Assistive Technology For Use by People With Amyotrophic Lateral Sclerosis,2015-06,COMPLETED,2010-08,PRINCIPAL_INVESTIGATOR,"Jane Huggins, PhD",University of Michigan,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,13.0,ACTUAL,"[{'name': 'P300 Brain Computer Interface Keyboard', 'description': 'Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.'}]",,
Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis,2018-09,COMPLETED,2013-08,SPONSOR,,"Corestemchemon, Inc.","['Amyotrophic Lateral Sclerosis', 'ALS']",INTERVENTIONAL,72.0,ACTUAL,"[{'name': 'HYNR-CS inj', 'description': 'Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.'}, {'name': 'Control group', 'description': 'No treatment of HYNR-CS inj'}]","['Amyotrophic lateral sclerosis', 'ALS', 'Motor neuron disease', 'MND', 'HYNR-CS inj', 'Autologous bone marrow derived stem cell', 'Intrathecal injection']",
Exposure to Neurotoxins as Risk Factors for ALS,2019-01-23,COMPLETED,2019-01-23,SPONSOR,,National Institute of Environmental Health Sciences (NIEHS),['ALS'],OBSERVATIONAL,397.0,ACTUAL,,"['Polymorphism', 'Neurodegenerative Diseases', 'ALS']",
Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).,2019-08,COMPLETED,2018-12,SPONSOR,,Neuroscience Trials Australia,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,43.0,ACTUAL,"[{'name': 'Triumeq', 'description': 'Triumeq, a combination of dolutegravir, abacavir and lamivudine is an anti-retroviral therapy indicated for people with HIV-1 infection.'}]","['ALS', 'Antiretroviral Therapy, Triumeq']",
Cortico-Spinal tDCS as Rehabilitative Intervention in Amyotrophic Lateral Sclerosis,2022-10,COMPLETED,2022-07-31,PRINCIPAL_INVESTIGATOR,Barbara Borroni,Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,"['Motor Neuron Disease, Familial', 'Amyotrophic Lateral Sclerosis With Dementia']",INTERVENTIONAL,31.0,ACTUAL,"[{'name': 'Anodal bilateral motor cortex and cathodal spinal tDCS', 'description': '10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)'}, {'name': 'Sham bilateral motor cortex and sham spinal tDCS', 'description': '10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)'}]","['Motor Neuron Disease', 'Amyotrophic Lateral Sclerosis', 'Transcranial direct current stimulation', 'tDCS', 'Non-invasive brain stimulation', 'Transcranial magnetic stimulation', 'TMS']",
"18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls",2018-08,COMPLETED,2018-12-03,SPONSOR,,Chang Gung Memorial Hospital,"[""Alzheimer's Disease"", 'Cortical Basal Syndrome', 'Frontotemporal Dementia', 'Progressive Supranuclear Palsy', 'Vascular Cognitive Impairment']",INTERVENTIONAL,36.0,ACTUAL,"[{'name': 'F-18', 'description': 'This is an open-label study to evaluate the performance of a novel tau imaging ligand in up to 36 subjects (12 AD, 3 FTD, 3 PSP, 3 CBS, 3 VCI and 12 HV).'}]",,
"A Multimodal Approach for Clinical Diagnosis and Treatment of Primary Progressive Aphasia, MAINSTREAM ID:3430931",2023-04,RECRUITING,2026-02,SPONSOR,,IRCCS Centro San Giovanni di Dio Fatebenefratelli,['Primary Progressive Aphasia'],INTERVENTIONAL,60.0,ESTIMATED,"[{'name': 'Active tDCS', 'description': 'Active tDCS (anode will be applied over the left DLPFC with the cathode over the right supraorbital region);'}, {'name': 'individualized language training', 'description': 'individualized language training'}, {'name': 'Placebo tDCS', 'description': 'Placebo tDCS (the current will be turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period);'}]","['Behavioral and neural effects of tDCS combined with language training', ""Alzheimer's disease and other dementias""]",
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia,2024-01,RECRUITING,2038-12,SPONSOR_INVESTIGATOR,"Leigh R. Hochberg, MD, PhD.","Leigh R. Hochberg, MD, PhD.","['Tetraplegia', 'Spinal Cord Injuries', 'Amyotrophic Lateral Sclerosis', 'Brain Stem Infarctions', 'Locked in Syndrome', 'Muscular Dystrophy']",INTERVENTIONAL,22.0,ESTIMATED,"[{'name': 'Placement of the BrainGate2 sensor(s) into the motor-related cortex', 'description': 'Up to four 4x4 mm BrainGate2 sensor(s) are placed into the motor-related cortex (including speech-related areas of cortex), connected to one or two percutaneous pedestals. Neural recordings are made at least weekly for a year or more.'}]","['Brain computer interface', 'Assistive device', 'Environmental control', 'Communication device', 'quadriplegia', 'tetraplegia']",
Oxidative Stress in Motor Neuron Disease: COSMOS Add-On Study,2015-08-03,COMPLETED,2015-08-03,SPONSOR,,National Institute of Neurological Disorders and Stroke (NINDS),"['Motor Neuron Disease', 'Primary Lateral Sclerosis']",OBSERVATIONAL,10.0,ACTUAL,,"['Motor Neuron Disease', 'Primary Lateral Sclerosis', 'Oxidative Stress', 'Physiology', 'PLS']",
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD),2023-11,RECRUITING,2024-07,PRINCIPAL_INVESTIGATOR,Bradley Boeve,Mayo Clinic,"['Frontotemporal Lobar Degeneration (FTLD)', 'Progressive Supranuclear Palsy (PSP)', 'Corticobasal Degeneration (CBD)', 'Behavioral Variant Frontotemporal Dementia (bvFTD)', 'Semantic Variant Primary Progressive Aphasia (svPPA)', 'Nonfluent Variant Primary Progressive Aphasia (nfvPPA)', 'FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)', 'Amyotrophic Lateral Sclerosis', 'Oligosymptomatic PSP (oPSP)', 'C9orf72', 'GRN Related Frontotemporal Dementia', 'MAPT Gene Mutation', 'TBK1 Gene Mutation', 'Oligosymptomatic Progressive Supranuclear Palsy']",OBSERVATIONAL,2100.0,ESTIMATED,,,Participants will have a referring diagnosis of an FTLD clinical syndrome or will be a member of a family with a strong family history of an FTLD syndrome.
Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS),2024-01,ACTIVE_NOT_RECRUITING,2027-01-08,SPONSOR,,Sanofi,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,305.0,ACTUAL,"[{'name': 'SAR443820', 'description': 'Tablet oral'}, {'name': 'Placebo', 'description': 'Tablet'}]",,
Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS),2016-04,COMPLETED,2016-02,PRINCIPAL_INVESTIGATOR,"Nicholas Maragakis, MD",Johns Hopkins University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,60.0,ACTUAL,"[{'name': 'Resistance Exercise', 'description': 'Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.'}, {'name': 'Endurance Exercise', 'description': 'Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.'}, {'name': 'Stretching/Range-of-Motion', 'description': 'Stretching and range of motion exercise is widely accepted as a ""standard of care"" for ALS management.'}]","['ALS', 'Exercise', 'Resistance', 'Endurance']",
Appetite and Related Factors in Patients With ALS,2021-06,UNKNOWN,2022-03-31,SPONSOR,,Peking University Third Hospital,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,200.0,ESTIMATED,"[{'name': 'Appetite rating scale CNAQ', 'description': 'Chinese version of Appetite rating scale CNAQ'}]",,ALS patients
CB3 Pilot (Communication Bridge: A Person-centered Internet-based Intervention for Individuals With Primary Progressive Aphasia),2024-01,COMPLETED,2023-07-12,PRINCIPAL_INVESTIGATOR,Emily Rogalski,Northwestern University,"['Aphasia', 'Primary Progressive Aphasia', 'Dementia', 'Communication', 'Alzheimer Disease']",INTERVENTIONAL,8.0,ACTUAL,"[{'name': 'Communication Bridgeâ„¢', 'description': 'Evidence-based speech language therapy treatment will be compared and contrasted.'}]",,
LIME Study (LFB IVIg MMN Efficacy Study),2016-07,COMPLETED,2016-07,SPONSOR,,Laboratoire franÃ§ais de Fractionnement et de Biotechnologies,['Motor Neuron Disease'],INTERVENTIONAL,23.0,ACTUAL,"[{'name': 'Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)'}, {'name': 'Biological: KiovigÂ® (Human normal Immunoglobulin for intravenous administration 100mg/mL)'}]",['Multifocal Motor Neuropathy'],
Safety Study of Oral Edaravone Administered in Subjects With ALS,2023-05,COMPLETED,2021-10-07,SPONSOR,,Mitsubishi Tanabe Pharma America Inc.,['ALS'],INTERVENTIONAL,185.0,ACTUAL,"[{'name': 'MT-1186', 'description': '* An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug free period\n* Subsequent treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period. Treatment cycles are every 4 weeks.'}]",,
Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis,2023-04,COMPLETED,2019-09-04,SPONSOR,,Mitsubishi Tanabe Pharma Corporation,['Japanese Patients With ALS'],INTERVENTIONAL,9.0,ACTUAL,"[{'name': 'MT-1186', 'description': 'Suspension'}]",,
Transcranial Magnetic Stimulation (TMS) for Primary Progressive Apraxia of Speech (PPAOS),2020-05,TERMINATED,2018-11-13,PRINCIPAL_INVESTIGATOR,Joyce Rios Gomes Osman,University of Miami,['Apraxia Speech'],INTERVENTIONAL,4.0,ACTUAL,"[{'name': 'Transcranial Magnetic Stimulation (TMS)', 'description': 'Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.'}]",,
A Study of the Expression of Nogo and Reticulon Genes in Skeletal Muscle of Patients With Amyotrophic Lateral Sclerosis,2015-03,TERMINATED,2012-07,SPONSOR,,"University Hospital, Strasbourg, France",['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,79.0,ACTUAL,,"['Amyotrophic lateral sclerosis', 'Nogo gene', 'reticulon genes']","University Hospital, Strasbourg, France"
Effects of a Self-care Educational Program Via Telerehabilitation in Caregivers,2023-05,NOT_YET_RECRUITING,2023-12,PRINCIPAL_INVESTIGATOR,"Ana Raquel Rodrigues Lindquist, PhD",Universidade Federal do Rio Grande do Norte,['Quality of Life'],INTERVENTIONAL,22.0,ESTIMATED,"[{'name': 'Telerehabilitation', 'description': 'Subjects will participate in a six-week self-care education program with weekly synchronous meetings using Google Meet or WhatsApp and an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with a schedule for weekly organization.'}, {'name': 'Education', 'description': 'Participants will receive an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with orientations on the importance of reading and implementing the guidelines described in the booklet.'}]","['Caregiver', 'Caregiver Burden', 'Telemedicine']",
A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis,2011-12,COMPLETED,2011-06,SPONSOR,,Newron Sweden AB,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,18.0,ACTUAL,"[{'name': 'sNN0029', 'description': 'Continuous ICV infusion at one of three dose levels'}, {'name': 'Placebo', 'description': 'Continuous ICV infusion'}]","['ALS', 'VEGF165', 'Safety', 'Intracerebroventricular', 'Infusion', 'Implantable']",
Holter of Movement in Patients With Amyotrophic Lateral Sclerosis.,2024-01,RECRUITING,2028-01,SPONSOR_INVESTIGATOR,Dr. StÃ©phanie Delstanche,Dr. StÃ©phanie Delstanche,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,30.0,ESTIMATED,"[{'name': 'Actimyo', 'description': 'Actimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.'}]","['Actimyo', 'Accelerometry', 'Daily living']",Patients diagnosed with amyotrophic lateral sclerosis
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes,2023-09,RECRUITING,2026-12-30,PRINCIPAL_INVESTIGATOR,"Anne-Marie Alexandra Wills, MD",Massachusetts General Hospital,"['PSP', 'CBD', 'Progressive Supranuclear Palsy', 'FTD', 'Corticobasal Degeneration', 'Frontotemporal Dementia', 'Frontotemporal Lobar Degeneration']",OBSERVATIONAL,60.0,ESTIMATED,"[{'name': 'PAMSys', 'description': 'Wearable accelerometer and gyroscope for measuring movement'}, {'name': 'LEGSys', 'description': 'Wearable accelerometer and gyroscope for measuring movement'}]",,The study intends to enroll a diverse population of individuals representative of the general PSP population. There are no restrictions based upon race or ethnic origin. This study will recruit both male and female participants aged 40 years or older with a clinical diagnosis of possible or probable PSP phenotype as defined by the 2017 MDS criteria.
Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis,2016-01,WITHDRAWN,2017-05,PRINCIPAL_INVESTIGATOR,rokhsareh meamar,"Alzahra Hospital, Iran",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'mesenchymal stem cell', 'description': 'intra spinal injection of 1 Ã—10(8) mesenchymal stem cells +10cc normal saline'}]",,
"A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)",2023-03-22,COMPLETED,2021-09-06,SPONSOR,,Sanofi,['Amyotrophic Lateral Sclerosis (Healthy Volunteers)'],INTERVENTIONAL,18.0,ACTUAL,"[{'name': 'SAR443820', 'description': 'Tablet by oral administration'}, {'name': 'SAR443820', 'description': 'Capsule by oral administration'}]",,
ALS and Airway Clearance (ALSAC) Therapy,2021-10,COMPLETED,2017-09-17,SPONSOR,,The University of Texas Health Science Center at San Antonio,"['Amyotrophic Lateral Sclerosis', 'Respiratory Muscle Weakness']",INTERVENTIONAL,28.0,ACTUAL,"[{'name': 'High Frequency Chest Wall Oscillation', 'description': 'The HFCWO aims to mobilize the secretions to the pharynx to allow the patient to expel the secretions. However, many ALS patients are unable to expel their secretions due to atrophied expiratory muscles. The HFCWO device uses a small air compressor with a vest that wraps around the chest to induce airflows that pull secretions from the walls of the airways, thin the secretions and move them up the airways towards the larger airways and pharynx.'}, {'name': 'Mechanical insufflation/exsufflation', 'description': 'A noninvasive therapy, removes secretions in patients who have an ineffective cough because their peak cough flows are less than 270 L/min. This device applies a positive pressure to the airway and rapidly switches to a negative pressure applied to the airway. The rapid switch between the two types of pressure simulates a natural cough, thus assisting with expulsion of the secretions.'}]","['Amyotrophic Lateral Sclerosis', 'Airway Clearance', 'Mechanical Insufflation Exsufflation', 'High Frequency Chest Wall Compression Oscillation']",
Pridopidine in Amyotrophic Lateral Sclerosis (EAP 2),2023-11,AVAILABLE,,SPONSOR,,Prilenia,['Amyotrophic Lateral Sclerosis'],EXPANDED_ACCESS,,,"[{'name': 'Pridopidine', 'description': 'Pridopidine 45 mg once daily p.o. (or via feeding tube) over a 2-week up-titration period; followed by pridopidine 45 mg twice daily p.o. (or via feeding tube) for the remainder of the treatment period (through Week 104)'}]","['Amyotrophic Lateral Sclerosis', 'Pridopidine', ""Lou Gehrig's disease""]",
ALS Spinal Cord Gray and White Matter Study,2023-11,RECRUITING,2025-10-01,PRINCIPAL_INVESTIGATOR,Regina Schlaeger,"University Hospital, Basel, Switzerland",['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,80.0,ESTIMATED,"[{'name': 'Magnetic Resonance Imaging', 'description': 'Magnetic Resonance Imaging of the spinal cord using radially acquired Averaged Magnetization Inversion Recovery Acquisitions (rAMIRA)'}]","['Amyotrophic Lateral Sclerosis', 'Spinal Cord Magnetic Resonance Imaging']","All patients diagnosed with possible, probable, and definite Amyotrophic Lateral Sclerosis acc. to the El Escorial aged 18 years or older can participate in this study. Healthy control persons are chosen to individually match the included patients. Additionally, patients with other motor neuron diseases (not ALS) will be included."
Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis,2023-09,COMPLETED,2017-12,SPONSOR,,"Helixmith Co., Ltd.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,18.0,ACTUAL,[{'name': 'VM202'}],"['ALS', ""Lou Gehrig's disease"", 'neurodegenerative disease']",
rTMS Treatment of Primary Progressive Aphasia,2023-03,COMPLETED,2022-08-31,SPONSOR,,Peking Union Medical College Hospital,"['Primary Progressive Aphasia', 'Repetitive Transcranical Magnetic Stimulation']",INTERVENTIONAL,40.0,ACTUAL,"[{'name': 'Magstim rTMS', 'description': 'The device is made in London,UK'}]",,
Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis,2016-10,COMPLETED,2016-08,PRINCIPAL_INVESTIGATOR,"Albert Christian Ludolph, Prof.",University of Ulm,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,252.0,ACTUAL,"[{'name': 'Rasagiline'}, {'name': 'Placebo', 'description': 'a sugar pill manufactured to mimic Rasagiline 1 mg tablet'}]","['amyotrophic lateral sclerosis', 'survival time', 'ALS functioning Rating Scale', 'quality of life', 'survival']",
Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA),2022-04,RECRUITING,2024-10,SPONSOR,,"National University Hospital, Singapore",['Breast Cancer'],INTERVENTIONAL,86.0,ESTIMATED,"[{'name': 'Cohort A', 'description': 'Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.'}, {'name': 'Cohort B', 'description': 'Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.'}]","['FTD/TPI', 'TAS-102', 'Trifluridine']",
A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS,2016-01,TERMINATED,2015-10,SPONSOR,,Newron Sweden AB,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,11.0,ACTUAL,"[{'name': 'sNN0029 infusion solution', 'description': '4 Âµg/day, continuous i.c.v administration'}]",,
A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS),2020-07,COMPLETED,2020-06-30,SPONSOR,,MediciNova,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,35.0,ACTUAL,"[{'name': 'ibudilast', 'description': 'Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration16. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.'}]",['ALS'],
HEALEY ALS Platform Trial - Regimen G DNL343,2023-05,ENROLLING_BY_INVITATION,2025-08,SPONSOR_INVESTIGATOR,"Merit E. Cudkowicz, MD","Merit E. Cudkowicz, MD",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,240.0,ESTIMATED,"[{'name': 'DNL343', 'description': 'DNL343 is administered orally once daily per day for 24 weeks.'}, {'name': 'Matching Placebo', 'description': 'Matching placebo is administered orally once daily per day for 24 weeks.'}]","['ALS', 'Placebo-Controlled', 'Double-Blind', 'Regimen Specific Appendix', ""Lou Gehrig's Disease"", 'DNL343', 'Denali Therapeutics']",
Nutritional Prognostic Factors in ALS,2018-04,COMPLETED,2016-07-31,PRINCIPAL_INVESTIGATOR,Michele Barone,University of Bari,"['Nutritional Deficiency', 'Neuro-Degenerative Disease', 'Gastrostomy']",OBSERVATIONAL,47.0,ACTUAL,"[{'name': 'Nutritional assessment', 'description': 'BMI and cholesterol levels evaluation'}]",,"This study included 47 consecutive patients referring to the Neurological ALS Tertiary Centre, Department of Basic Medical Sciences, Neurosciences and Sense Organs, who underwent PEG tube placement from 2006 to 2015 and were referred to the artificial nutrition team of the Gastroenterology Unit, Department of Emergency and Organ Transplantation, of the same University Hospital. All patients fulfilled revised El Escorial criteria for probable or definite classical ALS."
rTMS in Treatment of Spasticity,2022-11,TERMINATED,2022-08-16,SPONSOR,,"Hospital for Special Surgery, New York",['ALS'],INTERVENTIONAL,3.0,ACTUAL,"[{'name': 'Mag Stim', 'description': 'rTMS'}]",,
Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants,2018-04,COMPLETED,2017-12-14,SPONSOR,,"Genentech, Inc.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,24.0,ESTIMATED,"[{'name': 'Reference capsule GDC-0134', 'description': 'Oral administration of a single dose of 200 milligrams (mg) GDC-0134 reference capsule administered as two 100 mg capsules.'}, {'name': 'Prototype capsule GDC-0134', 'description': 'Oral administration of a single dose of 200 mg GDC-0134 prototype capsule administered as one 200 mg capsule.'}, {'name': 'rabeprazole', 'description': 'Oral administration of 20 mg rabeprazole once daily on Days -3, -2 and -1 as well as on Day 1 two hours prior to each administration of GDC-0134 during Period 4.'}]",,
"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)",2023-12,RECRUITING,2028-03,SPONSOR,,"Ionis Pharmaceuticals, Inc.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,77.0,ESTIMATED,"[{'name': 'ION363', 'description': 'ION363 will be administered by IT bolus injection.'}, {'name': 'Placebo', 'description': 'Placebo will be administered by IT bolus injection.'}]","['Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations', 'Amyotrophic Lateral Sclerosis', 'Sarcoma Mutations']",
A Programme for Amyotrophic Lateral Sclerosis Care in Europe,2017-08,UNKNOWN,2018-03-31,SPONSOR,,Sheffield Teaching Hospitals NHS Foundation Trust,"['ALS (Amyotrophic Lateral Sclerosis)', 'MND (Motor Neurone DIsease)']",OBSERVATIONAL,115.0,ESTIMATED,,"['ALS, MND, Care, Patient journey']",A mix of incident and prevalent cases will be included in order to capture patients at different stages of the disease trajectory. The total study population will contain 600 patients (300 newly diagnosed and 300 prevalent).
Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS),2011-03,UNKNOWN,,,,"Charite University, Berlin, Germany",['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,40.0,ESTIMATED,"[{'name': 'Olanzapine', 'description': 'Randomized, placebo-controlled, parallel group trial to evaluate the effectiveness and tolerability of an oral dose of 10 mg Olanzapine in combination with Riluzole for the treatment of Loss of Appetite in patients with amyotrophic lateral sclerosis (ALS)'}]","['ALS', 'olanazapine', 'Loss of Apptetite', 'Appetite Loss', 'Malnutrition', 'Cachexia', 'Zyprexa']",
DIAGALS: Relation Between Tar DNA Binding Protein(TDP)-43 et Nrf-2 in ALS: a Track to Improve Diagnosis and Prognosis of the Disease,2023-01,NOT_YET_RECRUITING,2025-08,SPONSOR,,"University Hospital, Tours",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,60.0,ESTIMATED,"[{'name': 'Blood sample', 'description': 'The intervention is to take a blood sample every 6 months for 1 year which is not part of health routine care'}, {'name': 'Blood sample', 'description': 'The intervention is to take a blood sample at baseline.'}]",,
PET Scan of Brain Metabolism in Relation to Age and Disease,2002-08,COMPLETED,2002-08,,,National Institute of Neurological Disorders and Stroke (NINDS),"[""Alzheimer's Disease"", 'Brain Neoplasm', 'Niemann Pick Disease']",OBSERVATIONAL,123.0,,[{'name': '15 O Water'}],"[""Alzheimer's Disease"", 'Positron Emission Tomography', 'Brain Phospholipid', 'Fatty Acids', '11C Arachidonate', 'Signal Transduction', 'Brain']",
PRE-Symptomatic Studies in Amyotrophic Lateral Sclerosis,2023-03,ACTIVE_NOT_RECRUITING,2027-12,PRINCIPAL_INVESTIGATOR,Michael Benatar,University of Miami,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,100.0,ESTIMATED,,"['Disease onset', 'Disease progression']",People affected with ALS (either familial or sporadic) and healthy controls
Rapamycin Treatment for ALS,2022-08,COMPLETED,2022-02-15,PRINCIPAL_INVESTIGATOR,JESSICA MANDRIOLI,Azienda Ospedaliero-Universitaria di Modena,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,63.0,ACTUAL,"[{'name': 'Rapamycin', 'description': 'tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage'}, {'name': 'Placebo Oral Tablet', 'description': 'tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage'}]","['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease', 'Rapamycin']",
A Systematic Investigation of Phonetic Complexity Effects on Articulatory Motor Performance in Progressive Dysarthria,2022-05,COMPLETED,2022-02-28,PRINCIPAL_INVESTIGATOR,Mili Kuruvilla,University of Missouri-Columbia,"['Amyotrophic Lateral Sclerosis', 'Parkinson Disease']",INTERVENTIONAL,100.0,ACTUAL,"[{'name': 'Phonetic complexity effects on speech motor performance', 'description': 'Use of 3D electromagnetic articulography to examine phonetic complexity effects of single word stimuli at the articulatory kinematic level in talkers each with preclinical, mild, and moderate dysarthria, relative to healthy controls.'}]","['Dysarthria', 'Speech motor performance', 'Speech motor control', 'Speech kinematics']",
Safety of Caprylic Triglycerides in ALS: A Pilot Study,2018-04,COMPLETED,2018-04-25,PRINCIPAL_INVESTIGATOR,Dr. Dale J. Lange,Weill Medical College of Cornell University,['ALS'],INTERVENTIONAL,10.0,ESTIMATED,"[{'name': 'Axona', 'description': 'medical powder, supplement food'}]",,
Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients,2005-01,COMPLETED,,,,Nantes University Hospital,['Dementia'],INTERVENTIONAL,52.0,ACTUAL,[{'name': 'memantine'}],"['frontotemporal dementia', 'MÃ©mantine', 'Patients with frontotemporal dementia']",
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS),2018-04,COMPLETED,2013-05,SPONSOR_INVESTIGATOR,"Yunxia Wang, MD","Yunxia Wang, MD",['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,36.0,ACTUAL,"[{'name': 'rasagiline', 'description': 'rasagiline 2 mg daily for 12 months'}]",,
Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis,2024-01,RECRUITING,2024-12,SPONSOR,,MaaT Pharma,"['Amyotrophic Lateral Sclerosis', 'ALS']",INTERVENTIONAL,15.0,ESTIMATED,"[{'name': 'MaaT033', 'description': 'MaaT033 is a Microbiome Ecosystem Therapy (MET), composed of allogeneic, full-ecosystem pooled biotherapeutic gut microbiota.'}]","['Microbiotherapy', 'Amyotrophic Lateral Sclerosis', 'Neurodegenerative disease', 'ALS']",
Arimoclomol in Amyotropic Lateral Sclerosis,2023-08,COMPLETED,2020-12-18,SPONSOR,,ZevraDenmark,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,245.0,ACTUAL,"[{'name': 'Arimoclomol', 'description': '2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily'}, {'name': 'Placebo', 'description': '2 matched placebo capsules taken 3 times daily'}]","['Arimoclomol', 'ALS']",
Virtual Peer-to-peer Support Programme for Carers of MND,2023-04,RECRUITING,2024-12-31,PRINCIPAL_INVESTIGATOR,Louise Rose,King's College London,"['Motor Neuron Disease', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,154.0,ESTIMATED,"[{'name': 'Virtual peer-to-peer support', 'description': 'See arm description'}]",['caregiver'],
Language Treatment for Progressive Aphasia,2015-01,COMPLETED,2010-12,PRINCIPAL_INVESTIGATOR,Regina Jokel,Baycrest,"['Primary Progressive Aphasia', 'Nonfluent Progressive Aphasia', 'Semantic Dementia']",INTERVENTIONAL,7.0,ACTUAL,"[{'name': 'Errorless learning', 'description': 'Language testing,20 sessions of language therapy, and 2 neuroimaging sessions for participants with progressive aphasia Language testing and 1 imaging session for healthy controls'}]","['progressive aphasia', 'semantic dementia', 'neuroimaging', 'treatment', 'errorless learning']",
Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement,2007-04,COMPLETED,2007-09,,,Johns Hopkins University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,60.0,ESTIMATED,[{'name': 'noninvasive positive pressure ventilation'}],"['bipap', 'lou gehrigs disease', 'motor neuron disease', 'respiratory muscles']",
tDCS Effect on Cognitive Functions From Patients With Alzheimer's Disease or Progressive Primary Aphasia,2017-10,UNKNOWN,2018-07-31,SPONSOR,,Centre Hospitalier Universitaire de Besancon,"[""Alzheimer's Disease"", 'Progressive Primary Aphasia', 'Early or Mild State']",INTERVENTIONAL,52.0,ESTIMATED,"[{'name': 'transcranial Direct Current Stimulation (tDCS)', 'description': 'After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 2 session per day during 5 consecutive days. Subjects will be monitored during tDCS sessions for any side effects or adverse events.'}]",,
Electronic-health Application To Measure Outcomes REmotely Clinical Trial,2020-04,COMPLETED,2018-03,PRINCIPAL_INVESTIGATOR,"Anne-Marie Alexandra Wills, MD",Massachusetts General Hospital,"['Neurodegenerative Disease', 'Weight Loss', 'Amyotrophic Lateral Sclerosis', ""Parkinson's Disease"", ""Huntington's Disease"", 'Cachexia']",INTERVENTIONAL,78.0,ACTUAL,"[{'name': 'In-Person Nutritional Counseling by a Registered Dietitian'}, {'name': 'Nutritional counseling using an e-Health Application'}]",,
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech,2023-11,RECRUITING,2028-06,PRINCIPAL_INVESTIGATOR,Jennifer Whitwell,Mayo Clinic,"['PPA', 'Non-fluent Aphasia', 'Apraxia of Speech', 'Primary Progressive Non-fluent Aphasia', 'Primary Progressive Aphasia']",INTERVENTIONAL,50.0,ESTIMATED,"[{'name': 'AV-1451', 'description': 'This is used to assess Tau burden in the brain.'}]","['apraxia of speech', 'non-fluent aphasia', 'aphasia']",
Intermuscular Coherence as a Biomarker for ALS,2023-05,RECRUITING,2025-12-31,SPONSOR,,University of Chicago,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,650.0,ESTIMATED,,['ALS'],"AIM 1: The study population includes patients with symptomatology suggestive of ALS who are referred to neuromuscular clinics at one of the four participating centers.

AIM 2: All healthy subjects between 20 and 80 years old.

AIM 3: Patients with suspected ALS who had an initially detectible IMC-Î²Î³."
"Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)",2018-03,COMPLETED,2015-09,SPONSOR,,Brainstorm-Cell Therapeutics,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,14.0,ACTUAL,"[{'name': 'MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF'}]","['Mesenchymal Strmal Cells (MSC)', 'Amyotrophic Lateral Sclerosis (ALS)', 'Neuroprotection', 'Neurodegeneration', 'Stem cells']",
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism,2017-12,TERMINATED,2010-02,SPONSOR,,"Masonic Cancer Center, University of Minnesota","[""Hurler's Syndrome"", 'Maroteaux-Lamy Syndrome', 'Sly Syndrome', 'Alpha Mannosidosis', 'Fucosidosis', 'Aspartylglucosaminuria', 'Sphingolipidoses', 'Krabbe Disease', ""Wolman's Disease"", 'Niemann-Pick Disease Type B', 'Niemann-Pick Disease, Type C']",INTERVENTIONAL,18.0,ACTUAL,"[{'name': 'Stem Cell Transplantation', 'description': ""The purpose of hematopoietic stem cell transplantation is to introduce blood producing cells from a normal donor. These cells can either provide what is missing in the body to the other cells, or can change the body's immune response to the substances that have accumulated in the body. These normal hematopoietic stem cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut). The new donor cells repopulate the blood and bone marrow system and enter the organs of the body, including the brain. Wherever these cells go, they will produce the needed enzyme.""}, {'name': 'Cyclophosphamide', 'description': 'Days before Transplant Drug Frequency\n\n* 4 Cyclophosphamide Once, given over 2 hours\n* 3 Cyclophosphamide Once, given over 2 hours\n* 2 Cyclophosphamide Once, given over 2 hours\n* 1 Cyclophosphamide Once, given over 2 hours'}, {'name': 'Campath-1H', 'description': 'Days before Transplant Drug Frequency\n\n12 Campath-1H Once, given over 2 hours\n\n11 Campath-1H Once, given over 2 hours\n\n10 Campath-1H Once, given over 2 hours'}, {'name': 'Busulfan', 'description': 'Days before Transplant Drug Frequency\n\n9 Busulfan Four times per day\n\n8 Busulfan Four times per day\n\n7 Busulfan Four times per day\n\n6 Busulfan Four times per day'}]","['Inborn errors of metabolism', 'Sphingolipidoses', 'Recessive Leukodystrophies- GLD, Krabbe disease, MLD', 'Peroxisomal Disorders', 'Wolman syndrome', 'Niemann-Pick B patients', 'Niemann-Pick C subtype 2']",
Correlation Between Intestinal Microflora Metabolites and Amyotrophic Lateral Sclerosis,2021-06,COMPLETED,2021-06-01,SPONSOR,,Peking University Third Hospital,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,40.0,ACTUAL,"[{'name': 'diagnosed with ALS', 'description': 'diagnosed with ALS'}]",,patients diagnosed with Sporadic ALS
R(+)PPX High Dose Treatment of ALS,2010-09,COMPLETED,2009-01,,,"Bennett, James P., Jr., M.D., Ph.D.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,10.0,ACTUAL,"[{'name': 'R(+) pramipexole dihydrochloride monohydrate', 'description': '100 mg tid orally daily'}]","['neuroprotection', 'oxidative stress']",
Social Cognition in Ageing and in Frontotemporal Lobar Degeneration,2013-10,UNKNOWN,2014-11,SPONSOR,,"University Hospital, Caen","['Frontotemporal Lobar Degeneration', 'Aging']",INTERVENTIONAL,80.0,ESTIMATED,"[{'name': 'Cognitive assessment'}, {'name': 'Brain imaging examination MRI'}]",,
Natural History Characterization in Symptomatic and Asymptomatic Progranuline Gene Mutation Carriers,2019-03,UNKNOWN,2022-02,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,['Frontotemporal Lobar Degeneration'],INTERVENTIONAL,90.0,ESTIMATED,"[{'name': 'Behavioral : Characterization', 'description': 'Behavioral scales and neuropsychological tests; MRI, SPECT/PET'}]","['Frontotemporal Dementia,', 'biomarkers,', 'brain Imaging PET']",
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia,2023-10,RECRUITING,2026-12,SPONSOR_INVESTIGATOR,"Leigh R. Hochberg, MD, PhD.","Leigh R. Hochberg, MD, PhD.","['Anarthria', 'Dysarthria', 'Tetraplegia', 'Spinal Cord Injuries', 'Amyotrophic Lateral Sclerosis', 'Brain Stem Infarctions', 'Locked in Syndrome', 'Muscular Dystrophies']",INTERVENTIONAL,2.0,ESTIMATED,"[{'name': 'BrainGate Neural Interface System', 'description': 'Placement of the BrainGate2 sensor(s) into the speech-related cortex'}]",,
"An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis",2016-01,TERMINATED,2015-10,SPONSOR,,Newron Sweden AB,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,15.0,ACTUAL,"[{'name': 'sNN0029', 'description': 'ICV infusion'}]","['ALS', 'VEGF165', 'Safety', 'Intracerebroventricular', 'Infusion', 'Implantable']",
Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis,2007-04,COMPLETED,2007-02,,,UMC Utrecht,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,165.0,ACTUAL,[{'name': 'Sodium Valproate'}],"['ALS', 'Sodium Valproate', 'randomised trial', 'Amyotrophic Lateral Sclerosis (ALS)']",
Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis,2019-05,COMPLETED,2017-04-10,PRINCIPAL_INVESTIGATOR,Seung Hyun Kim,Hanyang University Seoul Hospital,"['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease', 'Neuromuscular Disease', 'Neurodegenerative Disease', 'Central Nervous System Disease']",INTERVENTIONAL,6.0,ACTUAL,"[{'name': 'HYNR-CS-Allo', 'description': 'The patients enrolled in the trial will be successively allocated into three cohorts for HYNR-CS-Allo inj., 0.25 X 10\\^6 cells/kg, 0.5 X 10\\^6 cells/kg, 1 X 10\\^6 cells/kg, according to the 3+3, up and down protocol design. The first treatment cohort will be 0.5 X 10\\^6 cells/kg dose cohort.'}]","['Amyotrophic Lateral Sclerosis', 'ALS', 'Neurodegenerative disease', 'Motor Neuron Disease', 'Central Nervous System Disease', 'Neuromuscular Disease', 'Bone marrow derived stem cell', 'stem cell therapy', 'intrathecal injection']",
NeuroCognitive Communicator: Safety Study,2022-07,RECRUITING,2024-04-15,SPONSOR,,Ottawa Hospital Research Institute,"['Motor Neuron Disease, Amyotrophic Lateral Sclerosis', 'Tetraplegia']",INTERVENTIONAL,2.0,ESTIMATED,"[{'name': 'NeuroCognitive Communicator', 'description': 'Comprises an electrode array in prefrontal cortex, another in motor cortex, Blackrock NeuroPort system and connectors, augmentative assistive communication application, robotic arm, and virtual reality environment.'}]","['Brain-Computer Interface', 'Brain-Machine Interface', 'Prefrontal Cortex']",
First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis,2017-09,COMPLETED,2011-09-09,SPONSOR,,GlaxoSmithKline,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,76.0,ACTUAL,"[{'name': 'PLACEBO', 'description': 'Placebo'}, {'name': 'GSK1223249', 'description': 'I.V Infusion'}]",,
The Ontario Neurodegenerative Disease Research Initiative,2019-09,COMPLETED,2018-04-30,SPONSOR,,Ontario Neurodegeneration Disease Research Initiative,"['Alzheimer Disease', 'Amyotrophic Lateral Sclerosis', 'Frontotemporal Dementia', 'Parkinson Disease', 'Stroke']",OBSERVATIONAL,522.0,ACTUAL,[{'name': 'Observational Cohort'}],,"Approximately six hundred (600) participants who have one of the following diseases: VCI (150), AD/MCI (150); PD (150); FTD (60) and ALS (90) are to be enrolled."
"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants",2024-01,RECRUITING,2024-08-27,SPONSOR,,Vesper Biotechnologies ApS,"['Dementia, Frontotemporal']",INTERVENTIONAL,78.0,ESTIMATED,"[{'name': 'VES001', 'description': 'VES001 is an oral, blood brain barrier penetrating ligand of sortilin.'}, {'name': 'Placebo', 'description': 'A matching dosage form, indistinguishable from the active treatment will be used as the placebo treatment.'}]",,
The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS,2020-10,UNKNOWN,2023-10-31,SPONSOR,,Ruijin Hospital,"['Amyotrophic Lateral Sclerosis', 'Respiratory Function', 'Scopolamine']",INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'Scopolamine, atropine, edaravone and dexmedetomidine', 'description': 'The patients were treated with scopolamine, atropine, edaravone and dexmedetomidine dissolved in saline.'}, {'name': 'Edaravone', 'description': 'The patients was treated with edaravone dissolved in the same volume of saline as the intervention applied in the experimental group.'}]",,
Miglustat in Niemann-Pick Type C Disease,2010-03,COMPLETED,2008-01,,,Actelion,['Niemann-Pick Type C Disease'],INTERVENTIONAL,29.0,ACTUAL,"[{'name': 'miglustat', 'description': 'Patients aged 12 years or more randomised to the treatment group will receive 200 mg OGT 918 three times daily initially for twelve months. An additional sub-study of up to 12 patients aged under 12 years will receive a lower dose of OGT 918 according to their BSA'}]","['Zavesca', 'miglustat', 'Niemann-Pick Type C', 'Actelion']",
IC14 for Treatment of Amyotrophic Lateral Sclerosis,2020-05,WITHDRAWN,2021-12-15,SPONSOR,,Implicit Bioscience,"['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease']",INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'IC14', 'description': 'Monoclonal antibody against CD14'}, {'name': 'Placebo', 'description': 'sterile normal saline for injection prepared to be identical to study drug'}]",['monoclonal antibody'],
Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS),2017-10,WITHDRAWN,2009-07,PRINCIPAL_INVESTIGATOR,d_yarnitsky,Rambam Health Care Campus,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,0.0,ACTUAL,,,Amyotrophic lateral sclerosis and Healthy subjects
Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis,2013-09,SUSPENDED,2014-05,SPONSOR,,TCA Cellular Therapy,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,6.0,ESTIMATED,"[{'name': 'autologous bone marrow-derived stem cells', 'description': 'All patients will receive a unique one-time intrathecal infusion of the cell product suspended in infusion medium.'}]","['ALS', ""Lou Gehrig's Disease""]",
"Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia",2009-08,UNKNOWN,2009-10,,,GAAD Medical Research Institute Inc.,['Pick Disease of the Brain'],INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Radiation: Far Infrared Radiation (5Î¼m to 20Î¼m wavelength)', 'description': 'Far Infrared Radiation (5Î¼m to 20Î¼m wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.'}]","['Brain Atrophy, Circumscribed Lobar', 'Circumscribed Lobar Atrophy of the Brain', 'Lobar Atrophy (Brain)', 'Pick Disease', ""Pick's Disease"", 'Picks Disease of Brain']",
"The Influence of Vascular Burden, Amyloid Plaque and Tau Protein in Patients With Vascular Cognitive Impairment and Dementia With Tauopathy",2023-04,RECRUITING,2025-11-30,SPONSOR,,Chang Gung Memorial Hospital,"[""Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia""]",INTERVENTIONAL,220.0,ESTIMATED,"[{'name': 'PMPBB3', 'description': 'F-18 PMPBB3 PET Imaging'}, {'name': 'AV45', 'description': 'F-18 AV45 PET Imaging'}]","[""Vascular cognitive impairment, Alzheimer's disease, fronto-temporal dementia, amyloid plaque, tau protein""]",
Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C,2023-05,ACTIVE_NOT_RECRUITING,2026-01-31,SPONSOR,,ZevraDenmark,"['Niemann-Pick Disease, Type C']",INTERVENTIONAL,50.0,ACTUAL,"[{'name': 'arimoclomol'}, {'name': 'Placebo'}]","['NPC1', 'Niemann-Pick Type C', 'Niemann-Pick', 'arimoclomol', 'lysosomal storage disorder', 'lysosomal storage disease', 'NPC2', 'NP-C']",
Evaluation of Palliative Care for Patients With ALS and Their Caregivers,2022-09,ACTIVE_NOT_RECRUITING,2022-10-30,SPONSOR,,Ottawa Hospital Research Institute,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,66.0,ACTUAL,"[{'name': 'Palliative Care consultation outside standard of care', 'description': ""The ALS patients and their caregivers will receive a consultation with a palliative care physician. This will take approximately one hour and occur in their location of choice (ie. often the patient's home). Subsequent palliative care consultations will occur at the discretion of the ALS patient and the palliative care physician.""}]","['amyotrophic lateral sclerosis', 'palliative care', 'caregivers']",
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies,2016-12,COMPLETED,2016-08,PRINCIPAL_INVESTIGATOR,Danna Jennings,Molecular NeuroImaging,"[""Alzheimer's Disease (AD)"", 'Progressive Supranuclear Palsy (PSP)', 'Cortical Basal Syndrome (CBS)', 'Frontal Temporal Dementia (FTD)']",INTERVENTIONAL,7.0,ACTUAL,"[{'name': '[18F]MNI-815 (MNI-815)', 'description': 'All enrolled subjects will undergo an \\[18F\\]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo \\[18F\\]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.'}]",,
tDCS and Speech Therapy for Motor Speech Disorders Caused by FTLD Syndromes: a Feasibility Study,2022-08,WITHDRAWN,2023-11-30,SPONSOR,,"University of California, San Francisco","['Nonfluent Aphasia, Progressive', 'Primary Progressive Nonfluent Aphasia', 'Primary Progressive Non Fluent Aphasia', 'Progressive Supranuclear Palsy', 'Corticobasal Degeneration', 'Behavioral Variant of Frontotemporal Dementia']",INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Halo Neuroscience Neurostimulator', 'description': 'Experimental: Neurostimulation of 2 milliamps anodal (active) tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework.\n\nActive comparator: Experimental: Sham tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of neurostimulation of 2 milliamps anodal (active) sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks.'}]","['Motor Speech Disorders', 'Dysarthria', 'Apraxia of Speech']",
Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products,2020-07,TERMINATED,2020-06-30,SPONSOR,,Children's Hospital of Philadelphia,"['ALS', 'Autism Spectrum Disorder', 'Cancer', 'Spasticity, Muscle', 'Dyskinetic Syndrome', 'Epilepsy', 'Glaucoma', 'Huntington Disease', 'Inflammatory Bowel Disease (IBD)', 'Multiple Sclerosis', 'Neuropathy', 'Opioid Use', 'Parkinson Disease', 'HIV/AIDS', 'Ptsd', 'Intractable Pain', 'Sickle Cell Disease', 'Terminal Illness']",OBSERVATIONAL,10.0,ACTUAL,"[{'name': 'Registry', 'description': 'Collect data on subjects'}, {'name': 'PK microsampling of blood', 'description': 'Obtain 5 microsamples of blood from subjects via a fingerstick.'}]",,"Patients \> 2 years old who are being treated with Dream, Shine, Ease or Soothe products manufactured by Ilera Healthcare for a state approved qualifying medical condition under the PA State Medical Marijuana Program."
Safety and Feasibility of the EyeControl Device,2019-08,COMPLETED,2017-02-28,SPONSOR,,Eyefree Assisting Communication Ltd,['ALS (Amyotrophic Lateral Sclerosis)'],INTERVENTIONAL,15.0,ACTUAL,"[{'name': 'EyeControl device', 'description': 'Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences'}]",,
Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate),2014-11,COMPLETED,2012-05,SPONSOR,,Knopp Biosciences,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,68.0,ACTUAL,"[{'name': 'Dexpramipexole', 'description': '300 mg - Oral Tablets'}, {'name': 'Dexpramipexole', 'description': '600 mg Oral Tablets'}, {'name': 'Dexpramipexole Placebo', 'description': 'Placebo - Oral Tablet'}, {'name': 'Moxifloxacin', 'description': '400 mg - Oral Tablet'}]",,
rTMS as a Treatment for PPA,2022-04,COMPLETED,2022-01-01,PRINCIPAL_INVESTIGATOR,"Mark C. Eldaief, MD",Massachusetts General Hospital,"['Logopenic Variant Primary Progressive Aphasia', 'Non-Fluent Primary Progressive Aphasia']",INTERVENTIONAL,12.0,ACTUAL,"[{'name': 'Active rTMS', 'description': 'All study participants will receive one block of active rTMS. Each block will consist of daily sessions of 20Hz active rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).'}, {'name': 'SHAM rTMS', 'description': 'All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of 20Hz SHAM rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).'}]","['rTMS', 'PPA']",
Cognitive Consequences of an Activation of the Cortical Drive to Breath (VENTIPSY),2021-07,COMPLETED,2019-07-04,SPONSOR,,Association pour le DÃ©veloppement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil,"['Ondine Syndrome', 'Healthy', 'Amyotrophic Lateral Sclerosis']",OBSERVATIONAL,65.0,ACTUAL,"[{'name': 'Neuropsychological tests', 'description': 'A battery of tests to evaluate the overall cognitive performance of the subjects (memory, executive, attentional or instrumental functions)'}]",,Patients and healthy volunteers
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP,2023-11,RECRUITING,2025-03-31,SPONSOR,,National Taiwan University Hospital,"['Amyotrophic Lateral Sclerosis', 'Plasmapheresis']",INTERVENTIONAL,20.0,ESTIMATED,"[{'name': 'Plasmapheresis', 'description': 'Regular plasmapheresis to remove anti-NRIP autoantibody'}]",,
Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis,2018-11,TERMINATED,2015-10-22,SPONSOR,,"University Hospital, Bordeaux","['Amyotrophic Lateral Sclerosis', 'ALS']",OBSERVATIONAL,5.0,ACTUAL,"[{'name': 'Clinical evaluation', 'description': 'Clinical evaluation using MRC scale, Norris bulbar scale, ALSFRS score and respiratory evaluation ( Vital Capacity, PiMax and SNIP) at M0, M4, M8, M12'}, {'name': 'Muscular biopsy', 'description': 'Muscular biopsy at M0'}, {'name': 'Lumbar puncture', 'description': 'Lumbar puncture at M0 and M12'}, {'name': 'Blood sampling', 'description': 'Blood sampling at M0, M4, M4, M8 and M12'}, {'name': 'Neurological assessments', 'description': 'Neurological assessments (MRC score and cognitive scales: MMS and BREF)'}, {'name': 'Neuro-muscular biopsy and lumbar puncture', 'description': 'Neuro-muscular biopsy and lumbar puncture for patients explored for peripheral neuropathy'}, {'name': 'Muscular biopsy', 'description': 'Muscular biopsy for patient explored for myopathy'}, {'name': 'Blood sample', 'description': 'Blood sample for qRT PCR, detection and quantification for miRNA'}, {'name': 'Cervical spinal cord and brain MRI', 'description': 'ALS patients : MRI at inclusion and Month 8 Control patients suffering from neuropathy : MRI at inclusion and Month 8 Control patients suffering from myopathy : MRI at inclusion Control subjects : MRI at inclusion'}]","['ALS', 'miRNA', 'biomarker', 'monocentric observational study']","Patients suffering from ALS, neuropathy, myopathy or control subjects having a shoulder surgery during which they will have a muscle (deltoid) biopsy"
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS),2023-03,WITHDRAWN,2022-03,SPONSOR,,Clene Nanomedicine,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Gold Nanocrystals', 'description': 'CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.'}]","['Neurodegeneration', 'gold', 'nanocrystal', 'NAD+', 'NADH', 'Redox', 'Redox Ratio', 'ALS', 'Amyotrophic Lateral Sclerosis', '31P-MRS', 'MRS', 'magnetic resonance spectroscopy', 'nanoparticle', 'nanomedicine']",
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease,2024-01-29,RECRUITING,2030-10-03,SPONSOR,,National Institute of Mental Health (NIMH),"['Dementia', ""Alzheimer's Disease"", 'ALS', ""Parkinson's Disease""]",INTERVENTIONAL,168.0,ESTIMATED,"[{'name': '11C-MC1', 'description': 'Injected IV followed by PET scanning'}, {'name': '11C-PS13', 'description': 'Injected IV followed by PET scanning'}, {'name': '18f-florbetaben', 'description': 'Injected IV followed by PET scanning'}]","['ALS', 'PET Imaging', 'Inflammation', 'Cyclooxygenase-2', 'Dementia', 'PD']",
Group-Based Telehealth Music Therapy Intervention for Patients With Dementia: A Pilot Study,2024-01,COMPLETED,2024-01-29,SPONSOR,,Geisinger Clinic,"['Behavioral and Psychiatric Symptoms of Dementia', 'Alzheimer Disease', 'Lewy Body Disease', 'Frontotemporal Dementia']",INTERVENTIONAL,48.0,ACTUAL,"[{'name': 'Music therapy intervention', 'description': 'The format of the sessions may include: a greeting song to orient the participant to the start of the session; singing of 1-3 preferred/chosen songs to address cognition and communication; two movement songs with instrument playing interventions to stimulate cognition and movement; songwriting for self-expression, cognitive, and emotional support; relaxation/mindfulness; a closing song to help the participant transition at the completion of the session, The music therapist also provides training to caregivers in techniques to utilize music for behavioral support.'}, {'name': 'Personalized music CD', 'description': 'Participants will receive a personalized music CD that they keep and can listen to as they wish.'}]",,
Long-term Effect of TMS in Primary Progressive Aphasia,2024-01,ACTIVE_NOT_RECRUITING,2024-07-31,PRINCIPAL_INVESTIGATOR,Jordi A Matias-Guiu,"Hospital San Carlos, Madrid","['Primary Progressive Aphasia', 'Frontotemporal Dementia', 'Alzheimer Disease']",INTERVENTIONAL,63.0,ACTUAL,"[{'name': 'Transcranial Magnetic Stimulation (active)', 'description': 'Theta-burst transcranial magnetic stimulation (active) delivered over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by 1 session per week.'}, {'name': 'Language therapy', 'description': 'Language therapy immediately after each TMS session. Daily sessions for two weeks followed by 1 session per week.'}, {'name': 'Transcranial Magnetic Stimulation (sham)', 'description': 'Theta-burst transcranial magnetic stimulation (sham) delivered over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by 1 session per week.'}]","['brain stimulation', 'transcranial magnetic stimulation']",
MIROCALS: Modifying Immune Response and OutComes in ALS,2022-04,COMPLETED,2021-07-22,SPONSOR,,Centre Hospitalier Universitaire de NÄ«mes,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,304.0,ACTUAL,"[{'name': 'Riluzole', 'description': 'All patients will be treated with Riluzole for a period of three months prior to final inclusion and randomization. Riluzole treatment will continue throughout the 18 months of follow-up planned for in this protocol.\n\nRiluzole treatment is part of routine care for patients with ALS.'}, {'name': 'IL-2', 'description': 'The dose of IL-2 to be used in this study will be 2.0 million IU/day.\n\nEach treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period.\n\nIn case of intolerance, a flexible dose-reduction schedule is available.'}, {'name': '5% glucose water solution', 'description': 'The placebo consists of 5% glucose water solution, which is the matrix with which low-dose IL-2 injections are prepared in the experimental arm. Placebo injections are prepared in exactly the same manner as IL-2 injections, just without the IL-2.\n\nEach treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period.'}]","['interleukin-2', 'low-dose interleukin-2']",
Hand Grasping Techniques on Eliciting the Grasp Reflex in Patients With Dementia,2019-10,COMPLETED,2018-05-23,PRINCIPAL_INVESTIGATOR,Lauren Fedor,Rowan University,['Dementia'],INTERVENTIONAL,1.0,ACTUAL,"[{'name': 'palmar grasp without dorsal stimulation', 'description': 'The patient will then be asked to keep the arms at 90 degrees and the researcher will slightly stroke palm and fingers of both hands of the patient simultaneously. After completion of each technique, the presence or absence of the response will be noted. In addition, the prominence of the response on the rating scale will be obtained as explained below.\n\nThe scaling of the grasp response is as followed:\n\n1. Flexion at the distal interphalangeal joint of the hand\n2. Flexion at the proximal interphalangeal joint of the hand\n3. Flexion at the metacarpal-phalangeal joint of the hand'}, {'name': 'standard palmar grasp test with dorsal stimulation', 'description': ""The patient will be asked to put their arms at 90 degrees and the researcher will hold one hand at the wrist and dorsum of the palm and lightly stroke the palm and fingers. The patient will be instructed to relax hands and not hold on while doing the grasp and see if the response persists. The same technique will be repeated for the patient's other hand.""}]",['dementia'],
ECOCAPTURE for the Assessment of Apathy Under Real-life Conditions,2021-04,UNKNOWN,2023-09,SPONSOR,,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France","['Frontotemporal Dementia, Behavioral Variant', 'Alzheimer Disease']",OBSERVATIONAL,120.0,ESTIMATED,"[{'name': 'Remote collection of passive and active data for 28 consecutive days', 'description': 'Passive sensor data: collected continuously for 28 days, from a multi-sensor wearable bracelet worn by each member of the dyad; Active questionnaire data: collected once a week during the four weeks of monitoring (and at the end of the 28 days for patient-caregiver dyads), from questionnaires filled by one partner of the dyad (for patient-caregiver dyads, this will be the caregiver) using a smartphone application.'}]",,"20 patient-caregiver dyads with patients suffering from behavioral variant front-temporal dementia, 20 patient-caregiver dyads with patients suffering from Alzheimer disease, 20 healthy control dyads"
Propranolol in Primary Progressive Aphasia,2023-10,RECRUITING,2026-10,PRINCIPAL_INVESTIGATOR,David Beversdorf,University of Missouri-Columbia,"['Aphasia, Primary Progressive']",INTERVENTIONAL,20.0,ESTIMATED,"[{'name': 'Propranolol', 'description': 'Propranolol will be given on a titration schedule in which participants will begin with small doses of the drug and increase to a larger dosage over the course of three weeks. Propranolol will be taken for a total of 9 weeks.'}, {'name': 'Magnetic Resonance Imaging (MRI)', 'description': 'Magnetic Resonance Imaging (MRI) will be performed at 3 Tesla and 7 Tesla, for both propranolol and placebo arms.'}, {'name': 'Placebo', 'description': 'Placebo will be given on the same schedule as the propranolol regime.'}]",,
Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis,2020-11,TERMINATED,2012-08,PRINCIPAL_INVESTIGATOR,Robert C. Basner,Columbia University,"['Amyotrophic Lateral Sclerosis', 'Motor Neuron Disease']",INTERVENTIONAL,8.0,ACTUAL,"[{'name': 'noninvasive positive pressure ventilation', 'description': 'Each subject will undergo 2 hours of high-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 12 cm H2O and an expiratory positive airway pressure of 3 cm H2O.'}, {'name': 'noninvasive positive pressure ventilation', 'description': 'Each subject will undergo 2 hours of low-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 6 cm H2O and an expiratory positive airway pressure of 3 cm H2O.'}]",['noninvasive ventilation'],
Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD),2023-08,TERMINATED,2023-06-27,SPONSOR,,Wave Life Sciences Ltd.,"['ALS', 'FTD']",INTERVENTIONAL,35.0,ACTUAL,"[{'name': 'WVE-004', 'description': 'WVE-004 is a stereopure antisense oligonucleotide (ASO)'}, {'name': 'Placebo', 'description': 'Artificial cerebrospinal fluid (aCSF)'}]",,
Alleviating Persistent Dyspnea in Amyotrophic Lateral Sclerosis Patients Treated With Non-Invasive Ventilation Through Immersive Virtual Reality,2023-10,NOT_YET_RECRUITING,2025-12,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,35.0,ESTIMATED,"[{'name': 'Immersive virtual reality (IVR) & Music therapy', 'description': 'The patient will be offered a digital therapy session based on immersive virtual reality (IVR) and a music therapy session, 60 minutes apart. The IVR session will be based on medical hypnosis (GAMIDAÂ®) and the music therapy session will be based on the choice of music the patient wishes. Each session will last 15 minutes. Patients will start either with the medical hypnosis session by IVR or with the music session depending on the randomization carried out before the start of the study. The random order will be provided by software (CleanWeb).'}]","['Persistent Dyspnea', 'Non-Invasive Ventilation', 'Immersive Virtual Reality']",
Sleep Disorders and the Onset and Progression of ALS,2021-06,UNKNOWN,2022-03-31,SPONSOR,,Peking University Third Hospital,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,200.0,ESTIMATED,"[{'name': 'sleep disorder', 'description': 'ALS patients with or without sleep disorder'}]",,"patients diagnosed as probable, or definite ALS"
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE,2016-08,COMPLETED,2015-12,SPONSOR,,Clionsky Neuro Systems Inc.,"['Mild Cognitive Impairment', 'Dementia', 'Hypoxia', 'Hyperhomocysteinemia', 'Vitamin B 12 Deficiency', 'Iron Deficiency', 'Anemia', 'TBI', 'Neurodegenerative Disorders', ""Alzheimer's Disease"", 'Vascular Dementia', 'Brain Injuries', 'Tauopathies', ""Parkinson's Disease"", 'Lewy Body Dementia', 'Frontotemporal Dementia', 'TDP-43 Proteinopathies']",OBSERVATIONAL,900.0,ACTUAL,,"['Psuedobulbar affect, PBA']","Cohort 1: Consecutive patients presenting for care for cognitive impairment in a non-academic, non-hospital based, dementia specialty practice in Springfield, MA Cohort 2: Convenience sample of patients referred to neuropsychological testing and treated by non-dementia specialists in Springfield, MA"
Telemonitoring in NIV MND (OptNIVent),2022-03,NOT_YET_RECRUITING,2022-12-31,SPONSOR,,Liverpool University Hospitals NHS Foundation Trust,"['Motor Neuron Disease, Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,15.0,ESTIMATED,"[{'name': 'Telemonitoring via CareportalÂ®', 'description': ""The question sets and overnight oximetry results will be monitored and screened by a call centre commissioned by the Liverpool Clinical Commissioning Group (LCCG). The call centre will screen the weekly data and contact clinicians where appropriate (i.e. NIV team, MND specialist nurse, or patient's GP). PVI data will be examined by NIV physiotherapists, where required, following the contact from LCCG to ensure the maximum benefits of NIV to patients.""}]","['non-invasive ventilation', 'Telehealth', 'Telemonitoring']",
Study of Cognitive and Emotional Disorders in Amyotrophic Lateral Sclerosis,2014-03,UNKNOWN,2015-05,SPONSOR,,"University Hospital, Caen",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,90.0,ESTIMATED,"[{'name': 'MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research', 'description': 'At T0 and T9 or 12 monts, are performed :\n\n* Imaging : fMRI at rest and anatomical MRI\n* Neuropsychological assessments : general cognitive functioning, theory of mind, executive functions ...'}]",['Amyotrophic lateral sclerosis'],
A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),2017-08,COMPLETED,2017-03-31,SPONSOR,,"Eisai Co., Ltd.",['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,135.0,ACTUAL,"[{'name': 'E0302 (mecobalamin)', 'description': 'Intramuscular injection, mecobalamin twice a week.'}]","['Amyotrophic Lateral Sclerosis', 'Motor Neurons', 'Muscular Atrophy']",
Cerebro Spinal Fluid Collection (CSF),2023-04,RECRUITING,2030-12,SPONSOR,,"University Hospital, Strasbourg, France","['Alzheimer Disease', 'Dementia With Lewy Bodies', 'Frontotemporal Dementia', ""Parkinson's Disease Dementia"", 'Multiple System Atrophy']",OBSERVATIONAL,10000.0,ESTIMATED,"[{'name': 'Lumbar punction', 'description': 'Lumbar punction'}]","['CSF library', 'Database of patients with cognitive disorders']",All patients with cognitive disorders observed at the memory center of Strasbourg and in whom a lumbar puncture is performed as part of the patient's diagnosis.
A Registered Cohort Study on Amyotrophic Lateral Sclerosis,2021-02,RECRUITING,2059-07,PRINCIPAL_INVESTIGATOR,"Ning Wang, MD., PhD.",First Affiliated Hospital of Fujian Medical University,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,2000.0,ESTIMATED,,"['amyotrophic lateral sclerosis', 'natural history', 'genetics', 'prognostic factors']",ALS patients who are diagnosed in the First Affiliated Hospital of Fujian Medical University
A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B),2023-03-22,COMPLETED,2022-07-01,SPONSOR,,Sanofi,['Amyotrophic Lateral Sclerosis (Healthy Volunteers)'],INTERVENTIONAL,16.0,ACTUAL,"[{'name': 'SAR443820', 'description': 'Tablet by oral administration'}, {'name': 'SAR443820', 'description': 'Capsule by oral administration'}, {'name': 'Erythromycin ethyl succinate', 'description': 'Tablet by oral administration'}, {'name': 'Itraconazole', 'description': 'Capsule by oral administration'}]",,
"Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation",2015-05,UNKNOWN,,SPONSOR,,FORUM Pharmaceuticals Inc,['Granulin Mutation'],INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'FRM-0334'}, {'name': 'Placebo'}]","['Histone deacetylase inhibitor', 'Frontotemporal dementia', 'Granulin']",
mGluR5 Imaging in ALS Using PET,2022-04,RECRUITING,2025-04,SPONSOR_INVESTIGATOR,Nathalie Braun,Nathalie Braun,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ESTIMATED,"[{'name': '[ 18 F]PSS232', 'description': '\\[ 18 F\\]PSS232 for imaging metabotropic glutamate receptor subtype 5 and comparing expression of the receptor in healthy persons and ALS patients'}]","['Receptor, Metabotropic Glutamate 5', 'Brain / diagnostic imaging', 'Positron-Emission Tomography / methods', 'Radiopharmaceuticals / pharmacokinetics*', 'PSS232', 'Humans', 'Adult']",
Growth Hormone in Amyotrophic Lateral Sclerosis,2010-05,COMPLETED,2010-05,,,Federico II University,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,40.0,ESTIMATED,"[{'name': 'Growth Hormone (Somatropin)', 'description': 'The initial dose will be 2U s.c. every other day. The dose will be progressively increased to reach 1.5-2x the normal levels of IGF-I.'}, {'name': 'Placebo', 'description': 'Same as for Growth hormone group'}]","['Amyotrophic Lateral Sclerosis', 'ALS', 'Growth Hormone', 'IGF-I']",
Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD),2023-01,TERMINATED,2023-06-30,SPONSOR,,Wave Life Sciences Ltd.,"['ALS', 'FTD']",INTERVENTIONAL,8.0,ACTUAL,"[{'name': 'WVE-004', 'description': 'WVE-004 is a stereopure antisense oligonucleotide. It is administered via intrathecal injection'}]",,
Contralateral R1 in Amyotrophic Lateral Sclerosis,2024-01,NOT_YET_RECRUITING,2025-03-01,SPONSOR,,Hospices Civils de Lyon,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,120.0,ESTIMATED,"[{'name': 'blink reflex evaluation', 'description': 'A blink reflex evaluation will be performed in all subjects'}]","['Amyotrophic lateral sclerosis', 'ALS', 'Electroneuromyography', 'ENMG']","Patients referred to the neurophysiology unit from the Hospices civils de Lyon, for a suspicion of motor neuron disease.

And healthy volunteers for the third group."
Dysfunctions and Plasticity Mechanisms of Motor System Assessed by Cortico-cortical and Cortico-muscular Coherence Analysis in Amyotrophic Lateral Sclerosis,2015-08,SUSPENDED,,SPONSOR,,Assistance Publique Hopitaux De Marseille,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'electroencephalograms (EEG)'}, {'name': 'electro-myography (EMG)'}]",,
Safety/Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in ALS,2019-05,UNKNOWN,2021-10,PRINCIPAL_INVESTIGATOR,Seung Hyun Kim,Hanyang University Seoul Hospital,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,6.0,ACTUAL,"[{'name': 'HYNRCS-Allo inj', 'description': 'The patients enrolled in the trial will be successively allocated into single cohort for HYNRCS-Allo inj., 1.0 X 10\\^6 cells/kg according to the protocol design.'}]","['ALS', 'Motor Neuron Disease', 'Neuromuscular Disease', 'Neurodegenerative Disease', 'Central Nervous System Disease', 'HLA-haplo matched allogenic bone marrow derived stem cells']",
Retinal Imaging in Neurodegenerative Disease,2024-01,RECRUITING,2025-12-31,SPONSOR,,Duke University,"[""Alzheimer's Disease"", 'Mild Cognitive Impairment', ""Parkinson's Disease"", 'Multiple Sclerosis', 'Huntington Disease', 'Lewy Body Dementia', 'Frontotemporal Dementia', 'Amyotrophic Lateral Sclerosis (ALS)', 'APOE-4 Positive', 'Traumatic Brain Injury', 'Concussion', 'Post-Traumatic Stress Disorder', 'Down Syndrome', 'Neuro-Degenerative Disease', 'Normal Cognition']",OBSERVATIONAL,2000.0,ESTIMATED,"[{'name': 'Retinal and Choroidal Imaging', 'description': 'Non-invasive OCT, OCTA, and UWF fundus photography of retina'}]","['OCT angiography (OCTA)', 'Optical Coherence Tomography (OCT)', 'Vessel Density', 'Superficial Capillary Plexus', 'Retinal microvasculature', 'Scanning Laser Ophthalmoscopy', 'Ultra-widefield (UWF) Imaging', 'Perfusion Density', 'Retinal Nerve Fiber Layer', 'Ganglion Cell Inner Plexiform Layer', 'Choroidal Vascularity Index']",Neurology Clinics and the community.
Counterfactual Thinking in Amyotrophic Lateral Sclerosis,2023-03,RECRUITING,2023-09-30,SPONSOR,,Istituto Auxologico Italiano,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,157.0,ESTIMATED,"[{'name': 'Neuropsychological instruments', 'description': 'Neuropsychological instruments assessing cognitive (including counterfactual abilities), behavioural and psychopathological features'}]",,ALS patients coming to clinical attention and community resident healthy controls
Computational Tools for Early Diagnosis of Memory Disorders,2017-05,COMPLETED,2017-04,PRINCIPAL_INVESTIGATOR,Hilkka Soininen,University of Eastern Finland,"['Alzheimer Disease', 'Frontotemporal Dementia', 'Dementia, Vascular', 'Mild Cognitive Impairment']",OBSERVATIONAL,126.0,ACTUAL,,"['Alzheimer Disease', 'Frontotemporal Dementia', 'Dementia, Vascular', 'Mild Cognitive Impairment', 'Diagnosis', 'Risk factors', 'Biomarkers', 'AD', 'FTD', 'VAD', 'MCI']","Control subjects with normal cognition

The Alzheimer's disease, Fronto-temporal dementia, Vascular dementia, and Mild Cognitive Impairment will be recruited during their visit in the Neurological clinic at the Kuopio University Hospital."
Respiratory Muscle Training (RMT) in ALS,2023-01,COMPLETED,2022-11-29,SPONSOR,,Duke University,['ALS'],INTERVENTIONAL,9.0,ACTUAL,"[{'name': 'Respiratory Muscle Training', 'description': 'Two commercially available pressure-threshold RMT devices that utilize a spring-loaded flange to provide resistance against inspiration and expiration independent of respiratory flow rate will be used to provide the necessary range of resistance. Each participant will use two RMT devices, one for IMT and one for EMT.'}]",,
Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1,2023-09,RECRUITING,2025-12,SPONSOR,,"Cyclo Therapeutics, Inc.","['Niemann-Pick Disease, Type C1']",INTERVENTIONAL,93.0,ESTIMATED,"[{'name': 'Hydroxypropyl-beta-cyclodextrin', 'description': 'Dose is 2000 mg/kg body weight provided every 2 weeks intravenously'}, {'name': 'Placebo', 'description': '0.5N saline provided every 2 weeks intravenously'}]","['NPC1', 'cyclodextrin', 'Niemann-Pick', 'Niemann-Pick Type C', 'NPC', 'Niemann Pick C', 'Niemann Pick Type C', 'Niemann Pick']",
"Dysphagia, QoL and Attitudes Towards PEG in ALS Patients",2023-09,RECRUITING,2026-03-31,SPONSOR,,"University Rehabilitation Institute, Republic of Slovenia",['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,60.0,ESTIMATED,"[{'name': 'Iowa Oral Performance Instrument (IOPI)', 'description': 'IOPI measures the peak pressure of the tongue strength and endurance using a disposable bulb placed on a hard palate behind the front teeth or at the base of the tongue. The participants will be asked to press the bulb with their tongue with maximum pressure, three times. To measure the endurance, the participants will be asked to hold the pressure for as long as they can.'}, {'name': 'Mann Assessment of Swallowing Ability (MASA)', 'description': 'MASA is a standard clinical swallowing assessment protocol including general patient examination, on-the-outside visible signs of oral preparatory and transportation phase and pharyngeal phase of swallowing function.'}, {'name': 'Fiberoptic Endoscopic Evaluation of Swallowing', 'description': 'The subjects will ingest up to 10 boluses ranging in thickness and volume (from thin to extremely-thick and a cookie).'}, {'name': 'Respiratory function measurements', 'description': 'Respiratory function measurements will include forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP), all expressed in percentage of predicted values. Conventional methods of testing will be applied.'}]",,"The study will include adult ALS patients able to visit the study site for in-person procedures every 3 months, and their close relatives."
"Performance of AclarusDxâ„¢, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center",2012-07,COMPLETED,,SPONSOR,,Exonhit,"[""Alzheimer's Disease"", 'Mild Cognitive Impairment', 'Vascular Dementia', 'Fronto-temporal Dementia', 'Primary Progressive Aphasia', ""Parkinson' Disease Dementia"", 'Mixed Dementia']",OBSERVATIONAL,160.0,ACTUAL,,"[""Alzheimer's disease"", 'AD', 'Non AD dementia', 'Mild Cognitive Impairment', 'MCI', 'Vascular dementia', 'Fronto-temporal dementia', 'Primary progressive aphasia', ""Parkinson's Disease dementia"", 'Mixed dementia', 'Blood signature', 'Diagnosis', 'AclarusDx', ""Alzheimer's Disease and other non-AD dementia"", 'Exonhit']",Caucasian patients that are newly referred to a Reference Memory Center with a complaint of memory impairment will be enrolled in the study.
Magnetic Resonance Imaging (MRI) in Amyotrophic Lateral Sclerosis (ALS),2015-08,WITHDRAWN,2015-04,PRINCIPAL_INVESTIGATOR,Dr. Jeffrey Rothstein,Johns Hopkins University,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,0.0,ACTUAL,[{'name': '7 Tesla MRI'}],,
Diaphragmatic Pacer Placement: Anesthetic Management (DP),2016-10,COMPLETED,2015-10,SPONSOR,,Institut Guttmann,"['Spinal Cord Injuries', 'Amyotrophic Lateral Sclerosis', 'Respiratory Paralysis']",OBSERVATIONAL,16.0,ACTUAL,"[{'name': 'Diaphragmatic Pacer', 'description': ""The surgical procedure of DP implantation consists in placing four intramuscular electrodes, using a conventional abdominal laparoscopy with four ports. It consists in locating the optimum point for electrode insertion. The process involves mapping between 30 and 50 different points in each hemidiaphragm by applying an electric stimulus of 2-24 mA at 100 Âµsec pulse widths11. It results in both qualitative and quantitative assessment of diaphragmatic movement. Site of main electrode is identified as the location of each hemidiaphragm's change of maximum pressure and site of secondary electrode as replica of main site. Once the sites are identified intramuscular electrode placement phase is initiated. Finally the electrodes are tunneled out to the corresponding percutaneous exit site.""}]","['Pacemaker, Artificial', 'Diaphragmatic pacing']",all patients conducted to diaphragmatic pacer placement from December 2007 to July 2015 at our institution
Communication Bridge Speech Therapy Research Study,2022-11,COMPLETED,2020-01,PRINCIPAL_INVESTIGATOR,Emily Rogalski,Northwestern University,"['Primary Progressive Aphasia', 'Frontotemporal Dementia']",INTERVENTIONAL,57.0,ACTUAL,"[{'name': 'Monthly Check-in Session', 'description': ""Subjects in the Check-In group will have an online session with a speech-language pathologist 3-, 4-, and 5-months from the subject's enrollment date.""}]","['primary progressive aphasia', 'progressive nonfluent aphasia', 'progressive aphasia', 'frontotemporal dementia', 'frontotemporal lobar degeneration']",
Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia,2023-06,RECRUITING,2027-11-30,SPONSOR,,University of Texas at Austin,"['Primary Progressive Aphasia', 'Dementia', 'Dementia, Frontotemporal', 'Alzheimer Disease', 'Neurodegenerative Diseases', 'Frontotemporal Lobar Degeneration', 'Apraxia, Motor', 'Dysarthria', 'Communication Disorders', 'Language Disorders', 'Speech Disorders', 'Neurocognitive Disorders', 'Aphasia', 'Bilingual Aphasia']",INTERVENTIONAL,60.0,ESTIMATED,"[{'name': 'Video-Implemented Script Training for Aphasia (VISTA)', 'description': 'Participants with nonfluent/agrammatic variant primary progressive aphasia (PPA) or a predominantly nonfluent profile work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes two (one hour each) teletherapy sessions per week with a clinician targeting clear and accurate script production, script memorization, and conversational usage of scripts. The participant completes 30 minutes of independent, computer-based practice 5-7 times per week, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts.'}, {'name': 'Lexical Retrieval Training (LRT)', 'description': 'Participants with logopenic variant PPA, participants with semantic variant PPA, and participants with a predominantly anomic profile will work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) teletherapy sessions per week with a clinician plus 30 minutes of additional independent, computer-based practice exercises 5-7 times per week.'}]","['Dementia, ADRD', 'Bilingualism', 'Multilingualism', 'Primary Progressive Aphasia', 'Bilingual Primary Progressive Aphasia', 'Cognitive Reserve', 'Language Decline', 'Bilingual Language Decline', 'Speech-Language Therapy', 'Bilingual Speech-Language Therapy', 'Spanish speakers', 'Spanish-Catalan Bilinguals', 'Spanish-English Bilinguals', 'Hispanic', 'CatalÃ¡n', 'Catalan', 'Spanish', 'Castellano', 'Speech Therapy', 'Latino', 'Cognition']",
Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis,2019-05,WITHDRAWN,2018-03-27,SPONSOR,,Aquestive Therapeutics,['ALS'],INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Riluzole Oral Soluble Film', 'description': 'Riluzole Oral Soluble Film (ROSF) containing Riluzole 50mg .'}]",['Amyotrophic Lateral Sclerosis'],
Application of Miglustat in Patients With Niemann-Pick Type C,2012-11,COMPLETED,2010-12,SPONSOR,,National Taiwan University Hospital,['Niemann-Pick Disease Type C'],INTERVENTIONAL,5.0,ACTUAL,"[{'name': 'Miglustat', 'description': 'miglustat 200mg tid for adult. For children surface area correction will be made. A lower dose may be used initially to decrease side effect.'}]","['Niemann-Pick disease type C', 'miglustat']",
Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma,2022-11,TERMINATED,2022-09-30,SPONSOR,,Sunnybrook Health Sciences Centre,"['Cholangiocarcinoma', 'Bile Duct Cancer']",INTERVENTIONAL,8.0,ACTUAL,"[{'name': 'Trifluridine/Tipiracil', 'description': 'FTD/TPI is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. Trifluridine is the active cytotoxic component of FTD/TPI; its triphosphate form is incorporated into DNA, with such incorporation appearing to result in its anti- tumor effects. Tipiracil hydrochloride is a potent inhibitor of thymidine phosphorylase and, when combined with trifluridine to form FTD/TPI, prevents the rapid degradation of the trifluridine, allowing for the maintenance of adequate plasma levels of the active drug.'}]","['Cholangiocarcinoma', 'Bile Duct Cancer', 'FTD/TPI', 'TRIFLURIDINE/TIPIRACIL']",
CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS,2017-08,UNKNOWN,2018-03-30,SPONSOR,,"Chemigen, LLC",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,21.0,ESTIMATED,"[{'name': 'CC100', 'description': 'synthetic caffeic acid phenethylester'}, {'name': 'Placebos', 'description': 'Diluent'}]",,
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects,2020-07,COMPLETED,2020-06-30,PRINCIPAL_INVESTIGATOR,Bradley Boeve,Mayo Clinic,['Familial Frontotemporal Dementia'],OBSERVATIONAL,398.0,ACTUAL,,"['Frontotemporal Dementia', 'MAPT', 'PGRN', 'C9ORF72']","Have a mutation, or be a relative of an individual with a mutation, in one of the three most common genes associated with Frontotemporal Dementia - microtubule associated protein tau (MAPT), progranulin (PGRN; also known as granulin or GRN), or chromosome 9 open reading frame 72 (C9ORF72)."
Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS,2016-01,COMPLETED,2015-12,PRINCIPAL_INVESTIGATOR,Maurizio Inghilleri,University of Roma La Sapienza,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,50.0,ACTUAL,"[{'name': 'endocannabinoid palmitoylethanolamide (PEA)', 'description': 'Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily'}, {'name': 'Riluzole', 'description': 'Riluzole 50 mg twice daily'}]",,
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISIONâ„¢) as a Useful Cognitive Biomarker for Alzheimer's Disease.,2014-03,COMPLETED,2014-02,SPONSOR,,"Neuronetrix, Inc.","['Memory Disorders', 'Alzheimer Disease', 'Dementia', 'Cognitive Impairment', 'Frontotemporal Dementia']",OBSERVATIONAL,204.0,ACTUAL,"[{'name': 'COGNISIONâ„¢ System', 'description': '30 minute ERP test and 3 minute resting EEG data collected from cognitively healthy and AD to validate ERP and qEEG as useful cognitive biomarkers for AD.'}]","['Alzheimer', 'Memory disorder', 'dementia', 'cognitive behavioral decline', 'vascular dementia', 'front temporal dementia']",Subjects between 60 and 90 years old meeting DSM-IV criteria for dementia of the Alzheimer's type and NINCDS-ADRDA criteria for probable AD will be recruited in the AD cohort. Matched cognitively healthy volunteers will be recruited for the Control group.
Functional Near-Infrared Spectroscopy (fNIRS) Combined With Diffuse Correlation Spectroscopy (DCS) in Neurocognitive Disease as Compared to Healthy Neurotypical Controls,2023-11-16,RECRUITING,2026-03-01,SPONSOR,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),"['Juvenile Neuronal Ceroid Lipofuscinosis', 'Smith-Lemli-Opitz Syndrome', 'Creatine Transporter Deficiency', 'Niemann-Pick Disease Type C1']",OBSERVATIONAL,100.0,ESTIMATED,,"['Brain Hypometabolism', 'Cerebral Blood Flow', 'Portable Brain Imaging', 'Cerebral O2 Changes', 'Neurocognitive Disorders', 'Natural History']","individuals 6 months and older without known health or medical issues (i.e. healthy volunteers), and individuals with known neurocognitive disorders (i.e. affected). Healthy volunteers will be age- and sex-matched to the affected cohort"
Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS,2024-01,RECRUITING,2025-02-28,SPONSOR,,PTC Therapeutics,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,258.0,ESTIMATED,"[{'name': 'PTC857', 'description': 'PTC8657 will be administered as an oral solution twice a day.'}, {'name': 'Placebo', 'description': 'Matching placebo will be administered as an oral solution twice a day.'}]",,
Clinical Trial on the Use of Cell Therapy in the Treatment of Patients With Amyotrophic Lateral Sclerosis,2021-04,UNKNOWN,2023-09-01,SPONSOR,,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,['ALS (Amyotrophic Lateral Sclerosis)'],INTERVENTIONAL,100.0,ESTIMATED,"[{'name': 'MNC (Mononuclear cells)', 'description': '* Intramuscular infusion of autologous BM CMN into the TA muscle of one of the lower limbs (experimental side)\n* Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)'}, {'name': 'Placebo / Saline', 'description': '- Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)'}]",,
An Open Label Extension Study of Monepantel in Individuals With Motor Neurone Disease,2023-12,NOT_YET_RECRUITING,2025-04-01,SPONSOR,,PharmAust Ltd,['Motor Neuron Disease'],INTERVENTIONAL,12.0,ESTIMATED,"[{'name': 'Monepantel', 'description': 'Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals'}]",,
Peripheral Neurofilament Levels and Amyotrophic Lateral Sclerosis,2020-07,COMPLETED,2019-05-01,SPONSOR,,Peking University Third Hospital,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,103.0,ACTUAL,"[{'name': 'LMND-ALS', 'description': 'in line with LMND -ALS inclusion criteria, and CMAP amplitude of peripheral motor nerves (CMAP amplitude of the 10 peripheral motor nerves with the most obvious CMAP amplitude decline was selected as the CMAP amplitude for grouping of the patients) was less than the median of CMAP amplitude of LMND -ALS group.'}, {'name': 'UMND-ALS', 'description': 'The main clinical manifestations were limb stiffness and spasm, obvious pyramidal tract signs, relatively mild muscle atrophy and fasciculation, and no significant decrease in amplitude of electromyography CMAP.'}, {'name': 'FAS and FLS', 'description': 'The clinical symptoms were confined to upper limbs (FAS) or lower limbs (FLS) for more than 12 months, and the main manifestations were lower motor neuron involvement signs such as muscle weakness and atrophy.'}]",['Amyotrophic Lateral Sclerosis; Neurofilament levels'],"Patients with lower motor neuron involvement (LMND-ALS), who have visited the Department of Neurology of the Third Hospital of Beijing Medical University since August 2017, meet the diagnostic criteria for ALS in 1998."
An Efficacy and Safety Study of Ravulizumab in ALS Participants,2022-12,TERMINATED,2021-10-17,SPONSOR,,"Alexion Pharmaceuticals, Inc.","['Amyotrophic Lateral Sclerosis', 'ALS']",INTERVENTIONAL,382.0,ACTUAL,"[{'name': 'Placebo', 'description': 'Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.'}, {'name': 'Ravulizumab', 'description': 'Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.'}]","['Ravulizumab', 'ALXN1210', 'Ultomiris', 'Motor Neuron Disease', 'Amyotrophic Lateral Sclerosis', 'ALS']",
"Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine",2013-04,COMPLETED,2010-11,SPONSOR,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),"['Niemann-Pick Disease, Type C']",INTERVENTIONAL,35.0,ACTUAL,"[{'name': 'N-Acetyl Cysteine', 'description': '900mg effervescent tablet; Dosed as 15 mg/kg/day (maximum dose 900 mg per day) for one week, advanced to 30 mg/kg/day (maximum dose 1800 mg per day) for the second week, and then advanced to 60 mg/kg/day (maximum dose 2700 mg) for the remainder of the trial (6 additional weeks).'}]","['Niemann-Pick Disease, Type C', 'Biomarkers', 'N-Acetyl Cysteine', 'Oxidized Cholesterol', 'Neurodegeneration', 'NPC']",
A P300 Brain Computer Interface to Operate Power Wheelchair Tilt,2016-06,COMPLETED,2010-08,PRINCIPAL_INVESTIGATOR,"Jane Huggins, PhD",University of Michigan,"['Healthy', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,16.0,ACTUAL,"[{'name': 'Using a BCI to control wheelchair tilt', 'description': 'Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) during each session and use a P300 based BCI to type words and control wheelchair tilt. Subjects will be asked to participate in 3 sessions.'}]","['Brain computer interface', 'wheelchair control']",
Regulatory T Cells for Amyotrophic Lateral Sclerosis,2024-02,RECRUITING,2027-12,SPONSOR,,"Cellenkos, Inc.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,66.0,ESTIMATED,"[{'name': 'CK0803', 'description': 'CK0803 (cryopreserved, allogeneic, cord blood derived T regulatory cells that express neurotropic homing markers) will be administered intravenously'}, {'name': 'Excipient', 'description': 'Excipient'}]","['ALS', 'Cellenkos', 'T Regulatory Cells', 'Randomized Placebo Control Trial', 'Umbilical cord blood', 'Amyotrophic Lateral Sclerosis']",
ALS Reversals - Lunasin Regimen,2018-11,COMPLETED,2017-09-13,SPONSOR_INVESTIGATOR,"Richard Bedlack, M.D., Ph.D.","Richard Bedlack, M.D., Ph.D.",['ALS (Amyotrophic Lateral Sclerosis)'],INTERVENTIONAL,60.0,ACTUAL,"[{'name': 'Lunasin Regimen', 'description': 'LunaRich X Capsules, Reliv Now, ProVantage'}, {'name': 'Historical control', 'description': 'Matched historical controls will be identified from the PatientsLikeMe database.'}]",,
Memantine Therapy in Amyotrophic Lateral Sclerosis,2009-11,COMPLETED,2009-10,,,"Phoenix Neurological Associates, LTD",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,20.0,ACTUAL,[{'name': 'Memantine'}],['ALS'],
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,2022-04,COMPLETED,2020-07-23,SPONSOR,,"Orion Corporation, Orion Pharma",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,496.0,ACTUAL,"[{'name': 'Levosimendan', 'description': 'Levosimendan 1 mg capsule for oral administration'}, {'name': 'Placebo for levosimendan', 'description': 'Placebo capsule for oral administration'}]",,
Davunetide (AL-108) in Predicted Tauopathies - Pilot Study,2019-04,COMPLETED,2012-12,PRINCIPAL_INVESTIGATOR,Adam Boxer,"University of California, San Francisco","['Predicted Tauopathies, Including', 'Progressive Supranuclear Palsy', 'Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17', 'Corticobasal Degeneration Syndrome', 'Progressive Nonfluent Aphasia']",INTERVENTIONAL,12.0,ACTUAL,"[{'name': 'davunetide (AL-108, NAP)', 'description': 'Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with davunetide 15 mg administered intranasally.'}, {'name': 'Placebo nasal spray', 'description': 'Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with placebo administered intranasally.'}]","['Frontotemporal Dementia', 'Corticobasal Degeneration', 'Progressive Nonfluent Aphasia', 'Progressive Supranuclear Palsy', 'FTLD', 'FTD', 'PNFA', 'CBD', 'PSP', 'Predicted tauopathies, including:', 'Progressive Supranuclear Palsy (PSP)', '(CBS)', 'Progressive Nonfluent Aphasia (PNFA)']",
Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS),2010-10,COMPLETED,,,,"Neuraltus Pharmaceuticals, Inc.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,56.0,ESTIMATED,"[{'name': 'NP001', 'description': 'Cohort 1: 0.3 mg/kg NP001(6:2 active:placebo) Cohort 2: 1.1 mg/kg NP001(6:2 active:placebo) Cohort 3: 2.1 mg/kg NP001(6:2 active:placebo) Cohort 4: 4.3 mg/kg NP001(6:2 active:placebo)'}, {'name': 'Placebo', 'description': 'Cohort 1: placebo Cohort 2: placebo Cohort 3: placebo Cohort 4: placebo'}]",,
AMDX-2011P Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy,2023-01,RECRUITING,2023-12,SPONSOR,,Amydis Inc.,"['Parkinson Disease', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,36.0,ESTIMATED,"[{'name': 'AMDX2011P', 'description': 'AMDX2011P single bolus injection intravenous for diagnostic review'}]","['Parkinsons', 'ALS']",
"Safety, Tolerability, and Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Amyotrophic Lateral Sclerosis (ALS) Patients With SOD1 Mutations",2023-11,NOT_YET_RECRUITING,2032-02-27,SPONSOR,,UniQure Biopharma B.V.,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,42.0,ESTIMATED,"[{'name': 'AMT-162', 'description': 'AMT-162, the investigational product (IP), is a non-replicating, rep/cap-deleted, self-complementary Recombinant adeno-associated virus (rAAV) vector based on adeno-associated virus (AAV) serotype rh10 and contains complementary deoxyribonucleic acid (cDNA) encoding an artificial miRNA targeting the SOD1 gene.'}]","['Gene Therapy', 'AAV (adeno-associated virus)', 'serotype Rh10 AAV', 'ALS', 'SOD1']",
Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-RÂ® Inj.) Treatment in Patients With ALS,2023-07,ACTIVE_NOT_RECRUITING,2026-05-03,SPONSOR,,"Corestemchemon, Inc.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,115.0,ESTIMATED,"[{'name': 'Lenzumestrocel', 'description': 'Single cycle administration group : injections twice in a 26-day interval Multiple administration group : injections twice in a 26-day interval followed by repeated three times injections every three months'}, {'name': 'Riluzole', 'description': 'concomitant administration of Riluzole to all groups, except subjects to whom Riluzole administration is deemed impossible owing to adverse events as determined by medical experts'}, {'name': 'Placebo Comparator', 'description': 'Single cycle administration group: Placebo comparator is injected three times every three months after injection of Lenzumestrocel twice in a 26-day interval.\n\nControl group: Placebo comparator is injected twice in a 26-day interval followed by repeated three times injcections every three months'}]","['Amyotrophic lateral sclerosis', 'Mesenchymal stem cell', 'cell therapy', 'ALS', 'neuroprotection', 'Phase 3 clinical trial']",
"A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)",2023-08,RECRUITING,2025-01-18,SPONSOR,,AL-S Pharma,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,63.0,ESTIMATED,"[{'name': 'AP-101', 'description': 'Participants receive AP-101 by intravenous infusion (IV).'}, {'name': 'Placebo', 'description': 'Participants receive placebo by IV.'}]","['Familial Amyotrophic Lateral Sclerosis', 'Sporadic Amyotrophic Lateral Sclerosis']",
Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis),2008-10,COMPLETED,2007-09,,,US Department of Veterans Affairs,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,40.0,ACTUAL,"[{'name': 'sodium phenylbutyrate', 'description': 'histone deacteylase inhibitor'}]","['ALS', 'histone deacetylase inhibition', 'open label', 'safety study', 'sodium phenylbutyrate']",
Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS),2016-08,COMPLETED,2020-10-27,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,"['Frontotemporal Lobar Degeneration', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,100.0,ESTIMATED,[{'name': 'characterization'}],"['frontotemporal Dementia', 'Amyotrophic lateral sclerosis', 'Biomarkers', 'brain Imaging PET']",
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,2017-11,COMPLETED,2015-01-22,SPONSOR,,GlaxoSmithKline,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,304.0,ACTUAL,"[{'name': 'Ozanezumab', 'description': 'Ozanezumab injection solution'}, {'name': 'Placebo', 'description': 'Normal saline (0.9% sodium chloride) infusion'}]","['Amyotrophic lateral sclerosis', 'efficacy', 'ozanezumab', 'safety']",
Multimodal Brain Imaging Study,2021-06,UNKNOWN,2021-09-01,SPONSOR,,Peking University Third Hospital,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,40.0,ESTIMATED,"[{'name': 'MRI,', 'description': 'In this project, multi-modal brain imaging methods, such as resting-state functional MRI, task-state functional MRI, structural MRI and diffusion tensor imaging, will be used to analyze brain structure, gray matter morphology, white matter fibrous brain functional activation mode and brain functional connectivity network, and other dimensions.\n\nIn particular, combined with the brain functional activities of ALS patients in the cognitive processing task of language understanding and language use, the brain network damage of ALS patients in motor and executive function was compared, and the neural activities and network mechanism of specific changes in language cognitive processing in ALS patients were investigated. Combined with the clinical neuropsychological behavior evaluation data'}]",,"(I) Study population

1. Inclusion criteria:

1. Satisfied clinically possible ALS, laboratory supported suspected ALS, clinically suspected ALS or clinically confirmed ALS in the diagnostic criteria of ALS EL Escorial revised in 1998
2. Ages 18-70
3. Agree and sign the informed consent

2. Exclusion criteria:

1. Severe respiratory dysfunction, unable to cooperate with NMR examination
2. Severe dysarthria and limb dysfunction, unable to cooperate with the neuropsychological examination
3. Patients with absolute or relative contraindications to MRI, including: a) Patients with cardiac pacemakers, cochlear implants, built-in pumps, nerve stimulators, artificial metal heart valves, etc.; B) After ligation of aneurysm clip (except non-paramagnetic, such as titanium alloy); C) Internal ferromagnetic metal implants (excluding metal IUD and fixed dentures); D) Claustrophobic; E) Patients with epilepsy
4. Pregnant patients
5. illiterate"
UPenn Observational Research Repository on Neurodegenerative Disease,2024-02,RECRUITING,2070-05-30,SPONSOR,,University of Pennsylvania,"['Frontotemporal Degeneration(FTD)', 'Primary Progressive Aphasia(PPA)', 'Familial Frontotemporal Lobar Degeneration (fFTLD)', 'Amyotrophic Lateral Sclerosis(ALS)', 'Lewy Body Disease(LBD)', 'Progressive Supranuclear Palsy(PSP)', 'Corticobasal Syndrome(CBS)', 'Posterior Cortical Atrophy(PCA)', ""Alzheimer's Disease(AD)""]",OBSERVATIONAL,1000.0,ESTIMATED,"[{'name': 'No intervention', 'description': 'No intervention'}]",,"To better understand neurodegenerative diseases, the investigators will include people living with these illnesses, people at risk of developing these illnesses, and people without neurodegenerative disease who wish to contribute to science as controls."
Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS,2022-11,TERMINATED,2022-08-16,SPONSOR,,"Hospital for Special Surgery, New York",['ALS'],INTERVENTIONAL,3.0,ACTUAL,"[{'name': 'rTMS', 'description': 'repetitive transcranial magnetic stimulation'}]",,
Real World Testing of a Brain-Computer Interface,2023-12,COMPLETED,2023-09-30,PRINCIPAL_INVESTIGATOR,Katya Hill,University of Pittsburgh,"['Amyotrophic Lateral Sclerosis', 'Brain Stem Stroke', 'Cerebral Palsy', 'Traumatic Brain Injury', 'Speech Disorders']",OBSERVATIONAL,19.0,ACTUAL,"[{'name': 'Speech generating device (SGD) evaluation including BCI access', 'description': ""At the initial evaluation the participants will review the full range of AAC options and speech generating devices (SGDs) and complete a speech and language evaluation. The second evaluation date will involve a trial of SGDs matched to the participant's assessment results. The third visit is the trial of an AAC system with BCI access. Should the dry electrode headgear for BCI access prove ineffective, then the gel electrode cap will be offered to the participant for trial. At the end of the third visit, the evaluation results will be discussed with participant and family, and they will be asked to select the preferred SGD.""}, {'name': 'Training and treatment', 'description': ""Participants receive training on the selected SGD followed by monthly treatment sessions from the SLP who monitors performance. In some cases the participants' SGD will be an AAC system with BCI access. In this case training will also include an identified system support person. Use of the SGD is monitored on a monthly basis through home visits and/or tele-practice sessions, when requested. Technical support for the SGD is provided on an as needed basis or when requested by the participant or support person.""}]",,Individuals with severe communication disabilities and minimal movement impairment.
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis,2016-09,UNKNOWN,2019-08,PRINCIPAL_INVESTIGATOR,Gerson Chadi,University of Sao Paulo General Hospital,['AMYOTROPHIC LATERAL SCLEROSIS'],INTERVENTIONAL,28.0,ESTIMATED,[{'name': 'Two intrathecal MSC injections'}],"['ALS', 'mesenchymal stem cells', 'intrathecal']",
Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in France,2023-08,RECRUITING,2025-01-30,SPONSOR,,Sanofi,['Acid Sphingomyelinase Deficiency (ASMD)'],OBSERVATIONAL,55.0,ESTIMATED,"[{'name': 'Olipudase alfa', 'description': 'GZ402665'}]",,All patients with a confirmed diagnosis of ASMD under early access to olipudase alfa in France (with a written informed consent)
A Study of PBFT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN),2024-02,RECRUITING,2027-08,SPONSOR,,"Passage Bio, Inc.","['Frontotemporal Dementia', 'FTD', 'FTD-GRN', 'Dementia Frontotemporal']",INTERVENTIONAL,15.0,ESTIMATED,"[{'name': 'PBFT02', 'description': 'PBFT02'}]","['frontotemporal dementia', 'Progranulin Mutations', 'FTD-GRN', 'Gene Therapy', 'Dementia Gene Therapy', 'AAV1', 'Fronto-temporal Dementia']",
The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS.,2023-09,RECRUITING,2025-08-31,SPONSOR,,Haukeland University Hospital,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,380.0,ESTIMATED,"[{'name': 'EH301 (Nicotinamide Riboside/Pterostilbene)', 'description': 'Comparison of 2 different dosages with placebo in newly diagnosed ALS patients and comparison of high dose with placebo in earlier ALS patients.'}]",,
The Care Ecosystem Consortium Effectiveness Study,2023-11,RECRUITING,2025-12-31,SPONSOR,,"University of California, San Francisco","['Dementia', 'Dementia, Vascular', 'Dementia With Lewy Bodies', 'Dementia Alzheimers', 'Frontotemporal Dementia']",INTERVENTIONAL,2550.0,ESTIMATED,"[{'name': 'Care Ecosystem', 'description': ""Applying the principles of person-and-family centered and collaborative care to dementia, the Care Ecosystem (CE) offers proactive, protocol-guided phone- and web-based caregiver support, guidance, and care coordination that extends the reach of dementia primary and specialty care. Care is delivered primarily via the phone and web by unlicensed Care Team Navigators (CTNs), who are trained and supervised by a team of dementia specialists with nursing, social work, and pharmacy expertise. Care Protocols guide proactive, quality care that is documented in the electronic health record (EHR).\n\nThe CTN is an unlicensed, trained dementia care guide who served as the PWD's and caregiver's primary point of contact to the program under nurse supervision. Care team navigators respond to caregivers' immediate needs first, then screen for common problems and provide personalized support and standardized education using the care plan protocols.""}]",,
Stratification of Presymptomatic Amyotrophic Lateral Sclerosis: the Development of Novel Imaging Biomarkers,2024-01,RECRUITING,2025-07-21,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,120.0,ESTIMATED,"[{'name': 'Neuroimaging and electrophysiology', 'description': 'Brain and spinal cord MRI, transcranial magnetic stimulation; Motor Unit Number Estimation, EEG'}]","['MRI', 'ALS', 'FTD', 'MUNE', 'C9orfF72', 'presymptomatic']",
Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS),2009-03,COMPLETED,2009-01,,,University of Lisbon,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,63.0,ACTUAL,"[{'name': 'Memantine (Ebixa)', 'description': '10 mg bid'}, {'name': 'riluzole', 'description': 'riluzole 50 mg bid'}, {'name': 'Placebo'}]","['amyotrophic lateral sclerosis', 'motor neuron disease', 'memantine', 'clinical trial']",
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia,2022-10,RECRUITING,2026-10,SPONSOR,,"University Hospital, Lille","['Alzheimer Disease', 'Frontotemporal Dementia']",OBSERVATIONAL,102.0,ESTIMATED,"[{'name': 'Lumbar puncture', 'description': '5 mL of CSF'}, {'name': 'blood sample', 'description': '6x5 mL of blood sample collected :1 dry tube, 2 EDTA tubes, 1 fluoride tube, and 2 polypropylene tubes'}]","['Alzheimer disease', 'Frontotemporal Dementia', 'tanycytes', 'metabolism', 'hormone', 'cerebrospinal fluid', 'blood', 'hypothalamus']",Subjects intended to participate will be recruited in Lille in the memory clinic and in the memory clinic network Meotis (North of France above Paris)
Efficacy and Safety of Plasma Exchange With AlbuteinÂ® 5% in Participants With Amyotrophic Lateral Sclerosis,2021-04,COMPLETED,2019-08-15,SPONSOR,,Grifols Therapeutics LLC,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,12.0,ACTUAL,"[{'name': 'Albutein 5%', 'description': 'Albutein is manufactured from human plasma. The dose of Albutein 5% for replacement following plasma removal will be calculated based on gender, weight, and the hematocrit of the participant.'}, {'name': 'Plasma Exchange', 'description': 'Plasma Exchange will be performed using albutein 5% as the replacement solution.'}]",,
"Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures",2023-11,RECRUITING,2031-12-31,SPONSOR,,"Target ALS Foundation, Inc.","['Amyotrophic Lateral Sclerosis', 'Movement Disorders', 'Degenerative Disorder', 'Motor Neuron Disease']",OBSERVATIONAL,280.0,ESTIMATED,,"['Amyotrophic Lateral Sclerosis', 'ALS Amyotrophic Lateral Sclerosis', 'Target ALS', 'Longitudinal Biofluids', 'Barrow Neurological Institute', 'New York Genome Center', 'Biofluids Biorepository', 'Genomic-wide association studies']","Clinic patients, with suspected, possible, probable-laboratory supported, and definite Amyotrophic Lateral Sclerosis, (ALS) according to revised El Escorial Criteria (EEC). Healthy volunteers will be family or friends of Clinic patients with suspected, possible probable, probable laboratory supported and definite Amyotrophic Lateral Sclerosis (ALS) according to revised El Escorial Criteria (EEC)."
The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS),2011-03,COMPLETED,2010-12,,,University of Alberta,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,42.0,ESTIMATED,[{'name': 'Memantine'}],"['Amyotrophic Lateral Sclerosis', 'ALS', 'Motor Neuron Disease', 'MND', 'Memantine']",
Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program,2017-01,COMPLETED,2016-11,PRINCIPAL_INVESTIGATOR,Christine Barr,Drexel University College of Medicine,"['Amyotrophic Lateral Sclerosis', 'Neurodegenerative Disease', 'Motor Neuron Disease']",OBSERVATIONAL,205.0,ACTUAL,,"['Amyotrophic Lateral Sclerosis', 'Cerebrospinal Fluid', 'Neurodegenerative Disease', 'Motor Neuron Disease', 'Autonomic Nervous System', 'Neurodegenerative Diseases', 'Movement Disorders']","ALS clinic patients at MDA/ALS Center of Hope, along with families and caregivers. Also those with ALS who have donated their bodies to research."
A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS),2012-11,COMPLETED,2012-09,SPONSOR,,"Neuraltus Pharmaceuticals, Inc.",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,136.0,ACTUAL,"[{'name': 'NP001', 'description': 'Low dose of NP001'}, {'name': 'NP001', 'description': 'High dose of NP001'}, {'name': 'Placebo', 'description': 'normal saline'}]",['ALS'],
Treating Primary Progressive Aphasia (PPA) Using tDCS,2023-10,RECRUITING,2024-07,SPONSOR,,University of Pennsylvania,['Primary Progressive Aphasia'],INTERVENTIONAL,62.0,ESTIMATED,"[{'name': 'Transcranial Direct Current Stimulation (tDCS)', 'description': 'tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. The current, 1.5 mA, is approximately of the same intensity as the current provided by a 9-volt battery. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp.'}, {'name': 'Sham tDCS', 'description': 'tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 1.5 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.'}, {'name': 'Modified Contraint-Induced Language Therapy (mCILT)', 'description': 'Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.'}]","['non-invasive brain stimulation', 'transcranial direct current stimulation (tDCS)', 'speech therapy']",
Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS,2024-01,NOT_YET_RECRUITING,2026-07,SPONSOR,,Johns Hopkins University,['ALS'],INTERVENTIONAL,20.0,ESTIMATED,"[{'name': '[11C]CPPC PET ligand', 'description': 'Radioactive PET ligand to determine microglia expression of colony stimulating factor 1 receptor (CSF1R).'}]",['Biomarkers'],
Investigation on Home Care Needs of ALS Patients and Their Caregivers,2021-06,COMPLETED,2021-05-01,SPONSOR,,Peking University Third Hospital,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,20.0,ACTUAL,"[{'name': 'The questionnaire survey', 'description': 'Questionnaires were issued and collected by 6 competent nurses with strict training, data entry by 2 researchers, statistical analysis by 1 researcher, and quality control by the other 2 researchers throughout the process.'}]",,"Six rigorously trained nurses in charge will issue and collect the questionnaire, two researchers will enter the data, one researcher will perform statistical analysis of the data, and the other two researchers will control the quality of the whole process."
Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease,2023-08,TERMINATED,2022-04-11,SPONSOR,,Mandos LLC,"['Niemann-Pick Disease, Type C']",INTERVENTIONAL,66.0,ACTUAL,"[{'name': 'Adrabetadex', 'description': 'Mallinckrodt test formulation, administered intrathecal (IT) via lumbar puncture (LP) infusion.'}]","['Niemann-Pick Type C1 (NPC1) Disease', 'neurologic disease', 'gross motor dysfunction', 'fine motor dysfunction', 'dysphagia', 'swallowing problems', 'cognitive dysfunction', 'gait abnormalities', 'pediatrics']",
"Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C",2024-01-02,RECRUITING,,SPONSOR,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),"['Niemann-Pick Disease, Type C']",OBSERVATIONAL,900.0,ESTIMATED,,"['Lysosomal Storage', 'Biomarkers', 'Longitudinal', 'Natural History', 'Niemann Pick Type C', 'NPC', 'Lysosomal Storage Disorder']",Patients of any age with Niemann-Pick type C
Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease,2023-06,COMPLETED,2023-06-02,SPONSOR,,University of Florida,"['Amyotrophic Lateral Sclerosis (ALS)', 'Neuromuscular Diseases']",INTERVENTIONAL,29.0,ACTUAL,"[{'name': 'Acute Intermittent Hypoxia', 'description': 'AIH entails continuous breathing as the level of oxygen in the air is decreased, then returned to normal. Participants will alternate between breathing normal air and breathing hypoxic air (air that has less oxygen). Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH). Breathing, muscle activity and heart activity will be monitored before, during and after the procedure. The intervals will last 1 minute each.'}, {'name': 'Sham Acute Intermittent Hypoxia', 'description': 'Participants will complete the sham acute intermittent hypoxia, consisting of a single 45 minute session of breathing air with normal oxygen levels. All aspects of this procedure will otherwise be the same as for the AIH procedure. Breathing, muscle activity and heart activity will be monitored before, during and after the procedure.'}]","['acute intermittent hypoxia (AIH)', 'respiratory motor function', 'hypoxia', 'normoxia', 'EMG (electromyography)']",
Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia,2020-10,COMPLETED,2012-12,SPONSOR,,"University of California, San Francisco","['Frontal Lobe Dementia', 'Frontotemporal Lobe Dementia', 'Semantic Dementia']",INTERVENTIONAL,81.0,ACTUAL,"[{'name': 'memantine', 'description': 'memantine 10mg BID'}, {'name': 'Placebo pill', 'description': 'Placebo pill BID'}]","['Randomized', 'Double-Blind', 'Placebo-Controlled', 'memantine', 'Namenda', 'Frontotemporal Dementia', 'Semantic Dementia', 'FTD', 'SD', 'dementia', 'behavioral decline', 'cognitive decline']",
A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD),2023-08,COMPLETED,2023-05-15,SPONSOR,,Sanofi,['Sphingomyelin Lipidosis'],INTERVENTIONAL,84.0,ACTUAL,"[{'name': 'Investigational Procedures', 'description': 'The investigational assessments will be performed'}]",,
The Effect of Low-Ä°ntensity Combined Exercises in Patients With Early Stage ALS.,2023-01,RECRUITING,2023-06,PRINCIPAL_INVESTIGATOR,Xhennet Muriqi,Istanbul University - Cerrahpasa (IUC),['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,30.0,ESTIMATED,"[{'name': 'Supervised exercise', 'description': 'The supervised group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks.'}, {'name': 'Home exercise', 'description': 'The home group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks in the home.'}]","['Amyotrophic lateral sclerosis', 'balance', 'fatigue', 'quality of life']",
Studies in Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Motor Neuron Disorders,2023-08,RECRUITING,2038-12,PRINCIPAL_INVESTIGATOR,Bjorn E. Oskarsson,Mayo Clinic,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,3000.0,ESTIMATED,,,Eligible subjects with ALS or suspected ALS or family history of ALS will be identified from patients seen in the Department of Neurology at Mayo Clinic Jacksonville. Inclusion criteria include standardized diagnostic criteria for ALS as used in ALS therapeutic trials and patients with clinically suspected ALS.
EMPOWER Early Feasibility Study: Non-invasive BCI to Control a Wheelchair for People With Paralysis,2024-01,NOT_YET_RECRUITING,2025-01,SPONSOR,,Synaptrix Labs Inc.,"['Neurologic Disorder', 'Paralysis', 'Paralysis; Stroke', 'Amyotrophic Lateral Sclerosis', 'Spinal Cord Injuries', 'Cervical Spinal Cord Injury', 'Tetraplegic; Paralysis', 'Quadriplegia/Tetraplegia']",INTERVENTIONAL,6.0,ESTIMATED,"[{'name': 'Intervention/Treatment', 'description': 'Non-invasive EEG headband device'}]","['Amyotrophic Lateral Sclerosis', 'Quadriplegia/Tetraplegia']",
Use of 1 Minute Sit to Stand Test for Physical Capacity and Effort Related Desaturation in Amyotrophic Lateral Sclerosis,2023-12,NOT_YET_RECRUITING,2025-03-01,PRINCIPAL_INVESTIGATOR,Ayse Asena Yekdaneh,Istanbul University - Cerrahpasa (IUC),['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,35.0,ESTIMATED,,"['Amyotrophic Lateral Sclerosis', 'Physical capacity', 'Desaturation', 'Dyspne']","Individuals with ALS who come to BakÄ±rkÃ¶y Psychiatric Hospital, Neurology Clinic and meet the inclusion criteria"
Quantitative and Repetitive TMS in ALS,2023-08,RECRUITING,2026-04-15,SPONSOR,,Sunnybrook Health Sciences Centre,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,15.0,ESTIMATED,"[{'name': 'Repetitive Transcranial Magnetic Stimulation', 'description': 'Accelerated rTMS using continuous theta burst stimulation inhibitory paradigms over bilateral M1 hand region outputted at 90% of resting motor threshold, using bursts of 3 pulses at 50 Hz. Bursts are repeated at 5 Hz for a total of 600 pulses over 40 seconds. ALS patients will receive rTMS bilaterally at a regimen of cTBS for 40 seconds per treatment, for up to 8 treatment sessions per day, delivered one per hour, over 5 days.'}]","['ALS', 'Repetitive transcranial magnetic stimulation', 'Corticospinal Excitability', 'Motor Neuron Disease', 'MR Spectroscopy', 'Cortical Hyperexcitability']",
Rehabilitation and Prophylaxis of Anomia in Primary Progressive Aphasia,2023-09,ACTIVE_NOT_RECRUITING,2024-06-30,PRINCIPAL_INVESTIGATOR,"Aaron Meyer, PhD",Georgetown University,"['Aphasia, Primary Progressive', 'Anomia', 'Alzheimer Disease']",INTERVENTIONAL,84.0,ACTUAL,"[{'name': 'Phonological', 'description': 'This treatment involves picture viewing and word repetition.'}, {'name': 'Orthographic', 'description': 'This treatment involves picture viewing, reading, and writing.'}, {'name': 'Semantic', 'description': 'This treatment involves learning about the semantic features (meaning) of each trained word.'}, {'name': 'Lexical', 'description': 'This treatment involves learning about the lexical features (letters and sounds) of each trained word.'}, {'name': 'Untrained', 'description': 'These words are not trained during the treatment phase.'}]",,
Clinical Trial of Ultra-high Dose Methylcobalamin for ALS,2018-06,UNKNOWN,2020-03-31,PRINCIPAL_INVESTIGATOR,Ryuji Kaji,University of Tokushima,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,128.0,ESTIMATED,"[{'name': 'methylcobalamin', 'description': 'Patients receive methylcobalamin 50mg intramuscular injection twice a week.'}, {'name': 'saline solution', 'description': 'Patients receive saline solution intramuscular injection twice a week.'}]","['ALS', 'motor neuron disease', ""Lou Gehrig's disease""]",
HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262,2023-10,ENROLLING_BY_INVITATION,2024-10,SPONSOR_INVESTIGATOR,"Merit E. Cudkowicz, MD","Merit E. Cudkowicz, MD",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,300.0,ESTIMATED,"[{'name': 'ABBV-CLS-7262 Dose 1', 'description': 'ABBV-CLS-7262 is administered orally once per day for 24 weeks.'}, {'name': 'ABBV-CLS-7262 Dose 2', 'description': 'ABBV-CLS-7262 is administered orally once per day for 24 weeks.'}, {'name': 'Matching Placebo', 'description': 'Matching placebo is administered orally once per day for 24 weeks.'}]","['ALS', 'Placebo-Controlled', 'Double-Blind', 'Regimen Specific Appendix', ""Lou Gehrig's Disease"", 'ABBV-CLS-7262', 'Calico Life Sciences']",
Genetic Frontotemporal Dementia Initiative for Neurodevelopment,2023-03,RECRUITING,2035-03,PRINCIPAL_INVESTIGATOR,Dr. Elizabeth Finger,Western University,"['Frontotemporal Dementia', 'Family Members']",OBSERVATIONAL,200.0,ESTIMATED,,,Youths between the ages of 9 and 16 inclusive at time of enrollment who have a 1st or 2nd degree biological relative with genetic FTD (i.e. a known mutation in biological parent or grandparent). Parents or guardians of potential GENFI NeuroDev participants are all aware of the autosomal dominant genetic nature of FTD in their family prior to being approached for potential participation in this study.
Flortaucipir PET Imaging in Subjects With FTD,2020-09,COMPLETED,2018-10-24,SPONSOR,,Avid Radiopharmaceuticals,['Frontotemporal Dementia'],INTERVENTIONAL,16.0,ACTUAL,"[{'name': 'Flortaucipir F18', 'description': '370 megabecquerel (MBq)(10 millicurie \\[mCi\\]) injection, single dose'}, {'name': 'Brain PET scan', 'description': 'positron emission tomography (PET) scan of the brain'}]",,
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech,2023-04,RECRUITING,2027-07,PRINCIPAL_INVESTIGATOR,Keith A. Josephs,Mayo Clinic,"['Apraxia of Speech', 'Non-fluent Aphasia', 'Primary Progressive Aphasia', 'Primary Progressive Nonfluent Aphasia']",OBSERVATIONAL,47.0,ESTIMATED,"[{'name': 'Testing protocol for the study', 'description': 'All patients will see a Neurologist for a neuro exam and consult, see a Speech Pathologist for assessment of speech and language skills, see the Study Coordinator for neuropsych testing (brief tests of thinking, memory, visual spatial skills, etc), undergo an MRI of the brain and a DaTscan of the brain.'}]",['apraxia of speech'],Patients that have been diagnosed as having Progressive Apraxia of Speech.
Care of Persons With Dementia in Their Environments (COPE) in Programs of All-Inclusive Care of the Elderly (PACE),2023-06,ENROLLING_BY_INVITATION,2024-05-31,SPONSOR,,University of Pennsylvania,"['Frontotemporal Dementia', 'Dementia', 'Multi-Infarct Dementia', 'Vascular Dementia', 'Mixed Dementia', 'Alzheimer Disease', 'Lewy Body Disease', 'Pick Disease', 'Neurocognitive Disorders']",INTERVENTIONAL,120.0,ESTIMATED,"[{'name': 'COPE online training', 'description': 'The intervention being tested is PACE staff training in COPE - accomplished with the creation of self-paced online learning modules.\n\nThe modules will include rich multimedia content and interactive assessments to keep the learner engaged and will allow for easy packaging of the content into the latest interoperability standards for such content including the latest Shareable Content Object Reference Model (SCORM) specifications, which will allow for repurposing and sharing with other institutions and will be designed using a hyperlearning model with four dimensions. The self-paced modules will be highly interactive featuring integrated multimedia content, assessments, and learner evaluations to allow PACE staff to engage with the content at a high level and practice application in simulated scenarios. Each module will require approximately 45-60 minutes/module for the learner to complete.le for the learner to complete.'}]",,
Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral Sclerosis,2008-04-21,COMPLETED,2008-04-21,,,National Institute of Environmental Health Sciences (NIEHS),"['Amyotrophic Lateral Sclerosis', 'ALS']",OBSERVATIONAL,0.0,,,"['Case-Control Study', 'Death Certificates', 'National Death Index', 'Cause of Death Information', 'Lead Exposure', 'Amyotrophic Lateral Sclerosis', 'ALS']",
"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",2023-07,COMPLETED,2021-07-16,SPONSOR,,Biogen,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,176.0,ACTUAL,"[{'name': 'Tofersen', 'description': 'Administered as specified in the treatment arm.'}, {'name': 'Placebo', 'description': 'Administered as specified in the treatment arm.'}]","['IONIS-SOD1Rx', 'SOD1', 'ALS']",
Investigation on the Cortical Communication (CortiCom) System,2024-02,RECRUITING,2026-08-31,SPONSOR,,Johns Hopkins University,"['Tetraplegia', 'Locked-in Syndrome', 'Brainstem Stroke', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,3.0,ESTIMATED,"[{'name': 'Surgical implantation of CortiCom system', 'description': 'Implantation of Cortical communication system, consisting of one or two Electrocorticography (ECoG) grids connected to a transcutaneous patient pedestal.'}]","['Tetraplegia', 'ALS', 'Locked-in Syndrome', 'Brainstem stroke', 'Brain Computer Interface', 'Rehabilitation', 'Stroke', 'Hopkins']",
Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia,2018-08,COMPLETED,2017-12-21,PRINCIPAL_INVESTIGATOR,Elizabeth Finger,Lawson Health Research Institute,['Frontotemporal Dementia'],INTERVENTIONAL,52.0,ACTUAL,"[{'name': 'Intranasal oxytocin', 'description': 'Oxytocin can be given intravenously (with a needle) or intranasally (a spray into the nose). The intravenous form of drug is approved by Health Canada for use in pregnancy. The intranasal formulation is not currently approved for use by Health Canada, but is used in Europe to induce labour in pregnant women or aid lactation (breastfeeding). Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3.'}, {'name': 'Saline Nasal Mist', 'description': 'Participants will be randomized to receive placebo on either study visit 2 or 3.'}]","['Frontotemporal Dementia', 'emotion', 'oxytocin', 'fMRI']",
Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS),2018-05,TERMINATED,2015-08,SPONSOR,,University of Michigan,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,20.0,ACTUAL,"[{'name': 'MRI', 'description': 'Subjects will have magnetic resonance imaging(MRI)scans of the cervical spine(neck). This involves lying on a table and sliding into a scanner consisting of a large magnet. This will take approximately one hour to complete. All subjects will be instructed to remove all jewelry and other metal-containing objects for the scan. During the MRI scan loud noises may be heard. Subjects may have a soft brace for the neck for positioning purposes.'}, {'name': 'Clinical Exam', 'description': 'Brief neurological exam will be performed.'}]",,
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS),2017-04,COMPLETED,2008-09,SPONSOR,,Mitsubishi Tanabe Pharma Corporation,['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,206.0,ACTUAL,"[{'name': 'MCI-186', 'description': ""Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).""}, {'name': 'Placebo of MCI-186', 'description': ""Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).""}]","['Amyotrophic lateral sclerosis', 'free radical scavenger']",
Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS),2014-12,COMPLETED,2013-02,SPONSOR_INVESTIGATOR,Nazem Atassi,Nazem Atassi,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,60.0,ACTUAL,"[{'name': 'creatine', 'description': 'creatine monohydrate powder'}, {'name': 'tamoxifen', 'description': 'Tamoxifen citrate capsules'}]","['ALS', ""Lou Gehrig's Disease"", 'Amyotrophic Lateral Sclerosis', 'Creatine', 'Tamoxifen', 'Selection Design']",
Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial,2023-11,RECRUITING,2026-12,SPONSOR,,University of Edinburgh,"['Motor Neuron Disease, Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,800.0,ESTIMATED,"[{'name': 'Memantine Hydrochloride Oral Solution', 'description': 'Memantine hydrocholoride taken once daily'}, {'name': 'Trazodone Hydrochloride oral solution', 'description': 'Trazodone Hydrochloride taken once daily'}, {'name': 'Placebo oral solution', 'description': 'Placebo taken once daily'}, {'name': 'Amantadine Hydrochloride Oral Solution', 'description': 'Amantadine Hydrochloride taken once daily'}]",,
HEALEY ALS Platform Trial - Regimen D Pridopidine,2023-08,COMPLETED,2022-07-14,SPONSOR_INVESTIGATOR,"Merit E. Cudkowicz, MD","Merit E. Cudkowicz, MD",['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,163.0,ACTUAL,"[{'name': 'Pridopidine', 'description': 'Administration: Oral\n\nDose: 45mg twice daily'}, {'name': 'Matching Placebo', 'description': 'Administration: Oral\n\nDose: one capsule twice daily'}]","['ALS', 'Placebo-Controlled', 'Double-Blind', 'Regimen Specific Appendix', ""Lou Gehrig's Disease"", 'Pridopidine', 'Prilenia Therapeutics']",
T-regulatory Cells in ALS,2021-09,UNKNOWN,2022-08-31,PRINCIPAL_INVESTIGATOR,Jason R. Thonhoff,The Methodist Hospital Research Institute,['ALS (Amyotrophic Lateral Sclerosis)'],INTERVENTIONAL,12.0,ESTIMATED,"[{'name': 'Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections', 'description': 'For the first 6-months of the study: T-regulatory cells taken from a patient, increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient + 3 times per week subcutaneous Interleukin-2 injections'}, {'name': 'Monthly placebo infusions + 3 times per week placebo injections', 'description': 'For first 6-months of study: monthly placebo infusions + 3 times per week subcutaneous placebo injections'}, {'name': 'Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections', 'description': 'For the second 6-months of the study: all participants will receive T-regulatory cells taken from the patient, that have been increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient (Treg cell owner) + 3 times per week subcutaneous Interleukin-2 injections.'}]","[""Lou Gehrig's Disease""]",
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment,2023-01,ACTIVE_NOT_RECRUITING,2024-03-01,SPONSOR,,Amylyx Pharmaceuticals Inc.,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,600.0,ESTIMATED,"[{'name': 'Placebo', 'description': 'Matching Placebo Comparator'}, {'name': 'AMX0035', 'description': 'Proprietary formulation of taurursodiol and sodium phenylbutyrate'}]",,
Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia,2023-01,RECRUITING,2030-06-01,PRINCIPAL_INVESTIGATOR,Keith A. Josephs,Mayo Clinic,"['Primary Progressive Aphasia', 'Behavioral Variant of Frontotemporal Dementia', 'Frontotemporal Dementia, Behavioral Variant']",INTERVENTIONAL,200.0,ESTIMATED,"[{'name': 'F-18 AV 1451', 'description': 'Tau binding agent'}]","['PPA', 'bvFTD', 'FTD']",
Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS),2017-02,WITHDRAWN,2013-07,PRINCIPAL_INVESTIGATOR,Pushpa Narayanaswami,Beth Israel Deaconess Medical Center,"['Parkinson Disease', 'Amyotrophic Lateral Sclerosis']",INTERVENTIONAL,0.0,ACTUAL,"[{'name': 'Incobotulinum Toxin A', 'description': 'Xeomin 70-100 units injected in the parotid and submandibular glands of subjects'}, {'name': 'placebo', 'description': 'Sterile preservative free 0.9% saline'}]","['ALS', 'PD']",
"A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS",2019-07,COMPLETED,2019-06-26,SPONSOR,,Avera McKennan Hospital & University Health Center,"['Amyotrophic Lateral Sclerosis', 'ALS']",INTERVENTIONAL,5.0,ACTUAL,"[{'name': 'probiotic', 'description': 'a proprietary probiotic formulation'}]","['ALS', 'Amyotrophic Lateral Sclerosis']",
Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease,2017-03,COMPLETED,2015-12,PRINCIPAL_INVESTIGATOR,Giancarlo Comi,Ospedale San Raffaele,"['Motor Neuron Disease', 'Amyotrophic Lateral Sclerosis (ALS)']",INTERVENTIONAL,60.0,ACTUAL,"[{'name': 'Cannabis Sativa extract Oromucosal spray', 'description': 'Comparison between active drug (Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml) vs placebo'}]","['Motor Neuron Disease', 'Amyotrophic lateral sclerosis', 'Cannabinoids', 'Sativex', 'Spasticity']",
Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS),2021-09,COMPLETED,2014-08,PRINCIPAL_INVESTIGATOR,Michael D Weiss,University of Washington,['Sporadic Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,75.0,ACTUAL,"[{'name': 'Mexiletine'}, {'name': 'Placebo'}]","['SALS', 'Mexiletine', 'Safety']",
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology,2023-10,RECRUITING,2026-09-30,SPONSOR_INVESTIGATOR,"Peter Ljubenkov, MD","Peter Ljubenkov, MD",['Semantic Dementia'],INTERVENTIONAL,64.0,ESTIMATED,"[{'name': 'Verdiperstat', 'description': 'Oral, extended release (ER) tablet'}]",,
Amyotrophic Lateral Sclerosis Registry Rhineland-Palatinate,2016-04,COMPLETED,2015-09,PRINCIPAL_INVESTIGATOR,Joachim Wolf,Klinikum Ludwigshafen,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,200.0,ACTUAL,,"['incidence', 'phenotype', 'mortality']","residents of the state of Rhineland-Palatinate, Germany (4 million inhabitants)"
Dexpramipexole Renal PK Study,2014-11,COMPLETED,2012-01,SPONSOR,,Knopp Biosciences,"['Amyotrophic Lateral Sclerosis', 'Renal Insufficiency']",INTERVENTIONAL,36.0,ACTUAL,"[{'name': 'Dexpramipexole (dose 1)'}, {'name': 'Dexpramipexole (dose 2)'}]",,
Salivary Biomarker Discovery by Raman Spectroscopy in ALS (SalivALS),2023-01,RECRUITING,2027-12-01,SPONSOR,,Fondazione Don Carlo Gnocchi Onlus,['Amyotrophic Lateral Sclerosis'],OBSERVATIONAL,80.0,ESTIMATED,"[{'name': 'Raman analysis of saliva with data collection and analysis', 'description': 'Saliva collection and processing to all the enrolled subjects and consecutive Raman analysis of the biological fluid. Statistical processing of the collected data.'}]","['Raman Spectroscopy', 'Amyotrophic Lateral Sclerosis', 'Biomarker', 'Diagnosis']",The study population will be recruited from the primary care clinic patients under treatment at Fondazione Don Carlo Gnocchi - IRCCS Santa Maria Nascente and at Istituto Auxologico Italiano in Milan (Italy)
Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS),2021-02,COMPLETED,2020-01-07,PRINCIPAL_INVESTIGATOR,"Sabrina Paganoni, M.D.",Massachusetts General Hospital,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,48.0,ACTUAL,"[{'name': 'Inosine', 'description': 'Subjects on inosine will receive 1-6 capsules a day of 500 mg inosine titrated to target urate levels of 7 - 8 mg/dL.'}, {'name': 'Placebo', 'description': 'Subjects on placebo will receive 1-6 capsules a day of 500 mg placebo (sugar pill) titrated to target urate levels of 7 - 8 mg/dL.'}]","['ALS', 'Inosine', 'Uric acid', 'Urate', 'Glutathione', 'Biomarker', 'Oxidative stress', 'Oxidative damage']",
"A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN",2023-02,NOT_YET_RECRUITING,2024-08-30,SPONSOR,,"Guangzhou Magpie Pharmaceuticals Co., Ltd.",['Healthy'],INTERVENTIONAL,16.0,ESTIMATED,"[{'name': 'Tetramethylpyrazine nitrone (TBN) tablet / Placebo', 'description': 'Subjects will be administered multiple oral doses of TBN or matching placebo tablets twice a day for 6 consecutive days and a last dose in the morning of Day 7.'}]","['Phase 1', 'Amyotrophic lateral sclerosis', 'TBN']",
Premorbid Personality Profile of Patients With Cognitive and Behavioral Disorders,2023-09,NOT_YET_RECRUITING,2027-02-01,SPONSOR,,Nantes University Hospital,"['Behavioral Variant of Frontotemporal Disorder (bvFTD)', 'Phenocopy Frontotemporal Dementia (phFTD)', 'Frontal Variant of Alzheimer Disease', 'Bipolar Disorder']",OBSERVATIONAL,120.0,ESTIMATED,"[{'name': 'Submission of the NEO-PI-3 questionnaire', 'description': 'The questionnaire contains 240 statements. For each statement, the patient chooses the answer that best corresponds to their choice (FD: strongly disagree - D: disagree - N: neutral - A: agree - FA: strongly agree).'}, {'name': 'Submission of the Interpersonal Reactivity Index questionnaire (IRI)', 'description': 'The test assesses two cognitive and two affective components of empathy that influence each other and affect attitudes and behaviors toward others.'}]","['bvFTD', 'fvAD', 'phFTD', 'bipolar disorder,personality']","The study will be conducted among eligible patients with bvFTD, fvAD, phFTD, followed to Memory Resource and Research Centre at Nantes university Hospital CMRR or referred to the department for a neuropsychological assessment (bipolar disorder). It will prospectively enroll 120 participants."
"A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis",2011-11,COMPLETED,2002-10,SPONSOR,,Novartis Pharmaceuticals,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,44.0,ACTUAL,[{'name': 'TCH346'}],['(ALS)'],
Satisfaction of Patients With Amyotrophic Lateral Sclerosis Regarding Home Assisted Teleconsultation,2022-11,NOT_YET_RECRUITING,2024-08-31,SPONSOR,,AGIR Ã  Dom,"['ALS', 'Charcot Disease']",INTERVENTIONAL,40.0,ESTIMATED,"[{'name': 'Teleconsultation assisted by a physiotherapist or nurse', 'description': ""A home health care provider (with expertise in NIV) will be asked to attend the 2 home teleconsultation sessions.\n\nThis assistance will make it possible to help, if necessary, the patient to settle in and connect, collect the elements necessary for the doctor's consultation and adjust, if necessary, the NIV settings. He will also be responsible for administering the questionnaires to the patient as well as to his family caregiver.""}]",,
Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy,2023-04,COMPLETED,2020-04-22,SPONSOR,,Mitsubishi Tanabe Pharma Corporation,['Japanese Patients With ALS'],INTERVENTIONAL,6.0,ACTUAL,"[{'name': 'MT-1186', 'description': 'Suspension'}]",,
A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),2014-12,COMPLETED,2014-07,SPONSOR,,"Eisai Co., Ltd.",['Amyotrophic Lateral Sclerosis (ALS)'],INTERVENTIONAL,373.0,ACTUAL,"[{'name': 'E0302 (mecobalamin)', 'description': 'Intramuscular injection, mecobalamin 25 mg twice a week for 3.5 years.'}, {'name': 'E0302 (mecobalamin)', 'description': 'Intramuscular injection, mecobalamin 50 mg twice a week for 3.5 years.'}, {'name': 'Placebo', 'description': 'Intramuscular injection, placebo twice a week for 3.5 years.'}]","['Amyotrophic Lateral Sclerosis (ALS)', 'motor neurons', 'muscular atrophy', ""Lou Gehrig's Disease""]",
Investigating Lysosomal Storage Diseases in Minority Groups,2017-04,UNKNOWN,2018-12,SPONSOR,,O & O Alpan LLC,"['Lysosomal Storage Disorders', 'Gaucher Disease', 'Fabry Disease', 'Pompe Disease', 'Niemann-Pick Disease']",OBSERVATIONAL,20000.0,ESTIMATED,,"['Lysosomal storage disorders', 'LSD', 'Gaucher disease', 'Fabry disease', 'Pompe disease', 'Niemann-Pick disease']","The study population will comprise of patients of healthcare institutions in the Washington, D.C. metro area ."
Multimodal Imaging Outcome Measures for ALS (Image ALS),2022-04,TERMINATED,2022-03-17,SPONSOR,,University of Pennsylvania,['ALS'],INTERVENTIONAL,2.0,ACTUAL,"[{'name': '[11C]-PBR28', 'description': 'A dose of â‰¤ 20 mCi (approximate range for most studies is anticipated to be 5-20 mCi) of \\[11C\\]-PBR28 will be administered by IV injection to the patient under the direct supervision of a Nuclear Medicine Authorized User. A lesser activity may be injected if, in the opinion of a nuclear medicine authorized user complete imaging data could be generated.\n\nSubjects will undergo an approximately 90 minute dynamic PET/CT scan over the brain starting at approximately the same time as the \\[11C\\]-PBR-28 injection. Scans will be acquired using a Philips PET/CT time-of-flight Ingenuity scanner (Philips Healthcare, Cleveland, OH, USA). At the end of the dynamic imaging the participant will be allowed to get off the scanner.'}]",,
Characterisation of Primary Progressives Aphasias,2017-02,UNKNOWN,2017-11,SPONSOR,,Assistance Publique - HÃ´pitaux de Paris,['Aphasia Primary Progressive'],INTERVENTIONAL,155.0,ESTIMATED,"[{'name': 'Behavioural testing'}, {'name': 'Brain imaging', 'description': 'MRI, PET'}, {'name': 'Genetic screening', 'description': 'APOE, Progranulin'}]",,
"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPG302 in Healthy Volunteers and ALS Participants",2024-01,RECRUITING,2024-12,SPONSOR,,Spinogenix,['Amyotrophic Lateral Sclerosis'],INTERVENTIONAL,112.0,ESTIMATED,"[{'name': 'SPG302', 'description': 'synthetic small molecule'}, {'name': 'Placebo', 'description': 'Placebo'}]","['Amyotrophic Lateral Sclerosis', 'regenerative', 'synapse']",
"Validation of the ""ExSpironÂ©"" in Patients With ALS",2023-11,NOT_YET_RECRUITING,2025-09,PRINCIPAL_INVESTIGATOR,Peter Wijkstra,University Medical Center Groningen,"['Amyotrophic Lateral Sclerosis', 'Neuromuscular Diseases']",INTERVENTIONAL,10.0,ESTIMATED,"[{'name': 'ExSprion', 'description': 'The primary objective is the validation of the ExSpironÂ© non-invasive monitor in patients diagnosed with ALS.'}]",['ALS'],
European Registry on Rare Neurological Diseases,2021-09,NOT_YET_RECRUITING,2025-12,PRINCIPAL_INVESTIGATOR,Prof. Dr. Ludger SchÃ¶ls,University Hospital Tuebingen,['Rare Diseases'],OBSERVATIONAL,5000.0,ESTIMATED,"[{'name': 'Data set as defined by the ERN Research Workgroup of the European Commission', 'description': 'The ERN-RND registry will be restricted to the minimum data set as defined by the ERN Research Workgroup of the European Commission. This includes the following data:\n\n* Name of specialist center\n* Pseudonym:\n* Date of birth: For confidentiality reasons the ERN-RND registry will restrict this information to the Year of birth\n* Sex\n* Date of death: For confidentiality reasons the ERN-RND registry will restrict this information to the Year of death\n* Age of onset\n* Orphacode for specific rare disease: https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=DE\n* Online Mendelian Inheritance in Man (OMIM) code as defined for genetic diseases: https://www.omim.org/\n* Human Phenotype Ontology (HPO) terms for key features: https://hpo.jax.org/app/\n* Agreement to be contacted for research purposes: Yes/No\n* Biological samples (Yes / No)\n* Link to a biobank (Link / No)\n* Classification of disability (Disease group specific score)'}]","['Rare Diseases', 'Ataxia', 'Hereditary Spastic Spinal Paralysis', 'Neurodegeneration with Brain Iron Accumulation', 'Leukodystrophy', 'Dystonia', 'Atypical Parkinsonism', ""Huntington's Disease"", 'Chorea Huntington', 'European Reference Network on Rare Neurological Diseases', 'Frontotemporal Dementia']","Patients suffering of one of the rare neurological diseases indicated according to the inclusion criteria or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by a RND. Patients visiting in TÃ¼bingen, Germany the specialist center Department of Neurology and/ or the Department of Neuropediatric Diseases at the University Hospital."
Virtual Reality as an Adjunct to Management of Pain and Anxiety in Palliative Care,2021-03,UNKNOWN,2021-03-30,PRINCIPAL_INVESTIGATOR,Stefan Riel,Riverview Health Centre,"['Cancer', 'Heart Failure', 'Copd', 'ALS']",INTERVENTIONAL,8.0,ESTIMATED,"[{'name': 'Virtual Reality', 'description': 'Participants will have access to an Oculus Quest Virtual Reality Headset every second day as an alternative to opioids for pain management and benzodiazepines for anxiety management'}]","['Palliative Care', 'Virtual Reality', 'Pain', 'Anxiety']",
